0000950170-24-12549410-Q Lyra Therapeutics, Inc. 20241112202411121624501624501624500 0 0000950170-24-125494 10-Q 76 20240930 20241112 20241112 Lyra Therapeutics, Inc. 0001327273 3841 000000000 DE 1231 10-Q 34 001-39273 241448684 480 ARSENAL WAY WATERTOWN MA 02472 617-373-4600 480 ARSENAL WAY WATERTOWN MA 02472 480 Biomedical, Inc. 20120927 Arsenal Vascular, Inc. 20110826 Arsenal Medical, Inc. 20090414 10-Q 1 lyra-20240930.htm 10-Q 10-Q 0001327273--12-31Q3falseApril 30, 2027May 31, 20280001327273us-gaap:RetainedEarningsMember2023-04-012023-06-300001327273us-gaap:PrivatePlacementMemberlyra:PreFundedWarrantsMemberlyra:SecuritiesPurchaseAgreementMember2023-05-250001327273us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001327273lyra:WatertownLeaseMember2023-07-312023-07-310001327273lyra:CantorFitzgeraldCoMember2023-09-012023-09-010001327273lyra:RetentionCostsMemberlyra:TwentyTwentyFourRestructuringPlanMember2024-01-012024-09-300001327273us-gaap:FairValueMeasurementsRecurringMemberlyra:USGovernmentAgencyAndForeignNationalBankSecuritiesMember2023-12-310001327273us-gaap:CommonStockMember2023-05-252023-05-250001327273us-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember2023-05-252023-05-250001327273srt:MaximumMemberlyra:PreFundedWarrantsMember2023-12-310001327273us-gaap:LetterOfCreditMemberlyra:WalthamLeaseMember2022-05-310001327273us-gaap:RetainedEarningsMember2024-03-310001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001327273lyra:OfficeAndLaboratoryMemberlyra:WalthamLeaseMember2022-05-3100013272732023-07-012023-09-300001327273us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001327273lyra:OfficeAndLaboratoryMemberlyra:WalthamLeaseMember2022-05-012022-05-310001327273732023-06-300001327273us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001327273us-gaap:EquipmentMember2023-12-3100013272732024-01-012024-03-310001327273us-gaap:RetainedEarningsMember2023-12-3100013272732023-04-012023-06-300001327273us-gaap:WarrantMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember2024-09-300001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001327273us-gaap:CommonStockMember2023-07-012023-09-300001327273us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000013272732022-05-012022-05-310001327273us-gaap:AdditionalPaidInCapitalMember2023-03-310001327273lyra:ImpairmentOfRightOfUseAssetMember2024-01-012024-09-3000013272732024-06-300001327273us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001327273us-gaap:WarrantMember2023-01-012023-09-300001327273us-gaap:PrivatePlacementMember2022-04-132022-04-130001327273lyra:ComputerSoftwareAndEquipmentMember2023-12-310001327273lyra:DevelopmentActivitiesPerformanceObligationMember2023-01-012023-12-310001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001327273lyra:WalthamSubleaseMemberus-gaap:LetterOfCreditMember2023-12-3100013272732024-07-012024-09-3000013272732023-01-012023-12-310001327273lyra:CombinedPerformanceObligationMember2024-09-300001327273us-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember2023-05-2500013272732023-12-310001327273us-gaap:PerformanceSharesMember2024-09-300001327273us-gaap:AdditionalPaidInCapitalMember2024-09-300001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001327273us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001327273us-gaap:CertificatesOfDepositMemberlyra:WatertownLeaseMember2023-07-310001327273lyra:WatertownLeaseMemberus-gaap:LetterOfCreditMember2023-07-310001327273us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMember2024-01-012024-09-300001327273us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001327273lyra:CommonWarrantsMember2024-01-012024-09-300001327273lyra:MilestoneAchievementsMember2022-02-280001327273us-gaap:CommonStockMemberlyra:TwoThousandTwentyFourPsusMember2024-03-012024-03-310001327273us-gaap:CommonStockMember2023-12-310001327273us-gaap:RetainedEarningsMember2024-04-012024-06-300001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001327273us-gaap:RetainedEarningsMember2023-03-310001327273lyra:ImpairmentOfRightOfUseAssetMember2024-07-012024-09-300001327273us-gaap:CommonStockMember2022-12-310001327273us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001327273us-gaap:AdditionalPaidInCapitalMember2024-03-310001327273lyra:ControlledEquityOfferingSalesAgreementMember2024-01-012024-09-300001327273us-gaap:EmployeeSeveranceMember2024-05-162024-06-300001327273lyra:TwentyThousandTwentyIncentiveAwardPlanMembersrt:ChiefExecutiveOfficerMemberlyra:TwoThousandTwentyFourPerformanceOptionMember2024-03-012024-03-310001327273lyra:DevelopmentActivitiesPerformanceObligationMember2024-09-300001327273us-gaap:CommonStockMember2023-03-310001327273us-gaap:ValuationTechniqueDiscountedCashFlowMember2024-01-012024-09-300001327273lyra:AtTheMarketMember2024-01-012024-03-3100013272732023-01-012023-09-300001327273us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001327273lyra:TwentyThousandTwentyIncentiveAwardPlanMember2024-01-012024-09-300001327273lyra:PostMilestoneMember2024-09-300001327273us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001327273us-gaap:PrivatePlacementMember2024-01-012024-09-300001327273us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001327273us-gaap:FairValueMeasurementsRecurringMember2024-09-300001327273us-gaap:CommonStockMember2023-01-012023-03-310001327273us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000013272732022-12-3100013272732020-05-050001327273lyra:WalthamSubleaseMemberlyra:OfficeAndLaboratoryMember2023-12-310001327273us-gaap:LeaseholdImprovementsMember2024-09-300001327273us-gaap:RetainedEarningsMember2024-06-300001327273us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001327273us-gaap:PrivatePlacementMember2023-05-252023-05-250001327273us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2022-04-132022-04-130001327273us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001327273lyra:StockOptionsAndRestrictedStockUnitsMember2024-09-300001327273us-gaap:RetainedEarningsMember2024-09-300001327273us-gaap:PrivatePlacementMemberlyra:PreFundedWarrantsMember2022-04-132022-04-130001327273us-gaap:CommonStockMember2024-03-310001327273us-gaap:CommonStockMember2023-09-300001327273us-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember2024-01-012024-09-300001327273us-gaap:AdditionalPaidInCapitalMember2023-12-310001327273us-gaap:CommonStockMember2023-06-3000013272732024-01-012024-09-300001327273lyra:ExecutiveChairMemberlyra:TwoThousandTwentyFourPsusMemberlyra:TwentyThousandTwentyIncentiveAwardPlanMember2024-03-012024-03-310001327273us-gaap:AdditionalPaidInCapitalMember2023-09-3000013272732024-03-310001327273us-gaap:CommonStockMember2024-04-012024-06-300001327273us-gaap:RetainedEarningsMember2024-07-012024-09-300001327273us-gaap:AdditionalPaidInCapitalMember2023-06-300001327273lyra:DevelopmentActivitiesPerformanceObligationMember2024-01-012024-09-300001327273us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-3000013272732024-11-010001327273srt:MinimumMemberlyra:PreFundedWarrantsMember2023-12-310001327273us-gaap:WarrantMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember2023-05-250001327273lyra:WatertownLeaseMember2024-01-012024-09-300001327273lyra:PreFundedWarrantsMember2023-12-310001327273lyra:InducementAwardPlanMember2024-01-012024-09-300001327273us-gaap:CommonStockMember2024-01-012024-03-310001327273lyra:CommonWarrantsMember2024-09-3000013272732024-09-300001327273lyra:TwentyTwentyFourRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2024-01-012024-09-300001327273lyra:TwoThousandTwentyFourPsusMember2024-09-302024-09-300001327273us-gaap:LeaseholdImprovementsMember2023-12-310001327273us-gaap:RetainedEarningsMember2022-12-310001327273us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001327273us-gaap:EmployeeStockMember2024-09-300001327273us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001327273lyra:TwentyTwentyFourRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-09-300001327273us-gaap:WarrantMember2024-09-300001327273us-gaap:RetainedEarningsMember2023-06-300001327273us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001327273us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001327273us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001327273us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001327273us-gaap:CommonStockMemberlyra:TwoThousandTwentyFourPerformanceOptionMember2024-03-012024-03-310001327273us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001327273lyra:CombinedPerformanceObligationMember2022-12-310001327273lyra:RetentionCostsMemberlyra:TwentyTwentyFourRestructuringPlanMember2024-09-300001327273lyra:TwentyTwentyFourRestructuringPlanMember2024-09-300001327273lyra:DevelopmentActivitiesPerformanceObligationMember2022-12-310001327273us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001327273us-gaap:RestrictedStockUnitsRSUMember2024-09-300001327273lyra:PreFundedWarrantsMember2024-01-012024-09-300001327273us-gaap:AdditionalPaidInCapitalMember2024-06-300001327273lyra:ATMAgreementMember2024-02-142024-02-140001327273us-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMemberlyra:PreFundedWarrantsMember2024-01-012024-09-300001327273us-gaap:RetainedEarningsMember2023-07-012023-09-300001327273us-gaap:PrivatePlacementMemberlyra:PreFundedWarrantsMemberlyra:SecuritiesPurchaseAgreementMember2024-09-300001327273lyra:CommonWarrantsMember2023-12-310001327273us-gaap:RetainedEarningsMember2023-09-300001327273us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMember2024-01-012024-09-300001327273us-gaap:CommonStockMember2024-06-300001327273us-gaap:CommonStockMember2024-09-300001327273us-gaap:CommonStockMemberlyra:ControlledEquityOfferingSalesAgreementMemberlyra:CantorFitzgeraldCoMembersrt:MaximumMember2024-03-222024-03-220001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001327273us-gaap:AdditionalPaidInCapitalMember2022-12-310001327273us-gaap:WarrantMember2024-01-012024-09-3000013272732024-04-012024-06-300001327273us-gaap:CommonStockMember2023-04-012023-06-300001327273us-gaap:PrivatePlacementMember2022-04-130001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001327273us-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMemberlyra:PreFundedWarrantsMember2023-05-252023-05-250001327273us-gaap:PerformanceSharesMember2024-03-012024-03-310001327273us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001327273lyra:TwentyTwentyFourRestructuringPlanMemberus-gaap:OtherRestructuringMember2024-01-012024-09-300001327273us-gaap:RetainedEarningsMember2024-01-012024-03-310001327273us-gaap:WalthamSubleaseMemberlyra:OfficeAndLaboratoryMember2023-12-012023-12-310001327273us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001327273lyra:CombinedPerformanceObligationMember2023-12-310001327273us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001327273lyra:TwoThousandTwentyFourPerformanceOptionMember2024-03-012024-03-310001327273us-gaap:RetainedEarningsMember2023-01-012023-03-310001327273lyra:PreFundedWarrantsMember2023-05-252023-05-250001327273lyra:TwentyTwentyFourRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2024-09-300001327273us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember2023-05-252023-05-2500013272732023-03-310001327273us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-3000013272732023-09-300001327273lyra:DevelopmentActivitiesPerformanceObligationMember2023-12-3100013272732024-03-222024-03-220001327273us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001327273lyra:TwentyTwentyFourRestructuringPlanMember2024-09-300001327273us-gaap:EmployeeStockOptionMember2024-09-300001327273lyra:TwentyTwentyFourRestructuringPlanMember2024-01-012024-09-300001327273lyra:ClinicalSupplyAgreementMember2024-09-300001327273us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001327273lyra:WalthamLeaseMember2024-01-012024-09-300001327273us-gaap:CommonStockMember2024-07-012024-09-300001327273lyra:MilestoneAchievementsMember2022-02-012022-02-280001327273us-gaap:FairValueMeasurementsRecurringMember2023-12-310001327273us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberlyra:USGovernmentAgencyAndForeignNationalBankSecuritiesMember2023-12-310001327273us-gaap:FurnitureAndFixturesMember2023-12-310001327273us-gaap:FurnitureAndFixturesMember2024-09-300001327273lyra:ComputerSoftwareAndEquipmentMember2024-09-300001327273us-gaap:WarrantMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember2024-01-012024-09-3000013272732023-01-012023-03-310001327273us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001327273us-gaap:CommonStockMemberlyra:ControlledEquityOfferingSalesAgreementMemberlyra:CantorFitzgeraldCoMembersrt:MaximumMember2023-09-012023-09-010001327273us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001327273lyra:MilestoneAchievementsMember2024-09-300001327273us-gaap:EquipmentMember2024-09-300001327273us-gaap:PrivatePlacementMemberlyra:PreFundedWarrantsMember2022-04-130001327273us-gaap:EmployeeStockOptionMember2024-01-012024-09-30xbrli:pureiso4217:USDxbrli:sharesutr:sqftxbrli:shareslyra:Leaselyra:Employeeiso4217:USDlyra:Vote Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39273 Â Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Â Â Delaware 84-1700838 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 480 Arsenal WayWatertown, MA 02472 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (617) 393-4600 Â N/A (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchange on which registered Common Stock, $0.001 par value per share Â LYRA Â The Nasdaq Global Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232. 405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Â Â Â Â Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Â Â Â Â Â Â Â Â Â Â Emerging growth company Â â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of November 1, 2024, the registrant had 65,457,648 shares of common stock, $0.001 par value per share, outstanding. Â Â Â Â SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or

the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements, including but not limited, to statements regarding: â€¢our restructuring initiatives and our ability to continue as a going concern; â€¢our estimates and statements regarding our future revenue, future results of operations, and financial position; â€¢the sufficiency of our cash and cash equivalents to fund our operations; â€¢plans to develop, manufacture, and commercialize LYR-210; â€¢the timing of our ongoing or planned clinical trials for LYR-210, and any future product candidates; â€¢the timing of and our ability to obtain and maintain regulatory approvals for LYR-210, and any future product candidates; â€¢the clinical utility of LYR-210; â€¢our commercialization, marketing, and manufacturing capabilities and strategy; â€¢our expectations about the willingness of healthcare professionals to use LYR-210, and any future product candidates; â€¢our expectations regarding the development and commercialization of LYR-210 pursuant to the terms of the LianBio License Agreement (as defined below); â€¢our intellectual property position; â€¢our competitive position and developments and projections relating to our competitors or our industry; â€¢the impact of laws and regulations; â€¢risks associated with the COVID-19 pandemic ("COVID-19") and related macroeconomic factors, which may adversely impact our business and clinical trials; â€¢our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or the JOBS Act; â€¢our business strategy; â€¢our projected research and development costs; and â€¢the plans and objectives of management for future operations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Â Â In some cases, you can identify forward-looking statements by terms such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œcould,â€ â€œintend,â€ â€œtarget,â€ â€œproject,â€ â€œcontemplate,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotential,â€ â€œwouldâ€ or â€œcontinueâ€ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words or expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under the sections in this Quarterly Report on Form 10-Q entitled â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Unless the context requires otherwise, we use the terms â€œLyra,â€ â€œthe Company,â€ â€œwe,â€ â€œus,â€ â€œourâ€ and similar designations in this Quarterly Report on Form 10-Q to refer to Lyra Therapeutics, Inc. and its wholly owned subsidiary, Lyra Therapeutics Securities Corporation. Â Â Summary Risk Factors Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. â€œRisk Factorsâ€ in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following: â€¢any potential financial or strategic option we pursue in order to maximize shareholder value may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all; â€¢we are attempting to sublease or assign our three leaseholds, which represent significant operating costs, and there can be no assurance that we will accomplish this effort on favorable terms, or at all, which would adversely affect our business, results of operations and financial condition; â€¢we have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future; â€¢our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern; â€¢we need significant additional funding in order to complete development of and obtain regulatory approval for our product candidates and commercialize our products, if approved. The failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint has made it more difficult for the Company to raise capital. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, and/or discontinue operations; â€¢following the failure of our ENLIGHTEN 1 Phase 3 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS) to meet its primary endpoint, which was announced in May 2024, there is significant uncertainty about the Companyâ€™s ability to complete development of LYR-210 and our ability to obtain regulatory approval for LYR-210 is at least significantly delayed and may not be possible; â€¢our common stock may be delisted from The Nasdaq Global Market if we cannot regain compliance with Nasdaqâ€™s continued listing requirements, which could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock; â€¢in connection with a cost reduction initiative following the failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint, we implemented a reduction in force impacting approximately 87 employees, which was effected during May and June 2024, and this loss of key personnel significantly and adversely affects our ability to manufacture our product candidates, among other activities; â€¢we are no longer engaged in the manufacturing of our product candidates in-house; â€¢our business is highly dependent on the success of our most advanced product candidate, LYR-210, which requires on-going clinical testing before we can seek regulatory approval and potentially launch our product. If LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed; â€¢clinical trials required for our lead product candidate and any future product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired; â€¢any failure by a third party to conduct our pre-clinical or clinical trials according to good clinical practices and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates; â€¢even if LYR-210 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success; Â Â â€¢we are party to a collaboration, and may enter into other collaborations, that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential; â€¢if LianBio is unable to find a third party to acquire its rights under the LianBio License Agreement, it may materially harm our business, financial condition, results of operations and prospects; â€¢managing our obligations under our license and other strategic agreements may divert management time and our limited resources, causing delays or disruptions to our business; â€¢our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities; â€¢failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions; â€¢developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets; â€¢the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; â€¢failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue; â€¢if we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our market; â€¢the impact of international terrorism, political unrest and wars on our business; and â€¢the impact of other events such as the COVID-19 pandemic may adversely impact our business and operations, including our clinical trials. Â Â Table of Contents Â Page PART I. FINANCIAL INFORMATION 2 Item 1. Condensed Consolidated Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations and Comprehensive Loss 3 Condensed Consolidated Statements of Stockholdersâ€™ Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3. Quantitative and Qualitative Disclosures About Market Risk 33 Item 4. Controls and Procedures 33 PART II. OTHER INFORMATION 34 Item 1. Legal Proceedings 34 Item 1A. Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 84 Item 3. Defaults Upon Senior Securities 84 Item 4. Mine Safety Disclosures 84 Item 5. Other Information 85 Item 6. Exhibits 86 Signatures 87 Â Â Â PART Iâ€”FINANCIAL INFORMATION Item 1. Financial Statements. Â LYRA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share data) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 23,800 Â Â $ 22,353 Â Short-term investments Â Â 27,826 Â Â Â 80,400 Â Prepaid expenses and other current assets Â Â 2,818 Â Â Â 2,068 Â Total current assets Â Â 54,444 Â Â Â 104,821 Â Property and equipment, net Â Â 1,613 Â Â Â 2,043 Â Operating lease right-of-use assets Â Â 20,707 Â Â Â 33,233 Â Restricted cash Â Â 1,992 Â Â Â 1,392 Â Other assets Â Â â€” Â Â Â 1,111 Â Total assets Â $ 78,756 Â Â $ 142,600 Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 2,292 Â Â $ 3,131 Â Restructuring liability Â Â 4,855 Â Â Â â€” Â Accrued expenses and other current liabilities Â Â 3,197 Â Â Â 9,374 Â Operating lease liabilities Â Â 4,003 Â Â Â 5,434 Â Deferred revenue Â Â 607 Â Â Â 1,658 Â Total current liabilities Â Â 14,954 Â Â Â 19,597 Â Operating lease liabilities, net of current portion Â Â 31,321 Â Â Â 21,447 Â Deferred revenue, net of current portion Â Â 11,862 Â Â Â 12,136 Â Total liabilities Â Â 58,137 Â Â Â 53,180 Â Commitments and contingenciesÂ (Note 13) Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock, $0.001Â par value, 10,000,000Â shares authorized at September 30, 2024Â Â Â and December 31, 2023; noÂ shares issued and outstanding at September 30, 2024 and Â Â Â December 31, 2023 Â Â Â â€” Â Â Â Â â€” Â Common stock, $0.001Â par value; 200,000,000Â shares authorized atÂ Â Â September 30, 2024 and December 31, 2023; 65,456,735Â and 57,214,550Â shares issued Â Â Â and outstanding at September 30, 2024 and December 31, 2023, respectively Â Â 65 Â Â Â 57 Â Additional paid-in capital Â Â 414,345 Â Â Â 400,685 Â Accumulated other comprehensive income, net of tax Â Â 20 Â Â Â 33 Â Accumulated deficit Â Â (393,811) Â Â (311,355) Total stockholdersâ€™ equity Â Â 20,619 Â Â Â 89,420 Â Total liabilities and stockholdersâ€™ equity Â $ 78,756 Â Â $ 142,600 Â Â See accompanying notes to unaudited condensed consolidated financial statements. 2 Â LYRA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share data) Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Collaboration revenue Â $ 195 Â Â $ 544 Â Â $ 1,325 Â Â $ 1,412 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 5,902 Â Â Â 12,368 Â Â Â 37,404 Â Â Â 35,763 Â Â General and administrative Â Â 3,931 Â Â Â 5,003 Â Â Â 14,888 Â Â Â 14,700 Â Â Impairment of property and equipment Â Â â€” Â Â Â â€” Â Â Â 1,883 Â Â Â 1,592 Â Â Impairment of right-of-use assets Â Â â€” Â Â Â â€” Â Â Â 22,836 Â Â Â â€” Â Â Restructuring and other related charges Â Â 2,804 Â Â Â â€” Â Â Â 9,254 Â Â Â â€” Â Â Total operating expenses Â Â 12,637 Â Â Â 17,371 Â Â Â 86,265 Â Â Â 52,055 Â Â Loss from operations Â Â (12,442) Â Â (16,827) Â Â (84,940) Â Â (50,643) Â Other income: Â Â Â Â Â Â Â Â Â Â Â Â Interest income Â Â 576 Â Â Â 1,192 Â Â Â 2,517 Â Â Â 3,161 Â Â Total other income Â Â 576 Â Â Â 1,192 Â Â Â 2,517 Â Â Â 3,161 Â Â Loss before income tax expense Â Â (11,866) Â Â (15,635) Â Â (82,423) Â Â (47,482) Â Income tax expense Â Â (7) Â Â (16) Â Â (33) Â Â (42) Â Net loss Â Â (11,873) Â Â (15,651) Â Â (82,456) Â Â (47,524) Â Other comprehensive loss: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unrealized holding gain (loss) on short-term investments, net of tax Â Â 24 Â Â Â 20 Â Â Â (13) Â Â (17) Â Comprehensive loss Â $ (11,849) Â $ (15,631) Â $ (82,469) Â $ (47,541) Â Net loss per share attributable to common stockholdersâ€” basic and diluted Â $ (0.18) Â $ (0.27) Â $ (1.27) Â $ (1.04) Â Weighted-average common shares outstandingâ€”Â Â basic and diluted Â Â 65,456,735 Â Â Â 56,953,685 Â Â Â 64,981,219 Â Â Â 45,894,643 Â Â Â See accompanying notes to unaudited condensed consolidated financial statements. 3 Â LYRA THERAPEUTICS, INC. Condensed Consolidated Statements of Stockholdersâ€™ Equity (unaudited) (in thousands, except share amounts) Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Other Comprehensive Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Income (Loss), net of tax Â Â Deficit Â Â Equity Â Balance at December 31, 2022 Â Â 31,827,659 Â Â $ 32 Â Â $ 329,387 Â Â $ 10 Â Â $ (248,675) Â $ 80,754 Â Â Exercise of common stock options Â Â 2,115 Â Â Â Â â€” Â Â Â 4 Â Â Â â€” Â Â Â â€” Â Â Â 4 Â Â Issuance of common stock upon RSUÂ Â vesting Â Â 7,041 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Unrealized loss on available-for-sale securities Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â (22) Â Â â€” Â Â Â (22) Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â 1,610 Â Â Â â€” Â Â Â â€” Â Â Â 1,610 Â Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (16,255) Â Â (16,255) Balance at March 31, 2023 Â Â 31,836,815 Â Â $ 32 Â Â $ 331,001 Â Â $ (12) Â $ (264,930) Â $ 66,091 Â Issuance of common stock and pre-funded warrants, Â Â net of issuance costs of $3,332 Â Â 17,652,962 Â Â $ 18 Â Â $ 46,650 Â Â Â â€” Â Â Â â€” Â Â Â $ 46,668 Â Exercise of common stock options Â Â 55,262 Â Â Â Â â€” Â Â Â 97 Â Â Â Â â€” Â Â Â â€” Â Â Â 97 Â Unrealized loss on available-for-sale securities Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â (15) Â Â Â â€” Â Â Â (15) Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â 1,354 Â Â Â â€” Â Â Â â€” Â Â Â 1,354 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (15,618) Â Â (15,618) Balance at June 30, 2023 Â Â 49,545,039 Â Â $ 50 Â Â $ 379,102 Â Â $ (27) Â $ (280,548) Â $ 98,577 Â Issuance costs Â Â â€” Â Â Â Â â€” Â Â $ (150) Â Â â€” Â Â Â â€” Â Â $ (150) Exercise of common stock options Â Â 520 Â Â Â Â â€” Â Â Â 2 Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2 Â Unrealized gain on available-for-sale securities Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â 20 Â Â Â Â â€” Â Â Â 20 Â Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â 1,441 Â Â Â Â â€” Â Â Â â€” Â Â Â 1,441 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (15,651) Â Â (15,651) Balance at September 30, 2023 Â Â 49,545,559 Â Â $ 50 Â Â $ 380,395 Â Â $ (7) Â $ (296,199) Â $ 84,239 Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Other Comprehensive Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Â Â Â Amount Â Â Capital Â Â Income (Loss), net of tax Â Â Deficit Â Â Equity Â Balance at December 31, 2023 Â Â 57,214,550 Â Â $ 57 Â Â $ 400,685 Â Â $ 33 Â Â $ (311,355) Â $ 89,420 Â Exercise of common stock options Â Â 918 Â Â Â Â â€” Â Â Â 3 Â Â Â Â â€” Â Â Â â€” Â Â Â 3 Â Shares issued under ATM, net of issuance costs of $150 Â Â 1,041,666 Â Â Â 1 Â Â Â 4,849 Â Â Â â€” Â Â Â Â â€” Â Â Â 4,850 Â Exercise of pre-funded warrants Â Â 1,255,500 Â Â Â 1 Â Â Â 1 Â Â Â â€” Â Â Â 2 Â Exercise of common stock warrants Â Â 1,424,272 Â Â Â 2 Â Â Â 3,806 Â Â Â â€” Â Â Â â€” Â Â Â 3,808 Â Issuance of common stock upon RSUÂ Â vesting Â Â 27,869 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Unrealized loss on available-for-sale securities Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â (8) Â Â â€” Â Â Â (8) Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â 1,881 Â Â Â â€” Â Â Â â€” Â Â Â 1,881 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (22,452) Â Â (22,452) Balance at March 31, 2024 Â Â 60,964,775 Â Â $ 61 Â Â $ 411,225 Â Â $ 25 Â Â $ (333,807) Â $ 77,504 Â Exercise of pre-funded warrants Â Â 4,490,876 Â Â $ 4 Â Â $ 4 Â Â Â â€” Â Â Â â€” Â Â $ 8 Â Exercise of common stock options Â Â 84 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Unrealized loss on available-for-sale securities Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â (29) Â Â â€” Â Â Â (29) Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â 1,625 Â Â Â â€” Â Â Â â€” Â Â Â 1,625 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (48,131) Â Â (48,131) Balance at June 30, 2024 Â Â 65,455,735 Â Â $ 65 Â Â $ 412,854 Â Â $ (4) Â $ (381,938) Â $ 30,977 Â Issuance of common stock under ESPP Â Â 1,000 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Unrealized gain on available-for-sale securities Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â 24 Â Â Â â€” Â Â Â 24 Â Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â 1,491 Â Â Â Â â€” Â Â Â Â â€” Â Â Â 1,491 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (11,873) Â Â (11,873) Balance at September 30, 2024 Â Â 65,456,735 Â Â $ 65 Â Â $ 414,345 Â Â $ 20 Â Â $ (393,811) Â $ 20,619 Â Â 4 Â Â See accompanying notes to unaudited condensed consolidated financial statements. 5 Â LYRA THERAPEUTICS, INC. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Net loss Â $ (82,456) Â $ (47,524) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Stock-based compensation Â Â 4,777 Â Â Â 4,405 Â Depreciation expense Â Â 320 Â Â Â 193 Â Impairment of property and equipment Â Â 1,883 Â Â Â 1,592 Â Write-off of deferred financing costs Â Â 140 Â Â Â â€” Â Impairment of right-of-use assets Â Â 22,836 Â Â Â Â â€” Â Net amortization of premium on short-term investments Â Â (2,009) Â Â (2,408) Changes in operating assets and liabilities: Â Â Â Â Â Â Prepaid expenses and other current assets Â Â (750) Â Â 565 Â Operating lease right-of-use assets Â Â 570 Â Â Â 1,080 Â Other assets Â Â 1,111 Â Â Â (3,240) Accounts payable Â Â (774) Â Â 3,985 Â Accrued expenses and other current liabilities Â Â (5,400) Â Â (625) Restructuring Liability Â Â 4,855 Â Â Â â€” Â Operating lease liabilities Â Â (2,437) Â Â (857)

Deferred revenue Â Â (1,325) Â Â (1,412) Net cash used in operating activities Â Â (58,659) Â Â (44,246) Cash flows from investing activities: Â Â Â Â Â Â Purchases of property and equipment Â Â (2,396) Â Â (260) Purchases of short-term investments Â Â (47,949) Â Â (72,765) Maturity of short-term investments Â Â 102,519 Â Â Â 62,800 Â Net cash provided by (used in) investing activities Â Â 52,174 Â Â Â (10,225) Cash flows from financing activities: Â Â Â Â Â Â Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of Â Â Â Â Â Â Â issuance costs Â Â 8,819 Â Â Â 50,000 Â Payment of deferred offering costs Â Â (290) Â Â (3,332) Proceeds from exercise of stock options Â Â 3 Â Â Â 103 Â Net cash provided by financing activities Â Â 8,532 Â Â Â 46,771 Â Net increase (decrease) in cash, cash equivalents and restricted cash Â Â 2,047 Â Â Â (7,700) Cash, cash equivalents and restricted cash, beginning of period Â Â 23,745 Â Â Â 33,942 Â Cash, cash equivalents and restricted cash, end of period Â $ 25,792 Â Â $ 26,242 Â Â Â Â Â Â Â Â Supplemental disclosure of non-cash financing and investing activities: Â Â Â Â Â Â Property and equipment purchases included in accounts payable Â $ â€” Â Â $ 8 Â Modification of lease agreement Â $ â€” Â Â $ 4,931 Â Issuance Costs in accounts payable, accrued expenses, and other current liabilities Â $ â€” Â Â $ 150 Â Other assets included in accounts payable and other current liabilities Â $ â€” Â Â $ 2,740 Â Right of Use Asset in Exchange for Lease Liability Â $ 13,667 Â Â $ â€” Â Deferred offering costs included in accounts payable and accrued expenses Â $ â€” Â Â $ 161 Â Â See accompanying notes to unaudited condensed consolidated financial statements. 6 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(unaudited) 1. Organization, Restructuring, Going Concern and Basis of Presentation Lyra Therapeutics, Inc. (the â€œCompanyâ€) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Companyâ€™s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Companyâ€™s product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on November 21, 2005 and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc. The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.Restructuring On May 16, 2024, the Company reported that topline results from the Companyâ€™s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210, a bioabsorbable sinonasal implant (7500Âµg mometasone furoate), as a six-month treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210. The 52-week safety extension phase of the ENLIGHTEN 1 trial recently completed and data is expected in Q4 2024. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results are expected in the second quarter of 2025. In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors of the Company (the â€œBoard of Directorsâ€) approved a reduction in the Companyâ€™s workforce impacting 87 employees, which occurred during May and June 2024. In connection with the reduction in force, the Company stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses. Furthermore, the Company is currently in the process of marketing all three of its leased properties for sub-leasing arrangements.The Company has recorded a restructuring charge in the amount of $9.3 million for the nine months ended September 30, 2024, primarily related to severance and retention costs as further discussed in Note 4. The Company has also recorded an impairment charge for the write-down of property and equipment of $1.9 million and right-of-use assets in the amount of $22.8 million as further discussed in Notes 5 and 6. Â Going ConcernThe failure of the Companyâ€™s Phase 3 ENLIGHTEN 1 trial to meet its primary endpoint, which resulted in the Companyâ€™s restructuring during the second quarter of 2024, provides significant uncertainty regarding the Companyâ€™s ability to meet its business plans and conduct its future operations. The Company has incurred recurring net operating losses every year since inception and has an accumulated deficit of approximately $393.8 million at September 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future. At September 30, 2024, the Company had approximately $23.8 million of cash and cash equivalents and $27.8 million of short-term investments. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. From inception through September 30, 2024, the Company has raised an aggregate of $424.8 million to fund its operations, of which $162.1 million were gross proceeds from sales of redeemable convertible preferred stock, $96.3 million were net proceeds from the April 2022 financing, $46.5 million were net proceeds from the May 2023 Financing (as defined below), $57.3 million were net proceeds from the Companyâ€™s initial public offering, $23.9 million were net proceeds related to the Companyâ€™s Controlled Equity Offering Agreement (the â€œOriginal Sales Agreementâ€) dated September 1, 2023, $16.8 million were gross proceeds 7 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) from government contracts, $17.0 million were gross proceeds from the LianBio License Agreement, and $3.8 million were gross proceeds from the exercise of common stock warrants. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) assuming the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board of Directors has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. The Company is attempting to sublease all of its leased locations, and, may also seek to negotiate an early termination of its leases with its landlords. The Company may be unable to sublease its locations on favorable terms or at all. In addition, the Company may not be able to obtain an early termination of its leases with its landlords on favorable terms or at all. The Company will continue to evaluate its headcount of employees and may further reduce its workforce, which will result in additional severance and retention costs, which may impact the Companyâ€™s ability to meet objectives. If the Company decides to pursue any form of growth strategy in the future, it will need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to obtain funding as and when needed would have a negative impact on the Companyâ€™s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.Basis of Presentation The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on March 22, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUâ€) of the Financial Accounting Standards Board (â€œFASBâ€). In managementâ€™s opinion, these unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Companyâ€™s condensed consolidated financial statements for the periods presented. 2. Summary of Significant Accounting Policies The Companyâ€™s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2023, included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 22, 2024. Since the date of those financial statements, there have been no changes to its significant accounting policies except as noted below.Â Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholdersâ€™ equity that result from transactions and economic events other than those with stockholders. For the three and nine months ended September 30, 2024, other comprehensive loss consisted of unrealized losses, net of taxes from its short-term investments.Restricted Cash The Company had restricted cash of approximately $2.0 million as of September 30, 2024 and approximately $1.4 million as of December 31, 2023. These balances were held as of September 30, 2024 at one of the Companyâ€™s financial institutions to secure the Companyâ€™s letters of credit for its facility leases. 8 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) The Companyâ€™s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on such statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows: Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 23,800 Â Â $ 22,353 Â Restricted cash Â Â 1,992 Â Â Â 1,392 Â Total Â $ 25,792 Â Â $ 23,745 Â Â Â Â Â Â Â Net Loss per Share The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has included pre-funded warrants in its computation of basic net loss per share based on the nominal exercise price. The Company applies the two-class method to calculate its basic and diluted net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Companyâ€™s participating securities contractually entitle the holders of such shares to participate in dividends, but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) for the three and nine months ended September 30, 2024 and 2023: Â Â Â 2024 Â Â 2023 Â Stock options Â Â 6,387,089 Â Â Â 5,838,677 Â Common stock warrants Â Â 8,606,303 Â Â Â 10,030,575 Â Restricted stock units Â Â 867,472 Â Â Â 243,703 Â Total Â Â 15,860,864 Â Â Â 16,112,955 Â Â Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Companyâ€™s consolidated financial position, results of operations or cash flows.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, designed to improve reportable segment disclosures. The guidance expands the disclosures required for reportable segments in our annual and interim condensed consolidated financial statements, primarily through enhanced disclosures about significant segment expenses. The standard will be effective for us beginning with our annual reporting for fiscal year 2024 and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact of this standard on our segment disclosures.This standard requires disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker, â€œCODMâ€, and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. 9 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) The Company will include the required disclosure information in the notes to the financial statements for the year ending December 31, 2024 included in its 2024 Annual Report on Form 10-K and is required to apply ASU No. 2023-07 on a retrospective basis. The adoption of ASU No. 2023-07 will include expanded disclosure for its 2024 financial statements, but the Company does not expect that there will be a material impact to the financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes.Effective January 1, 2023, the Company adopted Accounting Standards Update (ASU) No. 2016-13, Financial Instrumentsâ€”Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entityâ€™s current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The adoption of ASU 2016-13 did not have a material impact on its consolidated financial statements. 3. Fair Value Measurements The following tables present information about the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: Â Â Â Â Â Fair Value Measurements at Reporting Date Using Â Â Â September 30, Â Â Quoted Prices in Active Markets for Identical Assets(Level 1) Â Â Significant Other Observable Inputs(Level 2) Â Â Significant Unobservable Inputs(Level 3) Â Â Â 2024 Â Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â

amounts are recorded as restructuring and other related charges within our condensed consolidated statements of operations and comprehensive loss as they are incurred. For the three months ended September 30, 2024, restructuring and other related charges were $2.8 million, which consisted of $0.9 million of severance costs, $1.8 million of retention costs, and $0.1 million of other costs. For the nine months ended September 30, 2024, restructuring and other related charges were $9.3 million, which consisted of $5.7 million of severance costs, $2.6 million of retention costs, and $1.0 million of other costs.Restructuring liability activities during the nine months ended September 30, 2024 (in thousands):Â Â Â January 1, Â Â Â Â Â Â Â Â Â September 30, Â Â Â 2024 Â Â Accruals Â Â Cash Payments Â Â 2024 Â 2024 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Â Â Severance Costs Â $ â€” Â Â $ 5,651 Â Â $ (3,435) Â $ 2,216 Â Retention Costs Â Â â€” Â Â Â 2,608 Â Â $ (74) Â $ 2,534 Â Other Costs Â Â â€” Â Â Â 995 Â Â Â (890) Â $ 105 Â Total Â $ â€” Â Â $ 9,254 Â Â $ (4,399) Â $ 4,855 Â Â 5. Property and Equipment and Related ImpairmentProperty and equipment consist of the following (in thousands) as of September 30, 2024 and December 31, 2023: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Property and equipment: Â Â Â Â Â Â Laboratory equipment Â $ 4,158 Â Â $ 2,736 Â Computer software and equipment Â Â 160 Â Â Â 105 Â Office furniture and fixtures Â Â 934 Â Â Â 662 Â Leasehold improvements Â Â 485 Â Â Â 461 Â Â Â Â Â Total Â $ 5,737 Â Â $ 3,964 Â Less: Accumulated depreciation Â Â (2,241) Â Â (1,921) Less: Impairment Â Â (1,883) Â Â â€” Â Property and equipment, net Â $ 1,613 Â Â $ 2,043 Â During the second quarter of 2024 and as a result of the Companyâ€™s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, the Company performed a recoverability test for its property and equipment. The Company concluded that the undiscounted cash flows associated with its property and equipment was less than the carrying value of the property and equipment. The Company compared the fair value of the property and equipment to the carrying value and recorded an impairment 11 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) charge in the amount of $1.9 million which is included as an impairment of property and equipment in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024. The Company determined fair market value of the equipment based on a third-party appraisal of the equipment through use of publicly available used equipment quotes. The equipment was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of September 30, 2024, and determined no additional impairment indicators existed. Â 6. Impairment of Right-of-Use AssetsIn connection with the Companyâ€™s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, in May 2024, the Company engaged a commercial real estate broker to market the Companyâ€™s three leased properties for sublease arrangements. As of September 30, 2024, the Company has not sublet any of its leased properties. Based upon these impairment indicators, the Company has performed a recoverability test over its right-of-use asset and concluded the right-of-use assets are impaired. As a result, the Company has recorded an impairment charge in the amount of $22.8 million, which is included as an impairment of right-of-use asset in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024. The right-of-use asset was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of September 30, 2024, and determined no additional impairment indicators existed.The Company engaged a valuation specialist to perform a fair value determination of the right-of-use assets using a discounted cash flow methodology, which included the following range of assumptions:Â Discount Rate Â 9.5-10.5% Â Term (years) Â 2.96-9.13 Â Expected Sublease Rent Increases Â Â 3.0 % Â 7. Preferred and Common StockThe Company has 10,000,000 shares of undesignated preferred stock, par value $0.001 per share. There were no shares issued or outstanding as of September 30, 2024 or September 30, 2023.The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.The Company currently has an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 (â€œForm S-3â€), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $300.0 million in the aggregate. Â September 2023 FinancingOn September 1, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Original Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $50.0 million. The offering and sale of up to $50.0 million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-256020) (the "Registration Statement"), which was originally filed with the SEC on May 11, 2021, and declared effective by the SEC on May 20, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on September 1, 2023.Pursuant to the Original Sales Agreement, Cantor may sell the shares in sales deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company has no obligation to sell any of the shares under the Original Sales Agreement and may at any time suspend or terminate the offering of the shares pursuant to the Original Sales Agreement upon notice to Cantor and subject to other conditions. Cantor will act as sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the shares requested to be sold by the Company, on mutually agreed terms between Cantor and the Company.The Original Sales Agreement contains customary representations, warranties and agreements by the Company, and indemnification obligations of the Company and Cantor and other obligations of the parties. Under the terms of the Original Sales 12 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) Agreement, the Company has agreed to pay Cantor a commission equal to 3.0% of the aggregate gross proceeds from any shares sold through it pursuant to the Original Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by Cantor in connection with the Original Sales Agreement. On February 14, 2024, the Company issued 1,041,666 shares under the Companyâ€™s ATM agreement with net proceeds of $4.8 million. On March 22, 2024, the Company amended and restated the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $75.0 million. The offering and sale of up to $75.0 million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-278163) (the "Registration Statement"), which was originally filed with the Securities and Exchange Commission on March 22, 2024, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on March 22, 2024 (the "Prospectus Supplement"). Â May 2023 FinancingOn May 25, 2023, the Company entered into the Purchase Agreement, with the purchasers, pursuant to which the Company agreed to sell securities to the Investors in a private placement (the â€œPrivate Placementâ€). The Purchase Agreement provided for the sale and issuance by the Company of: 17,652,962 shares of the Companyâ€™s common stock and accompanying warrants to purchase up to 8,826,481 shares of the Companyâ€™s common stock (Purchase Warrants), with an exercise price of $2.67 per share, for aggregate gross proceeds of $44.0 million. Each Purchase Warrant became exercisable on November 30, 2023, and expires on November 30, 2028. Additionally, the Company issued Pre-Funded Warrants to purchase 2,408,188 shares of the Companyâ€™s common stock (Pre-Funded Warrants), with an exercise price of $0.001 per share, and accompanying purchase warrants to purchase up to 1,204,094 shares of the Companyâ€™s common stock (Purchase Warrants), with an exercise price of $2.673 per share, for aggregate gross proceeds of $6.0 million. In total 10,030,575 Purchase Warrants were issued and 2,408,188 Pre-Funded Warrants were issued. The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028. The closing of the Private Placement occurred on May 31, 2023. The Company received an aggregate of $50.0 million in gross proceeds, or $46.5 million after deducting issuance costs. The Company has allocated the net proceeds among the common stock, the Purchase Warrants and the Pre-Funded Warrants using the relative fair value method for each of the above transactions. The Company has allocated $30.5 million to the shares of common stock, $4.2 million to the Pre-Funded Warrants and $12.0 million to the Purchase Warrants. The Companyâ€™s outstanding warrants are freestanding instruments and are classified within stockholdersâ€™ equity since the warrants are indexed to the Companyâ€™s common stock and meet the equity classification criteria. A total of 1,424,272 Purchase Warrants were exercised related to the May 2023 financing as of September 30, 2024 at a purchase price of $2.673 per share.Â April 2022 FinancingOn April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, Pre-Funded Warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million (the â€œApril 2022 Financingâ€). The Company received approximately $96.3 million in net proceeds after deducting estimated offering costs of $4.2 million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of 18,815,159 shares of common stock at $4.22 per share for gross proceeds to the Company of $79.4 million and (ii) certain investors purchased Pre-Funded Warrants to purchase an aggregate of 5,000,000 shares of common stock, with the exercise price of $0.001 per share for gross proceeds of $21.1 million to the Company. The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.The Pre-Funded Warrants were classified as a component of stockholdersâ€™ equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Companyâ€™s common stock and meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued 13 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Pre-Funded Warrants, of which $19.7 million was allocated to the Pre-Funded Warrants and recorded as a component of additional paid-in capital. All Pre-Funded Warrants issued in the April 2022 Financing were exercised as of June 30, 2024.The Company has reserved for future issuances the following shares of common stock as of September 30, 2024: Â Â Â As of September 30, 2024 Â Common stock warrants Â Â 8,606,303 Â Stock options and restricted stock units Â Â 10,075,165 Â Employee stock purchase plan Â Â 723,906 Â Total Â Â 19,405,374 Â Â 8. Common Stock WarrantsThe following table represents a summary of the warrants outstanding and exercisable as of September 30, 2024, all of which are equity-classified: Â Â Number of Common Warrants Â Average Exercise Price Â Weighted Average Remaining Contractual Term (Years) Â Aggregate Intrinsic Value Â Expiration Date Â Number of Pre-funded Warrants Â Â Weighted Average Exercise Price Â Weighted Average Remaining Contractual Term (Years) Â Aggregate Intrinsic Value Â Expiration Date Â Outstanding at December 31, 2023 Â Â 10,030,575 Â $ 2.673 Â Â 4.90 Â $ 25,700 Â November 30, 2028 Â Â 5,756,349 Â Â $ 0.001 Â Â 3.92 Â $ 30,200 Â April 2027-May 2028 Â Exercised Â Â (1,424,272) $ 2.673 Â Â Â $ 5,052 Â Â Â Â (5,756,349) Â $ 0.001 Â Â Â $ 37,770 Â Â Â Outstanding at September 30, 2024 Â Â 8,606,303 Â $ 2.673 Â Â 4.15 Â $ â€” Â November 30, 2028 Â Â â€” Â Â $ â€” Â Â â€” Â $ â€” Â Â â€” Â 9. Stock-Based Compensation Expense The Company currently grants equity-based awards under its 2020 Incentive Award Plan (â€œ2020 Planâ€) and its 2022 Employment Inducement Award Plan (â€œInducement Award Planâ€). The Company previously granted equity-based awards under its 2005 Equity Incentive Plan (â€œ2005 Planâ€) and 2016 Equity Incentive Plan (â€œ2016 Planâ€ and together with the 2020 Plan, the Inducement Award Plan and the 2005 Plan, the â€œPlansâ€). The Company also maintains the 2020 Employee Stock Purchase Plan (the â€œESPPâ€).A summary of the restricted stock unit activity under the Plans for the nine months ended September 30, 2024 was as follows: Â Â Shares Â Â Weighted-AverageGrant Date Fair Value Â Restricted stock units outstanding as of December 31, 2023 Â Â 105,048 Â Â $ 3.20 Â Granted Â Â 984,929 Â Â $ 5.49 Â Vested Â Â (27,869) Â $ 3.29 Â Forfeited Â Â (194,636) Â $ 4.28 Â Restricted stock units outstanding as of September 30, 2024 Â Â 867,472 Â Â $ 5.56 Â Â 14 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) A summary of the stock option activity under the Plans for the nine months ended September 30, 2024 was as follows: Â Â Shares Â Â Weighted-AverageExercisePrice Â Â Weighted-AverageRemainingContractualLife(in years) Â Â AggregateIntrinsicValue(in thousands) Â Outstanding at December 31, 2023 Â Â 5,709,980 Â Â $ 5.68 Â Â Â 8.0 Â Â $ 6,334 Â Granted Â Â 2,605,002 Â Â Â 4.89 Â Â Â Â Â Â Â Exercised Â Â (1,002) Â Â 3.96 Â Â Â Â Â Â Â Cancelled Â Â (1,926,891) Â Â 4.83 Â Â Â Â Â Â Â Outstanding at September 30, 2024 Â Â 6,387,089 Â Â $ 5.61 Â Â Â 7.9 Â Â $ â€” Â The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of certain options granted to executive officers, with the following weighted-average assumptions for the three and nine months ended September 30, 2024 and 2023: Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Risk-free interest rate Â Â 0.0 % Â Â 4.3 % Â Â 4.2 % Â Â 3.7 % Expected dividend yield Â Â â€” % Â Â â€” % Â Â â€” % Â Â â€” % Expected term (in years) Â Â â€” Â Â Â 6.1 Â Â Â 6.0 Â Â Â 6.0 Â Expected volatility Â Â 0.0 % Â Â 80.0 % Â Â 80.5 % Â Â 82.9 % The weighted-average fair value of options granted to employees, directors and non-employees during the three months ended September 30, 2023 was $2.57. There were no options granted to employees, directors or non-employees during the three months ended September 30, 2024. The weighted-average fair value of options granted to employees, directors and non-employees during the nine months ended September 30, 2024 and 2023 was $2.80 and $2.08, respectively.Stock-based compensation expense included in the Companyâ€™s consolidated statements of operations and comprehensive loss was as follows (in thousands): Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 214 Â Â $ 294 Â Â $ 627 Â Â $ 865 Â General and administrative Â Â 1,277 Â Â Â 1,147 Â Â Â 4,150 Â Â Â 3,540 Â Total Â $ 1,491 Â Â $ 1,441 Â Â $ 4,777 Â Â $ 4,405 Â For the period ended September 30, 2024, approximately $15,000 of the stock-based compensation expense was recorded as a liability. For the period ended September 30, 2023, the Company did not record any stock-based compensation expense as a liability.Unrecognized share-based compensation related to stock-based options amounted to $6.6 million at September 30, 2024 and is expected to be recognized over a weighted average period of approximately 2.86 years. Unrecognized share-based compensation related to restricted stock units amounted to $2.0 million at September 30, 2024 and is expected to be recognized over a weighted average period of approximately 2.4 years.In March 2024, the Company granted options to purchase 550,000 shares of common stock at an exercise price of $6.07 per share to its Chief Executive Officer (â€œ2024 Performance Optionâ€) and granted 385,000 RSUs to its Executive Chair (â€œ2024 PSUsâ€), each with performance-based vesting conditions under the 2020 Plan. Vesting of the 2024 Performance Option and the 2024 PSUs are based on the achievement of various clinical and regulatory milestones during the specified periods. For the performance-based stock awards, the Company measures stock compensation expense based on the fair value of the award on the grant date and then once the Company determines the performance criteria is probable of achievement, recognizes 15 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) such amount over the vesting term of the award, which is approximately 3.8 years. The Company determined the fair value of the 2024 Performance Option using the Black-Scholes option-pricing model using the following inputs: risk-free interest rate of 4.26%, volatility of 76.82%, expected dividend yield 0%, and expected term of 6.0 years.The Company measured the 2024 PSUs based on the fair value of the Companyâ€™s stock on the date of grant.As of March 31, 2024, the Company has determined that 183,333 shares of common stock subject to the 2024 Performance Option and 128,333 shares of common stock underlying the 2024 PSUs are probable to vest and as of September 30, 2024 has recognized approximately $214,000 of expense, which is included in stock-based compensation expense. As of September 30, 2024, there is $1.3 million of unrecognized stock compensation expense to be recognized in connection with all of the performance-based awards that are deemed to be probable as of September 30, 2024. As of September 30, 2024, there were 1,957,604 shares available for grant under the 2020 Plan and 863,000 shares available for grant under the Inducement Award Plan. During the nine month ended September 30, 2024, the Company issued 1,000 shares under the 2020 ESPP. As of September 40, 2024, there are a total of 723,906 shares available for issuance under the 2020 ESPP. Â 10. Collaboration AgreementUnder the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of September 30, 2024, as all milestone amounts were fully constrained based on the probability of achievement. The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2023. There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement. The amendment did not result in any change in the Companyâ€™s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the

allocation of the transaction price to the two performance obligations.LianBio announced that in October 2023 its Board of Directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in February 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Companyâ€™s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBioâ€™s rights under the LianBio License Agreement. The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in managementâ€™s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Companyâ€™s consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively. 16 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) There were no changes in the transaction price from December 31, 2023 to September 30, 2024. The following table reflects the transaction price (in thousands): Â Â As of September 30, 2024 Â Â Â Post-Milestone Â Combined Performance Obligation Â $ 11,862 Â Development Activities Performance Obligation Â Â 5,138 Â Total Â $ 17,000 Â The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands): Â Â As of September 30, 2024 Â Â Â Combined Performance Obligation Â Â Development Activities Performance Obligation Â Â Total Â Deferred revenue at December 31, 2022 Â $ 11,748 Â Â $ 3,604 Â Â $ 15,352 Â Revenue recognized Â Â â€” Â Â Â (1,558) Â Â (1,558) Deferred revenue at December 31, 2023 Â Â 11,748 Â Â Â 2,046 Â Â Â 13,794 Â Revenue recognized Â Â â€” Â Â Â (1,325) Â Â (1,325) Deferred revenue at September 30, 2024 Â $ 11,748 Â Â $ 721 Â Â $ 12,469 Â Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months. As of September 30, 2024, the parties still have not completed their negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule.Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Companyâ€™s directors are Managing Directors at Perceptive Advisors, LLC and one of these directors is also the Executive Chairman of LianBioâ€™s board of directors. 11. Income TaxesThe Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. Given the Companyâ€™s uncertainty regarding future taxable income, the Company maintains a full valuation allowance on its deferred tax assets. The Company recorded an income tax expense of $7,000 for the three months ended September 30, 2024 and $16,000 for the three months ended September 30, 2023 and $33,000 for the nine months ended September 30, 2024 and $42,000 for the nine months ended September 30, 2023, respectively. 12. Leases Watertown LeaseIn August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. The lease includes certain rent escalations. In July 2023, the Company amended the lease to extend the expiration of the lease term from April 2024 to April 2027. Under the terms of the amended lease, the Company no longer has the right to terminate the lease after January 1, 2024. The Company maintains a letter of credit of approximately $0.3 million securing its obligations under the operating lease which is secured by approximately $0.3 million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.The Company also has two leases for two separate spaces in the same building at 880 Winter Street in Waltham, Massachusetts. The Company refers to the first lease as the â€œWaltham Leaseâ€ and the second lease arrangement as the â€œWaltham 17 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) Subleaseâ€ as the Company, as a tenant, is subleasing space from under an existing lease arrangement whereby the lessee to the headlease has agreed to sublease the space to the Company under a sublease agreement.Waltham LeaseIn May 2022, the Company executed a lease agreement located at 880 Winter Street in Waltham, Massachusetts. The leased premises comprises approximately 29,000 square feet of office and lab space, and the lease initially provides for base rent of $2.2 million per year, which will increase 3% per year over the noncancellable term ending on June 30, 2033. The Company has the option to extend the lease for one additional five-year term and is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company did not include the option to extend the lease for the additional five-year term in its measurement of the right-of-use asset and lease liability.In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $1.1 million of deposits with the financial institution which is recorded as restricted cash.Waltham SubleaseIn December 2023, the Company executed a sublease agreement for additional lab and office space located at 880 Winter Street in Waltham, Massachusetts. The subleased premises comprise approximately 24,000 square feet, and the sublease provides for base rent of $1.8 million per year, which will increase 3% per year over the noncancellable term ending on November 30, 2032. The Company is also responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the subleased premises.Upon sublease commencement on January 3, 2024, the Company recorded the sublease as a component of its operating lease right-of-use asset and operating lease liabilities. In connection with the sublease, a security deposit was delivered to the sublandlord in the form of an irrevocable standby letter of credit collateralized by $0.6 million of deposits with the financial institution which is recorded as restricted cash.The components of lease cost recorded in the Companyâ€™s condensed consolidated financial statements were as follows (in thousands):Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Lease Cost: Â Â Â Â Â Â Â Â Â Â Â Â Operating lease cost Â $ 1,346 Â Â $ 483 Â Â $ 5,082 Â Â $ 1,371 Â Variable lease cost Â Â 608 Â Â Â 399 Â Â Â 1,866 Â Â Â 893 Â Total lease cost Â $ 1,954 Â Â $ 882 Â Â $ 6,948 Â Â $ 2,264 Â Â Variable lease payments include the Companyâ€™s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The weighted-average remaining lease term and discount rate related to the Companyâ€™s operating leases were as follows: Â Â As of September 30, 2024 Â Weighted-average remaining lease term (in years) Â Â 7.7 Â Weighted-average discount rate Â Â 6.20 % Â Maturity of the Companyâ€™s operating lease liabilities in accordance with ASC 842 as of September 30, 2024 were as follows (in thousands): 18 LYRA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS â€” Continued(unaudited) Period ended December 31, Â Â Â From October 1, 2024 to December 31, 2024 Â $ 1,546 Â 2025 Â Â 6,121 Â 2026 Â Â 6,494 Â 2027 Â Â 5,131 Â 2028 Â Â 4,507 Â Thereafter Â Â 20,652 Â Total maturities Â $ 44,451 Â Less: Imputed interest Â Â (9,127) Present value of operating lease liability Â $ 35,324 Â Less: current portion of operating lease liability Â Â (4,003) Total operating lease liability, net of current portion Â $ 31,321 Â Â The Company evaluated the above leases for impairment indicators and determined that the right-of-use assets were impaired. Additional details are included within Note 6 above. 13. Commitments and Contingencies Â On May 10, 2023, the Company filed a complaint in the Superior Court of the State of Delaware against a former contract manufacturer alleging breach of contract. The Company alleged in its complaint that the former contract manufacturer breached the Master Clinical Supply Agreement (â€œMCSAâ€). The Companyâ€™s complaint sought monetary damages and the return of equipment and materials that the Company owned. On July 20, 2023, the same contract manufacturer filed an answer and amended counterclaims to the Companyâ€™s May 10, 2023 complaint (the â€œLitigationâ€). Due to the legal proceeding and termination of agreement with this manufacturer, the Company recognized $1.6 million loss on impairment of long-lived assets during the year-ended December 31, 2023.On November 2, 2023, the Company entered into a settlement and release agreement, related to the Litigation, pursuant to which each of the Company and the contract manufacturer provided broad mutual releases of all claims relating to or arising out of the MCSA, including without limitation, all claims brought in the Litigation or that could have been brought in the Litigation. The Company and the former contract manufacturer agreed to jointly file a Stipulation of Dismissal with prejudice relating to the Litigation. The Company has a remaining liability of $0.4 million to be paid to the contract manufacturer during 2024 included within accrued liabilities and other current liabilities. 19 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition, and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods. The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A. Risk Factors. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Â Overview We are a clinical-stage biotechnology company focused on the development and commercialization of innovative, anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Our product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants designed to be administered in a simple in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. The drug embedded within LYR-210 and LYR-220 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. LYR-210 LYR-210 is designed to treat CRS patients who have failed previous medical management. LYR-210 has a smaller dimension and is intended for patients with and without nasal polyps. In May 2024, we announced topline results from the Companyâ€™s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of CRS. ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. At 24 weeks, the ENLIGHTEN 1 trial demonstrated the following results compared to baseline, which did not achieve statistical significance: â€¢In the primary efficacy analysis, treatment with LYR-210 resulted in a mean (standard deviation; SD) improvement in the 3CS score of 2.13 (2.17) points, compared to 2.06 (2.14) points in sham control. â€¢In the intent-to-treat (ITT) population, treatment with LYR-210 resulted in a mean (SD) improvement in the 3CS score of 2.35 (2.28) points, compared to 1.89 (2.07) points in sham control. â€¢In the ITT population, treatment with LYR-210 resulted in a mean (SD) improvement in the Sino-Nasal Outcome Test (SNOT-22) score of 20.2 (21.38) points, compared to 15.70 (18.55) points in sham control. â€¢Ethmoid sinus opacification (evaluated by computed tomography (CT) scans), did not achieve statistically significant improvement after treatment with LYR-210 compared to sham control. Â 20 Â LYR-210 was generally well tolerated, with no product-related serious adverse events. The most commonly reported adverse events in the study population were epistaxis, nasal odor, upper respiratory tract infection and sinusitis. The 52-week extension phase of the ENLIGHTEN 1 trial is complete and data is expected in Q4 2024. Safety data for LYR-210 in the extension phase was generally consistent with the 24-week primary treatment phase, including for those patients that received a repeat dosing, resulting in a 12-month treatment period. LYR-210 was generally well tolerated, with no product-related serious adverse events. The most commonly reported adverse events in the study population were chronic sinusitis, nasal odor, epistaxis, sinusitis, and nasopharyngitis. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results from the ENLIGHTEN 2 trial are expected in the second quarter of 2025. Â LYR-220 Our second pipeline product candidate, LYR-220, is designed for use in CRS patients who have failed previous medical management and who continue to require treatment to manage CRS symptoms despite having had ethmoid sinus surgery. LYR-220 employs a larger implant designed for patients whose nasal cavity is larger including those patients whose nasal cavity is larger after having undergone ethmoid sinus surgery. We conducted a Phase 2 clinical trial of LYR-220, called BEACON. The BEACON trial was a controlled parallel-group study to evaluate safety, tolerability, pharmacokinetics, and efficacy comparing two designs of the LYR-220 (7500Âµg MF) matrix to control, over a 24-week period, in approximately 70 symptomatic adult CRS subjects who have had a prior bilateral sinus surgery. In September 2023, we reported positive topline results from BEACON, demonstrating statistically significant and clinically relevant improvements in the 3CS and SNOT-22 scores at 24 weeks. In connection with the cost-cutting efforts announced in May 2024, the Company halted development efforts for LYR-220. Our Technology Our innovative and proprietary drug delivery technology is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. The technology is comprised of three interrelated components: â€¢a bioabsorbable mesh scaffold, which is designed to maximize surface area for drug release while maintaining underlying tissue function; â€¢an engineered elastomeric matrix, a polymeric matrix composed of polymers having elastic characteristics, which has advanced physical properties resulting in implants with â€œshape memoryâ€ that dynamically adapt to nasal anatomy; and â€¢a versatile polymer-drug complex, which is designed to deliver six months of continuous local drug therapy with a single treatment. Our operations to date have been limited to organizing and staffing our Company, business planning, raising capital, developing our technology, building our intellectual property portfolio and conducting research and development activities, including clinical manufacturing for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. On May 5, 2020, we completed our IPO in which we issued and sold 4,025,000 shares of our common stock (including shares issued upon the underwritersâ€™ exercise in full of their option to purchase additional shares of our common stock) at a public offering price of $16.00 per share, par value $0.001, for aggregate gross proceeds of $64.4 million. We received approximately $57.3 million in net proceeds after deducting underwriting discounts and commissions and offering expenses paid by us. The shares began trading on The Nasdaq Global Market on May 1, 2020. Upon completion of our IPO, all of our outstanding shares of convertible preferred stock converted into 8,335,248 shares of our common stock, par value $0.001. From inception through September 30, 2024, we have raised an aggregate of $424.8 million to fund our operations, of which $162.1 million were gross proceeds from sales of our redeemable convertible preferred stock, $96.3 million were net proceeds from our April 2022 financing, $46.5 million were net proceeds from our May 2023 Financing, $57.3 million were net proceeds from our initial public offering, $23.9 million were net proceeds related to our Controlled Equity Offering Agreement (the â€œOriginal Sales Agreementâ€) dated September 1, 2023, $16.8 million were gross proceeds from government contracts, $17.0 million were gross proceeds from the LianBio License Agreement, and $3.8 million were gross proceeds from the exercise of common stock warrants. Further, we currently have an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 (â€œForm S-3â€), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $300.0 million in the aggregate. We have incurred recurring net operating losses every year since inception and expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter 21 Â and year to year and could be substantial. Our net losses inception to date were $393.8 million at September 30, 2024. As of September 30, 2024, we had approximately $23.8 million of cash and cash equivalents and $27.8 million of short-term investments. These conditions raise substantial doubt about our ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. In May 2024, we announced a reduction in force of approximately 75% of our workforce, impacting 87 employees, in addition to other cost-cutting measures in order to preserve capital, including the stoppage of manufacturing and commercialization efforts for LYR-210 and pausing development efforts for LYR-220.

Nevertheless, we anticipate that we will continue to incur expenses as we continue the two ongoing ENLIGHTEN Phase 3 clinical trials of LYR-210. We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate. In the future, in the event we obtain financing and decide to restart our manufacturing activities, we may engage third party contract manufacturers to manufacture our products. We do not yet have a sales organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. As a result, we need substantial additional funding to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to fund our operations through public or private equity or debt financings or other sources, including strategic collaborations and licensing arrangements. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current product candidate or any additional product candidates, if developed. Because of the numerous risks and uncertainties associated with therapeutics product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. Based on our current operating plan, management has concluded that there is substantial doubt regarding our ability to continue as a going concern. As of September 30, 2024, we had cash and cash equivalents totaling $23.8 million and short-term investments totaling $27.8 million. Management believes that our existing cash, cash equivalents, and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2026. We have based these estimates on assumptions that may prove to be imprecise or incorrect, and we may use our available capital resources sooner than we currently expect. See â€œLiquidity and Capital Resources.â€ Because of the numerous risks and uncertainties associated with the development of our product candidates and any future product candidates and technology, and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research, development and manufacturing of our product candidates. If we raise additional funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Nasdaq Listing Notification On July 19, 2024, we received a written notice (the â€œNoticeâ€) from The Nasdaq Stock Market, LLC (â€œNasdaqâ€) notifying us that for the last 30 consecutive business days, the bid price for our common stock, par value $0.001 per share, had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1) (â€œthe Minimum Bid Price Requirementâ€). The Notice has no effect at this time on the listing of our common stock, which continues to trade on The Nasdaq Global Market under the symbol â€œLYRA.â€ In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we have a period of 180 calendar days, or until January 15, 2025 (the â€œCompliance Dateâ€) to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date. 22 Â In the event we do not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, we may be eligible for a second 180 calendar day compliance period. To qualify, we must submit an application to transfer the listing of the common stock to The Nasdaq Capital Market, which requires us to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. We would also need to pay an application fee to Nasdaq and to provide written notice of its intention to cure the deficiency during the additional compliance period. As part of its review process, Nasdaq will make a determination of whether it believes we will be able to cure this deficiency. If the Company does not qualify for or fails to regain compliance during the additional compliance period, then Nasdaq will notify us of its determination to delist our common stock, at which point we would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel. There can be no assurance that, if we decide to appeal any delisting determination, such appeal would be successful. We intend to actively monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with any other listing requirements. For more information, see â€œRisk Factorsâ€”Our common stock may be delisted from The Nasdaq Global Market if we cannot regain compliance with Nasdaqâ€™s continued listing requirements, which could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stockâ€ in Part II, Item 1A of this Quarterly Report on Form 10-Q. Recent Developments In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board approved a reduction in the Companyâ€™s workforce impacting 87 employees, which occurred during May and June 2024. Moreover, we stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses. We are currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. Furthermore, we are currently in the process of marketing all of our leased properties for sub-leasing arrangements, and, we may also seek to negotiate an early termination of our leases with our landlords. Financial Operations Overview Revenue To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. As of September 30, 2024, we have recognized $4.5 million of collaboration revenue from our LianBio License Agreement. If our development efforts for our product candidates are successful and result in regulatory approval and successful commercialization efforts, or additional collaboration agreements, we may generate revenue in the future from product sales, payments from additional collaboration or license agreements that we may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. We expect that any revenue over the next several years would be derived primarily from our collaboration agreement with LianBio. We cannot provide assurance as to the timing of future milestones or royalty payments from LianBio or that we will receive any of these payments at all, especially in view of LianBioâ€™s wind down activities. Collaboration Agreement On September 26, 2022, we entered into an amended LianBio License Agreement with LianBio to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. Under the terms of the LianBio License Agreement, we received an upfront payment of $12.0 million. In February 2022, the Company achieved a development milestone of $5.0 million for dosing the first patient in the U.S., and the related cash amount was achieved in April 2022. The Company is eligible to receive up to $135.0 million in future payments based upon the achievement of specified development, regulatory and commercialization milestones. Upon commercialization on a region-by-region basis, we will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories. LianBio will be responsible for the 23 Â clinical development and commercialization of LYR-210 in the licensed territories, and we will retain all rights to LYR-210 in all other geographies. As part of the LianBio License Agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to our LYR-220 product candidate. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LianBio, is a customer. At the commencement of the arrangement, we identified the following material promises: (1) license to develop and commercialize LYR-210, (2) manufacturing activities related to the clinical supply of LYR-210, (3) a non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (4) the Companyâ€™s performance of the development activities related to the global Phase 3 clinical trial. We determined that the license to develop and commercialize LYR-210, the manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure represent a single performance obligation because of the specialized nature of the LYR-210 manufacturing process whereby the license cannot be separated from the manufacturing activities related to the supply of LYR-210 and the right to manufacture LYR-210 is only available if there is a supply failure. For the purposes of ASC 606, we determined there were two distinct performance obligations: (1) the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure, and (2) the Companyâ€™s performance of the development activities related to the global Phase 3 clinical trial. Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, we determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations. The potential milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. Additionally, we determined that LianBioâ€™s right of first refusal to obtain development and commercial rights in the licensed territories to LYR-220 is an option as any agreement would be negotiated at armâ€™s length and as a result does not provide a material right to LianBio and as such, is not considered a performance obligation. We will recognize the revenue associated with the license to develop and commercialize LYR-210, manufacturing activities related to the clinical supply of LYR-210, and the non-exclusive license to manufacture LYR-210 and obligation to transfer manufacturing technology in the case of a supply failure combined performance obligation as the clinical supply of LYR-210 is delivered. We recognize revenue associated with the development activities related to the global Phase 3 clinical trial performance obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in managementâ€™s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on our consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively. LianBio announced that in October 2023 its Board of Directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in February 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Companyâ€™s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBioâ€™s rights under the LianBio License Agreement. 24 Â Operating Expenses Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. Research and Development Expenses Research and development expenses consist primarily of costs incurred for our research activities, including the development of and pursuit of regulatory approval of our most advanced product candidate, LYR-210, for the treatment of CRS, which include: â€¢employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions; â€¢expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with CROs, investigative sites, and consultants; â€¢costs of manufacturing our product candidates for use in our clinical trials, including fees paid to CMOs as well as other manufacturers that provide components of our product candidates for use in our potential future clinical trials; â€¢consulting and professional fees related to research and development activities; â€¢costs related to compliance with clinical regulatory requirements; and â€¢facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, and other supplies; and â€¢costs related to the termination of an agreement with a former contract manufacturer organization; and We expense research and development costs as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as clinical site activations, patient enrollment, or information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and may be reflected in our consolidated financial statements as prepaid or accrued research and development expenses. Our research and development expenses consist primarily of costs such as employee compensation, consulting fees, fees paid to CMOs and CRO expenses in connection with our preclinical and clinical development activities. We typically use our employee and infrastructure resources across our development programs and we do not allocate personnel costs and other internal costs to specific product candidates or development programs with the exception of the costs to manufacture our product candidates. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will decrease for the foreseeable future as we implemented a layoff of 75% of our workforce in May 2024 and ceased most manufacturing and CMC-related activities. Research and development expenses will be primarily focused on continuing the two ongoing ENLIGHTEN Phase 3 clinical trials of LYR-210. The successful development of LYR-210, and other potential future product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete the development of these product candidates. We are also unable to predict when, if ever, we will generate revenue and material net cash inflows from the commercialization and sale of any of our product candidates for which we may obtain marketing approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs, and timing of preclinical studies, clinical trials, and development of our product candidates will depend on a variety of factors, including: â€¢successful completion of clinical trials with safety, tolerability, and efficacy profiles for LYR-210, and any potential future product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority; â€¢approval of an IND for any potential future product candidate to commence planned or future clinical trials in the United States or foreign countries; 25 Â â€¢significant and changing government regulation and regulatory guidance; â€¢timing and receipt of marketing approvals from applicable regulatory authorities; â€¢making arrangements with CMOs for third-party clinical and commercial manufacturing to obtain sufficient supply of our product candidates; â€¢obtaining and maintaining patent and other intellectual property protection and regulatory exclusivity for our product candidates; â€¢commercializing the product candidates, if and when approved, whether alone or in collaboration with others; â€¢competition with other therapies; and â€¢business interruptions resulting from COVID-19. A change in the outcome of any of these variables with respect to the development, manufacture, or commercialization enabling activities of any of our product candidates would significantly change the costs, timing, and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we may be required to expend significant additional financial resources and time on the completion of clinical development. Â General and Administrative Expenses General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services, and insurance costs. We expect that our general and administrative expenses will remain stable in the future to support existing research and development activities. Additionally, we will continue to incur expenses associated with being a public company, including costs of accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs. Â Interest Income Interest income consists of interest income earned on our cash and cash equivalents and short-term investments. Â Income Tax Expense Income tax consists of income tax related to the Company's Massachusetts Security Corporation. The Company has not recorded any benefits related to its operating losses due to uncertainty regarding future taxable income. Critical Accounting Estimates Our managementâ€™s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have

been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods and estimates used to assess our ability to continue as a going concern. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions. 26 Â There have been no material changes to our critical accounting estimates from those described in Part II, Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Critical Accounting Estimatesâ€ in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 22, 2024. Recently Issued and Adopted Accounting Pronouncements We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 in our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our operations. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our results of operations for the three months ended September 30, 2024 and 2023 (in thousands): Â Â Â Three Months Ended September 30, Â Â Dollar Â Â Â 2024 Â Â 2023 Â Â Change Â Collaboration revenue Â $ 195 Â Â $ 544 Â Â $ (349) Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Research and development Â Â 5,902 Â Â Â 12,368 Â Â Â (6,466) General and administrative Â Â 3,931 Â Â Â 5,003 Â Â Â (1,072) Impairment of property and equipment Â Â â€” Â Â Â â€” Â Â Â â€” Â Impairment of right-of-use assets Â Â â€” Â Â Â â€” Â Â Â â€” Â Restructuring and other related charges Â Â 2,804 Â Â Â â€” Â Â Â 2,804 Â Total operating expenses Â Â 12,637 Â Â Â 17,371 Â Â Â (4,734) Loss from operations Â Â (12,442) Â Â (16,827) Â Â 4,385 Â Other income: Â Â Â Â Â Â Â Â Â Interest income Â Â 576 Â Â Â 1,192 Â Â Â (616) Total other income Â Â 576 Â Â Â 1,192 Â Â Â (616) Loss before income tax expense Â Â (11,866) Â Â (15,635) Â Â 3,769 Â Income tax expense Â Â (7) Â Â (16) Â Â 9 Â Net loss Â $ (11,873) Â $ (15,651) Â $ 3,778 Â Collaboration Revenue Collaboration revenue for the three months ended September 30, 2024 and 2023 was a result of revenue recognized under the LianBio License Agreement, which we entered into on May 31, 2021. The decrease period over period was primarily related to the completion of the primary study phase of the ENLIGHTEN 1 trial which was utilized for purposes of revenue recognition. Research and Development Expenses Research and development expenses decreased by $6.5 million from $12.4 million to $5.9 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. The decrease in research and development expenses for the three months ended September 30, 2024 was primarily attributable to a decrease in clinical related costs of $3.8 million as we completed both the BEACON trial for LYR-220 and the primary phase for the ENLIGHTEN 1 trial for LYR-210, and a decrease of $2.5 million in employee related costs primarily driven by the reduction in force that occurred in May 2024, a decrease in professional and consulting costs of $0.4 million and a decrease in product development and manufacturing costs of $0.4 million. This decrease in costs was partially offset by increases in allocated costs and depreciation of $0.6 million. General and Administrative Expenses General and administrative expenses decreased by $1.1 million from $5.0 million to $3.9 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. 27 Â The decrease in general and administrative expenses for the three months ended September 30, 2024 was primarily driven by a decrease in professional and consulting fees of $1.0 million as we scaled back activities subsequent to announcing in May 2024 that the ENLIGHTEN 1 trial did not meet its primary endpoint, in addition to a decrease in employee related costs of $0.5 million primarily due to the reduction in force that occurred in May 2024. These were partially offset by an increase in allocation and support costs of $0.4 million primarily due to the increased rent and facilities expenses for the Companyâ€™s three leased facilities for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Interest Income Interest income decreased by $0.6 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Interest income for both periods was primarily attributable to interest earned on the Companyâ€™s short-term investments and the decrease was largely due to the decrease in balance of short-term investments for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Income Tax Expense During the three months ended September 30, 2024 we recorded an income tax expense of $7,000 compared to $16,000 for the three month period ended September 30, 2023. This decrease in income tax expense was related to our Massachusetts Securities Corporation. Restructuring and Other Related Charges The Company incurred a restructuring charge in the amount of $2.8 million primarily related to severance and retention costs for the three months ended September 30, 2024 compared to no such charges for the same period in 2023. Comparison of the Nine Months Ended September 30, 2024 and 2023 The following table summarizes our results of operations for the nine months ended September 30, 2024 and 2023 (in thousands): Â Â Â Nine Months Ended September 30, Â Â Dollar Â Â Â 2024 Â Â 2023 Â Â Change Â Collaboration revenue Â $ 1,325 Â Â $ 1,412 Â Â $ (87) Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Research and development Â Â 37,404 Â Â Â 35,763 Â Â Â 1,641 Â General and administrative Â Â 14,888 Â Â Â 14,700 Â Â Â 188 Â Impairment of property and equipment Â Â 1,883 Â Â Â 1,592 Â Â Â 291 Â Impairment of right-of-use assets Â Â 22,836 Â Â Â â€” Â Â Â 22,836 Â Restructuring and other related charges Â Â 9,254 Â Â Â â€” Â Â Â 9,254 Â Total operating expenses Â Â 86,265 Â Â Â 52,055 Â Â Â 34,210 Â Loss from operations Â Â (84,940) Â Â (50,643) Â Â (34,297) Other income: Â Â Â Â Â Â Â Â Â Interest income Â Â 2,517 Â Â Â 3,161 Â Â Â (644) Total other income Â Â 2,517 Â Â Â 3,161 Â Â Â (644) Loss before income tax expense Â Â (82,423) Â Â (47,482) Â Â (34,941) Income tax expense Â Â (33) Â Â (42) Â Â 9 Â Net loss Â $ (82,456) Â $ (47,524) Â $ (34,932) Collaboration Revenue Collaboration revenue for the nine months ended September 30, 2024 and 2023 was a result of revenue recognized under the LianBio License Agreement, which we entered into on May 31, 2021. Collaboration revenue for the nine months ended September 30, 2024 and 2023 remained relatively consistent period over period. 28 Â Research and Development Expenses Research and development expenses increased by $1.6 million from $35.8 million to $37.4 million for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. The increase in research and development expenses for the nine months ended September 30, 2024 was primarily attributable to an increase of $4.4 million in allocated and support costs for shared activities within the organization driven by headcount allocation and rent increases, which occurred prior to the reduction in force, as well as an increase of $1.2 million in professional and consulting fees. This increase was offset by a decrease of $3.0 million in clinical related costs as we completed both the BEACON trial for LYR-220 and the primary study phase for the ENLIGHTEN 1 trial for LYR-210 as well as a decrease of $1.1 million in employee related costs. General and Administrative Expenses General and administrative expenses remained relatively consistent at $14.9 million for the nine months ended September 30, 2024 compared to $14.7 million for the nine months ended September 30, 2023. Interest Income Interest income decreased by $0.6 million to $2.5 million for the nine months ended September 30, 2024 compared to $3.1 million for the nine months ended September 30, 2023. This decrease in interest income was primarily attributable to the decreased interest earned on the Companyâ€™s short-term investments due to the decrease in balance of short-term investments for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. Income Tax Expense During the nine months ended September 30, 2024 the Company incurred income tax expense of $33,000 compared to $42,000 for the nine months ended September 30, 2023 related to our Massachusetts Securities Corporation. Impairment & Restructuring and Other Related Charges The Company incurred impairment costs related to property and equipment of $1.9 million for the nine months ended September 30, 2024 compared to $1.6 million for the same period in 2023. The Company incurred impairment costs related to our right-of-use asset of $22.8 million for the nine months ended September 30, 2024 compared to no such charges for the same period in 2023. The Company incurred a restructuring charge in the amount of $9.3 million primarily related to severance and retention costs for the nine months ended September 30, 2024 compared to no such charges for the same period in 2023. Liquidity and Capital Resources Sources of Liquidity From inception through September 30, 2024, we have raised an aggregate of $424.8 million to fund our operations, of which $162.1 million were gross proceeds from sales of our redeemable convertible preferred stock, $96.3 million were net proceeds from our April 2022 financing, $46.5 million were net proceeds from our May 2023 Financing, $57.3 million were net proceeds from our initial public offering, $23.9 million were net proceeds related to our Original Sales Agreement dated September 1, 2023, $16.8 million were gross proceeds from government contracts, $17.0 million were gross proceeds from the LianBio License Agreement, and $3.8 million were gross proceeds from the exercise of common stock warrants. As of September 30, 2024, we have not sold any securities under the Form S-3. On March 22, 2024, we entered into an Amended and Restated Controlled Equity Offering Agreement with Cantor pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Companyâ€™s common stock for aggregate gross proceeds of up to $75.0 million. 29 Â The following table provides information regarding our total cash and cash equivalents and short-term investments at September 30, 2024 and December 31, 2023 (in thousands): Â Â Â As of Â Â As of Â Â September 30,2024 Â Â December 31,2023 Â Cash and cash equivalents Â $ 23,800 Â Â $ 22,353 Â Short term investments Â Â 27,826 Â Â Â 80,400 Â Â Â Â Total Â $ 51,626 Â Â $ 102,753 Â We maintain the majority of our cash and cash equivalents in accounts with major highly rated multi-national and local financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions, and any inability to access or delay in accessing these funds could adversely affect our business and financial position. Â Cash Flows The following table provides information regarding our cash flows for the nine months ended September 30, 2024 and 2023 (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (58,659) Â $ (44,246) Net cash provided by (used in) investing activities Â Â 52,174 Â Â Â (10,225) Net cash provided by financing activities Â Â 8,532 Â Â Â 46,771 Â Net increase (decrease) in cash, cash equivalents and restricted cash Â $ 2,047 Â Â $ (7,700) Â Net Cash Provided By (Used In) Operating Activities The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities was $58.7 million for the nine months ended September 30, 2024, primarily resulting from our net loss of $82.5 million, and cash provided by changes in our operating assets and liabilities of $4.1 million, partially offset by non-cash adjustments of $27.9 million. Our net loss was primarily attributed to research and development activities, our general and administrative expenses as well as restructuring charges and impairments taken on our long-lived assets. Our net non-cash charges during the nine months ended September 30, 2024 primarily consisted of a $22.8 million impairment loss on our right-of-use assets, $4.8 million of share-based compensation expense, $0.3 million of depreciation expense and $1.9 million of impairment of long-lived assets, which were partially offset by $2.0 million of net amortization of discounts on short-term investments. Net cash used in operating activities was $44.2 million for the nine months ended September 30, 2023, primarily resulting from our net loss of $47.5 million and cash used for changes in our operating assets and liabilities of $0.5 million, partially offset by non-cash adjustments of $3.8 million. Our net loss was primarily attributed to research and development activities and our general and administrative expenses. Net cash used for our operating assets and liabilities of $0.5 million during the nine months ended September 30, 2023 consisted primarily of an increase in prepaid expenses, other current assets, and other assets of $2.7 million and a decrease in deferred revenue of $1.4 million, partially offset by an increase of $3.4 million in accounts payable and accrued expenses and a $0.2 million decrease in net operating lease assets and lease liabilities. Our net non-cash charges during the nine months ended September 30, 2023 primarily consisted of $4.4 million of share-based compensation expense, $0.2 million of depreciation expense and $1.6 million of impairment of long-lived assets, which were partially offset by $2.4 million of net amortization of premiums on short-term investments. Net Cash Provided By Investing Activities Net cash provided by investing activities was $52.2 million for the nine months ended September 30, 2024 compared to $10.2 million of cash used for investing activities for the nine months ended September 30, 2023. The increase in cash provided by investing activities of $62.4 million was primarily due to the net proceeds from the maturities of short-term investments. 30 Â Net Cash Provided by Financing Activities Net cash provided by financing activities was $8.5 million for the nine months ended September 30, 2024 compared to $46.8 million for the nine months ended September 30, 2023 due to less cash raised from equity financings in 2024. Funding Requirements We expect to continue to incur expenses in connection with our ongoing activities, primarily the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210. To the extent we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. Although management has concluded that there is substantial doubt regarding our ability to continue as a going concern, this conclusion is based on our analysis under applicable accounting standards. Based on our current business plan, we anticipate that our cash, cash equivalents and short-term investment balance is sufficient to fund our operating expenses and capital expenditures into the first quarter of 2026. However, we have based this estimate on assumptions that may prove to be wrong. If, for any reason, our expenses differ materially from our assumptions or we utilize our cash more quickly than anticipated, or if we are unable to obtain funding on a timely basis we may be required to revise our business plan and strategy, which may result in us further curtailing, delaying or discontinuing one or more of our research or development programs. As a result, our business, financial condition, and results of operations could be materially adversely affected. Managementâ€™s plans to obtain resources for the Company include obtaining capital from the sale of its equity securities, entering into strategic partnership arrangements and short-term borrowings from banks, stockholders or other related parties, if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans. Our future capital requirements will depend on many factors, including: â€¢the costs of conducting current and future clinical trial of LYR-210; â€¢the costs of manufacturing and testing additional material for one or more pivotal Phase 3 clinical trials of LYR-210 as well as potential future clinical studies we might conduct; â€¢the costs of scaling up our supply chain capacity to meet commercial demand; â€¢the scope, progress, results, and costs of discovery, pre-clinical development, laboratory testing, and clinical trials for other potential product candidates we may develop, if any; â€¢the costs, timing, and outcome of regulatory review of our product candidates; â€¢our ability to establish and maintain collaborations on favorable terms, if at all; â€¢the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time; â€¢the costs and timing of future commercialization activities, including cost of goods, product sales, marketing, manufacturing, and distribution, for any of our product candidates for which we receive marketing approval; â€¢the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; â€¢the costs of preparing, filing, and prosecuting patent applications, obtaining, maintaining, and enforcing our intellectual property rights, and defending intellectual property-related claims; â€¢the costs of operating as a public company; and 31 Â â€¢the cost of potential business interruptions resulting from COVID-19. Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Further, the global economy, including credit and financial markets, has periodically experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. All of these factors could impact our liquidity and future funding requirements, including but not limited to our ability to raise additional capital when needed on acceptable terms, if at all. The duration of any economic slowdown is uncertain and the impact on our business is difficult to predict. See â€œRisk Factorsâ€ Unstable global political or economic conditions may have serious adverse consequences on our business, financial condition and share price. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. We may have access to additional funds to be earned in connection with our LianBio License Agreement, if development activities are successful under that agreement. However, the future of this collaboration is uncertain in view of LianBioâ€™s major restructuring, as discussed herein. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, that could adversely impact our ability to conduct our business. If we raise funds

through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Emerging Growth Company Status The JOBS Act permits an â€œemerging growth companyâ€ such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, or December 31, 2025, (b) in which we have total annual gross revenues of $1.235 billion or more, or (c) in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our outstanding common stock held by non-affiliates exceeds $700 million as of last business day of our most recently completed second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years. 32 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3. Item 4. Controls and Procedures. Managementâ€™s Evaluation of Disclosure Controls and Procedures Limitations on Effectiveness of Controls and Procedures In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Evaluation of Disclosure Controls and Procedures Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2024. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting identified in managementâ€™s evaluation pursuant to Rules 13a-15(f) or 15d-15(f) of the Exchange Act during the three months ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 33 Â PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition. Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information contained in this Quarterly Report on Form 10-Q before making an investment in our common stock. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. See â€œSpecial Note Regarding Forward-Looking Statements.â€ Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below. Â Risks Related to Our Exploration of Strategic Options Any potential financial or strategic option we pursue in an effort to maximize shareholder value may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all. In May 2024, in connection with the Companyâ€™s announcement that we failed to meet the primary endpoint of our ENLIGHTEN 1 Phase 3 clinical trial, we announced our interest in potential strategic alternatives. We have not yet engaged a financial adviser to assist us in this effort. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction. The process of continuing to evaluate these strategic options may be costly, time-consuming and complex and we may incur significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges. Moreover, any potential financial or strategic option we pursue may not result in the identification of a suitable transaction, or if one is identified and pursued, may not be completed on attractive terms, or at all. There can be no assurance of completion of any particular course of action or a defined timeline for completion, and we can provide no assurance that any strategic alternative we pursue will have a positive impact on our results of operations or financial condition. Â We are attempting to sublease or assign our three leaseholds, which represent significant operating costs, and there can be no assurance that we will accomplish this effort on favorable terms, or at all, which could adversely affect our business, results of operations and financial condition. The Company has three leaseholds including two in Waltham, Massachusetts and one in Watertown, Massachusetts. These leaseholds represent significant operating costs for the Company. The Company has retained a broker to sublease or assign all three of the leaseholds in connection with the Companyâ€™s capital preservation efforts. There can be no assurance that the Company will find third parties to enter into a sublease or assignment of these leaseholds at terms that are favorable to the Company, on a timetable that is advantageous to the Company, or at all. The operating lease, as amended, for office and laboratory space in Watertown expires in April 2027 and comprises approximately 27,311 square feet. The lease provides for base rent of $2.0 million per year. The Company maintains a letter of credit of approximately $300,000 securing its obligations under the Watertown operating lease. The Company has two leases for space at 880 Winter Street in Waltham. The first lease comprises approximately 29,000 square feet of office and lab space, and the lease provides for base rent of $2.2 million per year, which will increase 3% per year over the noncancellable term ending on June 30, 2033. In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $1.1 million of deposits with the financial institution. In December 2023, the Company executed a sublease agreement for additional laboratory and office space located at 880 Winter Street in Waltham. The subleased premises comprise approximately 24,000 square feet, and the sublease provides for base rent of $1.8 million per year, which will increase 3% per year over the noncancellable term ending on November 30, 2032. The Company provided the landlord with a security deposit in the form of a letter of credit in the amount of approximately $600,000. 34 Â Under all three leases, the Company is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the respective leased premises. An inability to successfully sublease or assign all three of the leaseholds will negatively impact our capital preservation efforts and could materially and adversely affect our business, financial condition and the results of operations. Â Risks Related to Our Financial Position and Need for Additional Capital Â We have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future. We may never achieve or maintain profitability. We have incurred significant operating losses in each year since our inception, including operating losses of approximately $11.9 million and $15.6 million for the three months ended September 30, 2024 and 2023 respectively. In addition, we have not commercialized any products and have never generated any revenue from product sales. We have devoted almost all of our financial resources to research and development, including our pre-clinical development activities. In May 2024, our Board approved a reduction in force by up to 87 employees, effective on or about May 21, 2024 with respect to approximately 80 employees and effective on or about June 20, 2024 with respect to approximately seven employees (the â€œMay 2024 RIFâ€). The Boardâ€™s decision was based on the need to implement cost-reduction initiatives intended to reduce the Companyâ€™s ongoing operating expenses and maximize shareholder value. The Company incurred charges of approximately $9.5 million in connection with this workforce reduction, primarily consisting of severance payments, employee benefits and related costs. Certain of these expenses have been paid to former employees as of the date of these condensed consolidated financial statements and relate to the May 2024 reduction in force. The remaining expenses are included within accrued restructuring with anticipated payout at a later date, primarily pertaining to current employees. We expect to continue to incur significant additional operating losses for the foreseeable future and we may not achieve or maintain profitability in the future. In order to obtain FDA approval of any product candidate, we must submit to the FDA an NDA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as non-clinical or pre-clinical studies, as well as human tests, which are referred to as clinical trials. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our product candidates to marketing approval in even a single jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with CRS treatment product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of products or achieve or maintain profitability. Our expenses will also increase substantially if we: â€¢continue the two pivotal Phase 3 ENLIGHTEN clinical trials of our most advanced product candidate, LYR-210; â€¢seek regulatory and marketing approvals for LYR-210 if it successfully completes clinical trials, if any; â€¢establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; â€¢maintain, expand, and protect our intellectual property portfolio; â€¢utilize external vendors for support with respect to research, development, commercialization, regulatory, pharmacovigilance, and other functions; â€¢acquire or in-license other commercial products, product candidates, and technologies; â€¢make royalty, milestone, or other payments under any future in-license agreements; â€¢implement additional internal manufacturing capabilities, systems and infrastructure; and â€¢operate as a public company. Furthermore, our ability to successfully develop, commercialize, and license our products and generate product revenue is subject to substantial additional risks and uncertainties. Each of our product candidates will require additional pre-clinical and/or clinical development, potential regulatory approval in multiple jurisdictions, the development of or securing of manufacturing supply, capacity, and expertise, the use of external vendors, the building of a manufacturing and commercial organization, substantial 35 Â investment, and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholdersâ€™ equity and working capital. The amount of future losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the foreseeable future, and might never generate revenues from the sale of products. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of the clinical development of our product candidates; obtaining necessary regulatory approvals from the FDA and international regulatory agencies; establishing cost-effective manufacturing, generating sales, and achieving market acceptance of our products and marketing infrastructure to commercialize our product candidates for which we obtain approval; and raising sufficient funds to finance our activities. We might not succeed at any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected. Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern. We continue to operate with limited resources. We have incurred significant losses since our inception and have never generated revenue or profit, and it is possible we will never generate revenue or profit. Based on our current operating plans, and without additional funding, there is substantial doubt about our ability to continue as a going concern. See Part I, Item 2. â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ of this Quarterly Report on Form 10-Q for a discussion of our expected cash runway. This cash runway estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Until such time as the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements, but there can be no assurances that such financing will be available to us on satisfactory terms, or at all. Securing additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize any of our product candidates. If we are unable to obtain funding, we would be forced to delay, reduce or eliminate our research and development programs, which would adversely affect our business prospects. In addition, if we are unable to raise capital, we will also need to implement additional cost reduction measures, and any failure to effectively do so will harm our business, results of operations and future prospects. The perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations. If we are unable to continue as a going concern, investors could lose all or part of their investment in our Company. Â We need significant additional funding in order to complete development of, manufacture, and obtain regulatory approval for our product candidates and commercialize our products, if approved. Moreover, the failure of our ENLIGHTEN 1 Phase 3 trial to meet its primary endpoint has made it more difficult for us to raise capital. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts, and/or discontinue operations. We continue to need additional capital, which we may raise through equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements or other sources. The failure to meet the primary endpoint of our ENLIGHTEN 1 Phase 3 clinical trial has made it significantly more difficult for us to raise more capital. Additional sources of financing might not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned clinical trials or obtain approval of any of our product candidates from the FDA, or any foreign regulatory authorities, and could be forced to discontinue product development or reduce our operations. We will require substantial funds to further develop, manufacture, obtain approval for, and commercialize our product candidates, including LYR-210, for which we initiated two pivotal Phase 3 clinical trials. In May 2024 we suspended further development of LYR-220. We would also require substantial additional funds to further develop, obtain approval for, and commercialize, LYR-220. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: â€¢the scope and results of our pre-clinical studies and clinical trials, including any unforeseen costs we may incur as a result of pre-clinical study or clinical trial delays due to COVID-19 or other causes; 36 Â â€¢the scope and results of our pre-clinical studies and clinical trials, including any unforeseen costs we may incur as a result of pre-clinical study or clinical trial delays; â€¢the timing of, and the costs involved in, obtaining regulatory approvals for LYR-210; â€¢the costs and timing of changes in the regulatory environment and enforcement rules; â€¢the costs and timing in changes in pharmaceutical pricing and reimbursement infrastructure; â€¢the costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other patent-related costs, including any litigation costs and the results of such litigation; â€¢the effect of competing technological and market developments; â€¢the extent to which we in-license or acquire other products and technologies; and â€¢the cost of establishing sales, marketing, manufacturing, and distribution capabilities for our product candidates in regions where we choose to commercialize our products. Depending on our business performance, the economic climate, and market conditions, we may be unable to raise additional funds through any sources. Market volatility could also adversely impact our ability to access capital as and when needed. We maintain our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and U.S. treasury bills and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. Â Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our operations and our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, redeeming our stock, making certain investments, and engaging in certain merger, consolidation, or asset sale transactions, among other restrictions. If we raise additional funds through additional collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product

candidates that we would otherwise prefer to develop and market ourselves. We have no approved products. To date, we have no approved product on the market and have generated no product revenues. Unless we receive approval from the FDA or other regulatory authorities for our product candidates, we will not have product revenues. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from cash on hand and licensing fees and grants, if any. 37 Â LYR-210 is at a development stage and we have suspended further efforts on LYR-220. We are a biotechnology company focused on the development and commercialization of novel integrated drug and drug delivery solutions for the localized treatment of patients with CRS. Our product candidates are in clinical development, and favorable results in early-stage clinical trials may not be predictive of success in later clinical trials and may not lead to commercially viable products for any of several reasons. For example, we failed to meet the primary endpoint in our ENLIGHTEN 1 Phase 3 trials for LYR-210 which has a material adverse effect on our development plans for LYR-210. In May 2024 we also suspended further development of LYR-220. LYR-210, as well as LYR-220 if in the future we decide to advance it, will require significant additional development, clinical trials, regulatory authorizations, and additional investment by us before it can be commercialized. Â Our business is highly dependent on the success of our most advanced product candidate, LYR-210, which requires on-going clinical testing before we can seek regulatory approval and potentially launch our product. If LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed. Â A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for, and successfully commercialize our most advanced product candidate, LYR-210. We currently have no products that are approved for commercial sale and have not completed the development of any product candidates, and may never be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures will be devoted to LYR-210, which will each require continued clinical development and potential additional pre-clinical development, management of clinical and medical affairs and manufacturing activities, regulatory approval in multiple jurisdictions, the securing of manufacturing supply, the building of a manufacturing and commercial organization, substantial investment, and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that LYR-210 will be successful in ongoing or future clinical trials, receive regulatory approval, or be successfully commercialized even if we receive regulatory approval. Even if we receive approval to market LYR-210 from the FDA or other regulatory bodies, we cannot be certain that our product candidates will be successfully commercialized, profitable, widely accepted in the marketplace, or more effective than other commercially available alternatives. Nor can we be certain that, if and when approved, the safety and efficacy profile of LYR-210 and will be consistent with the profiles observed in clinical trials. We advanced LYR-210 through our Phase 2 randomized, controlled, patient blinded LANTERN clinical trial, evaluating the safety and efficacy in surgically-naÃ¯ve CRS patients who have failed previous medical management. The trial was designed to enroll 99 evaluable patients with the potential to increase to up to 150 patients and was initiated in May 2019 at sites in Australia, Austria, Czech Republic, New Zealand, and Poland. In December 2019, the FDA authorized our investigational new drug application, and, prior to the COVID-19 pandemic, we planned to enroll patients in the United States. However, in light of developments relating to the COVID-19 pandemic, as described below, we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and did not enroll any patients in the United States. On December 7, 2020, we reported top-line results from our Phase 2 LANTERN clinical trial, including that LYR-210 failed to meet the primary endpoint of the trial. We believe this was primarily due to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67) patients in our Phase 2 LANTERN clinical trial, a greater magnitude of change in composite score of the seven-day average of four cardinal symptoms from baseline at week 4 and/or a smaller standard deviation associated with the change from baseline at week 4 was required in order for the trial to achieve statistical significance for the primary endpoint. On May 6, 2024, we reported top-line results from our Phase 3 ENLIGHTEN 1 clinical trial, including that LYR-210 failed to meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. The 52-week extension phase of the ENLIGHTEN 1 trial is complete and full data are expected in Q4 2024. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing and topline data is expected in the second quarter of 2025. There can be no assurance that we will achieve the primary endpoint or any other endpoints in the ENLIGHTEN 2 Phase 3 clinical trial for LYR-210. If the required regulatory approvals for LYR-210 are not obtained or are significantly delayed, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed. For example, the Company may need to revise its regulatory strategy for LYR-210 since the Company failed to meet the primary endpoint of the ENLIGHTEN 1 Phase 3 clinical trial. Further, our competitors may be developing products with similar mechanisms of action and may experience problems with their products that could identify problems that would potentially harm our business. Â 38 Â If LianBio is unable to find a third party to acquire its rights under the LianBio License Agreement, it may materially harm our business, financial condition, results of operations and prospects. LianBio announced that in October 2023 its board of directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Companyâ€™s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBioâ€™s rights under the LianBio License Agreement. If LianBio is unable to find a third party to acquire LianBioâ€™s rights under the LianBio License Agreement, it may materially harm our business, financial condition, results of operations and prospects. Managing our obligations under our license and other strategic agreements may divert management time and attention, causing delays or disruptions to our business. Â We are party to the LianBio License Agreement, as amended. The LianBio License Agreement grants an exclusive license to develop and commercialize LYR-210 in Greater China (mainland China, Hong Kong, Macau, and Taiwan), Singapore, South Korea, and Thailand, or the Territory. Furthermore, under the LianBio License Agreement, LianBio has the first right to obtain a license to develop and commercialize LYR-220. Under the LianBio License Agreement, as amended, both parties agreed to negotiate prior to December 31, 2022 a clinical supply agreement to support clinical trials to be conducted by LianBio in the territory, i.e., PRC, Hong Kong, Macau, Taiwan, Singapore, South Korea, and Thailand. Subsequently, there was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement. Payments made by LianBio to the Company that have not yet been recognized as revenue are deferred as a contract liability on the Companyâ€™s consolidated balance sheet. The Company anticipated that the payments treated as a contract liability would be recognized as revenue as the clinical supply of LYR-210 was delivered and over the remaining time it takes to conduct the applicable trials. As of September 30, 2024, the parties still have not completed their negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule. We also may in the future enter into license and strategic agreements, which, subject us to various obligations, including diligence obligations, reporting and notification obligations, payment obligations for achievement of certain milestone as well as other material obligations. We may need to devote substantial time and attention to ensuring that we successfully integrate these transactions into our existing operations and are compliant with our obligations under these agreements, which may divert managementâ€™s time and attention away from our research and development programs or other day-to-day activities. Our license and strategic agreements are also complex and certain provisions in those agreements may be susceptible to multiple interpretations. In the event of any disagreement about the interpretation of these provisions, our management may need to devote a disproportionate amount of its attention to resolving these disagreements. Such disruptions may cause delays in our research and development programs and other business objectives. Our operating activities may be restricted by certain covenants in our license and strategic agreements, which could limit our development and commercial opportunities. In connection with our license and strategic agreements, we may agree to and be bound by negative covenants which may limit our development and commercial opportunities. For example, pursuant to the LianBio License Agreement, we made certain covenants to not commercialize a competing product anywhere in the Territory, nor collaborate with, enable, or otherwise authorize, license, or grant any right to any third party to commercialize a competing product anywhere in the Territory, subject to certain carve-outs. We also made certain covenants to grant an exclusive option to LianBio for the development and commercialization of LYR-220 in the Territory. These provisions may inhibit our development efforts, prevent us from forming strategic collaborations to develop and potentially commercialize any other product candidates and may materially harm our business, financial condition, results of operations and prospects. 39 Â Failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions. In order to market and sell our products in jurisdictions outside of the United States, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Additionally, we may be dependent on third-party collaborators to develop and commercialize our product candidates in certain international jurisdictions, such as in the case of our exclusive license agreement with LianBio for the development and commercialization of LYR-210 in the Territory. In the agreement with LianBio, while we have agreed that we must use commercially reasonable efforts to complete a global Phase 3 clinical trial for LR-210 and seek regulatory approval in the United States, LianBio must also use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize LYR-210 in the Territory. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in other jurisdictions. We and our third-party collaborators may not be able to file for marketing approvals, and even if we do, we may not obtain necessary approvals to commercialize our medicines in any market. We are party to a collaboration agreement, and may enter into other collaborations, that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential. Â Our drug development programs and the potential commercialization of our drug candidates will require substantial additional cash to fund expenses. For some of our drug candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those drug candidates in selected geographic territories or for selected patient populations. For example, we are party to the LianBio License Agreement to develop and commercialize LYR-210 in the Territory. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration or successfully maintain a collaboration will depend, among other things, upon our assessment of the collaboratorâ€™s resources and expertise, the terms and conditions of the proposed or existing collaboration and the proposed or existing collaboratorâ€™s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing therapies, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our drug candidate. The terms of any existing or additional collaborations or other arrangements that we may establish may not be favorable to us. We may in the future expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. 40 Â Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval Clinical trials required for our lead product candidate and any future product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired. We initiated the pivotal Phase 3 clinical trials for our most advanced product candidate, LYR-210. In May 2024 we suspended further clinical development on our other product candidate, LYR-220, in view of our failure to meet our primary endpoint in the ENLIGHTEN 1 Phase 3 clinical trial for LYR-210 and the need to preserve capital. It is impossible to predict if LYR-210 will prove effective and safe in humans or if we will receive regulatory approval, and the risk of failure through the development process is high. Given the similarities in the design of the ENLIGHTEN 1 and ENLIGHTEN 2 Phase 3 clinical trials, the risk that we fail to meet the primary endpoint in the ENLIGHTEN 2 Phase 3 clinical trial has increased since we failed to meet our primary endpoint in the ENLIGHTEN 1 Phase 3 clinical trial. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we may need to complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical development is a long, expensive, and uncertain process that is subject to significant delays. Due to known or unknown circumstances beyond our control, it may take us several years to complete our testing, and failure can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. We cannot assure you that any clinical trial that we are conducting, or may conduct in the future, will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analysis, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Delays associated with products for which we are directly conducting pre-clinical studies or clinical trials may cause us to incur additional operating expenses. The commencement and rate of completion of pre-clinical studies or clinical trials may be delayed by, or terminated because of, many factors, including: â€¢the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our pre-clinical studies or clinical trials; â€¢failure to obtain regulatory approval to commence a trial; â€¢failure to reach, or delays in reaching, an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; â€¢slower than expected rates of recruitment of patients or failure to recruit a sufficient number of patients; â€¢modification of pre-clinical studies or clinical trial protocols; â€¢changes in regulatory requirements for pre-clinical studies or clinical trials; â€¢the impact of unusual placebo effects; â€¢the lack of effectiveness during pre-clinical studies or clinical trials; â€¢the emergence of unforeseen safety issues or undesirable side effects; â€¢failure to obtain institutional review board, or the IRB, approval at each site; â€¢delays, suspension, or termination of clinical trials by the IRB responsible for overseeing the trial at a particular trial site; â€¢failure of patients in completing a trial or returning for post-treatment follow-up; 41 Â â€¢clinical sites deviating from trial protocol, dropping out of a trial, or failing to comply with regulatory requirements; â€¢failure to address patient safety concerns that arise during the course of a trial; â€¢failure to manufacture sufficient quantities of product candidate for use in clinical trials; â€¢government, IRB, or other regulatory delays or â€œclinical holdsâ€ requiring suspension or termination of the trials; and â€¢business interruptions resulting from pandemics. â€¢We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: â–ªwe may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; â–ªclinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or

regulators may require us, to conduct additional clinical trials or abandon development programs; â–ªthe number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; â–ªwe may be unable to enroll a sufficient number of patients in our clinical trials to ensure adequate statistical power to detect any statistically significant treatment effects; â–ªour third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; â–ªregulators, IRBs, or independent ethics committees, or IECs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or may require that we or our investigators suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks; â–ªwe may experience delays in reaching or fail to reach agreement on acceptable pre-clinical study or clinical trial contracts or pre-clinical study or clinical trial protocols with prospective trial sites; â–ªthe cost of pre-clinical studies or clinical trials of our product candidates may be greater than we anticipate and we may not have funds to cover the costs; â–ªthe supply or quality of our product candidates or other materials necessary to conduct pre-clinical studies or clinical trials of our product candidates, or commercialize our products, may be insufficient or inadequate; â–ªregulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; â–ªrecruitment for our clinical trials may be adversely affected by recruiting for competing trials or the approval of products competitive with our product candidates; and â–ªany current or future collaborators that conduct pre-clinical studies or clinical trials may face any of the above issues, and may conduct pre-clinical studies or clinical trials in ways they view as advantageous to them but that are suboptimal for us. Â If we are required to extend the duration of current pre-clinical studies or clinical trials or to conduct additional pre-clinical studies or clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete pre-clinical studies or clinical trials of our product candidates or other testing, if the results of these trials, studies, or tests are not positive or are only modestly positive, if there are safety concerns, or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may: â€¢incur unplanned costs; 42 Â â€¢be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; â€¢obtain marketing approval in some countries and not in others; â€¢obtain marketing approval for indications or patient populations that are not as broad as intended or desired; â€¢obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; â€¢be subject to additional post-marketing testing requirements; or â€¢have the product removed from the market after obtaining marketing approval. We could encounter delays if a clinical trial is materially modified, suspended, or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial, or by the FDA or other regulatory authorities. Such authorities may impose a material modification, suspension, or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects for our product candidates, or other products or product candidates in the same drug class, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. Furthermore, we may rely on CROs and clinical trial sites to ensure the proper and timely conduct of clinical trials and while we would have agreements governing their committed activities, we would have limited influence over their actual performance, as described in â€œâ€”Risks Related to Our Dependence on Third Parties.â€ Our most advanced product candidate, LYR-210, is in clinical development and will require the completion of clinical testing before we are prepared to submit an NDA for regulatory approval. We cannot predict if or when we might complete the development of LYR-210 and submit an NDA or whether any such NDA will be approved by the FDA. We may also seek feedback from the FDA or other regulatory authorities on our clinical development programs, and the FDA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. If the results of ongoing and future clinical trials for LYR-210 are positive, we plan to submit an NDA in the United States. However, no assurance can be given that we will be successful in the near term, obtain regulatory approval, or have any commercial sales of LYR-210. Any clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted in different ways by different reviewers and regulators, which could delay, limit, or prevent regulatory approval. Drug-related adverse events during a pre-clinical study or clinical trial could cause us to repeat a trial or study, perform an additional trial or study, expand the size and/or duration of a trial or study, terminate a trial or study, or even cancel a pre-clinical or clinical program. The failure of pre-clinical studies or clinical trials to demonstrate safety and effectiveness for the desired indications could harm the development of that product candidate and other product candidates. This failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical trials would delay the filing of our NDAs with the FDA and, ultimately, our ability to commercialize our product candidates and generate product revenues. A number of companies in the biotechnology and pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Even if our future and ongoing pre-clinical studies and clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of LYR-210, and/or any future product candidate. If we experience delays in the commencement or completion of, or have to extend or expand, our pre-clinical studies or clinical trials, or if we terminate a pre-clinical study or clinical trial prior to completion, the commercial prospects of LYR-210, or any future product candidate could be harmed, and our ability to generate revenues from LYR-210, or any future product candidate may be delayed. In addition, any delays in our pre-clinical studies or clinical trials could increase our costs, slow down the development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of pre-clinical studies or clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We are no longer engaged in manufacturing our product candidates. We previously transitioned most of our clinical manufacturing from a contract manufacturing organization, or CMO, to an in-house manufacturing facility at our Watertown headquarters to produce LYR-210 and LYR-220. We never previously completed a 43 Â technical transfer process to an in-house facility, built, owned or operated a commercial manufacturing facility, and there is no guarantee that we will be successful doing so. Since the May 2024 RIF, we are no longer engaged in the manufacture of our product candidates and we no longer intend to build out a commercial manufacturing capability. We believe we have sufficient supply of LYR-210 to complete our ENLIGHTEN 1 and ENLIGHTEN 2 Phase 3 clinical trial. We are also engaged in an effort to sublease or assign our three leaseholds which include manufacturing space. Throughout Item 1A, we refer to manufacturers, CMOs and suppliers interchangeably. Parts of our manufacturing process are still outsourced and we expect them to remain outsourced. Our CMOs provide multiple different types of services to us. For example, some CMOs provide raw materials for our in-house manufacturing effort; some CMOs perform analytical testing for our starting materials, intermediates, drug product, and stability studies; and some CMOs provide services like sterilizing, packaging, and labeling. Currently, our manufacturing activities are suspended and that suspension applies to third party CMOs that provide materials and services related to our manufacturing. If we restart our in-house manufacturing, it is common that various aspects of the development program, such as manufacturing methods and equipment, are altered along the way in an effort to optimize cost of goods, processes and results. Such changes carry the risk that these manufacturing efforts will not achieve these successfully or in a cost-efficient manner, or that we will be subject to additional requirements by the FDA or other regulatory bodies. Slight deviations resulting from technology transfer, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. Problems with our in-house manufacturing process could restrict our ability to meet our clinical and regulatory timelines, and market demand for our products. As a result of the May 2024 RIF, we no longer have a sufficient number of experienced scientific, quality and manufacturing personnel needed to operate our clinical and commercial manufacturing processes, which in the event we restart our manufacturing efforts, could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or facilities, or that of our CMOs, licensees and suppliers, could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional capital or capabilities. Our pre-clinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates and the development of our product candidates may be delayed or unsuccessful, which could prevent or delay regulatory approval and commercialization. Currently LYR-210 is our only product candidate still in clinical development. Notwithstanding the data obtained to date with respect to LYR-210 and LYR-220 in CRS, LYR-210 will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate any revenue from our product sales. In addition, if we encounter safety or efficacy problems, developmental delays or regulatory issues, delays caused by COVID-19, or other problems, our developmental plans and business could be significantly harmed. If the development of LYR-210, or any other future product candidate is unsuccessful, our ability to generate revenues will be significantly and adversely affected. Our development of current and future product candidates is subject to the risks of failure and delay inherent in the development of new products and product candidates, including: â€¢delays in product development, pre-clinical, or clinical testing or manufacturing; â€¢unplanned expenditures in product development, pre-clinical, or clinical testing or manufacturing; â€¢failure to receive regulatory approvals; â€¢failure to secure rights from third parties for new technology; â€¢failure to achieve market acceptance; and â€¢emergence of superior or equivalent products. 44 Â In addition, product candidates in later stages of clinical trials may fail to show the desired safety profiles and efficacy results despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory approval. Additionally, we have not conducted, nor do we believe we are required to conduct, any head-to-head trials comparing LYR-210 to other approved or experimental treatments for CRS. Any such head-to-head trial, if conducted, may show that LYR-210 is not more effective than any of such other drugs. Material adverse differences in the relative efficacy of LYR-210 could significantly harm the adoption of LYR-210 and our business prospects. Because of these risks, our research and development efforts may not result in any commercially viable products. If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed. Success in pre-clinical or earlier clinical trials may not be indicative of results in future clinical trials. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Pre-clinical studies and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, study pharmacokinetics and pharmacodynamics, and understand the side effects of product candidates at various doses and schedules. Success in pre-clinical studies and early clinical trials does not ensure that later, large-scale efficacy trials will be successful nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced, or later. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical studies and earlier-stage clinical trials. Data obtained from pre-clinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations, and prospects. If the FDA does not conclude that LYR-210 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for LYR-210 under Section 505(b)(2) are not as we expect, the approval pathway for LYR-210 may take significantly longer, cost significantly more, and entail significantly greater complications and risks than anticipated, and in either case may not be successful. We intend to seek FDA approval for LYR-210 through the Section 505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act, or FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDAâ€™s prior conclusions regarding the safety and effectiveness of approved drugs, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as we anticipate, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates, and complications and risks associated with the development of our product candidates, would likely substantially increase. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in competitive products reaching the market before our product candidates, which could impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization, or that a competitor would not obtain approval first along with subsequent market exclusivity from the FDA, thereby delaying potential approval of our product. 45 Â In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. Moreover, even if our product candidates are approved under Section 505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. Â We have conducted, are conducting, and, in the future, may conduct clinical trials for our product candidates in sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations. We have conducted and are conducting clinical trials for LYR-210 outside the United States, primarily in Europe, and we may in the future choose to conduct other clinical trials outside the United States for LYR-210, or any of our other future product candidates. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP, including review and approval by an IEC and receipt of informed consent from subjects. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for which we intend to seek approval for the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates. In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the United States, such as: â€¢regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials; â€¢foreign exchange fluctuations; â€¢manufacturing, customs, shipment, and storage requirements; â€¢cultural differences in

medical practice and clinical research; and â€¢the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought. Â Interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we may publish interim or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between interim or preliminary data and final data could significantly harm our business prospects. 46 Â Â LYR-210 will be regulated as a drug-device combination products, which may result in additional regulatory and other risks. LYR-210 is a drug-device combination products. We may experience delays in obtaining regulatory approval of LYR-210 given the increased complexity of the review process when approval of a combination product is sought under a single marketing application. LYR-210 will be regulated as drug-device combination products, which require coordination within the FDA and similar foreign regulatory agencies for review of the product candidatesâ€™ device and drug components. The determination whether a combination product requires a single marketing application or two separate marketing applications for each component is made by the FDA on a case-by-case basis. Although we believe a single marketing application for the approval of a combination product would be successful, there can be no assurance that the FDA will not determine that separate marketing applications are necessary. This determination could significantly increase the resources and time required to bring a particular combination product to market. Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process, as well as coordination between two different centers within FDA responsible for review of the different components of the combination product. Failure to successfully develop or supply the device component, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or third-party providers to obtain or maintain regulatory approval or clearance of the device component of LYR-210, as appropriate, could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in these product candidates reaching the market. Further, failure to successfully develop or supply the device, or to gain or maintain its approval, could adversely affect sales of LYR-210. Â If we fail to obtain the necessary U.S. regulatory approvals to commercialize any product candidate, we will not be able to generate revenue in the U.S. market. We cannot assure you that we will receive the approvals necessary to commercialize our product candidates, or any product candidate we acquire or develop in the future. We will need FDA approval to commercialize our product candidates in the United States and approvals from equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. Satisfaction of the FDAâ€™s regulatory requirements typically takes many years, depends upon the type, complexity, and novelty of the product candidate, and requires substantial resources for research, development, and testing. We cannot predict whether our research and clinical efforts will result in drugs that the FDA will determine are safe for humans and effective for their intended uses. The FDA has substantial discretion in the drug approval process and may require us to conduct additional pre-clinical and clinical testing, perform post-marketing studies, address manufacturing concerns, or otherwise limit or impose conditions on any approval we obtain. The approval process may also be delayed by changes in government regulation, the impact of COVID-19, future legislation or administrative action, or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may: â€¢delay commercialization of, and our ability to derive product revenues from, our product candidates; â€¢impose costly procedures on us; and â€¢diminish any competitive advantages that we may otherwise enjoy. Even if we receive approval of an NDA or comparable foreign regulatory filing for our product candidates, the FDA or the applicable foreign regulatory body may approve our product candidates for a more limited indication than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs. We cannot be sure that we will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of our product candidates will severely undermine our business by leaving us without a commercially available product, and therefore without any source of revenues, until another product candidate can be developed or obtained and ultimately approved. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will be able to obtain FDA approval to commercialize such product candidate. 47 Â Even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential. We intend, either on our own or through collaborations or partnerships, to market our products in international markets. In order to market any products in the European Union and many other foreign jurisdictions, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional pre-clinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, costly, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We cannot predict when or if, and in which territories, we, or any of our potential future collaborators, will obtain marketing approval to commercialize a product candidate. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidateâ€™s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that neither LYR-210, nor any future product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses in patients. Results from non-clinical studies and clinical trials can be interpreted in different ways. Even if we believe the non-clinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional pre-clinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available. Of the large number of potential products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy and costly approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects. Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. 48 Â Separately, in response to the COVID-19 pandemic the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts any resurgence of the virus or emergence of new variants may lead to further inspectional delays. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to future COVID-19 related concerns, including providing guidance regarding the conduct of clinical trials. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development activities and receipt of regulatory approvals could be delayed or otherwise adversely affected. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. For example, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data due to the COVID-19 pandemic, and, as a result, we initiated a separate characterization study in September 2020 as a follow-on to our Phase 2 LANTERN clinical trial in order to collect such data. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. We cannot predict how successful we will be at enrolling subjects in future clinical trials. The enrollment of patients depends on many factors, including: â€¢the patient eligibility criteria defined in the protocol; â€¢the size of the patient population required for analysis of the trialâ€™s primary endpoints; â€¢the proximity of patients to trial sites; â€¢the design of the trial; â€¢our ability to recruit clinical trial investigators with the appropriate competencies and experience; â€¢cliniciansâ€™ and patientsâ€™ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; â€¢the perceived risks and benefits of the product candidate in the trial; â€¢the availability of alternative therapies; â€¢our ability to obtain and maintain patient consents; â€¢the risk that patients enrolled in clinical trials will drop out of the trials before completion; and â€¢the impact of geopolitical events or other events such as the evolving COVID-19 pandemic. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays, or both, which could have a harmful effect on our ability to develop LYR-210 and/or any other future product candidates, or could render further development impossible. 49 Â Our product candidates may cause serious adverse events or undesirable side effects including injury and death or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval. If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any potential future collaborators, to market the drug could be compromised. Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive pre-clinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication, and failures can occur at any stage of testing. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the target indication. Serious adverse events, or SAEs, or undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our clinical trials or pre-clinical studies could reveal a high and unacceptable severity and prevalence of side effects, toxicities, or unexpected characteristics, including death. For example, in our Phase 1 clinical trial for our most advanced product candidate, LYR-210, there was one SAE in the active group (acute myocardial infarction), which was considered not related to LYR-210. In addition, subjects treated with LYR-210 have experienced adverse events, including epistaxis, rhinitis, rhinorrhea, facial pain, nasopharyngitis, sinusitis, upper respiratory tract infection, procedural headache, nasal discomfort, and nasal odor, among others. In our Phase 2 LANTERN clinical trial, treatment-related adverse events were reported in 16 patients, and all treatment-related adverse events except one (increased viscosity of upper respiratory secretion) were mild or moderate in nature. In addition, there was one patient in the LYR-210 (2,500 Âµg) group who had a serious adverse event of acarodermatitis in our Phase 2 LANTERN clinical trial, which was deemed to be not related to treatment. In the 24-week treatment phase of the Phase 3 ENLIGHTEN 1 clinical trial, the most commonly reported adverse events in the study population were epistaxis, nasal odor, upper respiratory tract infection and sinusitis. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, could materially modify, suspend, or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease pre-clinical studies or clinical trials, require us to conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated, or deny approval of our product candidates for any or all targeted indications. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We have historically trained and may in the future have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly. If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including: â€¢regulatory authorities may withdraw approvals of such product; â€¢we may be required to recall a product or change the way such product is administered to patients; â€¢additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product; â€¢regulatory authorities may require additional warnings on the label, such as a â€œblack boxâ€ warning or contraindication; â€¢regulatory authorities may require long-term patient registries for the product; â€¢we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients; â€¢the product could become less competitive; 50 Â â€¢we could be sued and held liable for harm caused to patients; and â€¢our reputation may suffer. There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or at all. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if

approved, and could significantly harm our business, results of operations, and prospects. Â Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization, could include intentional, reckless, or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, the European Medicines Agency, or the EMA, and other similar regulatory authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; (ii) manufacturing standards; or (iii) data privacy, security, fraud and abuse, and other healthcare laws and regulations. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of pre-clinical studies or clinical trials, creation of fraudulent data in pre-clinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. Â Our business and operations would suffer in the event of system failures. Our computer systems, as well as those of our CROs and other contractors, vendors, suppliers, and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including the impacts of climate change), international terrorism and conflicts, and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs and our business. For example, the loss of pre-clinical studies or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential, or proprietary information, we could incur liability and the further development of LYR-210, or any other product candidate could be delayed. In the ordinary course of our business, we directly or indirectly collect and store sensitive data, including intellectual property, confidential information, pre-clinical and clinical trial data, proprietary business information, personal data, and personally identifiable health information of our clinical trial subjects and employees, in our data centers and on our networks, or on those of third parties. The secure processing, maintenance, and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure has been and, from time to time, may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance, or other disruptions. For example, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with COVID-19. Although, to our knowledge, we have not experienced any material security breach, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings (including class actions), liability under laws that protect the 51 Â privacy of personal information, or significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our business reputation and delay our clinical development of our product candidates. Risks Related to Healthcare Laws and Other Legal Compliance Matters We will be subject to extensive and costly government regulation. Product candidates employing our technology will be subject to extensive and rigorous domestic government regulation including regulation by the FDA, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the United States Department of Health and Human Services, the United States Department of Justice, state and local governments, and their respective equivalents outside of the United States. The FDA regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record-keeping, reporting, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products. If products employing our technologies are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not they have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding United States regulation. Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. The regulatory review and approval process, which includes pre-clinical testing and clinical trials of each product candidate, is lengthy, expensive, and uncertain. We or our collaborators must obtain and maintain regulatory authorization to conduct pre-clinical studies and clinical trials. We or our collaborators must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the productâ€™s safety and efficacy, potency, and purity, for each intended use. The development and approval process takes many years, requires substantial resources, and may never lead to the approval of a product. Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue. If we, our collaborators, consultants, contract manufacturers, CROs, or other vendors fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things, delays in the approval of applications or supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications; warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other regulatory authorities against governmental contracts; and/or criminal prosecutions. Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and could adversely affect our business. In the United States, the EU, and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could prevent or delay marketing approval of our products in development, restrict or regulate post-approval activities involving any product candidates for which we obtain marketing approval, impact pricing and reimbursement, and impact our ability to sell any such products profitably. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. In addition, new regulations are frequently adopted and interpretations of existing healthcare statutes may change over time. For instance, in August 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. The IRA includes several provisions that may impact our business to varying degrees, including provisions that establish a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on many drugs reimbursed under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, and require companies to pay rebates to Medicare for drug prices that increase faster than inflation. The IRA permits the Secretary of the Department of Health and Human Services (â€œHHSâ€) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs 52 Â are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated. In addition, in response to the Biden administrationâ€™s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare and Medicaid Services (â€œCMSâ€) Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: â€¢an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; â€¢a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturerâ€™s outpatient drugs to be covered under Medicare Part D; â€¢new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting â€œtransfers of valueâ€ made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; â€¢an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; â€¢a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; â€¢extension of a manufacturerâ€™s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; â€¢expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturerâ€™s Medicaid rebate liability; â€¢a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and â€¢establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. On March 2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the constitutionality of the ACA, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal, or replace the ACA will impact the law and may impact our business or financial condition. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations. 53 Â Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. While any proposed measures will require authorization through additional legislation to become effective, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. In the EU, similar political, economic, and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In addition, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDAâ€™s regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDAâ€™s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU, or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA, the EMA, and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and

documents, requirements regarding the distribution of samples to physicians, and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. In addition, the sponsor of an approved NDA is subject to periodic inspections and other FDA monitoring and reporting 54 Â obligations, including obligations to monitor and report adverse events and other information such as the failure of a product to meet the specifications in the NDA. NDA sponsors must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. The FDA may require changes in the labeling of already approved drug products and require that sponsors conduct post-marketing studies. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a medication guide, physician communication plans, or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk mitigation tools. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales of the product. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. In addition, advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturersâ€™ communications regarding off-label use, and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDAâ€™s restrictions relating to the promotion of prescription products may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. The distribution of product samples to physicians must comply with the requirements of the FDCA. NDA sponsors must obtain FDA approval for product, manufacturing, and labeling changes, depending on the nature of the change. Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, consent decrees of permanent injunction, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts, including government contracts. In addition, later discovery of previously unknown adverse events or other problems with our products, or manufacturing processes, including adverse events of unanticipated severity or frequency, or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: â€¢restrictions on manufacturing such products; â€¢restrictions on the labeling or marketing of a product; â€¢restrictions on product distribution or use; â€¢requirements to conduct post-marketing studies or clinical trials; â€¢warning letters or holds on clinical trials; â€¢withdrawal of the products from the market; â€¢refusal to approve pending applications or supplements to approved applications that we submit; â€¢recall of products; â€¢fines, restitution, or disgorgement of profits or revenues; â€¢suspension or withdrawal of marketing approvals; â€¢refusal to permit the import or export of our products; â€¢product seizure or detention; or â€¢injunctions or the imposition of civil or criminal penalties. 55 Â Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues. If regulatory sanctions are applied or if regulatory approval is withheld or withdrawn, the value of our Company and our operating results will be adversely affected. The FDAâ€™s policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of LYR-210 and/or any other future product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects, and ability to achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Further, three decisions from the U.S. Supreme Court in July 2024 may lead to an increase in litigation against regulatory agencies that could create uncertainty and thus negatively impact our business. The first decision overturned established precedent that required courts to defer to regulatory agenciesâ€™ interpretations of ambiguous statutory language. The second decision overturned regulatory agenciesâ€™ ability to impose civil penalties in administrative proceedings. The third decision extended the statute of limitations within which entities may challenge agency actions. These cases may result in increased litigation by industry against regulatory agencies and impact how such agencies choose to pursue enforcement and compliance actions. However, the specific, lasting effects of these decisions, which may vary within different judicial districts and circuits, is unknown. We also cannot predict the extent to which FDA and SEC regulations, policies, and decisions may become subject to increasing legal challenges, delays, and changes. Â Â Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed, approved, or commercialized in a timely manner, or at all, which could negatively impact our business. The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the government agencyâ€™s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include: â€¢the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as 56 Â Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; â€¢the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; â€¢the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiaryâ€™s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; â€¢the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; â€¢the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; â€¢the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Childrenâ€™s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Such obligations include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives; â€¢federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; â€¢analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and â€¢similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant 57 Â penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Our business, financial condition, and results of operations may suffer in the event of information technology system failures, cyberattacks, data security incidents or deficiencies in our cybersecurity. We rely on our information technology systems and those of our third-party service providers for both internal and external operations that are critical to our business. We face numerous and evolving cybersecurity risks that threaten the confidentiality, integrity and availability of our information technology systems and data we and our third-party providers maintain, including personal information, clinical trial data, and confidential and proprietary intellectual property, financial information, trade secrets, and other business information. Our information technology systems and data, and those of our third-party service providers, contractors and consultants are vulnerable to attack, interruption and damage from computer viruses and malware (e.g. ransomware), bugs, misconfigurations, malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Attacks upon information technology systems and data are increasing in their frequency, levels of persistence, sophistication and intensity - including attacks conducted using artificial intelligence - and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems and data change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security incidents that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. There can also be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with, or effective in protecting our information technology systems and data. While we do not believe that we have experienced any material system failure or incident, from time to time, we and our third party providers have been the target of cybersecurity attacks, and we expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and number. While we do not believe that any incidents have had a material impact on our operations or financial results to date, we cannot guarantee that material incidents will not occur in the future. If such an incident were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We could also incur liabilities and the further development of our product candidates could be delayed. Further, any adverse impact to the availability, integrity or confidentiality of our information technology systems or data could expose us to legal claims or proceedings (including class actions), enforcement actions and investigations by regulatory authorities, and potentially result in penalties, fines and significant legal liability. We could also experience negative reputational impacts that cause an erosion of trust, and/or significant incident response, system restoration or remediation and future compliance costs. Any or all of the foregoing could materially adversely affect our business, results of operations, and financial condition. Finally, cyber insurance we maintain may not be sufficient to cover the financial, legal, business or reputational losses that may result from an incident, and we cannot guarantee that applicable insurance will be available to us in the future on economically reasonable terms or at all. We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection, and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business. We, and third parties on our behalf, receive, store, handle, transmit, use and otherwise process business information and information related to individuals, including from and about trial patients as well as our employees, business contacts, and service providers. We and our partners are subject to diverse state, federal, and international laws and regulations relating to data privacy and security, including, in the United States, the California Consumer Privacy Act, or the CCPA, and, in the EU and the European Economic Area, or EEA, the General Data Protection Regulation, or the GDPR. New privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened, creating an ever evolving patchwork of privacy laws. For 58 Â example, the CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches. Complying with these numerous, complex, and often changing laws and regulations is expensive and difficult, and failure or perceived failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss, or other unauthorized use or disclosure of personal information, whether by us or another third-party, could adversely affect our business, financial condition, and results of operations, including but not limited to:

damage to our reputation, an erosion of trust, and negative media attention; investigation costs; material fines and penalties; compensatory, special, punitive, and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services, and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; and injunctive relief. In Europe, the GDPR requires us, among other things, to make detailed disclosures to data subjects, to disclose the legal basis on which we can process personal data, to obtain valid consent for processing, to appoint data protection officers when sensitive personal data, such as health data, is processed on a large scale, and provides robust rights for data subjects, introduces mandatory data breach notification, imposes additional obligations on us when contracting with service providers, and requires us to adopt appropriate privacy governance including policies, procedures, training, and data audit. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having â€œadequateâ€ data protection laws, which could increase our costs and our ability to efficiently process personal data from the EEA. If we do not comply with our obligations under the GDPR, we could be exposed to fines of up to the greater of â‚¬20.0 million or up to 4% of our total global annual revenue in the event of a significant breach. In addition, we may be the subject of litigation and/or adverse publicity, which could adversely affect our business, results of operations, and financial condition. Additionally, following the United Kingdomâ€™s withdrawal from the EEA and the EU, companies have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of Â£17.5 million or 4% of global turnover. We cannot assure you that our third-party service providers with access to our or our customersâ€™, suppliersâ€™, trial patientsâ€™, and employeesâ€™ personal information and other sensitive or confidential information will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations, and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage, and transmission of such information. Â We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act. We are not currently classified as a covered entity or business associate under HIPAA. However, any person may be prosecuted under HIPAAâ€™s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAAâ€™s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Our clinical trial programs outside the United States may implicate international data protection laws, including the GDPR and legislation of the EU and EEA member states implementing it. Our activities outside the United States impose additional compliance requirements and generate additional risks of enforcement for noncompliance. Failure by our CROs and other third-party contractors to comply with the strict rules on the transfer of personal data outside of the European Union into the United States may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws, and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individualsâ€™ health information. The GDPR provides that EU and EEA member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric, or health data, which could limit our ability to use and share personal data or could cause our costs to increase. Moreover, patients about whom we or our collaborators obtain health information, as well as the providers who share this 59 Â information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individualsâ€™ privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. If we, our CROs, or other contractors or consultants fail to comply with applicable federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractorsâ€™ ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing, and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security, or reputational damage. Â We are subject to environmental, health, and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. Our operations, including our development, testing, and manufacturing activities, are subject to numerous environmental, health, and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures, and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Moreover, certain environmental laws may impose liability without regard to fault or legality of the action at the time of its occurrence. Environmental, health, and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our development efforts may be interrupted or delayed. Â We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our product candidates or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our policies and other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image, and goodwill, regardless of the truthfulness of such posts. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our common stock. Â Risks Related to Commercialization Developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets. Our industry has been characterized by extensive research and development efforts, rapid developments in technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical, biotechnology, and specialty pharmaceutical companies either marketing or developing therapeutics to treat CRS. Academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors may have or may develop superior technologies or approaches, which may provide them with competitive advantages. Our potential products may not compete successfully. If these competitors access the marketplace before we do with better or less expensive therapeutics, our product candidates, if approved for commercialization, may not be profitable to sell or worthwhile to continue to develop. Technology in the pharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any compounds, products, or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development. The success of our product candidates will depend upon factors such as product efficacy, safety, reliability, availability, timing, scope of regulatory approval, 60 Â acceptance, and price, among other things. Other important factors to our success include speed in developing product candidates, completing clinical development and laboratory testing, obtaining regulatory approvals, and manufacturing and selling commercial quantities of potential products. Our product candidates are intended to compete directly or indirectly with existing products and treatments. Even if approved and commercialized, our product candidates may fail to achieve market acceptance with hospitals, physicians, or patients. Hospitals, physicians, or patients may conclude that our potential products are less safe or effective or otherwise less attractive than these existing treatments. If our product candidates do not receive market acceptance for any reason, our revenue potential would be diminished, which would materially adversely affect our ability to become profitable. In addition, physicians may prefer to treat patients with CRS by performing ethmoid sinus surgeries which may reduce demand for our product candidates, once approved. There are a number of companies developing or marketing therapies for the treatment and management of CRS that may compete with our current product candidates, including many major pharmaceutical and biotechnology companies. These companies include, among others: Sanofi, GlaxoSmithKline, Regeneron, Optinose, Medtronic, Genentech and Novartis. Most of our competitors, including many of those listed above, have substantially greater capital resources, robust product candidate pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. As a result, our competitors may achieve product commercialization or patent protection earlier than we can. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or noncompetitive. The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers, and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Similarly, our product candidates are physician-administered treatments and as such, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. To the extent separate coverage and reimbursement should become available for LYR-210, we anticipate that it will be sold to physicians on a â€œbuy and billâ€ basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. We do not know if, or at what level, physicians may receive reimbursement for treating patients with CRS with our product candidates, or for performing the procedure to insert our product candidates, or if such reimbursement will be deemed adequate by such physicians. 61 Â Further, the status of reimbursement codes for any of our product candidates, if approved, could also affect reimbursement. J-Codes are reimbursement codes maintained by the Centers for Medicare and Medicaid Services, or CMS, that are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We currently do not have a specific J-Code for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a J-Code will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific J-Code is not available, physicians would need to use a non-specific miscellaneous J-Code to bill third-party payors for these physician-administered drugs. Because miscellaneous J-Codes may be used for a wide variety of products, health plans may have more difficulty determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can delay claims processing times as well as increase the likelihood for claim denials and claim errors. We cannot be sure that coverage and reimbursement in the United States, the EU, or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs and biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates. There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in the EU and other jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in

markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits. Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly 62 Â prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Our clinical studies were designed to demonstrate the safety and efficacy of LYR-210 based on FDA requirements and may not be seen as compelling to physicians or patients. Our success depends on the medical communityâ€™s acceptance of LYR-210, if approved, as a treatment for CRS patients. LYR-210 was previously studied in an open-label, Phase 1 clinical trial with 20 patients in New Zealand and Australia, which achieved its primary endpoint of safety at week 4. In the Phase 1 trial, we also observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores. Significant reduction in SNOT-22 scores was observed at week 1, and this reduction persisted through week 25, which was the end of the trial. In our Phase 2 LANTERN clinical trial, we reported positive top-line results but failed to achieve the primary endpoint. Although not statistically significant at week 4 (the primary endpoint), at the 7,500 Âµg dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at weeks 16, 20, and 24. Furthermore, at the 7,500 Âµg dose, LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm at weeks 8, 16, 20, and 24. Even if the results of these clinical trials suggest a favorable safety and efficacy profile, the study designs and results, and the designs and results of future clinical trials we conduct, may not be viewed as compelling to our physician customers or patients. If physicians do not find our data compelling, even if LYR-210 receives marketing approval they may choose not to use our products or limit their use. Our Phase 3 ENLIGHTEN 1 clinical trial failed to meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. The 52-week extension phase of the ENLIGHTEN 1 trial is complete and full data are expected in Q4 2024. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing and topline data is expected in the second quarter of 2025. There can be no assurance that we will achieve the primary endpoint or any other endpoints in the ENLIGHTEN 2 Phase 3 clinical trial for LYR-210. We also cannot assure you that any data that may be collected will be compelling to the medical community because the data may not be clinically meaningful and may not demonstrate that LYR-210 is an attractive procedure when compared against data from alternative treatments. Even if LYR-210 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success. If LYR-210 receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an adequate level of acceptance, or if we are unable to achieve an optimal cost of goods, we may not generate significant product revenues or become profitable. The degree of market acceptance of LYR-210, if approved for commercial sale, will depend on a number of factors, including but not limited to: â€¢perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our technology; â€¢the perception by members of the healthcare community, including physicians, or patients that the process of administering LYR-210 is not unduly cumbersome; â€¢the efficacy and potential advantages compared to alternative treatments; â€¢effectiveness of sales and marketing efforts; â€¢the cost of treatment in relation to alternative treatments; â€¢our ability to offer our products for sale at competitive prices; â€¢the convenience and ease of administration compared to alternative treatments; â€¢the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; â€¢the strength of marketing and distribution support; â€¢the timing of market introduction of competitive products; 63 Â â€¢the availability of third-party coverage and adequate reimbursement; â€¢product labeling or product implant requirements of the FDA, the EMA, or other regulatory authorities, including any limitations or warnings contained in a productâ€™s approved labeling; â€¢the prevalence and severity of any side effects; and â€¢any restrictions on the use of our product together with other medications. If our product candidates are approved, but do not achieve an adequate cost of goods or level of acceptance by physicians, healthcare payors, and patients, we may not generate sufficient revenue from these products, and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. In addition, our ability to successfully commercialize our product candidates will depend on our ability to manufacture our products at commercial scale, differentiate our products from competing products, and defend the intellectual property of our products. Because we expect sales of LYR-210, if approved, to generate substantially all of our product revenues for a substantial period, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing. If physicians or patients are not willing to change current practices and adopt our office-based administration procedure for LYR-210 may fail to gain market acceptance, and our business will be harmed. While we believe ENT physicians will be able to administer LYR-210, if successfully developed and approved, in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for ENT physicians to schedule separate surgical time, ENT physicians may not adopt our in-office procedure for a number of reasons, including: â€¢lack of significant experience with the placement procedure via a single-use applicator; â€¢lack of availability of adequate insurance coverage or reimbursement for the placement procedure; â€¢perceived inadequacy of evidence supporting clinical benefits or cost-effectiveness of the placement procedure and/or our products in general over existing alternatives; â€¢a perception that patients may be unable to tolerate the placement procedure in the physician office setting; and â€¢liability risks generally associated with the use of new products and procedures. If ENT physicians do not adopt the placement procedure for any reason, including those listed above, our ability to grow our business would be impaired, even if LYR-210 receives marketing approval. We believe recommendations and support of our products by notable ENT physicians could influence market acceptance and adoption. If we do not receive support from influential ENT physicians, our ability to achieve broad market acceptance for our products may be impaired. In addition, if patient receptivity toward treatment in an ENT physician office setting becomes less favorable in the future, this shift could negatively impact market acceptance of our products. Any negative change due to patient receptivity could also be compounded by patients reporting to physicians or other patients through word-of-mouth or social media. Additionally, while it is currently more cost-effective to the healthcare system for providers to perform the placement procedure in an ENT physicianâ€™s office than endoscopic sinus surgery in an operating room, healthcare economics are subject to change. If the use of our products were to cease being more cost-effective than endoscopic sinus surgery due to changes in reimbursement economics, our products may fail to gain market acceptance, and our business may be adversely affected. 64 Â If we are unable to successfully establish manufacturing, sales, marketing, and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing LYR-210, if approved, and we may not be able to generate any revenue. We do not have commercial infrastructure for the manufacturing, sales, marketing, or distribution of all of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. The failure to meet our primary endpoint in the ENLIGHTEN 1 Phase 3 trial has also adversely affected the Companyâ€™s commercialization plans for LYR-210. Factors that may inhibit our efforts to commercialize our product candidates on our own include: â€¢the failure to meet the primary endpoint of our ENLIGHTEN 1 Phase 3 trial and its effects on our ability to pursue a development strategy for LYR-210 and to raise capital to operate the business; â€¢the loss of skilled personnel as a result of the May 2024 RIF; â€¢our ability to manufacture sufficient quantities of our products; â€¢our inability to recruit and retain adequate numbers of effective sales and marketing personnel; â€¢the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; â€¢our inability to equip medical and sales personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare providers regarding applicable diseases and our future products; â€¢the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; â€¢our inability to develop or obtain sufficient operational functions to support our commercial activities; â€¢unforeseen costs and expenses associated with creating an independent sales and marketing organization; and â€¢our inability to set a suitable price or establish reasonable reimbursement rates for our product candidates. We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of LYR-210, or any future product candidates in markets outside of the United States. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaboratorâ€™s strategic interest in the product, and such collaboratorâ€™s ability to successfully market and sell the product. We intend to selectively pursue collaborative arrangements regarding the sale and marketing of LYR-210, if approved, for certain markets outside of the United States; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. If, in the future we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of LYR-210, we may be forced to delay the potential commercialization of LYR-210 or reduce the scope of our sales or marketing activities for LYR-210. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to LYR-210 or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. If we are unable to establish adequate sales, marketing, and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing LYR-210 and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. 65 Â The success of our business may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are evaluating the opportunities for the development and commercialization of our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and commercial sales, pricing, and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including: â€¢our customersâ€™ ability to obtain reimbursement for our product candidates in foreign markets; â€¢our inability to directly control commercial activities if we are relying on third parties; â€¢the burden of complying with complex and changing foreign regulatory, tax, accounting, and legal requirements; and â€¢reduced protection of intellectual property rights in some foreign countries, among others. Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions, and changes in tariffs. In some countries, particularly the countries in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. The sizes of the patient populations that our product candidates are intended to treat have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population than we anticipate, our revenue and ability to achieve profitability may be materially adversely affected. The precise incidence and prevalence of the conditions we aim to address with our programs is unknown and cannot be precisely determined. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new information may change the estimated incidence or prevalence of these diseases, and the incidence or prevalence of these diseases is subject to change. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the indications and conditions of use for which the product candidates are approved and may be marketed, acceptance by the medical community, and patient access, drug pricing, and reimbursement. The sizes of the patient populations that our product candidates are intended to treat in the United States and other major markets and elsewhere may turn out to be smaller than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, we may never achieve profitability despite obtaining such significant market share. Â If we cannot compete for market share against other drug companies, we may not achieve sufficient product revenues and our business will suffer. If our product candidates receive FDA approval, they will compete with a number of existing and future drugs and therapies developed, manufactured, and marketed by other companies. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower 66 Â cost. If our products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer. We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies, and other public and private research organizations. Many of these competitors may have compounds already approved or in development in the therapeutic categories that we are targeting with our current and future product candidates. In addition, many of these competitors, either alone or together with their collaborative partners, may operate larger research and development programs or have substantially greater financial resources than we do, as well as greater experience in developing product candidates; formulating and manufacturing products; and launching, marketing, and selling products, among others. If in the future we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. If LYR-210 is approved for commercialization, we may partner with third parties to market it in certain jurisdictions outside the United States. We expect that we will be subject to additional risks related to international pharmaceutical operations, including: â€¢different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries; â€¢reduced protection for intellectual property rights; â€¢foreign reimbursement, pricing, and insurance regimes; â€¢potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010, and similar anti-bribery and anticorruption laws in other jurisdictions; and â€¢production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor, and other legal requirements imposed by both the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biotechnology companies have found the process of marketing their own products in Europe to be very challenging. Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop. The use of LYR-210, in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. For example, complications arising from the placement procedure for LYR-210, or from the degradation or dislodgment of the LYR-210 implant within the sinuses after placement, or from foreign growth occurring in the sinus after placement, could give rise to product liability claims against us. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies, or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs, which may not be covered by insurance. In addition, regardless of merit or eventual outcome, product liability claims may result in significant consequences including: â€¢impairment of our business reputation and significant negative media attention; and â€¢product recalls, withdrawals or labeling, marketing, or promotional restrictions, among others. Risks Related to Our Dependence on Third Parties We suspended the manufacture our clinical materials in-house. If we restart our manufacturing, we may rely on third parties for certain development and manufacturing-related services and we do not currently have long-term contracts with any of these parties. Our continued reliance on third parties increases the risk

that we will not have sufficient quantities of such materials, 67 Â product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. We have previously relied on third parties for certain development and manufacturing-related services during clinical development of our product candidates, and may rely on third parties for certain manufacturing-related services if any of our product candidates receive marketing approval. Certain of these manufacturers are critical to our production and the loss of these manufacturers to one of our competitors or otherwise, or an inability to obtain quantities at an acceptable cost or quality, could delay, prevent, or impair our ability to timely conduct pre-clinical studies or clinical trials, and would materially and adversely affect our development and commercialization efforts. The facilities used by certain third-parties involved in the production of our product candidates or components of our product candidates may require FDA clearance pursuant to inspections that may be conducted after we submit an NDA to the FDA. While we may be able to mitigate risks through our diligence and contracting processes, when we utilize third parties for manufacturing, we are dependent on them for compliance with cGMP requirements for manufacture of drug products and other laws and regulations. If these third-party manufacturers cannot successfully manufacture or supply material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. Some of our contract manufacturers may not have produced a commercially-approved product and therefore may not have obtained the requisite FDA approvals to do so. In addition, we are limited in our ability to ensure third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved. The failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers or suppliers entails additional risks, including: â€¢breach of the manufacturing agreement by the third party; â€¢misappropriation of our proprietary information, including our trade secrets and know-how; and â€¢termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. The extent to which geopolitical events such as the current conflict between Russia and Ukraine or in the Middle East, or other events such as the evolving COVID-19 pandemic impact our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the event, and the actions undertaken to contain its negative effects and may cause delays. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. We rely on third parties to conduct our pre-clinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates. We are dependent on third parties to conduct our pre-clinical studies and clinical trials, including our planned and ongoing clinical trials for LYR-210. If we decide to conduct future clinical trials for LYR-210 or other product candidates, we expect to rely on 68 Â third parties to conduct those future clinical trials and pre-clinical studies. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs, and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators, and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. There is no guarantee that any such CROs, investigators, or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols, or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates. If any of our relationships with these third-parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding CROs, investigators, and other third parties involve additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Our relationships with these third parties may also be adversely affected by geopolitical events such as the current conflict between Russia and Ukraine and in the Middle East, or other events such as the evolving COVID-19 pandemic. For instance, COVID-19 and government measures taken in response have had a significant impact on our CROs, and we expect that they will face further disruption which may affect our ability to initiate and complete our pre-clinical studies and clinical trials. Though we carefully manage our relationships with our CROs, investigators, and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects. We may collaborate with third parties for the development and commercialization of LYR-210, and any of our future product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize LYR-210, or our future product candidates successfully, if at all. We may seek additional collaborative relationships for the development and commercialization of LYR-210, or any future product candidates. Failure to obtain a collaborative relationship for LYR-210, or any future product candidates may significantly impair the potential for these product candidates. We also may need to enter into collaborative relationships to provide funding to support our other research and development programs. Â If we seek, but are not able to establish, collaborations, we may have to alter our development and commercialization plans. Our product development programs and the potential commercialization of our product candidates will require substantial additional capital. We may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of our product candidates. We face significant competition in seeking appropriate collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product 69 Â candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue. Â Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete. We rely on third-party vendors, such as CROs, scientists, and collaborators to provide us with significant data and other information related to our projects, pre-clinical studies, or clinical trials and our business. If such third parties provide inaccurate, misleading, or incomplete data, our business, prospects, and results of operations could be materially adversely affected. Â We do not have multiple sources of supply for some of the components used in LYR-210, nor long-term supply contracts, and certain of our suppliers are critical to our production. If we were to lose a supplier, it could have a material adverse effect on our ability to complete the development of LYR-210. If we obtain regulatory approval for LYR-210, we would need to expand the supply of their components in order to commercialize them. We do not have multiple sources of supply for the components used in the manufacturing of LYR-210. We also do not have long-term supply agreements with any of our suppliers. We may not be able to establish additional sources of supply for our product candidates, or may be unable to do so on acceptable terms. Suppliers are subject to cGMP quality and regulatory requirements covering manufacturing, testing, quality control, and record keeping relating to our product candidates and are subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions in supply. Manufacturing suppliers are also subject to local, state, and federal regulations and licensing requirements. Failure by any of our suppliers to comply with all applicable regulations and requirements may result in long delays and interruptions in supply. The number of suppliers of the raw material components of our product candidates is limited. In the event it is necessary or desirable to acquire supplies from alternative suppliers, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. Additionally, certain of our suppliers are critical to our production and the loss of these suppliers to one of our competitors or otherwise would materially and adversely affect our development and commercialization efforts. As part of any marketing approval, regulatory authorities conduct inspections that must be successful prior to the approval of the product. Failure of manufacturing suppliers to successfully complete these regulatory inspections will result in delays. If supply from the approved supplier is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA amendment or supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on our ability to complete the development of LYR-210 or, if we obtain regulatory approval for LYR-210, to commercialize them. Risks Related to Our Intellectual Property If we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets. We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect our intellectual property and prevent others from duplicating LYR-210, and any future product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal, factual, and scientific questions and can be uncertain. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing 70 Â from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge the inventorship, ownership, validity, enforceability, or scope of such patents, which may result in such patents being narrowed or invalidated, or being held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. In addition, no assurances can be given that third parties will not create new products or methods that achieve similar results without infringing upon our patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. If the patent applications we hold with respect to our programs or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future products. Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents, or whether any issued patents will be found invalid or unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications before enactment of the Leahy-Smith Act on March 16, 2013, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for the patent covering a product, we may be open to competition from generic competing products. The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our product candidate, if approved, or practicing our own patented technology. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is either not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Once disclosed, we are likely to lose trade secret protection. Although we require all of our employees and consultants to assign their inventions to us, to the extent that employees or consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Further, although we require that all of our employees, consultants, collaborators, advisors, and any third parties who have access to our proprietary know-how, information, or technology enter into confidentiality agreements, we cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently discover our trade secrets or develop substantially equivalent information and techniques. Any of these parties may breach these agreements and we may not have adequate remedies for any specific breach. Misappropriation or unauthorized disclosure of our trade secrets or other confidential proprietary information could impair our competitive position and may have a material adverse effect on our business. Enforcing a claim that

a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets or other confidential proprietary information are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret or other confidential proprietary information. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. 71 Â Â Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. Our commercial success depends in part on our avoiding infringement, or allegations of infringement, of the patents and other proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination, and inter partes review proceedings before the United States Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. Many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to composition of matter, drug delivery, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We cannot guarantee that our technologies, products, compositions, and their uses do not or will not infringe third party patent or other intellectual property rights. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent, and the patentâ€™s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. If any third-party patents were held by a court of competent jurisdiction to cover the composition of matter of any of our product candidates, the manufacturing process of any of our product candidates, or the method of use for any of our product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, which may not be available or may not be available on commercially reasonable terms, or until such patents expire. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates and/or harm our reputation and financial results. Defense of these claims, regardless of their merit, could involve substantial litigation expense and could be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneysâ€™ fees for willful infringement, pay royalties, redesign our infringing products, in the case of claims concerning registered trademarks, rename our product candidates, or obtain one or more licenses from third parties, which may require substantial time and monetary expenditure, and which might be impossible or technically infeasible. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. Â We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. Competitors may infringe our patents, trademarks, copyrights, or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitorâ€™s or potential competitorâ€™s product. To counter infringement or unauthorized use, we may be required to file infringement claims on a country-by-country basis, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid, is unenforceable and/or is not infringed, or may construe the patentâ€™s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put 72 Â one or more of our patents at risk of being invalidated, interpreted narrowly, or held unenforceable, could put our patent applications at risk of not issuing, and could limit our ability to assert those patents against those parties or other competitors and curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Â Recent patent reform legislation has increased the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, and may diminish the value of patents in general. As is the case with other biotechnology companies, our commercial success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity and is therefore costly, time consuming, and inherently uncertain. Recent wide-ranging patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted and may also affect patent litigation. Under the Leahy-Smith Act, the United States transitioned from a â€œfirst-to-inventâ€ to a â€œfirst-to-fileâ€ system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art, and it expanded the scope of procedures that a third party may use to challenge a U.S. patent, including post grant review and inter partes review procedures. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. In addition, recent court rulings in cases such as Association for Molecular Pathology v. Myriad Genetics, Inc., BRCA1- &BRCA2-Based Hereditary Cancer Test Patent Litigation, and Promega Corp. v. Life Technologies Corp. have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO, and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Â We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. We may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employeeâ€™s former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or our ability to hire personnel, which, in any case of the foregoing, could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. 73 Â Â Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. The USPTO, European, and other patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business. Â Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. If we initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business. A defendant could also challenge our ownership of patents assigned to us. We cannot be certain that a third party would not challenge our rights to these patents and patent applications. Any legal proceeding or enforcement action can also be expensive and time-consuming. Â Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For patents that are eligible for extension of patent term, we expect to seek extensions of patent terms in the United States and, if available, in other countries. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional equivalent indications approved during the period of extension). We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise, or failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and pre-clinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. 74 Â Â We may not be able to protect our intellectual property rights throughout the world. Filing, prosecuting, and defending our intellectual property in countries throughout the world could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. Therefore, we may choose not to pursue or maintain protection for certain intellectual property in certain jurisdictions. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent such competitors from competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuit that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. In addition, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to â€œworkâ€ the invention in that country, or the third party has patented improvements) or limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected. While we seek to protect the trademarks we use in the United States and in other countries, we may be unsuccessful in obtaining

registrations and/or otherwise protecting these trademarks. If that were to happen, we may be prevented from using our names, brands, and trademarks unless we enter into appropriate royalty, license, or coexistence agreements, which may not be available or may not be available on commercially reasonable terms. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names, service marks, and domain names, then we may not be able to compete effectively, resulting in a material adverse effect on our business. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted, or declared generic, or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks, then we may not be able to compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. 75 Â Our proprietary rights may not adequately protect our technologies and product candidates, and do not necessarily address all potential threats to our competitive advantage. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: â€¢others may be able to make products that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own; â€¢others, including inventors or developers of our patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights; â€¢we might not have been the first to conceive and reduce to practice the inventions covered by our patents or patent applications; â€¢we might not have been the first to file patent applications covering certain of our patents or patent applications; â€¢it is possible that our pending patent applications will not result in issued patents, or; â€¢that there are prior public disclosures that could invalidate our patents; â€¢our issued patents may not provide us with any commercially viable products or competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; â€¢the Supreme Court of the United States, other U.S. federal courts, Congress, the USPTO, or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our collaboration partnersâ€™ patents; â€¢patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time; â€¢our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; â€¢ownership, validity, or enforceability of our patents or patent applications may be challenged by third parties; and â€¢the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business. Risks Related to Employee Matters The May 2024 RIF was undertaken to significantly reduce our ongoing operating expenses but it may not result in our intended outcomes and may yield unintended consequences and additional costs. In connection with the May 2024 RIF, we incurred charges of approximately $4.1 million in connection with the reduction in force, primarily consisting of severance payments, employee benefits and related costs. We incurred an additional $5.2 million in 76 Â charges for the restructuring subsequent to the May 2024 RIF. This amount primarily relates to ongoing retention efforts for current employees and have been reflected within the financial statements as of September 30, 2024. The reduction in force may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the reduction in force. In addition, while positions have been eliminated certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. The reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. If we are unable to realize the anticipated benefits from the reduction in force, or if we experience significant adverse consequences from the reduction in force, our business, financial condition, and results of operations may be materially adversely affected. In the future, we may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause us to incur debt or assume contingent liabilities, and subject us to other risks. In the future, we may enter into transactions to acquire other businesses, products, or technologies or enter into strategic partnerships, including licensing. If we do identify suitable acquisition or partnership candidates, we may not be able to make such acquisitions or partnerships on favorable terms, or at all. Any acquisitions or partnerships we make may not strengthen our competitive position, and these transactions may be viewed negatively by employees, customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business or partnership that are not covered by the indemnification we may obtain from the seller or our partner. In addition, we may not be able to successfully integrate any acquired personnel, technologies, and operations into our existing business in an effective, timely, and non-disruptive manner. Acquisitions or partnerships may also divert management attention from day-to-day responsibilities, lead to a loss of key personnel, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing, or size of future acquisitions or partnerships or the effect that any such transactions might have on our operating results. Risks Related to Our Common Stock Â Our common stock may be delisted from The Nasdaq Global Market if we cannot regain compliance with Nasdaqâ€™s continued listing requirements, which could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock. Our common stock is currently listed on The Nasdaq Global Market. To maintain the listing of our common stock on The Nasdaq Global Market, we are required to meet certain listing requirements, including related to the price of our common stock. On July 19, 2024, we received a Notice from Nasdaq notifying us that for the last 30 consecutive business days, the bid price for our common stock, par value $0.001 per share, had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1) (â€œthe Minimum Bid Price Requirementâ€). The Notice has no effect at this time on the listing of our common stock, which continues to trade on The Nasdaq Global Market under the symbol â€œLYRA.â€ In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we have a period of 180 calendar days, or until January 15, 2025 (the â€œCompliance Dateâ€) to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date. In the event we do not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, we may be eligible for a second 180 calendar day compliance period. To qualify, we must submit an application to transfer the listing of the common stock to The Nasdaq Capital Market, which requires us to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. We would also need to pay an application fee to Nasdaq and to provide written notice of its intention to cure the deficiency during the additional compliance period. As part of its review process, Nasdaq will make a determination of whether it believes we will be able to cure this deficiency. If the Company does not qualify for or fails to regain compliance during the additional compliance period, then Nasdaq will notify us of its determination to delist our common stock, at which point we would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel. There can be no assurance that, if we decide to appeal any delisting determination, such appeal would be successful. 77 Â We intend to actively monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement or maintain compliance with any other listing requirements. Delisting from The Nasdaq Global Market or any Nasdaq market could make trading our common stock more difficult for investors, potentially leading to declines in our share price and liquidity. In addition, without a Nasdaq market listing, stockholders may have a difficult time getting a quote for the sale or purchase of our common stock, the sale or purchase of our common stock would likely be made more difficult and the trading volume and liquidity of our common stock could decline. Delisting from Nasdaq could also result in negative publicity and could also make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of our common stock as currency or the value accorded by other parties. If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system, such as the OTCQB market, where an investor may find it more difficult to sell our common stock or obtain accurate quotations as to the market value of our common stock. We cannot assure you that our common stock, if delisted from Nasdaq, will be listed on another national securities exchange or quoted on an over-the counter quotation system. The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock. Our stock price may be volatile. The stock market in general and the market for smaller biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above your purchase price. The market price for our common stock may be influenced by many factors, including: â€¢the success of competitive products or technologies; â€¢actual or expected changes in our growth rate relative to our competitors; â€¢results of clinical trials of our product candidates or those of our competitors; â€¢developments related to our existing or any future collaborations; â€¢regulatory actions with respect to our product candidates or our competitorsâ€™ products and product candidates; â€¢regulatory or legal developments in the United States and other countries; â€¢development of new product candidates that may address our markets and make our product candidates less attractive; â€¢changes in physician, hospital, or healthcare provider practices that may make our product candidates less useful or appealing; â€¢announcements by us, our partners, or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments; â€¢developments or disputes concerning patent applications, issued patents, or other proprietary rights; â€¢the level of expenses related to any of our product candidates or clinical development programs; â€¢failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; â€¢the results of our efforts to discover, develop, acquire, or in-license additional product candidates or products; â€¢actual or expected changes in estimates as to financial results, development timelines, or recommendations by securities analysts; â€¢variations in our financial results or those of companies that are perceived to be similar to us; 78 Â â€¢changes in the structure of healthcare payment or reimbursement systems; â€¢market conditions in the pharmaceutical and biotechnology sectors; â€¢short selling activities; â€¢general economic, industry, and market conditions; and â€¢the other factors described in this â€œRisk Factorsâ€ section and elsewhere in this Quarterly Report on Form 10-Q. In addition, the trading prices for common stock of other biotechnology companies may become highly volatile as a result of geopolitical events such as the current conflicts between Russia and Ukraine and in the Middle East. The extent to which such events may impact our business, pre-clinical studies, and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Â A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Holders of approximately 60.1 million shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Rule 144 or until the rights terminate pursuant to the terms of the ninth amended and restated investor rights agreement between us and such holders. We have also registered all shares of common stock that we may issue under our equity compensation plans, which can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. We are an â€œemerging growth company,â€ and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. We are an â€œemerging growth company,â€ as defined in the JOBS Act, and may remain an emerging growth company until December 31, 2025. However, if certain events occur prior to such date, including if we become a â€œlarge accelerated filer,â€ our annual gross revenues exceed $1.235 billion, or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to such date. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: â€¢not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; â€¢not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditorâ€™s report providing additional information about the audit and the financial statements; â€¢reduced disclosure obligations regarding executive compensation; and â€¢exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We have taken advantage of reduced reporting burdens in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q including by providing only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. 79 Â If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well. The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property, or our stock performance, or if our target pre-clinical studies or clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Â We are a â€œsmaller reporting companyâ€ and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors. We are considered a â€œsmaller reporting company.â€ We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from disclosing certain executive compensation information and three years of financial statements. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock prices may be more volatile. Â Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. Provisions in our restated

certificate of incorporation and our amended and restated bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our Company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Among other things, these provisions include those establishing: â€¢a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our Board of Directors; â€¢no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; â€¢the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death, or removal of a director, which prevents stockholders from filling vacancies on our board of directors; â€¢the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; â€¢the ability of our board of directors to alter our bylaws without obtaining stockholder approval; â€¢the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend, or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; 80 Â â€¢a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; â€¢the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and â€¢advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholdersâ€™ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirerâ€™s own slate of directors or otherwise attempting to obtain control of us. Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Â Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us. Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation described above. We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes and in the application of the Securities Act by federal judges, as applicable, efficient administration of cases on a more expedited schedule relative to other forums, and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees, and agents as it may limit any stockholderâ€™s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees, or agents. The enforceability of similar choice of forum provisions in other companiesâ€™ certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations. General Risk Factors We have incurred and expect to continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices. As a public company, we incur significant legal, accounting, and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and made some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our Board of Directors. 81 Â We continue to evaluate these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. We may discover significant deficiencies or material weaknesses, which we may not successfully remediate on a timely basis or at all. Any failure to remediate any significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. The identification of one or more material weaknesses could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. Â Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain. On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, par value $0.001, which we refer to as the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain future earnings for the development, and operation of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common shares would be your sole source of gain on an investment in our common shares for the foreseeable future. Â Litigation could be costly and time-consuming and could result in additional liabilities. We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business or otherwise, such as claims brought by us against, vendors or collaborators, and/or claims brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients, or vendors of our customers, or stockholders. Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert managementâ€™s attention and resources, which may seriously harm our business, overall financial condition, and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or under insured could result in unanticipated costs, thereby adversely impacting our results of operations and resulting in a reduction in the trading price of our stock. Â We could be subject to securities class action litigation. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of managementâ€™s attention and resources, which could harm our business. Â Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, and property, auto, workersâ€™ compensation, umbrella, and directorsâ€™ 82 Â and officersâ€™ insurance. Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If we obtain marketing approval for LYR-210, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. Operating as a public company has made it more difficult and more expensive for us to obtain director and officer liability insurance, and in the future we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board of Directors, our board committees, or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations. Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect the Companyâ€™s current and projected business operations and its financial condition and results of operations. Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. The Company maintains the majority of its cash and cash equivalents in accounts with major U.S. institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our current and projected business operations, our financial condition and results of operations. Our ability to use our net operating losses and research and development credits to offset future taxable income may be subject to certain limitations. As of December 31, 2023, we had net operating loss carryforwards, or NOLs, of $128.3 million for federal income tax purposes and $48.3 million for state income tax purposes, which may be available to offset our future taxable income, if any, and begin to expire at various dates through 2043. As of December 31, 2023, we also had federal and state research and development credit carryforwards of $5.3 million, which begin to expire at various dates through 2043. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, or IRC, as amended, or the Code, a corporation that undergoes an â€œownership change,â€ generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and its research and development credit carryforwards to offset future taxable income. The Company had performed an IRC 382 study during the prior year which resulted in identifying three separate ownership changes that occurred on March 31, 2006, January 17, 2020, and April 13, 2022. We performed an update assessment to our 382 analysis in conjunction with the May 2023 financing noting no additional ownership change. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability. Â New tax legislation may impact our results of operations and financial condition. The Inflation Reduction Act of 2022 introduced, among other changes, a 15% corporate minimum tax on certain United States corporations and a 1% excise tax on certain stock redemptions by United States corporations. The U.S. government may enact further significant changes to the taxation of business entities. The likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict the ultimate impact of the Inflation Reduction Act or any such further changes on our business. 83 Â Â Unstable global, political or economic conditions may have serious adverse consequences on our business, financial condition and share price. The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If the equity and credit markets continue to deteriorate, or the United States enters a recession, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. In addition, international terrorism and conflicts could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business, results of operations and price of our common stock may be adversely affected. Â We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities on which we rely, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. For example, following Hurricane Maria, shortages in production and delays in a number of medical supplies produced in Puerto Rico resulted, and any similar interruption due to a natural disaster affecting us or any of our third-party manufacturers could materially delay our operations. Â International terrorism, political unrest, and wars, or other events such as the COVID-19 pandemic have previously and could in the future adversely impact our business and operations, including our clinical trials. International terrorism, political unrest and wars could delay or disrupt our business activity, and if any conflict escalates or spills over to or otherwise impacts additional regions, it could heighten many of the other risk factors described in this Item 1A. In addition, the COVID-19 global pandemic and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, has fallen. If the COVID-19 pandemic resurges, our

business and operations could be adversely affected again. Similarly, if another pandemic unfolds or if a geopolitical crisis escalates, our business and operations could be adversely affected. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Â Item 3. Defaults Upon Senior Securities. None. Â Item 4. Mine Safety Disclosures. Not applicable. 84 Â Â Item 5. Other Information. (a) Disclosure in lieu of reporting on a Current Report on Form 8-K. None. (b) Material changes to the procedures by which security holders may recommended nominees to the board of directors. None. (c) Insider trading arrangements and policies. During the three months ended September 30, 2024, no director or officer of the Company, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ intended to satisfy the affirmative defense of Rule 10b5-1(c) or â€œnon-Rule 10b5-1 trading arrangementâ€ as each term is defined in Item 408(a) of Regulation S-K. 85 Â Item 6. Exhibits. Â ExhibitNumber Description Â Form orSchedule ExhibitNo. Filing Datewith SEC SEC FileNumber Â Â Â Â Â Â Â Â Â Â 3.1 Â Restated Certificate of Incorporation of the Registrant, dated May 5, 2020 and the Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, dated June 13, 2024. Â 8-K 3.1 June 18, 2024 001-39273 Â Â Â Â Â Â Â Â Â Â 3.2 Â Amended and Restated Bylaws of the Registrant Â 8-K 3.1 December 18, 2023 001-39273 Â Â Â Â Â Â Â Â Â Â 4.1 Â Specimen Stock Certificate evidencing the shares of Common Stock of the Registrant Â S-1 4.2 April 27, 2020 333-236962 Â Â Â Â Â Â Â Â 31.1* Â Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 31.2* Â Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 32.1+ Â Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 32.2+ Â Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.INS* Â Inline XBRL Instance Document â€“ the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â Â Â Â Â Â Â Â Â Â Â Â 104* Â Cover Page Interactive Date File (embedded within the Inline XBRL document) Â Â Â Â Â Â * Filed herewith. + Furnished herewith. 86 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â LYRA THERAPEUTICS, INC. Date: November 12, 2024 By: /s/ Maria Palasis, Ph.D. Maria Palasis, Ph.D. President and Chief Executive Officer(Principal Executive Officer) Â Date: November 12, 2024 By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) Â 87 EX-31.1 2 lyra-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Maria Palasis, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Lyra Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: November 12, 2024 By: /s/ Maria Palasis, Ph.D. Maria Palasis, Ph.D. President and Chief Executive Officer(Principal Executive Officer) Â Â EX-31.2 3 lyra-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jason Cavalier, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Lyra Therapeutics, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: November 12, 2024 By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer(Principal Financial and Accounting Officer) Â Â EX-32.1 4 lyra-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Lyra Therapeutics, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: (1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2)the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Â Date: November 12, 2024 By: /s/ Maria Palasis, Ph.D. Maria Palasis, Ph.D. President and Chief Executive Officer(Principal Executive Officer) Â Â EX-32.2 5 lyra-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Lyra Therapeutics, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: (1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2)the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Â Date: November 12, 2024 By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer(Principal Financial and Accounting Officer) Â Â EX-101.SCH 6 lyra-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) (unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Restructuring and Other Related Charges link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Property and Equipment and Related Impairment link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Impairment of Right of Use Assets link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Preferred and Common Stock link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Short-term Investments link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stock-Based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Restructuring and Other Related Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Property and Equipment and Related Impairment (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Impairment of Right of Use Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Preferred and Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Common Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Short-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Stock-Based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Collaboration Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Restructuring and Other Related Charges (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Property and Equipment and Related Impairment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Impairment of Right of Use Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Impairment of Right of Use Assets - Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Short-term Investments - Schedule of Fair Value of Available-For-Sale Investments by Type of Security (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Short-term Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Preferred and Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Collaboration Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Collaboration Agreement - Summary of Transaction Price (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure -

Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Income Taxes - (Schedule of Effective Income Tax Rate Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Leases - Schedule of Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Change in performance obligation transaction price. Change In Performance Obligation Transaction Price Change in transaction price Conversion of stock, amount converted Conversion of Stock, Amount Converted Plan Name [Domain] Plan Name Summary of Warrants Outstanding and Exercisable Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs. Stock Issued During Period Shares Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs Issuance of common stock and pre-funded warrants, net of issuance costs, Shares Office Equipment [Member] Office Equipment Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Restructuring Charges, Total Restructuring Charges Restructuring and other related charges Restructuring charge Modification of lease agreement Modification of Lease Agreement Modification of Lease Agreement Shares, Outstanding Balance, Shares Balance, Shares Fair Value Hierarchy and NAV [Axis] Option Indexed to Issuer's Equity, Type [Axis] Thereafter Lessee Operating Lease Liability Payments Due After Year Four Lessee operating lease liability payments due after year four. Organization and basis of presentation. Organization And Basis Of Presentation [Table] Organization And Basis Of Presentation [Table] Level 2 Fair Value, Inputs, Level 2 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Area of Real Estate Property Area of property Impairment of right of use asset. Impairment of ROU asset Impairment Of Right Of Use Asset Impairment of right-of-use assets From October 1, 2024 to December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Leases [Text Block] Leases Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Restructuring Cost [Table] Development Activities Performance Obligation Development Activities Performance Obligation [Member] Development activities performance obligation. Stock, Class of Stock [Table] Schedule Of Stock By Class [Table] Other assets policy. Other Assets [Policy Text Block] Other Assets Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Noncash Investing and Financing Items [Abstract] Supplemental disclosure of non-cash financing and investing activities: Employee stock purchase plan Employee Stock [Member] Preferred and Common Stock Equity [Text Block] Title of Individual Title and Position [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right Debt Securities, Available-for-Sale, Unrealized Loss Unrealized loss on available-for-sale securities Asset impairment charge. Asset Impairment Charge [Line Item] Sale of Stock [Domain] Sale of Stock Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Schedule Of Discounted Cash Flow methodology Range Of Assumptions [Table Text Block] Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology Schedule of discounted cash flow methodology range of assumptions. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Entity Central Index Key Entity Central Index Key Entity Central Index Key Debt Securities, Available-for-Sale [Line Items] Proceeds to be occured from future issuance of common stock,. Proceeds To Be Occured From Future Issuance Of Common Stock Proceeds to be occured from future issuance of common stock Warrants Purchase Warrants Common stock warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Shares, Cancelled Milestone-based awards. Milestone Based Awards [Member] Milestone-based Awards Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Valuation Technique, Discounted Cash Flow [Member] Discounted Cash Flow Technique Retention costs Retention Costs Retention costs. Common Stock, Shares, Issued Common stock shares issued Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Market-conditions based awards. Market Conditions Based Awards [Member] Market-Conditions Based Awards Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Business Description and Basis of Presentation [Text Block] Organization, Restructuring, Going Concern and Basis of Presentation Income Statement [Abstract] Paid to the contract manufacture Estimated Litigation Liability Entity Address, State or Province Entity Address, State or Province Exercise of common stock warrants, Shares Stock issued during period, shares, Exercise of common stock warrants Stock issued during period, shares, Exercise of common stock warrants. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income tax expense Loss before income tax expense Class of Warrant or Right [Table] Class of warrant or right, expiration description Class of warrant or right, expiration description. Inducement award plan. Inducement Award Plan [Member] Inducement Award Plan Executive Chair Executive Chair [Member] Executive Chair. Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Shares available for grant Debt Securities, Available-for-Sale, Unrealized Loss Position, Total Debt Securities, Available-for-Sale, Unrealized Loss Position Debt securities, unrealized loss position Percentage of common shares increase automatically in each year. Percentage Of Common Shares Increase Automatically In Each Year Percentage of common shares increase automatically in each year Lease, Cost [Abstract] Lease Cost: Restructuring and Related Cost, Incurred Cost Restructuring and other related charges Gross proceeds from issuance of common stock Gross Proceeds From Issuance Of Common stock Gross proceeds from issuance of common stock. Cover [Abstract] Milestone Milestone achievements. Milestone Achievements [Member] Milestone Achievements Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share attributable to common stockholders- basic Lessee, Operating Lease, Option to Extend Lessee, Operating Lease, Option to Extend Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Operating Expenses [Abstract] Operating expenses: Waltham lease. Waltham Lease [Member] Waltham Lease Schedule of Cash and Cash Equivalents [Table Text Block] Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet Discounted cash flow technique expected sublease rent increases. Discounted Cash Flow Technique Expected Sublease Rent Increases Expected Sublease Rent Increases Share-Based Payment Arrangement, Expense Stock-based compensation expense Exercise of common stock warrants Exercise Of Common Stock Warrants Exercise of common stock warrants. Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Plan Name [Axis] Plan Name Shares, Outstanding December 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Shares, Outstanding at June 30, 2024 Number of awards outstanding Assets, Current [Abstract] Current assets: Common Stock, Capital Shares Reserved for Future Issuance Shares of common stock reserved for future issuances June executive options. June Executive Options [Member] June Executive Options Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited Accumulated other comprehensive income, net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Lessee, Operating Lease, Term of Contract Operating lease period Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Type of Restructuring [Domain] Fair Value, Recurring Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Senior Vice President Vice President [Member] Common Stock, Par or Stated Value Per Share Common stock par value Stock Options Unrealized holding gain (loss) on short-term investments, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Twenty thousand twenty employee stock purchase plan. Twenty Thousand Twenty Employee Stock Purchase Plan [Member] 2020 ESPP Statement of Cash Flows [Abstract] Counterparty Name [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Warrants to purchase common shares Exercisable warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Equity Components [Axis] Equity Components Entity Address, Address Line One Entity Address, Address Line One Employee-related Liabilities, Current Payroll and employee related expenses Employee-related Liabilities, Current, Total Employee Severance [Member] Employee Severance [Member] Severance Costs RSUs granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units outstanding shares, Granted Valuation Approach and Technique [Axis] Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Nonoperating Income (Expense) Total other income Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Debt Securities, Available-for-Sale, Unrealized Gain Unrealized gain on available-for-sale securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Short-term Investments Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted stock units outstanding, Ending Balance Restricted stock units outstanding, Beginning Balance Amendment Flag Amendment Flag Increase (Decrease) in Operating Lease Liability Operating lease liabilities Operating Lease, Liability, Noncurrent Total operating lease liability, net of current portion Operating lease liabilities, net of current portion Corporate Debt Securities [Member] Corporate Debt Securities Additional Paid in Capital, Common Stock Additional paid-in capital Restructuring Plan [Domain] Sale of Stock, Price Per Share Sale of stock, price per share Net loss Net losses Lessee, Lease, Description [Table] Lessee Lease Description [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of common stock options, Shares Shares, Exercised Research and Development Expense [Member] Research and Development Concentrations of credit risk and off-balance sheet risk. Concentrations Of Credit Risk And Off Balance Sheet Risk Policy [Text Block] Concentrations of Credit Risk and Off-Balance Sheet Risk Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement General and Administrative Expense General and administrative General and Administrative Expense, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Stock option expiration period Furniture and Fixtures [Member] Office Furniture and Fixtures Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Post-Milestone Post-Milestone [Member] Post-milestone. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Deferred Revenue, Current Deferred revenue Deferred Revenue, Current, Total Preferred Stock, Shares Issued Preferred stock, shares issued Proceeds from Stock Options Exercised Proceeds from exercise of stock options Lease related costs current Lease related costs current Lease-related costs Payables and Accruals [Abstract] Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement. Short-Term Investments, Total Short-Term Investments Short-term investments Operating Lease, Expense Initial base rent Deferred Revenue, Noncurrent Deferred revenue, net of current portion Deferred Revenue, Noncurrent, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Cancelled Proceeds from issuance of redeemable convertible preferred stock Proceeds from Issuance of Redeemable Convertible Preferred Stock Net proceeds after deducting issuance costs Net Proceeds After Deducting Issuance Costs Net proceeds after deducting issuance costs. Restricted Cash, Noncurrent Restricted cash Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Class of Stock [Domain] Severance Costs Severance costs Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Total Other Comprehensive Income (Loss), Net of Tax Warrant Two Warrant Two [Member] Warrant two. Collaborative Arrangement Disclosure [Text Block] Collaboration Agreement U.S. Government Agency and foreign national bank securities U.S. Government Agency and Foreign National Bank Securities [Member] U.S. Government agency and foreign national bank securities. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Common Stock, Shares, Outstanding Common stock shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Office and laboratory. Office And Laboratory [Member] Office and Laboratory Payments to Acquire Investments, Total Payments to Acquire Investments Purchases of short-term investments Gross proceeds from private placement Gross proceeds from issuance of private placement. Gross Proceeds From Issuance Of Private Placement Gross proceeds from private placement Short-Term Investments [Abstract] Restructuring Reserve, Accrual Adjustment Accruals Restructuring Liability Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Maturity of short-term investments Asset Impairment Charges [Abstract] Antidilutive Securities [Axis] Antidilutive Securities Entity Interactive Data Current Entity Interactive Data Current Equity Method Investments [Policy Text Block] Short-term Investments Lease Expiration Date Lease expiration date Document Quarterly Report Document Quarterly Report Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total Statement of Financial Position Location, Balance [Axis] Statistical Measurement [Axis] Statistical Measurement Accounting Policies. Accounting Policies [Line Items] Accounting Policies [Line Items] Operating Lease, Cost Operating lease cost Issuance Costs in accounts payable, accrued expenses, and other current liabilities Issuance costs in accounts payable accrued expenses and other current liabilities. Issuance Costs In Accounts Payable Accrued Expenses And Other Current Liabilities Issuance costs in accounts payable, accrued expenses, and other current liabilities Total assets Assets, Fair Value Disclosure Financial assets, fair value Assets, Fair Value Disclosure, Total Increase decrease in accrued expenses and other current liabilities. Increase Decrease In Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Lease, Cost Total lease cost Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents February twenty twenty two options. February Twenty Twenty Two Options [Member] February 2022 Options Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Summary of Maturity of Operating Lease Liabilities Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Summary of Restricted Stock Unit Activity Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available for future grant Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Proceeds from Issuance of Private Placement Net proceeds from private placement Number of warrants exercised Warrants exercised. Warrants Exercised Pre-funded warrants exercised Weighted Average Exercise Price of Warrants Exercised Class of Warrant or Right, Exercise Price of Warrants or Rights Exercised Class of warrant or right, exercise price of warrants or rights exercised. Statement of Income Location, Balance [Axis] Income Statement Location Assets Total assets Development activities performance obligation Development Activities Performance Obligation Development activities performance obligation. Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Restructuring Type [Axis] 2024 PSUs Two Thousand Twenty Four PSUs [Member] Two thousand twenty four PSUs. Loss on impairment of long-lived assets Impairment of Long-Lived Assets to be Disposed of Impairment of property and equipment Number of shares Underlying Warrants Exercisable Class Of Warrant Or Right Outstanding Exercisable Class Of warrant or right outstanding exercisable. Shares probable to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted stock units outstanding shares, Vested Future milestone payments receivable upon achievement of specified development, regulatory and commercialization. Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization Future milestone payments receivable Restructuring Reserve, Current Restructuring liability Organization and basis of presentation. Organization And Basis Of Presentation [Line Items] Organization And Basis Of Presentation [Line Items] New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Entity Address, City or Town Entity Address, City or Town Accumulated Other Comprehensive Income (Loss), net of tax AOCI Attributable to Parent [Member] Equity [Abstract] Other assets included in accounts payable and other current liabilities Other Assets Included In Accounts Payable And Other Current Liabilities Other assets included in accounts payable and other current liabilities. Other Restructuring Costs Other costs Payment of deferred offering costs Payment of deferred offering costs Payments of Stock Issuance Costs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Restricted stock units

outstanding shares, Forfeited Chief Medical Officer Chief Medical Officer [Member] Chief medical officer. Payments for Restructuring Cash Payments Third-party research and development expenses current. Third Party Research And Development Expenses Current Third-party research and development expenses Issuance of common stock under ESPP Issuance of Common Stock under ESPP Issuance of common stock under ESPP. Restructuring Cost and Reserve [Line Items] Depreciation Depreciation expense Depreciation, Total Private Placement [Member] Private Placement Twenty thousand twenty incentive award plan. Twenty Thousand Twenty Incentive Award Plan [Member] 2020 Plan Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Expense Shares available for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Corporate bonds and U.S. government and agency securities. Corporate Bonds And U.S.Government And Agency Securities [Member] Corporate Bonds and U.S. Government Agency Securities Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Other assets Other Assets [Member] Fair Value Disclosures [Abstract] Deferred offering costs incurred but not yet paid. Deferred Offering Costs Incurred But Not Yet Paid Deferred offering costs included in accounts payable and accrued expenses Shares issued under ATM, net of issuance costs of $150 Stock Issued During Period, Value, New Issues Combined Performance Obligation Combined Performance Obligation [Member] Combined performance obligation. Chief Executive Officer Chief Executive Officer [Member] Stock Issued During Period, Value, Stock Options Exercised Exercise of common stock options Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Liabilities, Current [Abstract] Current liabilities: Lease Contractual Term [Axis] Lease Contractual Term Document Type Document Type US Government Agencies Debt Securities [Member] Corporate Bonds and U.S. Government Agency Securities Less: Impairment Asset Impairment Charges, Total Asset Impairment Charges Impairment charge for write-down of property and equipment Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Issuance of common stock and pre-fundedwarrants, net of issuance costs Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs. Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs Statement of Financial Position Location, Balance [Domain] Lease, Cost [Table Text Block] Components of Lease Cost Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate intrinsic value of stock options exercised Research and Development Expense Research and development Research and Development Expense, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of shares granted Shares, Granted Executive option and June executive options. Executive Option And June Executive Options [Member] Executive Options and June Executive Option Discounted cash flow technique term. Discounted Cash Flow Technique Term Term (years) Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross Property and equipment, gross Proceeds from government contracts. Proceeds From Government Contracts Proceeds from government contracts Retention costs. Retention Costs [Member] Retention Costs Revenue Recognition, Milestone Method [Table Text Block] Summary of Transaction Price Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] ATM Agreement A T M Agreement [Member] ATM agreement. Payments for Rent Payments for Rent Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Debt securities, hold Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year. Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Immediately Preceding Calendar Year Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year Weighted Average Exercise Price of Warrants Outstanding, Ending Balance Weighted Average Exercise Price of Warrants Outstanding, Beginning Balance Exercise Price Warrants exercise price, per share Common stock par value Financial Instruments [Domain] 2024 Performance Option Two Thousand Twenty Four Performance Option [Member] Two thousand twenty four performance option. Class of Warrant or Right [Line Items] Sale of Stock [Axis] Sale of Stock Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Issue Date Class of Warrant or Right, Date from which Warrants or Rights Exercisable Asset Impairment Charges [Text Block] Impairment of Right of Use Assets Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Income Tax Disclosure [Text Block] Income Taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Secured Debt Secured debt obligations Secured Debt, Total Computer Software and Equipment Computer Software And Equipment [Member] Computer Software And Equipment [Member] Warrants and Rights Note Disclosure [Abstract] Other Restructuring [Member] Other Costs Short-Term Debt, Type [Axis] Short-term Debt, Type Revenue recognized Revenue recognized Deferred Revenue, Revenue Recognized Debt Securities, Available-for-Sale [Table] Short-Term Debt, Type [Domain] Short-term Debt, Type Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Liabilities and Equity [Abstract] Liabilities and Stockholdersâ€™ Equity Deferred Debt Issuance Cost, Writeoff Write-off of deferred financing costs Document Period End Date Document Period End Date Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Additional paid in capital stock issued issuance costs. Additional Paid In Capital Stock Issued Issuance Costs Issuance costs Stock-based compensation expense recorded as liability Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Effective Income Tax Rate Reconciliation, Percent Total Claims for breach of implied covenant of good and fair dealing Litigation Settlement, Amount Awarded to Other Party Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities excluded from calculation of diluted net loss per share Share based compensation arrangement unrecognized compensation expense recognition weighted average term. Share Based Compensation Arrangement Unrecognized Compensation Expense Recognition Weighted Average Term Unrecognized share based compensation amount recognition term Restructuring Reserve, Total Restructuring Reserve Restructuring reserve, beginning balance Restructuring reserve, ending balance APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Sale of Stock, Consideration Received on Transaction Gross proceeds under agreement Deferred revenue at ending Deferred revenue at beginning Deferred Revenue Deferred Revenue Deferred Revenue, Total Accrued expenses and other current liabilities disclosure. Accrued Expenses And Other Current Liabilities Disclosure [Text Block] Accrued Expenses and Other Current Liabilities Number of leased properties marketed for sublease arrangements. Number of Leased Properties Marketed for Sublease Arrangements Number of leased properties marketed for sublease arrangements Twenty twenty four restructuring plan. Twenty Twenty Four Restructuring Plan [Member] 2024 Restructuring Plan Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Income tax expense Income tax benefit Class of warrant or right warrant purchase price. Class Of Warrant Or Right Warrant Purchase Price Warrants purchase price Debt Securities, Available-for-Sale [Abstract] Trading Symbol Trading Symbol Equity, Attributable to Parent Balance Balance Total stockholdersâ€™ equity Pre-Milestone Pre-Milestone [Member] Pre-milestone. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Number of Warrants Outstanding, Ending Balance Number of Warrants Outstanding, Beginning Balance Number of shares Underlying Warrants Outstanding Class of Warrant or Right, Outstanding Percentage of aggregate commission. Percentage Of Aggregate Commission Percentage of aggregate commission Restricted Stock Units Restricted stock units Restricted Stock Units (RSUs) [Member] Sale of Stock, Number of Shares Issued in Transaction Sale of stock, number of shares issued (in shares) Variable Lease, Cost Variable lease cost Property, Plant and Equipment [Table] Option Indexed to Issuer's Equity, Type [Domain] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Stock-Based Compensation Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date Expiration date Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Losses Unrealized Losses Unrecognized stock compensation expense to be recognized Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Leases [Abstract] Restructuring and Related Costs [Table Text Block] Summary of Restructuring Liability Activities Equipment [Member] Equipment Use of Estimates, Policy [Policy Text Block] Use of Estimates Number of leases. Number of leases Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Class Of Stock [Line Items] Class of Stock [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Security Exchange Name Security Exchange Name Counterparty Name [Domain] Less: Impairment Impairment On Property Plant And Equipment Impairment on property plant and equipment. Operating Expenses Total operating expenses Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Class of Stock [Axis] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Fair Value Disclosures [Text Block] Fair Value Measurements Number of Warrants Exercised Number of warrants exercised Class of Warrant or Right, Exercised Class of warrant or right, exercised. 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average fair value of options granted to employees, directors and non-employees Maximum [Member] Maximum Restructuring and Related Activities Disclosure [Text Block] Restructuring and Other Related Charges Liabilities and Equity Total liabilities and stockholdersâ€™ equity Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs Financial Liabilities Fair Value Disclosure Financial liabilities, fair value Financial Liabilities Fair Value Disclosure, Total Upfront payment received. Upfront Payment Received Upfront payment received Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share attributable to common stockholders- diluted Leasehold Improvements [Member] Leasehold Improvements Entity Ex Transition Period Entity Ex Transition Period Summary of weighted average remaining lease terms and discount rate related to operating leases. Summary Of Weighted Average Remaining Lease Terms And Discount Rate Related To Operating Leases Table [Text Block] Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases Liabilities Total liabilities Common stock, voting rights Common Stock, Voting Rights Fair Value Hierarchy and NAV [Domain] Assets, Current Total current assets Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Shares issued under ATM, net of issuance costs, Shares Issuance of common stock Issuance of pre-funded warrants to purchase shares of common stock Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Change in deferred tax asset valuation allowance Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee, Operating Lease, Existence of Option to Extend [true false] Milestone Development Milestone Achieved Development milestone achieved. Entity Filer Category Entity Filer Category Property, Plant and Equipment [Abstract] Exercise of pre-funded warrants, Shares Stock Issued During Period Shares Exercise Of Pre Funded Warrants Stock issued during period, shares, Exercise of pre-funded warrants. Stock and warrants to be issued during period value preferred stock and warrants. Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants Stock and warrants to be issued during period value preferred stock and warrants Nonoperating Income (Expense) [Abstract] Other income: Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Amount representing interest Sales agreement. Sales Agreement [Member] Sales Agreement Going concern policy text block. Going Concern Policy [Text Block] Going Concern Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-Based Payment Arrangement, Noncash Expense, Total Aggregate Intrinsic Value, Outstanding Aggregate Intrinsic Value, Outstanding at September 30, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding December 31, 2021 Entity Registrant Name Entity Registrant Name Alternative Investment, Change in Valuation Technique [true false] Alternative investment, change in valuation technique Proceeds from license and collaboration agreement. Proceeds From License And Collaboration Agreement Proceeds from license and collaboration agreement Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Debt Instrument, Maturity Date Debt instrument expiration date Entity Emerging Growth Company Entity Emerging Growth Company Money Market Funds Money Market Funds [Member] Other Liabilities, Current Other Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding-basic Accrued expenses and other liabilities current. Accrued Expenses And Other Liabilities Current Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Restructuring and Related Cost, Number of Positions Eliminated Number of employees reduced Common Stock, Shares Authorized Common stock shares authorized Clinical Supply Agreement member. Clinical Supply Agreement [Member] Clinical Supply Agreement Proceeds from Issuance of Common Stock Net proceeds Common Stock Warrants Common Stock Warrants Disclosure [Text Block] The entire disclosure for common stock warrants. Level 1 Fair Value, Inputs, Level 1 [Member] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercise price per share, granted Weighted Average Exercise Price, Granted Financial Instrument [Axis] Discounted cash flow technique range of assumption. Discounted Cash Flow Technique Range Of Assumption [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding, Weighted Average Remaining Contractual Life (in years) Two thousand five and two thousand sixteen equity incentive plan. Two Thousand Five And Two Thousand Sixteen Equity Incentive Plan [Member] 2005 and 2016 Plan Common stock voting rights, number of votes. Common Stock Voting Rights Number Of Votes Number of common stock voting rights Stock issued during period shares vesting of restricted stock unit. Stock Issued During Period Shares Vesting Of Restricted Stock Unit Issuance of common stock upon RSU vesting, shares Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Lessee, operating lease, extended lease term. Lessee Operating Lease Extended Lease Term Extended lease term Shares of common stock reserved for future issuances. Shares Of Common Stock Reserved For Future Issuances Table [Text Block] Schedule of Common Stock Reserved for Future Issuances General and Administrative Expense [Member] General and Administrative Share-Based Payment Arrangement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Purchase price of shares as percentage lower of fair market value of common stock. Purchase Price Of Shares As Percentage Lower Of Fair Market Value Of Common Stock Purchase price of shares as percentage lower of fair market value of common stock Aggregate gross proceeds from issuance of warrants Proceeds from Issuance of Warrants Combined performance obligation Combined Performance Obligation Combined performance obligation Restructuring Plan [Axis] Debt Securities, Available-for-Sale, Total Debt Securities, Available-for-Sale Fair Value Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Under Plans Income Tax Disclosure [Abstract] Equity, Attributable to Parent [Abstract] Stockholdersâ€™ equity: Restricted cash. Restricted Cash Policy [Text Block] Restricted Cash Discounted cash flow technique discount rate. Discounted Cash Flow Technique Discount Rate Discount Rate Cantor Fitzgerald & Co. Cantor Fitzgerald & Co. [Member] Cantor Fitzgerald & Co. Statement [Table] Statement [Table] Property, Plant and Equipment [Table Text Block] Property Plant And Equipment Aggregate intrinsic Value of Warrants Exercised Warrants and Rights Exercised Intrinsic Value Warrants and rights exercised intrinsic value. Increase (Decrease) in Other Current Assets Other assets Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Authorized Securities Act File Number Entity File Number Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Lease initiation date Lease Initiation Date Lease initiation date Annual increase in number of shares available for issuance maximum number of common stock issued. Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued Maximum number of common shares issued Weighted Average Remaining Contractual Term of Warrants Outstanding Warrants and Rights Outstanding, Term Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State taxes, net of federal benefit Lease Contractual Term [Domain] Lease Contractual Term Statement of Financial Position [Abstract] Entity incorporation, date of incorporation Entity Incorporation, Date of Incorporation Operating Income (Loss) Loss from operations Shares issued and sold, public offering price Shares Issued, Price Per Share Weighted average price Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Letter of Credit

[Member] Letter of Credit Entity Shell Company Entity Shell Company Accrued Professional Fees, Current Professional and consulting fees Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Class of Warrant or Right [Domain] Class of Warrant or Right Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Entity Current Reporting Status Entity Current Reporting Status Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable, Weighted Average Remaining Contractual Life (in years) Adjustments to additional paid in capital common stock and warrants. Adjustments to Additional Paid in Capital Common Stock and Warrants Adjustments to additional paid in capital, sale of common stock and warrants Number of employees Number Of Employees Number Of Employees Property, Plant and Equipment Disclosure [Text Block] Property and Equipment and Related Impairment Subsequent Events [Abstract] Increase (Decrease) in Contract with Customer, Liability Deferred revenue Warrant Three Warrant Three [Member] Warrant three. Document Fiscal Year Focus Document Fiscal Year Focus Certificates of Deposit [Member] Certificate of Deposits Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Commercial Revenue Based Milestone Awards Commercial Revenue Based Milestone Awards [Member] Commercial revenue based milestone awards. Capital Expenditures Incurred but Not yet Paid Property and equipment purchases included in accounts payable Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Proceeds from issuance initial public offering Proceeds from Issuance Initial Public Offering City Area Code City Area Code Performance obligations. Performance Obligations [Member] Performance Obligations Liabilities, Current Total current liabilities Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Income tax computed at federal statutory rate Stock options and restricted stock units. Stock Options And Restricted Stock Units [Member] Stock Options and Restricted Stock Units Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number ATM At The Market [Member] At the market. Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Executive options. Executive Options [Member] Executive Options Gross proceeds for warrant exercises Proceeds from Warrant Exercises Commitments and Contingencies Disclosure [Abstract] Debt Securities, Available-for-Sale, Amortized Cost, Total Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Operating Lease, Liability, Current Operating lease liabilities Less: current portion of operating lease liability Accounting Policies. Accounting Policies [Table] Accounting Policies [Table] Estimated offering costs. Estimated Offering Costs Estimated offering costs Retained Earnings [Member] Accumulated Deficit Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Transition Report Document Transition Report 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Controlled Equity Offering Sales Agreement. Controlled Equity Offering Sales Agreement [Member] Controlled Equity Offering Sales Agreement Valuation Approach and Technique [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Conversion of stock, description Conversion of Stock, Description Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Permanent differences Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised COVID-19 Pandemic and CARES Act. C O V I D19 Pandemic And C A R E S Act Policy [Text Block] COVID-19 Pandemic and CARES Act Minimum [Member] Minimum Common Stock [Member] Common Stock Restricted Cash Restricted cash Restricted Cash, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Cash provided by financing activities. Cash Provided By Financing Activities Fund raised for operations Pre-Funded Warrants Pre-funded warrants. Pre Funded Warrants [Member] Pre Funded Warrants Weighted Average Grant Date Fair Value, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Beginning Balance Additional Paid-in Capital [Member] Additional Paid-in Capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Statement of Income Location, Balance [Domain] Income Statement Location 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other Assets, Noncurrent Other assets Performance-Based Stock Awards Performance Shares [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Schedule of Unrecognized Stock-Based Compensation Title of Individual Title and Position [Domain] Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance cost Impairment of right of use asset. Impairment Of Right Of Use Asset [Member] Impairment Of Right Of Use Asset Aggregate intrinsic Value of Warrants Outstanding, Ending Balance Aggregate intrinsic Value of Warrants Outstanding, Beginning Balance Warrants and Rights Outstanding Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 65,456,735 and 57,214,550 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Investment Income, Interest Interest income Prepaid rent Prepaid Rent Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Operating Lease, Liability Present value of operating lease liability Debt Securities, Available-for-Sale [Table Text Block] Schedule of Fair Value of Available-for-sale Investments by Type of Security Measurement Frequency [Axis] Commitments and Contingencies Commitments and contingencies (Note 13) Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding-diluted Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Warrant One Warrant One [Member] Warrant one. Lessee, Operating Lease, Renewal Term Operating Lease, renewal term Lessee, Operating Lease, Liability, to be Paid Total maturities Expiration date Expiration Date Warrants and Rights Outstanding, Maturity Date Watertown lease. Watertown Lease [Member] Watertown Lease Entity Small Business Entity Small Business U.S. Treasury Bills U.S. treasury bills US Treasury Securities [Member] Waltham Sublease Waltham Sublease [Member] Waltham sublease. Total Upfront payment recognition in future periods to settlement of obligation. Upfront Payment Recognition In Future Periods To Settlement Of Obligation Upfront payment recognition in future periods to settlement of obligation Total Number of warrants expired warrants expired warrants expired. Accretion (Amortization) of Discounts and Premiums, Investments Net amortization of premium on short-term investments Net amortization of premium on short-term investments Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Weighted Average Exercise Price, Outstanding December 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Outstanding at June 30, 2024 Exercise of common stock warrants Stock issued during period, value, exercise of common stock warrants Stock issued during period, value, exercise of common stock warrants. Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Debt securities, held Schedule of accrued expenses and other current liabilities. Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block] Schedule of Accrued Expenses and Other Current Liabilities Right of Use Asset in Exchange for Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Percentage of annual rent increment. Percentage Of Annual Rent Increment Percentage of annual rent increment Measurement Frequency [Domain] Deferred tax assets valuation allowance income tax expense (benefit). Deferred Tax Assets Valuation Allowance Income Tax Expense (Benefit) Deferred tax assets, valuation allowance income tax expense (benefit) Net proceeds from issuance of preferred stock allocated to warrants Proceeds from Issuance of Preferred Stock and Preference Stock Increase decrease in operating lease right-of-use asset. Increase Decrease In Operating Lease Right Of Use Asset Operating lease right-of-use assets Level 3 Fair Value, Inputs, Level 3 [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (in years) Deferred Revenue, Description Deferred revenue, description Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights Vesting rights Subsequent Events Subsequent Events [Text Block] Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Common Warrants Common Warrants [Member] Common warrants. Stock issued during period value vesting of restricted stock unit. Stock Issued During Period Value Vesting Of Restricted Stock Unit Issuance of common stock upon RSU vesting Exercise of pre-funded warrants Stock Issued During Period Values Exercise Of Pre Funded Warrants Stock issued during period, values, exercise of pre-funded warrants. XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Entity Registrant Name Lyra Therapeutics, Inc. Â Document Type 10-Q Â Current Fiscal Year End Date --12-31 Â Entity Common Stock, Shares Outstanding Â 65,457,648 Amendment Flag false Â Entity Central Index Key 0001327273 Â Entity Filer Category Non-accelerated Filer Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Shell Company false Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity File Number 001-39273 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 84-1700838 Â Entity Address, Address Line One 480 Arsenal Way Â Entity Address, City or Town Watertown Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02472 Â City Area Code 617 Â Local Phone Number 393-4600 Â Document Quarterly Report true Â Document Transition Report false Â Title of 12(b) Security Common Stock, $0.001 par value per share Â Trading Symbol LYRA Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant

is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 23,800 $ 22,353 Short-term investments 27,826 80,400 Prepaid expenses and other current assets 2,818 2,068 Total current assets 54,444 104,821 Property and equipment, net 1,613 2,043 Operating lease right-of-use assets 20,707 33,233 Restricted cash 1,992 1,392 Other assets Â 1,111 Total assets 78,756 142,600 Current liabilities: Â Â Accounts payable 2,292 3,131 Restructuring liability 4,855 Â Accrued expenses and other current liabilities 3,197 9,374 Operating lease liabilities 4,003 5,434 Deferred revenue 607 1,658 Total current liabilities 14,954 19,597 Operating lease liabilities, net of current portion 31,321 21,447 Deferred revenue, net of current portion 11,862 12,136 Total liabilities 58,137 53,180 Commitments and contingencies (Note 13) Stockholdersâ€™ equity: Â Â Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 65,456,735 and 57,214,550 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 65 57 Additional paid-in capital 414,345 400,685 Accumulated other comprehensive income, net of tax 20 33 Accumulated deficit (393,811) (311,355) Total stockholdersâ€™ equity 20,619 89,420 Total liabilities and stockholdersâ€™ equity $ 78,756 $ 142,600 X - DefinitionAccrued expenses and other liabilities current. + ReferencesNo definition available. + Details Name: lyra_AccruedExpensesAndOtherLiabilitiesCurrent Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts

of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock par value $ 0.001 $ 0.001 Common stock shares authorized 200,000,000 200,000,000 Common stock shares issued 65,456,735 57,214,550 Common stock shares outstanding 65,456,735 57,214,550 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-

02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Collaboration revenue $ 195 $ 544 $ 1,325 $ 1,412 Operating expenses: Â Â Â Â Research and development 5,902 12,368 37,404 35,763 General and administrative 3,931 5,003 14,888 14,700 Impairment of property and equipment 1,900 Â 1,883 1,592 Impairment of right-of-use assets Â Â 22,836 Â Restructuring and other related charges 2,804 Â 9,254 Â Total operating expenses 12,637 17,371 86,265 52,055 Loss from operations (12,442) (16,827) (84,940) (50,643) Other income: Â Â Â Â Interest income 576 1,192 2,517 3,161 Total other income 576 1,192 2,517 3,161 Loss before income tax expense (11,866) (15,635) (82,423) (47,482) Income tax expense (7) (16) (33) (42) Net loss (11,873) (15,651) (82,456) (47,524) Unrealized holding gain (loss) on short-term investments, net of tax 24 20 (13) (17) Comprehensive loss $ (11,849) $ (15,631) $ (82,469) $ (47,541) Net loss per share attributable to common stockholders- basic $ (0.18) $ (0.27) $ (1.27) $ (1.04) Net loss per share attributable to common stockholders- diluted $ (0.18) $ (0.27) $ (1.27) $ (1.04) Weighted-average common shares outstanding-basic 65,456,735 56,953,685 64,981,219 45,894,643 Weighted-average common shares outstanding-diluted 65,456,735 56,953,685 64,981,219 45,894,643 X - DefinitionImpairment of right of use asset. + ReferencesNo definition available. + Details Name: lyra_ImpairmentOfRightOfUseAsset Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99

-Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands Total Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss), net of tax Accumulated Deficit Balance at Dec. 31, 2022 $ 80,754 $ 32 $ 329,387 $ 10 $ (248,675) Balance, Shares at Dec. 31, 2022 Â 31,827,659 Â Â Â Exercise of common stock options 4 Â 4 Â Â Exercise of common stock options, Shares Â 2,115 Â Â Â Issuance of common stock upon RSU vesting, shares Â 7,041 Â Â Â Unrealized loss on available-for-sale securities (22) Â Â (22) Â Stock-based compensation 1,610 Â 1,610 Â Â Net Income (Loss) (16,255) Â Â Â (16,255) Balance at Mar. 31, 2023 66,091 $ 32 331,001 (12) (264,930) Balance, Shares at Mar. 31, 2023 Â 31,836,815 Â Â Â Balance at Dec. 31, 2022 80,754 $ 32 329,387 10 (248,675) Balance, Shares at Dec. 31, 2022 Â 31,827,659 Â Â Â Net Income (Loss) (47,524) Â Â Â Â Balance at Sep. 30, 2023 84,239 $ 50 380,395 (7) (296,199) Balance, Shares at Sep. 30, 2023 Â 49,545,559 Â Â Â Balance at Mar. 31, 2023 66,091 $ 32 331,001 (12) (264,930) Balance, Shares at Mar. 31, 2023 Â 31,836,815 Â Â Â Issuance of common stock and pre-fundedwarrants, net of issuance costs 46,668 $ 18 46,650 Â Â Issuance of common stock and pre-funded warrants, net of issuance costs, Shares Â 17,652,962 Â Â Â Exercise of common stock options 97 Â 97 Â Â Exercise of common stock options, Shares Â 55,262 Â Â Â Unrealized loss on available-for-sale securities (15) Â Â (15) Â Stock-based compensation 1,354 Â 1,354 Â Â Net Income (Loss) (15,618) Â Â Â (15,618) Balance at Jun. 30, 2023 98,577 $ 50 379,102 (27) (280,548) Balance, Shares at Jun. 30, 2023 Â 49,545,039 Â Â Â Issuance costs (150) Â (150) Â Â Exercise of common stock options 2 Â 2 Â Â Exercise of common stock options, Shares Â 520 Â Â Â Unrealized gain on available-for-sale securities 20 Â Â 20 Â Stock-based compensation 1,441 Â 1,441 Â Â Net Income (Loss) (15,651) Â Â Â Â (15,651) Balance at Sep. 30, 2023 84,239 $ 50 380,395 (7) (296,199) Balance, Shares at Sep. 30, 2023 Â 49,545,559 Â Â Â Balance at Dec. 31, 2023 89,420 $ 57 400,685 33 (311,355) Balance, Shares at Dec. 31, 2023 Â 57,214,550 Â Â Â Exercise of common stock options 3 Â 3 Â Â Exercise of common stock options, Shares Â 918 Â Â Â Shares issued under ATM, net of issuance costs of $150 4,850 $ 1 4,849 Â Â Shares issued under ATM, net of issuance costs, Shares Â 1,041,666 Â Â Â Exercise of pre-funded warrants 2 $ 1 1 Â Â Exercise of pre-funded warrants, Shares Â 1,255,500 Â Â Â Exercise of common stock warrants 3,808 $ 2 3,806 Â Â Exercise of common stock warrants, Shares Â 1,424,272 Â Â Â Issuance of common stock upon RSU vesting, shares Â 27,869 Â Â Â Unrealized loss on available-for-sale securities (8) Â Â (8) Â Stock-based compensation 1,881 Â 1,881 Â Â Net Income (Loss) (22,452) Â Â Â (22,452) Balance at Mar. 31, 2024 77,504 $ 61 411,225 25 (333,807) Balance, Shares at Mar. 31, 2024 Â 60,964,775 Â Â Â Balance at Dec. 31, 2023 $ 89,420 $ 57 400,685 33 (311,355) Balance, Shares at Dec. 31, 2023 Â 57,214,550 Â Â Â Exercise of common stock options, Shares 1,002 Â Â Â Â Net Income (Loss) $ (82,456) Â Â Â Â Balance at Sep. 30, 2024 20,619 $ 65 414,345 20 (393,811) Balance, Shares at Sep. 30, 2024 Â 65,456,735 Â Â Â Balance at Mar. 31, 2024 77,504 $ 61 411,225 25 (333,807) Balance, Shares at Mar. 31, 2024 Â 60,964,775 Â Â Â Exercise of common stock options, Shares Â 84 Â Â Â Exercise of pre-funded warrants 8 $ 4 4 Â Â Exercise of pre-funded warrants, Shares Â 4,490,876 Â Â Â Unrealized loss on available-for-sale securities (29) Â Â (29) Â Stock-based compensation 1,625 Â 1,625 Â Â Net Income (Loss) (48,131) Â Â Â (48,131) Balance at Jun. 30, 2024 30,977 $ 65 412,854 (4) (381,938) Balance, Shares at Jun. 30, 2024 Â 65,455,735 Â Â Â Issuance of common stock under ESPP Â 1,000 Â Â Â Unrealized gain on available-for-sale securities 24 Â Â 24 Â Stock-based compensation 1,491 Â 1,491 Â Â Net Income (Loss) (11,873) Â Â Â (11,873) Balance at Sep. 30, 2024 $ 20,619 $ 65 $ 414,345 $ 20 $ (393,811) Balance, Shares at Sep. 30, 2024 Â 65,456,735 Â Â Â X - DefinitionAdditional paid in capital stock issued issuance costs. + ReferencesNo definition available. + Details Name: lyra_AdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance of common stock under ESPP. + ReferencesNo definition available. + Details Name: lyra_IssuanceOfCommonStockUnderEspp Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period, shares, Exercise of common stock warrants. + ReferencesNo definition available. + Details Name: lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period, shares, Exercise of pre-funded warrants. + ReferencesNo definition available. + Details Name: lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs. + ReferencesNo definition available. + Details Name: lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares vesting of restricted stock unit. + ReferencesNo definition available. + Details Name: lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period, value, exercise of common stock warrants. + ReferencesNo definition available. + Details Name: lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs. + ReferencesNo definition available. + Details Name: lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period, values, exercise of pre-funded warrants. + ReferencesNo definition available. + Details Name: lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) (unaudited) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Jun. 30, 2023 Issuance cost Â $ 3,332 ATM Â Â Issuance cost $ 150 Â X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=lyra_AtTheMarketMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Cash flows from operating activities: Â Â Â Â Net loss Â $ (82,456) $ (47,524) Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Stock-based compensation Â 4,777 4,405 Â Depreciation expense Â 320 193 Â Impairment of property and equipment $ 1,900 1,883 1,592 $ 1,600 Write-off of deferred financing costs Â 140 Â Â Impairment of right-of-use assets Â 22,836 Â Â Net amortization of premium on short-term investments Â (2,009) (2,408) Â Changes in operating assets and liabilities: Â Â Â Â Prepaid expenses and other current assets Â (750) 565 Â Operating lease right-of-use assets Â 570 1,080 Â Other assets Â 1,111 (3,240) Â Accounts payable Â (774) 3,985 Â Accrued expenses and other current liabilities Â (5,400) (625) Â Restructuring Liability Â 4,855 Â Â Operating lease liabilities Â (2,437) (857) Â Deferred revenue Â (1,325) (1,412) Â Net cash used in operating activities Â (58,659) (44,246) Â Cash flows from investing activities: Â Â Â Â Purchases of property and equipment Â (2,396) (260) Â Purchases of short-term investments Â (47,949) (72,765) Â Maturity of short-term investments Â 102,519 62,800 Â Net cash provided by (used in) investing activities Â 52,174 (10,225) Â Cash flows from financing activities: Â Â Â Â Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs Â 8,819 50,000 Â Payment of deferred offering costs Â (290) (3,332) Â Proceeds from exercise of stock options Â 3 103 Â Net cash provided by financing activities Â 8,532 46,771 Â Net increase (decrease) in cash, cash equivalents and restricted cash Â 2,047 (7,700) Â Cash, cash equivalents and restricted cash, beginning of period Â 23,745 33,942 33,942 Cash, cash equivalents and restricted cash, end of period $ 25,792 25,792 26,242 $ 23,745 Supplemental disclosure of non-cash financing and investing activities: Â Â Â Â Property and equipment purchases included in accounts payable Â Â 8 Â Modification of lease agreement Â Â 4,931 Â Issuance Costs in accounts payable, accrued expenses, and other current liabilities Â Â 150 Â Other assets included in accounts payable and other current liabilities Â Â 2,740 Â Right of Use Asset in Exchange for Lease Liability Â $ 13,667 Â Â Deferred offering costs included in accounts payable and accrued expenses Â Â $ 161 Â X - DefinitionDeferred offering costs incurred but not yet paid. + ReferencesNo definition available. + Details Name: lyra_DeferredOfferingCostsIncurredButNotYetPaid Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionImpairment of right of use asset. + ReferencesNo definition available. + Details Name: lyra_ImpairmentOfRightOfUseAsset Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in accrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in operating lease right-of-use asset. + ReferencesNo definition available. + Details Name: lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance costs in accounts payable accrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: lyra_IssuanceCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionModification of Lease Agreement + ReferencesNo definition available. + Details Name: lyra_ModificationOfLeaseAgreement Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther assets included in accounts payable and other current liabilities. + ReferencesNo definition available. + Details Name: lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs + ReferencesNo definition available. + Details Name: lyra_ProceedsFromSaleOfCommonStockPurchaseWarrantsAndPreFundedWarrantsNetOfIssuanceCosts Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-

gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveAccrualAdjustment1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWrite-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_WriteOffOfDeferredDebtIssuanceCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (11,873) $ (48,131) $ (22,452) $ (15,651) $ (15,618) $ (16,255) $ (82,456) $ (47,524) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Organization, Restructuring, Going Concern and Basis of Presentation 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization, Restructuring, Going Concern and Basis of Presentation 1. Organization, Restructuring, Going Concern and Basis of Presentation Lyra Therapeutics, Inc. (the â€œCompanyâ€) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Companyâ€™s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Companyâ€™s product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on November 21, 2005 and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc. The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates.Restructuring On May 16, 2024, the Company reported that topline results from the Companyâ€™s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210, a bioabsorbable sinonasal implant (7500Âµg mometasone furoate), as a six-month treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal

obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210. The 52-week safety extension phase of the ENLIGHTEN 1 trial recently completed and data is expected in Q4 2024. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results are expected in the second quarter of 2025. In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors of the Company (the â€œBoard of Directorsâ€) approved a reduction in the Companyâ€™s workforce impacting 87 employees, which occurred during May and June 2024. In connection with the reduction in force, the Company stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses. Furthermore, the Company is currently in the process of marketing all three of its leased properties for sub-leasing arrangements.The Company has recorded a restructuring charge in the amount of $9.3 million for the nine months ended September 30, 2024, primarily related to severance and retention costs as further discussed in Note 4. The Company has also recorded an impairment charge for the write-down of property and equipment of $1.9 million and right-of-use assets in the amount of $22.8 million as further discussed in Notes 5 and 6. Â Going ConcernThe failure of the Companyâ€™s Phase 3 ENLIGHTEN 1 trial to meet its primary endpoint, which resulted in the Companyâ€™s restructuring during the second quarter of 2024, provides significant uncertainty regarding the Companyâ€™s ability to meet its business plans and conduct its future operations. The Company has incurred recurring net operating losses every year since inception and has an accumulated deficit of approximately $393.8 million at September 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future. At September 30, 2024, the Company had approximately $23.8 million of cash and cash equivalents and $27.8 million of short-term investments. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. From inception through September 30, 2024, the Company has raised an aggregate of $424.8 million to fund its operations, of which $162.1 million were gross proceeds from sales of redeemable convertible preferred stock, $96.3 million were net proceeds from the April 2022 financing, $46.5 million were net proceeds from the May 2023 Financing (as defined below), $57.3 million were net proceeds from the Companyâ€™s initial public offering, $23.9 million were net proceeds related to the Companyâ€™s Controlled Equity Offering Agreement (the â€œOriginal Sales Agreementâ€) dated September 1, 2023, $16.8 million were gross proceeds from government contracts, $17.0 million were gross proceeds from the LianBio License Agreement, and $3.8 million were gross proceeds from the exercise of common stock warrants. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) assuming the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board of Directors has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. The Company is attempting to sublease all of its leased locations, and, may also seek to negotiate an early termination of its leases with its landlords. The Company may be unable to sublease its locations on favorable terms or at all. In addition, the Company may not be able to obtain an early termination of its leases with its landlords on favorable terms or at all. The Company will continue to evaluate its headcount of employees and may further reduce its workforce, which will result in additional severance and retention costs, which may impact the Companyâ€™s ability to meet objectives. If the Company decides to pursue any form of growth strategy in the future, it will need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to obtain funding as and when needed would have a negative impact on the Companyâ€™s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so.Basis of Presentation The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on March 22, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUâ€) of the Financial Accounting Standards Board (â€œFASBâ€). In managementâ€™s opinion, these unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Companyâ€™s condensed consolidated financial statements for the periods presented. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies The Companyâ€™s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2023, included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 22, 2024. Since the date of those financial statements, there have been no changes to its significant accounting policies except as noted below.Â Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholdersâ€™ equity that result from transactions and economic events other than those with stockholders. For the three and nine months ended September 30, 2024, other comprehensive loss consisted of unrealized losses, net of taxes from its short-term investments.Restricted Cash The Company had restricted cash of approximately $2.0 million as of September 30, 2024 and approximately $1.4 million as of December 31, 2023. These balances were held as of September 30, 2024 at one of the Companyâ€™s financial institutions to secure the Companyâ€™s letters of credit for its facility leases. The Companyâ€™s statements of cash flows include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on such statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows: Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 23,800 Â Â $ 22,353 Â Restricted cash Â Â 1,992 Â Â Â 1,392 Â Total Â $ 25,792 Â Â $ 23,745 Â Â Â Â Â Â Â Net Loss per Share The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has included pre-funded warrants in its computation of basic net loss per share based on the nominal exercise price. The Company applies the two-class method to calculate its basic and diluted net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Companyâ€™s participating securities contractually entitle the holders of such shares to participate in dividends, but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) for the three and nine months ended September 30, 2024 and 2023: Â Â Â 2024 Â Â 2023 Â Stock options Â Â 6,387,089 Â Â Â 5,838,677 Â Common stock warrants Â Â 8,606,303 Â Â Â 10,030,575 Â Restricted stock units Â Â 867,472 Â Â Â 243,703 Â Total Â Â 15,860,864 Â Â Â 16,112,955 Â Â Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Companyâ€™s consolidated financial position, results of operations or cash flows.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, designed to improve reportable segment disclosures. The guidance expands the disclosures required for reportable segments in our annual and interim condensed consolidated financial statements, primarily through enhanced disclosures about significant segment expenses. The standard will be effective for us beginning with our annual reporting for fiscal year 2024 and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact of this standard on our segment disclosures.This standard requires disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker, â€œCODMâ€, and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The Company will include the required disclosure information in the notes to the financial statements for the year ending December 31, 2024 included in its 2024 Annual Report on Form 10-K and is required to apply ASU No. 2023-07 on a retrospective basis. The adoption of ASU No. 2023-07 will include expanded disclosure for its 2024 financial statements, but the Company does not expect that there will be a material impact to the financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes.Effective January 1, 2023, the Company adopted Accounting Standards Update (ASU) No. 2016-13, Financial Instrumentsâ€”Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entityâ€™s current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The adoption of ASU 2016-13 did not have a material impact on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 3. Fair Value Measurements The following tables present information about the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: Â Â Â Â Â Fair Value Measurements at Reporting Date Using Â Â Â September 30, Â Â Quoted Prices in Active Markets for Identical Assets(Level 1) Â Â Significant Other Observable Inputs(Level 2) Â Â Significant Unobservable Inputs(Level 3) Â Â Â 2024 Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â

http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring and Other Related Charges 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Restructuring and Other Related Charges 4. Restructuring and Other Related ChargesIn connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors approved a reduction in the Companyâ€™s workforce, impacting 87 employees, which occurred during May and June 2024. The Company incurred costs related to employee termination benefits and other costs associated with the restructuring mainly during the second quarter of 2024, with the remainder of the costs to be incurred through May 1, 2025. These amounts are recorded as restructuring and other related charges within our condensed consolidated statements of operations and comprehensive loss as they are incurred. For the three months ended September 30, 2024, restructuring and other related charges were $2.8 million, which consisted of $0.9 million of severance costs, $1.8 million of retention costs, and $0.1 million of other costs. For the nine months ended September 30, 2024, restructuring and other related charges were $9.3 million, which consisted of $5.7 million of severance costs, $2.6 million of retention costs, and $1.0 million of other costs.Restructuring liability activities during the nine months ended September 30, 2024 (in thousands):Â Â Â January 1, Â Â Â Â Â Â Â Â Â September 30, Â Â Â 2024 Â Â Accruals Â Â Cash Payments Â Â 2024 Â 2024 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Severance Costs Â $ â€” Â Â $ 5,651 Â Â $ (3,435) Â $ 2,216 Â Retention Costs Â Â â€” Â Â Â 2,608 Â Â $ (74) Â $ 2,534 Â Other Costs Â Â â€” Â Â Â 995 Â Â Â (890) Â $ 105 Â Total Â $ â€” Â Â $ 9,254 Â Â $ (4,399) Â $ 4,855 Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment and Related Impairment 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Property and Equipment and Related Impairment 5. Property and Equipment and Related ImpairmentProperty and equipment consist of the following (in thousands) as of September 30, 2024 and December 31, 2023: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Property and equipment: Â Â Â Â Â Â Laboratory equipment Â $ 4,158 Â Â $ 2,736 Â Computer software and equipment Â Â 160 Â Â Â 105 Â Office furniture and fixtures Â Â 934 Â Â Â Â 662 Â Leasehold improvements Â Â 485 Â Â Â 461 Â Â Â Â Â Total Â $ 5,737 Â Â $ 3,964 Â Less: Accumulated depreciation Â Â (2,241) Â Â (1,921) Less: Impairment Â Â (1,883) Â Â â€” Â Property and equipment, net Â $ 1,613 Â Â $ 2,043 Â During the second quarter of 2024 and as a result of the Companyâ€™s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, the Company performed a recoverability test for its property and equipment. The Company concluded that the undiscounted cash flows associated with its property and equipment was less than the carrying value of the property and equipment. The Company compared the fair value of the property and equipment to the carrying value and recorded an impairment charge in the amount of $1.9 million which is included as an impairment of property and equipment in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024. The Company determined fair market value of the equipment based on a third-party appraisal of the equipment through use of publicly available used equipment quotes. The equipment was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of September 30, 2024, and determined no additional impairment indicators existed. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Impairment of Right of Use Assets 9 Months Ended Sep. 30, 2024 Asset Impairment Charges [Abstract] Â Impairment of Right of Use Assets 6. Impairment of Right-of-Use AssetsIn connection with the Companyâ€™s Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, in May 2024, the Company engaged a commercial real estate broker to market the Companyâ€™s three leased properties for sublease arrangements. As of September 30, 2024, the Company has not sublet any of its leased properties. Based upon these impairment indicators, the Company has performed a recoverability test over its right-of-use asset and concluded the right-of-use assets are impaired. As a result, the Company has recorded an impairment charge in the amount of $22.8 million, which is included as an impairment of right-of-use asset in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024. The right-of-use asset was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of September 30, 2024, and determined no additional impairment indicators existed.The Company engaged a valuation specialist to perform a fair value determination of the right-of-use assets using a discounted cash flow methodology, which included the following range of assumptions:Â Discount Rate Â 9.5-10.5% Â Term (years) Â 2.96-9.13 Â Expected Sublease Rent Increases Â Â 3.0 % X - ReferencesNo definition available. + Details Name: us-gaap_AssetImpairmentChargesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported. + ReferencesNo definition available. + Details Name: us-gaap_AssetImpairmentChargesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred and Common Stock 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Preferred and Common Stock 7. Preferred and Common StockThe Company has 10,000,000 shares of undesignated preferred stock, par value $0.001 per share. There were no shares issued or outstanding as of September 30, 2024 or September 30, 2023.The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.The Company currently has an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 (â€œForm S-3â€), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $300.0 million in the aggregate. Â September 2023 FinancingOn September 1, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Original Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $50.0 million. The offering and sale of up to $50.0 million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-256020) (the "Registration Statement"), which was originally filed with the SEC on May 11, 2021, and declared effective by the SEC on May 20, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on September 1, 2023.Pursuant to the Original Sales Agreement, Cantor may sell the shares in sales deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company has no obligation to sell any of the shares under the Original Sales Agreement and may at any time suspend or terminate the offering of the shares pursuant to the Original Sales Agreement upon notice to Cantor and subject to other conditions. Cantor will act as sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the shares requested to be sold by the Company, on mutually agreed terms between Cantor and the Company.The Original Sales Agreement contains customary representations, warranties and agreements by the Company, and indemnification obligations of the Company and Cantor and other obligations of the parties. Under the terms of the Original Sales Agreement, the Company has agreed to pay Cantor a commission equal to 3.0% of the aggregate gross proceeds from any shares sold through it pursuant to the Original Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by Cantor in connection with the Original Sales Agreement. On February 14, 2024, the Company issued 1,041,666 shares under the Companyâ€™s ATM agreement with net proceeds of $4.8 million. On March 22, 2024, the Company amended and restated the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $75.0 million. The offering and sale of up to $75.0 million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-278163) (the "Registration Statement"), which was originally filed with the Securities and Exchange Commission on March 22, 2024, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on March 22, 2024 (the "Prospectus Supplement"). Â May 2023 FinancingOn May 25, 2023, the Company entered into the Purchase Agreement, with the purchasers, pursuant to which the Company agreed to sell securities to the Investors in a private placement (the â€œPrivate Placementâ€). The Purchase Agreement provided for the sale and issuance by the Company of: 17,652,962 shares of the Companyâ€™s common stock and accompanying warrants to purchase up to 8,826,481 shares of the Companyâ€™s common stock (Purchase Warrants), with an exercise price of $2.67 per share, for aggregate gross proceeds of $44.0 million. Each Purchase Warrant became exercisable on November 30, 2023, and expires on November 30, 2028. Additionally, the Company issued Pre-Funded Warrants to purchase 2,408,188 shares of the Companyâ€™s common stock (Pre-Funded Warrants), with an exercise price of $0.001 per share, and accompanying purchase warrants to purchase up to 1,204,094 shares of the Companyâ€™s common stock (Purchase Warrants), with an exercise price of $2.673 per share, for aggregate gross proceeds of $6.0 million. In total 10,030,575 Purchase Warrants were issued and 2,408,188 Pre-Funded Warrants were issued. The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028. The closing of the Private Placement occurred on May 31, 2023. The Company received an aggregate of $50.0 million in gross proceeds, or $46.5 million after deducting issuance costs. The Company has allocated the net proceeds among the common stock, the Purchase Warrants and the Pre-Funded Warrants using the relative fair value method for each of the above transactions. The Company has allocated $30.5 million to the shares of common stock, $4.2 million to the Pre-Funded Warrants and $12.0 million to the Purchase Warrants. The Companyâ€™s outstanding warrants are freestanding instruments and are classified within stockholdersâ€™ equity since the warrants are indexed to the Companyâ€™s common stock and meet the equity classification criteria. A total of 1,424,272 Purchase Warrants were exercised related to the May 2023 financing as of September 30, 2024 at a purchase price of $2.673 per share.Â April 2022 FinancingOn April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, Pre-Funded Warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million (the â€œApril 2022 Financingâ€). The Company received approximately $96.3 million in net proceeds after deducting estimated offering costs of $4.2 million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of 18,815,159 shares of common stock at $4.22 per share for gross proceeds to the Company of $79.4 million and (ii) certain investors purchased Pre-Funded Warrants to purchase an aggregate of 5,000,000 shares of common stock, with the exercise price of $0.001 per share for gross proceeds of $21.1 million to the Company. The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027.The Pre-Funded Warrants were classified as a component of stockholdersâ€™ equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Companyâ€™s common stock and meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Pre-Funded Warrants, of which $19.7 million was allocated to the Pre-Funded Warrants and recorded as a component of additional paid-in capital. All Pre-Funded Warrants issued in the April 2022 Financing were exercised as of June 30, 2024.The Company has reserved for future issuances the following shares of common stock as of September 30, 2024: Â Â Â As of September 30, 2024 Â Common stock warrants Â Â 8,606,303 Â Stock options and restricted stock units Â Â 10,075,165 Â Employee stock purchase plan Â Â 723,906 Â Total Â Â 19,405,374 Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock Warrants 9 Months Ended Sep. 30, 2024 Warrants and Rights Note Disclosure [Abstract] Â Common Stock Warrants 8. Common Stock WarrantsThe following table represents a summary of the warrants outstanding and exercisable as of September 30, 2024, all of which are equity-classified: Â Â Number of Common Warrants Â Average Exercise Price Â Weighted Average Remaining Contractual Term (Years) Â Aggregate Intrinsic Value Â Expiration Date Â Number of Pre-funded Warrants Â Â Weighted Average Exercise Price Â Weighted Average Remaining Contractual Term (Years) Â Aggregate Intrinsic Value Â Expiration Date Â Outstanding at December 31, 2023 Â Â 10,030,575 Â $ 2.673 Â Â 4.90 Â $ 25,700 Â November 30, 2028 Â Â 5,756,349 Â Â $ 0.001 Â Â 3.92 Â $ 30,200 Â April 2027-May 2028 Â Exercised Â Â (1,424,272) $ 2.673 Â Â Â $ 5,052 Â Â Â Â (5,756,349) Â $ 0.001 Â Â Â $ 37,770 Â Â Â Outstanding at September 30, 2024 Â Â 8,606,303 Â $ 2.673 Â Â 4.15 Â $â€” Â November 30, 2028 Â Â â€” Â Â $â€” Â Â â€” Â $â€” Â Â â€” Â X - DefinitionThe entire disclosure for common stock warrants. + ReferencesNo definition available. + Details Name: lyra_CommonStockWarrantsDisclosureTextBlock Namespace Prefix: lyra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation Expense 9. Stock-Based Compensation Expense The Company currently grants equity-based awards under its 2020 Incentive Award Plan (â€œ2020 Planâ€) and its 2022 Employment Inducement Award Plan (â€œInducement Award Planâ€). The Company previously granted equity-based awards under its 2005 Equity Incentive Plan (â€œ2005 Planâ€) and 2016 Equity Incentive Plan (â€œ2016 Planâ€ and together with the 2020 Plan, the Inducement Award Plan and the 2005 Plan, the â€œPlansâ€). The Company also maintains the 2020 Employee Stock Purchase Plan (the â€œESPPâ€).A summary of the restricted stock unit activity under the Plans for the nine months ended September 30, 2024 was as follows: Â Â Shares Â Â Weighted-AverageGrant Date Fair Value Â Restricted stock units outstanding as of December 31, 2023 Â Â 105,048 Â Â $ 3.20 Â Granted Â Â 984,929 Â Â $ 5.49 Â Vested Â Â (27,869) Â $ 3.29 Â Forfeited Â Â (194,636) Â $ 4.28 Â Restricted stock units outstanding as of September 30, 2024 Â Â 867,472 Â Â $ 5.56 Â Â A summary of the stock option activity under the Plans for the nine months ended September 30, 2024 was as follows: Â Â Shares Â Â Weighted-AverageExercisePrice Â Â Weighted-AverageRemainingContractualLife(in years) Â Â AggregateIntrinsicValue(in thousands) Â Outstanding at December 31, 2023 Â Â 5,709,980 Â Â $ 5.68 Â Â Â 8.0 Â Â $ 6,334 Â Granted Â Â 2,605,002 Â Â Â 4.89 Â Â Â Â Â Â Â Exercised Â Â (1,002) Â Â 3.96 Â Â Â Â Â Â Â Cancelled Â Â (1,926,891) Â Â 4.83 Â Â Â Â Â Â Â Outstanding at September 30, 2024 Â Â 6,387,089 Â Â Â $ 5.61 Â Â Â 7.9 Â Â $â€” Â The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of certain options granted to executive officers, with the following weighted-average assumptions for the three and nine months ended September 30, 2024 and 2023: Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Risk-free interest rate Â Â 0.0 % Â Â 4.3 % Â Â 4.2 % Â Â 3.7 % Expected dividend yield Â Â Â€” % Â Â Â€” % Â Â Â€” % Â Â Â€” % Expected term (in years) Â Â Â€” Â Â Â 6.1 Â Â Â 6.0 Â Â Â 6.0 Â Expected volatility Â Â 0.0 % Â Â 80.0 % Â Â 80.5 % Â Â 82.9 % The weighted-average fair value of options granted to employees, directors and non-employees during the three months ended September 30, 2023 was $2.57. There were no options granted to employees, directors or non-employees during the three months ended September 30, 2024. The weighted-average fair value of options granted to employees, directors and non-employees during the nine months ended September 30, 2024 and 2023 was $2.80 and $2.08, respectively.Stock-based compensation expense included in the Companyâ€™s consolidated statements of operations and comprehensive loss was as follows (in thousands): Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 214 Â Â $ 294 Â Â $ 627 Â Â $ 865 Â General and administrative Â Â 1,277 Â Â Â 1,147 Â Â Â 4,150 Â Â Â 3,540 Â Total Â $ 1,491 Â Â $ 1,441 Â Â $ 4,777 Â Â $ 4,405 Â For the period ended September 30, 2024, approximately $15,000 of the stock-based compensation expense was recorded as a liability. For the period ended September 30, 2023, the Company did not record any stock-based compensation expense as a liability.Unrecognized share-based compensation related to stock-based options amounted to $6.6 million at September 30, 2024 and is expected to be recognized over a weighted average period of approximately 2.86 years. Unrecognized share-based compensation related to restricted stock units amounted to $2.0 million at September 30, 2024 and is expected to be recognized over a weighted average period of approximately 2.4 years.In March 2024, the Company granted options to purchase 550,000 shares of common stock at an exercise price of $6.07 per share to its Chief Executive Officer (â€œ2024 Performance Optionâ€) and granted 385,000 RSUs to its Executive Chair (â€œ2024 PSUsâ€), each with performance-based vesting conditions under the 2020 Plan. Vesting of the 2024 Performance Option and the 2024 PSUs are based on the achievement of various clinical and regulatory milestones during the specified periods. For the performance-based stock awards, the Company measures stock compensation expense based on the fair value of the award on the grant date and then once the Company determines the performance criteria is probable of achievement, recognizes such amount over the vesting term of the award, which is approximately 3.8 years. The Company determined the fair value of the 2024 Performance Option using the Black-Scholes option-pricing model using the following inputs: risk-free interest rate of 4.26%, volatility of 76.82%, expected dividend yield 0%, and expected term of 6.0 years.The Company measured the 2024 PSUs based on the fair value of the Companyâ€™s stock on the date of grant.As of March 31, 2024, the Company has determined that 183,333 shares of common stock subject to the 2024 Performance Option and 128,333 shares of common stock underlying the 2024 PSUs are probable to vest and as of September 30, 2024 has recognized approximately $214,000 of expense, which is included in stock-based compensation expense. As of September 30, 2024, there is $1.3 million of unrecognized stock compensation expense to be recognized in connection with all of the performance-based awards that are deemed to be probable as of September 30, 2024. As of September 30, 2024, there were 1,957,604 shares available for grant under the 2020 Plan and 863,000 shares available for grant under the Inducement Award Plan. During the nine month ended September 30, 2024, the Company issued 1,000 shares under the 2020 ESPP. As of September 40, 2024, there are a total of 723,906 shares available for issuance under the 2020 ESPP. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreement 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Collaboration Agreement 10. Collaboration AgreementUnder the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of September 30, 2024, as all milestone amounts were fully constrained based on the probability of achievement. The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2023. There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement. The amendment did not result in any change in the Companyâ€™s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.LianBio announced that in October 2023 its Board of Directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in February 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Companyâ€™s collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBioâ€™s rights under the LianBio License Agreement. The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in managementâ€™s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Companyâ€™s consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively.There were no changes in the transaction price from December 31, 2023 to September 30, 2024. The following table reflects the transaction price (in thousands): Â Â As of September 30, 2024 Â Â Â Post-Milestone Â Combined Performance Obligation Â $ 11,862 Â Development Activities Performance Obligation Â Â 5,138 Â Total Â $ 17,000 Â The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands): Â Â As of September 30, 2024 Â Â Â Combined Performance Obligation Â Â Development Activities Performance Obligation Â Â Total Â Deferred revenue at December 31, 2022 Â $ 11,748 Â Â $ 3,604 Â Â $ 15,352 Â Revenue recognized Â Â Â€” Â Â Â (1,558) Â Â (1,558) Â Deferred revenue at December 31, 2023 Â Â 11,748 Â Â Â 2,046 Â Â Â 13,794 Â Revenue recognized Â Â Â€” Â Â Â (1,325) Â Â (1,325) Â Deferred revenue at September 30, 2024 Â $ 11,748 Â Â $ 721 Â Â $ 12,469 Â Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months. As of September 30, 2024, the parties still have not completed their negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule.Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Companyâ€™s directors are Managing Directors at Perceptive Advisors, LLC and one of these directors is also the Executive Chairman of LianBioâ€™s board of directors. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes 11. Income TaxesThe Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the

year. Given the Companyâ€™s uncertainty regarding future taxable income, the Company maintains a full valuation allowance on its deferred tax assets. The Company recorded an income tax expense of $7,000 for the three months ended September 30, 2024 and $16,000 for the three months ended September 30, 2023 and $33,000 for the nine months ended September 30, 2024 and $42,000 for the nine months ended September 30, 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Leases 12. Leases Watertown LeaseIn August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. The lease includes certain rent escalations. In July 2023, the Company amended the lease to extend the expiration of the lease term from April 2024 to April 2027. Under the terms of the amended lease, the Company no longer has the right to terminate the lease after January 1, 2024. The Company maintains a letter of credit of approximately $0.3 million securing its obligations under the operating lease which is secured by approximately $0.3 million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy.The Company also has two leases for two separate spaces in the same building at 880 Winter Street in Waltham, Massachusetts. The Company refers to the first lease as the â€œWaltham Leaseâ€ and the second lease arrangement as the â€œWaltham Subleaseâ€ as the Company, as a tenant, is subleasing space from under an existing lease arrangement whereby the lessee to the headlease has agreed to sublease the space to the Company under a sublease agreement.Waltham LeaseIn May 2022, the Company executed a lease agreement located at 880 Winter Street in Waltham, Massachusetts. The leased premises comprises approximately 29,000 square feet of office and lab space, and the lease initially provides for base rent of $2.2 million per year, which will increase 3% per year over the noncancellable term ending on June 30, 2033. The Company has the option to extend the lease for one additional five-year term and is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company did not include the option to extend the lease for the additional five-year term in its measurement of the right-of-use asset and lease liability.In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $1.1 million of deposits with the financial institution which is recorded as restricted cash.Waltham SubleaseIn December 2023, the Company executed a sublease agreement for additional lab and office space located at 880 Winter Street in Waltham, Massachusetts. The subleased premises comprise approximately 24,000 square feet, and the sublease provides for base rent of $1.8 million per year, which will increase 3% per year over the noncancellable term ending on November 30, 2032. The Company is also responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the subleased premises.Upon sublease commencement on January 3, 2024, the Company recorded the sublease as a component of its operating lease right-of-use asset and operating lease liabilities. In connection with the sublease, a security deposit was delivered to the sublandlord in the form of an irrevocable standby letter of credit collateralized by $0.6 million of deposits with the financial institution which is recorded as restricted cash.The components of lease cost recorded in the Companyâ€™s condensed consolidated financial statements were as follows (in thousands):Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Lease Cost: Â Â Â

Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows: Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 23,800 Â Â $ 22,353 Â Restricted cash Â Â 1,992 Â Â Â 1,392 Â Total Â $ 25,792 Â Â $ 23,745 Â Â Â Â Â Â Â Â Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) for the three and nine months ended September 30, 2024 and 2023: Â Â Â 2024 Â Â 2023 Â Stock options Â Â 6,387,089 Â Â Â 5,838,677 Â Common stock warrants Â Â 8,606,303 Â Â Â 10,030,575 Â Restricted stock units Â Â 867,472 Â Â Â 243,703 Â Total Â Â 15,860,864 Â Â Â 16,112,955 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis The following tables present information about the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: Â Â Â Â Â Fair Value Measurements at Reporting Date Using Â Â Â September 30, Â Â Quoted Prices in Active Markets for Identical Assets(Level 1) Â Â Significant Other Observable Inputs(Level 2) Â Â Significant Unobservable Inputs(Level 3) Â Â Â 2024 Â Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 16,976 Â Â $ 16,976 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â $ 16,976 Â Â $ 16,976 Â Â $ â€” Â Â $ â€” Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. treasury bills Â $ 27,826 Â Â $ â€” Â Â $ 27,826 Â Â $ â€” Â Total Short-term investments Â $ 27,826 Â Â $ â€” Â Â $ 27,826 Â Â $ â€” Â Â Â Â Â Â Fair Value Measurements at Reporting Date Using Â Â Â December 31, Â Â Quoted Prices in Active Markets for Identical Assets(Level 1) Â Â Significant Other Observable Inputs(Level 2) Â Â Significant Unobservable Inputs(Level 3) Â Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Assets: Â Money market funds Â $ 11,167 Â Â $ 11,167 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â $ 20,147 Â Â $ 11,167 Â Â $ 8,980 Â Â $ â€” Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. treasury bills Â $ 76,918 Â Â $ â€” Â Â $ 76,918 Â Â $ â€” Â Â Â Â U.S. Government Agency and foreign national bank securities Â Â 3,482 Â Â Â â€” Â Â Â 3,482 Â Â Â â€” Â Total Short-term investments Â $ 80,400 Â Â $ â€” Â Â $ 80,400 Â Â $ â€” Â Â X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring and Other Related Charges (Tables) 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Summary of Restructuring Liability Activities Restructuring liability activities during the nine months ended September 30, 2024 (in thousands):Â Â Â January 1, Â Â Â Â Â Â Â Â Â September 30, Â Â Â 2024 Â Â Accruals Â Â Cash Payments Â Â 2024 Â 2024 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Â Â Severance Costs Â $ â€” Â Â $ 5,651 Â Â $ (3,435) Â $ 2,216 Â Retention Costs Â Â Â€” Â Â Â 2,608 Â Â $ (74) Â $ 2,534 Â Other Costs Â Â Â€” Â Â Â 995 Â Â Â (890) Â $ 105 Â Total Â $ â€” Â Â $ 9,254 Â Â $ (4,399) Â $ 4,855 Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment and Related Impairment (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Property Plant And Equipment Property and equipment consist of the following (in thousands) as of September 30, 2024 and December 31, 2023: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Property and equipment: Â Â Â Â Â Â Laboratory equipment Â $ 4,158 Â Â $ 2,736 Â Computer software and equipment Â Â 160 Â Â Â 105 Â Office furniture and fixtures Â Â 934 Â Â Â 662 Â Leasehold improvements Â Â 485 Â Â Â 461 Â Â Â Â Â Total Â $ 5,737 Â Â $ 3,964 Â Less: Accumulated depreciation Â Â (2,241) Â Â (1,921) Less: Impairment Â Â (1,883) Â Â â€” Â Property and equipment, net Â $ 1,613 Â Â $ 2,043 Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Impairment of Right of Use Assets (Tables) 9 Months Ended Sep. 30, 2024 Asset Impairment Charges [Abstract] Â Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology The Company engaged a valuation specialist to perform a fair value determination of the right-of-use assets using a discounted cash flow methodology, which included the following range of assumptions:Â Discount Rate Â 9.5-10.5% Â Term (years) Â 2.96-9.13 Â Expected Sublease Rent Increases Â Â 3.0 % X - DefinitionSchedule of discounted cash flow methodology range of assumptions. + ReferencesNo definition available. + Details Name: lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock Namespace Prefix: lyra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetImpairmentChargesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred and Common Stock (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Schedule of Common Stock Reserved for Future Issuances The Company has reserved for future issuances the following shares of common stock as of September 30, 2024: Â Â Â As of September 30, 2024 Â Common stock warrants Â Â 8,606,303 Â Stock options and restricted stock units Â Â 10,075,165 Â Employee stock purchase plan Â Â 723,906 Â Total Â Â 19,405,374 Â X - DefinitionShares of common stock reserved for future issuances. + ReferencesNo definition available. + Details Name: lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock Namespace Prefix: lyra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock Warrants (Tables) 9 Months Ended Sep. 30, 2024 Warrants and Rights Note Disclosure [Abstract] Â Summary of Warrants Outstanding and Exercisable The following table represents a summary of the warrants outstanding and exercisable as of September 30, 2024, all of which are equity-classified: Â Â Number of Common Warrants Â Average Exercise Price Â Weighted Average Remaining Contractual Term (Years) Â Aggregate Intrinsic Value Â Expiration Date Â Number of Pre-funded Warrants Â Â Weighted Average Exercise Price Â Weighted Average Remaining Contractual Term (Years) Â Aggregate Intrinsic Value Â Expiration Date Â Outstanding at December 31, 2023 Â Â 10,030,575 Â $ 2.673 Â Â 4.90 Â $ 25,700 Â November 30, 2028 Â Â 5,756,349 Â Â $ 0.001 Â Â 3.92 Â $ 30,200 Â April 2027-May 2028 Â Exercised Â Â (1,424,272) $ 2.673 Â Â Â $ 5,052 Â Â Â Â (5,756,349) Â $ 0.001 Â Â Â Â $ 37,770 Â Â Â Outstanding at September 30, 2024 Â Â 8,606,303 Â $ 2.673 Â Â 4.15 Â $ â€” Â November 30, 2028 Â Â â€” Â Â $ â€” Â Â Â â€” Â $ â€” Â Â â€” Â X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Restricted Stock Unit Activity A summary of the restricted stock unit activity under the Plans for the nine months ended September 30, 2024 was as follows: Â Â Shares Â Â Weighted-AverageGrant Date Fair Value Â Restricted stock units outstanding as of December 31, 2023 Â Â 105,048 Â Â $ 3.20 Â Granted Â Â 984,929 Â Â $ 5.49 Â Vested Â Â (27,869) Â $ 3.29 Â Forfeited Â Â (194,636) Â $ 4.28 Â Restricted stock units outstanding as of September 30, 2024 Â Â 867,472 Â Â $ 5.56 Â Â Summary of Stock Option Activity Under Plans A summary of the stock option activity under the Plans for the nine months ended September 30, 2024 was as follows: Â Â Shares Â Â Weighted-AverageExercisePrice Â Â Weighted-AverageRemainingContractualLife(in years) Â Â AggregateIntrinsicValue(in thousands) Â Outstanding at December 31, 2023 Â Â 5,709,980 Â Â $ 5.68 Â Â 8.0 Â Â $ 6,334 Â Granted Â Â 2,605,002 Â Â Â 4.89 Â Â Â Â Â Â Â Â Exercised Â Â (1,002) Â Â 3.96 Â Â Â Â Â Â Â Â Cancelled Â Â (1,926,891) Â Â 4.83 Â Â Â Â Â Â Â Â Outstanding at September 30, 2024 Â Â 6,387,089 Â Â $ 5.61 Â Â Â 7.9 Â Â $ â€” Â Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of certain options granted to executive officers, with the following weighted-average assumptions for the three and nine months ended September 30, 2024 and 2023: Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Risk-free interest rate Â Â 0.0 % Â Â 4.3 % Â Â 4.2 % Â Â 3.7 % Expected dividend yield Â Â â€” % Â Â â€” % Â Â â€” % Â Â â€” % Expected term (in years) Â Â â€” Â Â Â 6.1 Â Â Â 6.0 Â Â Â 6.0 Â Expected volatility Â Â 0.0 % Â Â 80.0 % Â Â 80.5 % Â Â 82.9 % Schedule of Stock-Based Compensation Expense Stock-based compensation expense included in the Companyâ€™s consolidated statements of operations and comprehensive loss was as follows (in thousands): Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 214 Â Â $ 294 Â Â $ 627 Â Â $ 865 Â General and administrative Â Â 1,277 Â Â Â 1,147 Â Â Â 4,150 Â Â Â 3,540 Â Total Â $ 1,491 Â Â $ 1,441 Â Â $ 4,777 Â Â $ 4,405 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data

Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreement (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Summary of Transaction Price The following table reflects the transaction price (in thousands): Â Â As of September 30, 2024 Â Â Â Post-Milestone Â Combined Performance Obligation Â $ 11,862 Â Development Activities Performance Obligation Â Â 5,138 Â Total Â $ 17,000 Â Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands): Â Â As of September 30, 2024 Â Â Â Combined Performance Obligation Â Â Development Activities Performance Obligation Â Â Total Â Deferred revenue at December 31, 2022 Â $ 11,748 Â Â $ 3,604 Â Â $ 15,352 Â Revenue recognized Â Â â€” Â Â Â (1,558) Â Â (1,558) Deferred revenue at December 31, 2023 Â Â 11,748 Â Â Â 2,046 Â Â Â 13,794 Â Revenue recognized Â Â â€” Â Â Â (1,325) Â Â (1,325) Deferred revenue at September 30, 2024 Â $ 11,748 Â Â $ 721 Â Â $ 12,469 Â X - DefinitionTabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueByArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones. + ReferencesNo definition available. + Details Name: us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Components of Lease Cost The components of lease cost recorded in the Companyâ€™s condensed consolidated financial statements were as follows (in thousands):Â Â Â Three Months EndedSeptember 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Lease Cost: Â Â Â Â Â Â Â Â Â Â Â Â Operating lease cost Â $ 1,346 Â Â $ 483 Â Â $ 5,082 Â Â $ 1,371 Â Variable lease cost Â Â 608 Â Â Â 399 Â Â Â 1,866 Â Â Â 893 Â Total lease cost Â $ 1,954 Â Â $ 882 Â Â $ 6,948 Â Â $ 2,264 Â Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases The weighted-average remaining lease term and discount rate related to the Companyâ€™s operating leases were as follows: Â Â As of September 30, 2024 Â Weighted-average remaining lease term (in years) Â Â 7.7 Â Weighted-average discount rate Â Â 6.20 % Summary of Maturity of Operating Lease Liabilities Maturity of the Companyâ€™s operating lease liabilities in accordance with ASC 842 as of September 30, 2024 were as follows (in thousands): Period ended December 31, Â Â Â From October 1, 2024 to December 31, 2024 Â $ 1,546 Â 2025 Â Â 6,121 Â 2026 Â Â 6,494 Â 2027 Â Â 5,131 Â 2028 Â Â 4,507 Â Thereafter Â Â 20,652 Â Total maturities Â $ 44,451 Â Less: Imputed interest Â Â (9,127) Present value of operating lease liability Â $ 35,324 Â Less: current portion of operating lease liability Â Â (4,003) Total operating lease liability, net of current portion Â $ 31,321 Â X - DefinitionSummary of weighted average remaining lease terms and discount rate related to operating leases. + ReferencesNo definition available. + Details Name: lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock Namespace Prefix: lyra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details) $ in Thousands 2 Months Ended 3 Months Ended 9 Months Ended Mar. 22, 2024 USD ($) May 25, 2023 USD ($) Apr. 13, 2022 USD ($) Jun. 30, 2024 Employee Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Lease Dec. 31, 2023 USD ($) Organization And Basis Of Presentation [Line Items] Â Â Â Â Â Â Â Entity incorporation, date of incorporation Â Â Â Â Â Nov. 21, 2005 Â Restructuring charge Â Â Â Â $ 2,804 $ 9,254 Â Impairment charge for write-down of property and equipment Â Â Â Â Â 1,900 Â Impairment Of Right Of Use Asset Â Â Â Â Â 22,836 Â Fund raised for operations Â Â Â Â Â 424,800 Â Proceeds from issuance of redeemable convertible preferred stock Â Â Â Â Â 162,100 Â Proceeds from issuance initial public offering Â Â Â Â Â 57,300 Â Accumulated deficit Â Â Â Â (393,811) (393,811) $ (311,355) Cash and cash equivalents Â Â Â Â 23,800 23,800 22,353 Short-term investments Â Â Â Â $ 27,826 27,826 $ 80,400 Proceeds from government contracts Â Â Â Â Â 16,800 Â Gross proceeds for warrant exercises Â Â Â Â Â 3,800 Â Proceeds from license and collaboration agreement Â Â Â Â Â $ 17,000 Â Stock and warrants to be issued during period value preferred stock and warrants $ 300,000 Â Â Â Â Â Â Number of leased properties marketed for sublease arrangements | Lease Â Â Â Â Â 3 Â Private Placement Â Â Â Â Â Â Â Organization And Basis Of Presentation [Line Items] Â Â Â Â Â Â Â Net proceeds from private placement Â Â $ 96,300 Â Â $ 96,300 Â Private Placement | Purchase Agreement Â Â Â Â Â Â Â Organization And Basis Of Presentation [Line Items] Â Â Â Â Â Â Â Net proceeds from private placement Â $ 50,000 Â Â Â Â Â Net proceeds from issuance of preferred stock allocated to warrants Â 46,500 Â Â Â 46,500 Â Private Placement | Pre Funded Warrants Â Â Â Â Â Â Â Organization And Basis Of Presentation [Line Items] Â Â Â Â Â Â Â Gross proceeds for warrant exercises Â Â $ 21,100 Â Â Â Â Controlled Equity Offering Sales Agreement Â Â Â Â Â Â Â Organization And Basis Of Presentation [Line Items] Â Â Â Â Â Â Â Net proceeds Â Â Â Â Â $ 23,900 Â Employee Severance [Member] Â Â Â Â Â Â Â Organization And Basis Of Presentation [Line Items] Â Â Â Â Â Â Â Number of employees reduced | Employee Â Â Â 87 Â Â Â Common Stock Â Â Â Â Â Â Â Organization And Basis Of Presentation [Line Items] Â Â Â Â Â Â Â Net proceeds Â $ 30,500 Â Â Â Â Â Â X - DefinitionDate when an entity was incorporated + ReferencesNo definition available. + Details Name: dei_EntityIncorporationDateOfIncorporation Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionCash provided by financing activities. + ReferencesNo definition available. + Details Name: lyra_CashProvidedByFinancingActivities Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionImpairment of right of use asset. + ReferencesNo definition available. + Details Name: lyra_ImpairmentOfRightOfUseAsset Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of leased properties marketed for sublease arrangements. + ReferencesNo definition available. + Details Name: lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements Namespace Prefix: lyra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOrganization and basis of presentation. + ReferencesNo definition available. + Details Name: lyra_OrganizationAndBasisOfPresentationLineItems Namespace Prefix: lyra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionProceeds from government contracts. + ReferencesNo definition available. + Details Name: lyra_ProceedsFromGovernmentContracts Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from license and collaboration agreement. + ReferencesNo definition available. + Details Name: lyra_ProceedsFromLicenseAndCollaborationAgreement Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock and warrants to be issued during period value preferred stock and warrants. + ReferencesNo definition available. + Details Name: lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of positions eliminated during the period as a result of restructuring activities. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=lyra_ControlledEquityOfferingSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accounting Policies [Line Items] Â Â Restricted cash $ 1,992 $ 1,392 X - DefinitionAccounting Policies. + ReferencesNo definition available. + Details Name: lyra_AccountingPoliciesLineItems Namespace Prefix: lyra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Â Â Cash and cash equivalents $ 23,800 $ 22,353 Restricted cash 1,992 1,392 Total $ 25,792 $ 23,745 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Potentially dilutive securities excluded from calculation of diluted net loss per share 15,860,864 16,112,955 Employee Stock Option Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Potentially dilutive securities excluded from calculation of diluted net loss per share 6,387,089 5,838,677 Common stock warrants Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Potentially dilutive securities excluded from calculation of diluted net loss per share 8,606,303 10,030,575 Restricted stock units Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Potentially dilutive securities excluded from calculation of diluted net loss per share 867,472 243,703 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Short-term investments $ 27,826 $ 80,400 Fair Value, Recurring [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents 16,976 20,147 Short-term investments 27,826 80,400 Fair Value, Recurring [Member] | Money Market Funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents 16,976 11,167 Fair Value, Recurring [Member] | U.S. Treasury Bills Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents Â 8,980 Short-term investments 27,826 76,918 Fair Value, Recurring [Member] | U.S. Government Agency and foreign national bank securities Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Short-term investments Â 3,482 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents 16,976 11,167 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents 16,976 11,167 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents Â 8,980 Short-term investments $ 27,826 80,400 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | U.S. Treasury Bills Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash equivalents Â 8,980 Short-term investments Â 76,918 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | U.S. Government Agency and foreign national bank securities Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Short-term investments Â $ 3,482 X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Additional Information (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Fair Value Disclosures [Abstract] Â Â Financial assets, fair value $ 0 $ 0 Financial liabilities, fair value $ 0 $ 0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 47 R40.htm IDEA: XBRL

DOCUMENT v3.24.3 Restructuring and Other Related Charges (Additional Information) (Details) $ in Millions 2 Months Ended 3 Months Ended 9 Months Ended Jun. 30, 2024 Employee Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Restructuring Cost and Reserve [Line Items] Â Â Â Restructuring and other related charges Â $ 2.8 $ 9.3 Severance costs Â 0.9 5.7 Retention costs Â 1.8 2.6 Other costs Â $ 0.1 $ 1.0 Employee Severance [Member] Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Number of employees reduced | Employee 87 Â Â X - DefinitionRetention costs. + ReferencesNo definition available. + Details Name: lyra_RetentionCosts Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherRestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostIncurredCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of positions eliminated during the period as a result of restructuring activities. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Restructuring Cost and Reserve [Line Items] Â Accruals $ 4,855 2024 Restructuring Plan Â Restructuring Cost and Reserve [Line Items] Â Accruals 9,254 Cash Payments (4,399) Restructuring reserve, ending balance 4,855 2024 Restructuring Plan | Severance Costs Â Restructuring Cost and Reserve [Line Items] Â Accruals 5,651 Cash Payments (3,435) Restructuring reserve, ending balance 2,216 2024 Restructuring Plan | Retention Costs Â Restructuring Cost and Reserve [Line Items] Â Accruals 2,608 Cash Payments (74) Restructuring reserve, ending balance 2,534 2024 Restructuring Plan | Other Costs Â Restructuring Cost and Reserve [Line Items] Â Accruals 995 Cash Payments (890) Restructuring reserve, ending balance $ 105 X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveAccrualAdjustment1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=lyra_TwentyTwentyFourRestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=lyra_RetentionCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property Plant And Equipment [Line Items] Â Â Property and equipment, gross $ 5,737 $ 3,964 Accumulated depreciation (2,241) (1,921) Less: Impairment (1,883) Â Property and equipment, net 1,613 2,043 Equipment Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 4,158 2,736 Computer Software and Equipment Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 160 105 Office Furniture and Fixtures Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 934 662 Leasehold Improvements Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross $ 485 $ 461 X - DefinitionImpairment on property plant and equipment. + ReferencesNo definition available. + Details Name: lyra_ImpairmentOnPropertyPlantAndEquipment Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment and Related Impairment - Additional Information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Property, Plant and Equipment [Abstract] Â Â Â Â Impairment of property and equipment $ 1,900 $ 1,883 $ 1,592 $ 1,600 X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Impairment of Right of Use Assets - Additional Information (Details) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Lease Asset Impairment Charge [Line Item] Â Â Impairment of ROU asset Â $ 22,836 Number of leased properties marketed for sublease arrangements | Lease Â 3 Impairment Of Right Of Use Asset Â Â Asset Impairment Charge [Line Item] Â Â Impairment of ROU asset $ 22,800 $ 22,800 X - DefinitionAsset impairment charge. + ReferencesNo definition available. + Details Name: lyra_AssetImpairmentChargeLineItem Namespace Prefix: lyra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionImpairment of right of use asset. + ReferencesNo definition available. + Details Name: lyra_ImpairmentOfRightOfUseAsset Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of leased properties marketed for sublease arrangements. + ReferencesNo definition available. + Details Name: lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements Namespace Prefix: lyra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-

gaap_IncomeStatementLocationAxis=lyra_ImpairmentOfRightOfUseAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Impairment of Right of Use Assets - Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology (Details) - Discounted Cash Flow Technique 9 Months Ended Sep. 30, 2024 Asset Impairment Charge [Line Item] Â Expected Sublease Rent Increases 3.00% Maximum Â Asset Impairment Charge [Line Item] Â Discount Rate 10.50% Term (years) 9 years 1 month 17 days Minimum Â Asset Impairment Charge [Line Item] Â Discount Rate 9.50% Term (years) 2 years 11 months 15 days X - DefinitionAsset impairment charge. + ReferencesNo definition available. + Details Name: lyra_AssetImpairmentChargeLineItem Namespace Prefix: lyra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscounted cash flow technique discount rate. + ReferencesNo definition available. + Details Name: lyra_DiscountedCashFlowTechniqueDiscountRate Namespace Prefix: lyra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDiscounted cash flow technique expected sublease rent increases. + ReferencesNo definition available. + Details Name: lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases Namespace Prefix: lyra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDiscounted cash flow technique term. + ReferencesNo definition available. + Details Name: lyra_DiscountedCashFlowTechniqueTerm Namespace Prefix: lyra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred and Common Stock - Additional Information (Details) 3 Months Ended 9 Months Ended Mar. 22, 2024 USD ($) Feb. 14, 2024 USD ($) shares Sep. 01, 2023 USD ($) May 25, 2023 USD ($) $ / shares shares Apr. 13, 2022 USD ($) $ / shares shares Mar. 31, 2024 shares Sep. 30, 2024 USD ($) Vote $ / shares shares Dec. 31, 2023 $ / shares shares Sep. 30, 2023 shares May 05, 2020 $ / shares shares Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Preferred stock, shares authorized | shares Â Â Â Â Â Â Â 10,000,000 10,000,000 Â 10,000,000 Preferred stock, par value | $ / shares Â Â Â Â Â Â Â $ 0.001 $ 0.001 Â $ 0.001 Preferred stock, shares issued | shares Â Â Â Â Â Â Â 0 0 0 Â Preferred stock, shares outstanding | shares Â Â Â Â Â Â Â 0 0 0 Â Common stock, voting rights Â Â Â Â Â Â Â The holders of common stock are entitled to one vote for each share held. Â Â Â Number of common stock voting rights | Vote Â Â Â Â Â Â Â 1 Â Â Â Stock and warrants to be issued during period value preferred stock and warrants $ 300,000,000 Â Â Â Â Â Â Â Â Â Â Gross proceeds for warrant exercises Â Â Â Â Â Â Â $ 3,800,000 Â Â Â ATM Agreement Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Issuance of common stock | shares Â 1,041,666 Â Â Â Â Â Â Â Â Net proceeds Â $ 4,800,000 Â Â Â Â Â Â Â Â Cantor Fitzgerald & Co. Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of aggregate commission Â Â 3.00% Â Â Â Â Â Â Â Controlled Equity Offering Sales Agreement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Net proceeds Â Â Â Â Â Â Â 23,900,000 Â Â Â Private Placement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Aggregate gross proceeds from issuance of warrants Â Â Â $ 12,000,000 Â Â Â Â Â Â Gross proceeds from private placement Â Â Â Â $ 100,500,000 Â Â Â Â Â Net proceeds from private placement Â Â Â Â 96,300,000 Â 96,300,000 Â Â Â Estimated offering costs Â Â Â Â $ 4,200,000 Â Â Â Â Â Shares issued and sold, public offering price | $ / shares Â Â Â Â Â $ 4.22 Â Â Â Â Â Private Placement | Purchase Agreement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Warrants to purchase common shares | shares Â Â Â 8,826,481 Â Â Â Â Â Â Warrants exercise price, per share | $ / shares Â Â Â $ 2.67 Â Â Â Â Â Â Aggregate gross proceeds from issuance of warrants Â Â Â $ 44,000,000 Â Â Â Â Â Â Net proceeds from private placement Â Â Â 50,000,000 Â Â Â Â Â Â Net proceeds from issuance of preferred stock allocated to warrants Â Â Â 46,500,000 Â Â 46,500,000 Â Â Â Pre Funded Warrants Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Warrants exercise price, per share | $ / shares Â Â Â Â Â Â Â Â $ 0.001 Â Â Aggregate gross proceeds from issuance of warrants Â Â Â $ 4,200,000 Â Â $ 19,700,000 Â Â Â Number of warrants exercised | shares Â Â Â Â Â Â 5,756,349 Â Â Â Pre Funded Warrants | Private Placement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Issuance of common stock | shares Â Â Â Â Â 5,000,000 Â Â Â Â Warrants exercise price, per share | $ / shares Â Â Â Â Â $ 0.001 Â Â Â Â Â Gross proceeds for warrant exercises Â Â Â Â $ 21,100,000 Â Â Â Â Â Pre Funded Warrants | Private Placement | Purchase Agreement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Warrants to purchase common shares | shares Â Â Â 2,408,188 Â Â 2,408,188 Â Â Â Warrants exercise price, per share | $ / shares Â Â Â $ 0.001 Â Â Â Â Â Â Aggregate gross proceeds from issuance of warrants Â Â Â $ 6,000,000 Â Â Â Â Â Â Class of warrant or right, expiration description Â Â Â Â Â The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028. Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Issuance of common stock | shares Â Â Â Â Â 1,041,666 Â Â Â Â Net proceeds Â Â Â Â $ 30,500,000 Â Â Â Â Â Â Common Stock | Private Placement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Issuance of common stock | shares Â Â Â Â 18,815,159 Â Â Â Â Â Gross proceeds from issuance of common stock Â Â Â Â $ 79,400,000 Â Â Â Â Common Stock | Private Placement | Purchase Agreement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Issuance of common stock | shares Â Â Â 17,652,962 Â Â Â Â Â Â Common Stock | Maximum | Controlled Equity Offering Sales Agreement | Cantor Fitzgerald & Co. Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Gross proceeds under agreement 75,000,000 Â $ 50,000,000 Â Â Â Â Â Â Â Â Proceeds to be occured from future issuance of common stock $ 75,000,000 Â $ 50,000,000 Â Â Â Â Â Â Â Purchase Warrants | Private Placement | Purchase Agreement Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Warrants to purchase common shares | shares Â Â Â 1,204,094 Â Â 10,030,575 Â Â Â Warrants exercise price, per share | $ / shares Â Â Â Â $ 2.673 Â Â Â $ 2.673 Â Â Â Class of warrant or right, expiration description Â Â Â Â Â Â Â Each Purchase Warrant became exercisable on November 30, 2023, and expires on November 30, 2028. Â Â Â Number of warrants exercised | shares Â Â Â Â Â Â 1,424,272 Â Â Â Â X - DefinitionClass of warrant or right, exercised. + ReferencesNo definition available. + Details Name: lyra_ClassOfWarrantOrRightExercised Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or right, expiration description. + ReferencesNo definition available. + Details Name: lyra_ClassOfWarrantOrRightExpirationDescription Namespace Prefix: lyra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCommon stock voting rights, number of votes. + ReferencesNo definition available. + Details Name: lyra_CommonStockVotingRightsNumberOfVotes Namespace Prefix: lyra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionEstimated offering costs. + ReferencesNo definition available. + Details Name: lyra_EstimatedOfferingCosts Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGross proceeds from issuance of common stock. + ReferencesNo definition available. + Details Name: lyra_GrossProceedsFromIssuanceOfCommonStock Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross proceeds from issuance of private placement. + ReferencesNo definition available. + Details Name: lyra_GrossProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of aggregate commission. + ReferencesNo definition available. + Details Name: lyra_PercentageOfAggregateCommission Namespace Prefix: lyra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionProceeds to be occured from future issuance of common stock,. + ReferencesNo definition available. + Details Name: lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock and warrants to be issued during period value preferred stock and warrants. + ReferencesNo definition available. + Details Name: lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWarrants exercised. + ReferencesNo definition available. + Details Name: lyra_WarrantsExercised Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes

precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_ATMAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=lyra_CantorFitzgeraldCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=lyra_ControlledEquityOfferingSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) Sep. 30, 2024 shares Class of Stock [Line Items] Â Shares of common stock reserved for future issuances 19,405,374 Common stock warrants Â Class of Stock [Line Items] Â Shares of common stock reserved for future issuances 8,606,303 Stock Options and Restricted Stock Units Â Class of Stock [Line Items] Â Shares of common stock reserved for future issuances 10,075,165 Employee stock purchase plan Â Class of Stock [Line Items] Â Shares of common stock reserved for future issuances 723,906 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=lyra_StockOptionsAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Common Warrants Â Â Class of Warrant or Right [Line Items] Â Â Number of Warrants Outstanding, Beginning Balance 10,030,575 Â Number of Warrants Exercised (1,424,272) Â Number of Warrants Outstanding, Ending Balance 8,606,303 Â Weighted Average Exercise Price of Warrants Outstanding, Beginning Balance $ 2.673 Â Weighted Average Exercise Price of Warrants Exercised 2.673 Â Weighted Average Exercise Price of Warrants Outstanding, Ending Balance $ 2.673 Â Weighted Average Remaining Contractual Term of Warrants Outstanding 4 years 1 month 24 days 4 years 10 months 24 days Aggregate intrinsic Value of Warrants Outstanding, Beginning Balance $ 25,700 Â Aggregate intrinsic Value of Warrants Exercised $ 5,052 Â Expiration Date Nov. 30, 2028 Nov. 30, 2028 Pre-Funded Warrants Â Â Class of Warrant or Right [Line Items] Â Â Number of Warrants Outstanding, Beginning Balance 5,756,349 Â Number of Warrants Exercised (5,756,349) Â Weighted Average Exercise Price of Warrants Outstanding, Beginning Balance $ 0.001 Â Weighted Average Exercise Price of Warrants Exercised $ 0.001 Â Weighted Average Remaining Contractual Term of Warrants Outstanding Â 3 years 11 months 1 day Aggregate intrinsic Value of Warrants Outstanding, Beginning Balance $ 30,200 Â Aggregate intrinsic Value of Warrants Exercised $ 37,770 Â Minimum | Pre-Funded Warrants Â Â Class of Warrant or Right [Line Items] Â Â Expiration Date Â Apr. 30, 2027 Maximum | Pre-Funded Warrants Â Â Class of Warrant or Right [Line Items] Â Â Expiration Date Â May 31, 2028 X - DefinitionClass of warrant or right, exercise price of warrants or rights exercised. + ReferencesNo definition available. + Details Name: lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised Namespace Prefix: lyra_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or right, exercised. + ReferencesNo definition available. + Details Name: lyra_ClassOfWarrantOrRightExercised Namespace Prefix: lyra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWarrants and rights exercised intrinsic value. + ReferencesNo definition available. + Details Name: lyra_WarrantsAndRightsExercisedIntrinsicValue Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lyra_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=lyra_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Restricted stock units outstanding, Beginning Balance | shares 105,048 Restricted stock units outstanding shares, Granted | shares 984,929 Restricted stock units outstanding shares, Vested | shares (27,869) Restricted stock units outstanding shares, Forfeited | shares (194,636) Restricted stock units outstanding, Ending Balance | shares 867,472 Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares $ 3.2 Weighted Average Grant Date Fair Value, Granted | $ / shares 5.49 Weighted Average Grant Date Fair Value, Vested | $ / shares 3.29 Weighted Average Grant Date Fair Value, Forfeited | $ / shares 4.28 Weighted Average Grant Date Fair Value, Ending Balance | $ / shares $ 5.56 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration XML 57 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Share-Based Payment Arrangement [Abstract] Â Â Shares, Outstanding December 31, 2023 5,709,980 Â Shares, Granted 2,605,002 Â Shares, Exercised (1,002) Â Shares, Cancelled (1,926,891) Â Shares, Outstanding at June 30, 2024 6,387,089 5,709,980 Weighted Average Exercise Price, Outstanding December 31, 2023 $ 5.68 Â Weighted Average Exercise Price, Granted 4.89 Â Weighted Average Exercise Price, Exercised 3.96 Â Weighted Average Exercise Price, Cancelled 4.83 Â Weighted Average Exercise Price, Outstanding at June 30, 2024 $ 5.61 $ 5.68 Outstanding, Weighted Average Remaining Contractual Life (in years) 7 years 10 months 24 days 8 years Aggregate Intrinsic Value, Outstanding Â $ 6,334 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 58 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement [Abstract] Â Â Â Â Risk-free interest rate 0.00% 4.30% 4.20% 3.70% Expected term (in years) Â 6 years 1 month 6 days 6 years 6 years Expected volatility 0.00% 80.00% 80.50% 82.90% X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 59 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Number of shares granted Â Â Â Â 2,605,002 Â Â Shares of common stock reserved for future issuances 19,405,374 Â 19,405,374 Â 19,405,374 Â Â RSUs granted Â Â Â Â Â 984,929 Â Â Common stock shares issued 65,456,735 Â 65,456,735 Â 65,456,735 Â 57,214,550 Stock-based compensation expense Â Â $ 1,491,000 $ 1,441,000 $ 4,777,000 $ 4,405,000 Â Exercise price per share, granted Â Â Â Â $ 4.89 Â Â Weighted-average fair value of options granted to employees, directors and non-employees Â Â $ 0 $ 2.57 $ 2.8 $ 2.08 Â Stock-based compensation expense recorded as liability $ 15,000 Â $ 15,000 $ 0 $ 15,000 $ 0 Â Shares probable to vest Â Â Â Â Â 27,869 Â Â Risk-free interest rate Â Â 0.00% 4.30% 4.20% 3.70% Â Volatility Â Â Â 0.00% 80.00% 80.50% 82.90% Â Expected term Â Â Â Â 6 years 1 month 6 days 6 years 6 years Â Number of awards outstanding 6,387,089 Â 6,387,089 Â 6,387,089 Â 5,709,980 Stock Options Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Unrecognized expense $ 6,600,000 Â $ 6,600,000 Â $ 6,600,000 Â Â Unrecognized share based compensation amount recognition term Â Â Â Â 2 years 10 months 9 days Â Â Restricted Stock Units Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Unrecognized expense 2,000,000 Â 2,000,000 Â $ 2,000,000 Â Â Unrecognized share based compensation amount recognition term Â Â Â Â 2 years 4 months 24 days Â Â Performance-Based Stock Awards Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting period Â 3 years 9 months 18 days Â Â Â Â Â Unrecognized stock compensation expense to be recognized 1,300,000 Â $ 1,300,000 Â $ 1,300,000 Â Â 2024 Performance Option Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Risk-free interest rate Â 4.26% Â Â Â Â Â Volatility Â 76.82% Â Â Â Â Â Expected dividend yield Â 0.00% Â

Â Â Â Â Expected term Â 6 years Â Â Â Â Â 2024 Performance Option | Common Stock Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Number of shares granted Â 183,333 Â Â Â Â Â 2024 PSUs Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Stock-based compensation expense $ 214,000,000 Â Â Â Â Â Â 2024 PSUs | Common Stock Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Shares probable to vest Â 128,333 Â Â Â Â Â 2020 Plan Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Shares available for grant Â Â Â Â 1,957,604 Â 2020 Plan | 2024 Performance Option | Chief Executive Officer Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Number of shares granted Â 550,000 Â Â Â Â Â Exercise price per share, granted Â $ 6.07 Â Â Â Â Â 2020 Plan | 2024 PSUs | Executive Chair Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â RSUs granted Â 385,000 Â Â Â Â Â Inducement Award Plan Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Shares available for grant Â Â Â Â 863,000 Â Â 2020 ESPP Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Shares available for issuance 723,906 Â 723,906 Â 723,906 Â Â X - DefinitionShare based compensation arrangement unrecognized compensation expense recognition weighted average term. + ReferencesNo definition available. + Details Name: lyra_ShareBasedCompensationArrangementUnrecognizedCompensationExpenseRecognitionWeightedAverageTerm Namespace Prefix: lyra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPerformanceOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=lyra_TwoThousandTwentyFourPsusMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=lyra_ExecutiveChairMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=lyra_InducementAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Stock-based compensation expense $ 1,491 $ 1,441 $ 4,777 $ 4,405 Research and Development Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Stock-based compensation expense 214 294 627 865 General and Administrative Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Stock-based compensation expense $ 1,277 $ 1,147 $ 4,150 $ 3,540 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreement - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Feb. 28, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Deferred revenue, description Â Â Â Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of September 30, 2024, as all milestone amounts were fully constrained based on the probability of achievement. Â Combined performance obligation Â $ 8,400,000 Â $ 8,400,000 Â Development activities performance obligation Â 3,600,000 Â 3,600,000 Â Collaboration revenue Â 195,000 $ 544,000 1,325,000 $ 1,412,000 Change in transaction price Â Â Â 0 Â Clinical Supply Agreement Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Upfront payment recognition in future periods to settlement of obligation Â 12,000,000 Â 12,000,000 Â Milestone Achievements Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Upfront payment recognition in future periods to settlement of obligation $ 5,000,000 Â Â Â Â Combined performance obligation 3,500,000 Â Â Â Â Development activities performance obligation Â 1,500,000 Â 1,500,000 Â Collaboration revenue $ 5,000,000 Â Â Â Â Post-Milestone Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Upfront payment recognition in future periods to settlement of obligation Â 17,000,000 Â 17,000,000 Â Combined performance obligation Â 11,862,000 Â 11,862,000 Â Development activities performance obligation Â $ 5,138,000 Â $ 5,138,000 Â X - DefinitionChange in performance obligation transaction price. + ReferencesNo definition available. + Details Name: lyra_ChangeInPerformanceObligationTransactionPrice Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCombined performance obligation + ReferencesNo definition available. + Details Name: lyra_CombinedPerformanceObligation Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDevelopment activities performance obligation. + ReferencesNo definition available. + Details Name: lyra_DevelopmentActivitiesPerformanceObligation Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUpfront payment recognition in future periods to settlement of obligation. + ReferencesNo definition available. + Details Name: lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of the transaction or nature of business giving rise to deferred revenue or unearned revenue, other than annual membership fees. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_ClinicalSupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_MilestoneAchievementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreement - Summary of Transaction Price (Details) $ in Thousands Sep. 30, 2024 USD ($) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Combined performance obligation $ 8,400 Development activities performance obligation 3,600 Post-Milestone Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Combined performance obligation 11,862 Development activities performance obligation 5,138 Total $ 17,000 X - DefinitionCombined performance obligation + ReferencesNo definition available. + Details Name: lyra_CombinedPerformanceObligation Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDevelopment activities performance obligation. + ReferencesNo definition available. + Details Name: lyra_DevelopmentActivitiesPerformanceObligation Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUpfront payment recognition in future periods to settlement of obligation. + ReferencesNo definition available. + Details Name: lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_PostMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details) - USD ($) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Deferred revenue at beginning $ 13,794 $ 15,352 Revenue recognized (1,325) (1,558) Deferred revenue at ending 12,469 13,794 Combined Performance Obligation Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Deferred revenue at beginning 11,748 11,748 Deferred revenue at ending 11,748 11,748 Development Activities Performance Obligation Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Deferred revenue at beginning 2,046 3,604 Revenue recognized (1,325) (1,558) Deferred revenue at ending $ 721 $ 2,046 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously reported as deferred or unearned revenue. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueRevenueRecognized1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_CombinedPerformanceObligationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=lyra_DevelopmentActivitiesPerformanceObligationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Deferred tax assets, valuation allowance income tax expense (benefit) $ 7,000 $ 16,000 $ 33,000 $ 42,000 X - DefinitionDeferred tax assets valuation allowance income tax expense (benefit). + ReferencesNo definition available. + Details Name: lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 65 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Additional Information (Details) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jul. 31, 2023 USD ($) Dec. 31, 2023 USD ($) ftÂ² May 31, 2022 USD ($) ftÂ² Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Lease Sep. 30, 2023 USD ($) Lessee Lease Description [Line Items] Â Â Â Â Â Â Restricted cash Â $ 1,392 Â $ 1,992 Â $ 1,992 Â Lessee, Operating Lease, Option to Extend Â Â one additional five-year term Â Â Â Â Operating lease cost Â Â Â $ 1,346 $ 483 $ 5,082 $ 1,371 Number of leased properties marketed for sublease arrangements | Lease Â Â Â Â Â 3 Â Watertown Lease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Â Extended lease term 2027-04 Â Â Â Â Â Â Lessee, Operating Lease, Existence of Option to Extend [true false] Â Â Â Â Â true Â Waltham Lease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Â Number of leases | Lease Â Â Â Â Â 2 Â Office and Laboratory | Waltham Lease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Â Initial base rent Â Â $ 2,200 Â Â Â Â Area of property | ftÂ² Â Â 29,000 Â Â Â Â Percentage of annual rent increment Â Â 3.00% Â Â Â Â Office and Laboratory | Waltham

Sublease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Â Initial base rent Â $ 1,800 Â Â Â Â Â Area of property | ftÂ² Â 24,000 Â Â Â Â Â Percentage of annual rent increment Â 3.00% Â Â Â Â Â Certificate of Deposits | Watertown Lease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Restricted cash $ 300 Â Â Â Â Â Letter of Credit | Watertown Lease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Restricted cash $ 300 Â Â Â Â Â Letter of Credit | Waltham Lease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Restricted cash Â Â $ 1,100 Â Â Â Â Â Letter of Credit | Waltham Sublease Â Â Â Â Â Â Â Lessee Lease Description [Line Items] Â Â Â Â Â Â Restricted cash Â $ 600 Â Â Â Â Â X - DefinitionLessee, operating lease, extended lease term. + ReferencesNo definition available. + Details Name: lyra_LesseeOperatingLeaseExtendedLeaseTerm Namespace Prefix: lyra_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionNumber of leased properties marketed for sublease arrangements. + ReferencesNo definition available. + Details Name: lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements Namespace Prefix: lyra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of leases. + ReferencesNo definition available. + Details Name: lyra_NumberOfLeases Namespace Prefix: lyra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual rent increment. + ReferencesNo definition available. + Details Name: lyra_PercentageOfAnnualRentIncrement Namespace Prefix: lyra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_LeaseContractualTermAxis=lyra_WatertownLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=lyra_WalthamLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=lyra_WalthamSubleaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Components of Lease Cost (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Lease Cost: Â Â Â Â Operating lease cost $ 1,346 $ 483 $ 5,082 $ 1,371 Variable lease cost 608 399 1,866 893 Total lease cost $ 1,954 $ 882 $ 6,948 $ 2,264 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 67 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details) Sep. 30, 2024 Leases [Abstract] Â Weighted-average remaining lease term (in years) 7 years 8 months 12 days Weighted-average discount rate 6.20% X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 68 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Summary of Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases [Abstract] Â Â From October 1, 2024 to December 31, 2024 $ 1,546 Â 2025 6,121 Â 2026 6,494 Â 2027 5,131 Â 2028 4,507 Â Thereafter 20,652 Â Total maturities 44,451 Â Less: Amount representing interest (9,127) Â Present value of operating lease liability 35,324 Â Less: current portion of operating lease liability (4,003) $ (5,434) Total operating lease liability, net of current portion $ 31,321 $ 21,447 X - DefinitionLessee operating lease liability payments due after year four. + ReferencesNo definition available. + Details Name: lyra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: lyra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 69 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Loss on impairment of long-lived assets $ 1,900 $ 1,883 $ 1,592 $ 1,600 Paid to the contract manufacture $ 400 $ 400 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin Financial_Report.xlsx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`_;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]6 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1[JJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M:,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M/ND!R0O;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N()>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C? C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH"\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+] <,E'#^4[YU_T74.N?O;=.INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&! (.)O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3 ,;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M%H-L6?M1[1_L!0 Q!\ !@ !X;"]W;W)K!W_PM\=XO!'RBUIQKLE+'"7JHK/2.GW7ZRE_Q6.F3D7* M$_AE(63,-)S*94^EDK,@%\51CSK.H!>S,.E,QOFU!SD9BTQ'8<(?)%%9'#.Y MO>21V%QTW, [NPF.X7&ESH3<9IVS)YUS_GCY(..M5+D$8\T2%(B&2+RXZ4_?= MS/.,(+_CCY!OU-XQ,2C/0GPQ)[?!1<(1][6Q8/!OS6<\BHP3E..?TK13 M/=,(]X]W[CXF8/\W>1JH D34XUS+>'7$'1Z9C7W"5JQ217XYZ&IQE-SR^=+PMGVN!\3MZ+1*\4N 8\>*WO02FKHM)=42\I M:CCGZ2GQG!-"'=JWE&>&R^_%7K3 M^<^I0XKDW^JCA>]>:\W,]K\)N)-9?DK^FSTA(: MX]^V-U0X].T.IH>^4RGS^44'NJ#BY9A7N&%K/J M%4 ;U$J)RUVG^]&&A*I:(@TJI %:IEDFI2&Z"97//(O*9,VEZ)H%1PTJ(NW6[M+NUZK@T2%;:$'%:0PT.:Z4S$,8Q=#,[Z9\-!?S3NK2U\HXIOA/)-H5$&> <.\B9@5]GBA?S&MS8\W,EQ'->C0SKT;(RHMB6CZ]3SK',(MY4T8P:PQ@TZW%-**^(;/O4BZS/XAPVA#UR&(D#' MFC>LJHV_<>;'#=]RTIJ5'L:Z/[C>P$5[;,+-&AE165O&.NVX:+[X'V-9K-,M%KO#KKN'A8*?&N8RZ7IA/^ M @YZA=8C;MC(>8STX];QQSTH_UR_D"=86:DP7W<7PZL5$G=K;JS'R#^TSC_T MX/Q#[K/XV1I:+M\P@7S7]XP,1.L,1/'04O).@P#1#8]]7W+ (_W:&:YMBUKG(GI0 M+JI0J\[[(,4Z3'Q[!>.>[Z=6T&,$(UH'(WI0,*I 'X32T # _#-/F\0EWA$7+ MD%I)CY&1:)V1*)YM\M8ZE9PU@^$& W=HQ3I&-J)U-J)XE+D3^1IL)1)T-L5-MO'.OVQ\XCI7O&)F(UIF(XBFF6FU^S)B$ 2/:EJLQ*R;NU13[<%E+1*\.1!Z> M9>IOS'7J:V9\PZPQ]>&ZMI!U*/+PV/(4:LA[8D%<^N/S3V3. 4Q"C[02XDZO MO^E+^[YQ"%B0IDV3-HHR3E,MBI\KZ$HX1D[PZ)GEXIH$*#O*O"-OX6416=MS@ M[O.C=1;!96VY]C; \.RRJTU8NO@KEBQYXZ;0&TWT_G5U+IC@@N_EK"WMT]J M5I7Y]K$BOHGFQ99I=;7:HI[F&[.]^O9B? _L],XM212*^ *ES.H0)719;QL6) M%FF^Z_HLM!9Q?KCB+.#2W " .+X30NQ/S@&KC?O(O4$L#!!0 (!:#;%D% M&UZ?'08 "H: 8 >&PO=V]R:W-H965T&ULK5EM<&$F <>)XIDWFYN[#W67B]NZS G*L*2"*A)/226][+\KK:<. 20I;FZF&RU+LYF,Q5O><;4J2QX#D\VLLR8 MAMOR;J:*DK.D=LK2&?&\<)6QD4J6R_JWZW*UE)5.1>RON+ M*9X_7 C[R;. #!;+0MVQ]=Q> M/T7_K4X>DKEEBE_*]%^1Z.W%))J@A&]8E>H;>?\[;Q(*3+Q8IJK^C^X;6V^" MXDIIF37.@" 3^?Z;/32%Z#A@?\2!- [DI0ZT<:!UHGMD=5I73+/5LI3WJ#36 M$,U8+2UD><[0V@17Z M6.6L2@0\^81.T+?U%?KX_A-ZCT2.OFYEI5B>J.5, QX3=18W;7_9MTU&VE[S MXA11;XJ(1WR+^Z7;_8K'X(YK=WKL/H,J'$I!#J4@=3PZ5HJJ+'FN$5,*VHO[4&$=RBP+NQ6AD>5SL9 [N,$W>;G$0E[((=6D>=W4CD"&1Q !DZ0UR4OF$@0 M?RC,5%)U8:7>\A)F<'=,/V7 '0]P1CGJP+49>&-E1AP?4H1/U5ZE9^@* X:#M MP/=/#^'0"GM^1+ =X_R &A%*:$C MB!<'Q LGXAN82Z6(S5IOE@ ;NL6PFHL%Z8&S&-&.T1$V[+6DY+GK64^>\<*Y MW5^[$#?1CI* ST@2'6;%+YA@CB3PH-EY-_Z2Y;%#/LD'%NT<$MW^&5\EPIV M*U*A!;>3'GY3UGNK:,=)M[KH'<3W.8YE!12""O;(;E-N39@.YR49C'R+%<5T M;-2TA(?=<%*9%]7@A7O1#\VBA4]&V)NVXHBZQ=% 8=23 M\74I-$UT3SUM>WB+F74//^L->SUS'",J(;PRV:F=,3"I+ M(1[,Y,\M1Q#!"E$VEA0 -G #-+4."'"K]K4:IYIA+OC)_>/9?*8S)(JF(GT M.XMU,K5&%HEA18M4WXOM)Z@3\HU?)%)5?I-M%1N,+1(52HNL%B-!QGCU2Q_K M0NP(W,$!@5<+O',%_5K0+Q.MR,JT[JBFX42*+9$F&MW,H*Q-J<9L&#>O<:$E MWF6HT^%,\!A?"L0$1TJD+*8:)[>*>(XWZ)#/CLOO($*Y M6\K[;,F-E6C*X37E\$J__B$ECEVHB5N0CXU@$1E,R%XJ57??C9JFTQ-[[MV95JY3WH)C8+\EKE-(*IA2M.@=R %;Y[XPZ=#UV)_R>S5AGZ31GZQ]S#.:XE MD!(;1LP>K@B.95D0],"NM*NO(+2R_QM;$*GYSCNQ-[LYG,JJ@4Z:$ '+P.M M^I#00B="LC\0=P%7GOX.BNM4GV?,9P2VL/T&VW\5-E.JZ$;V]TB>LQZ+:$$. M&\CAJR!Q,U":\ICQ=1? I\"3IL8@6:="0!D=)9R++<'&6F,=;-3BK54]%M2!' M#>3H?,BSVG2T5R?/Z>[3OQBZ,--.M[#&/H#?QCT_6>\^X%^X+D# MWS^ ZSK_MC/GQ< G&K9V/ .[(_ M[VS(YOCT!"H#:0+P_DH(_30Q^WYSS@O_E!+ P04 " 6@VQ9 M.(^W<&< #'@ & 'AL+W=O/E&W))]/ 4 MI/.++#M5*;R]%(SM>LH/K"'!UBI?UER M45"E\5J)#>"T47=J,A'Q/.B44&SX,'AP8=LM5;FP6A\M:$K=L 4I\U[H>]&391%5K!29KQ$@BVO!V_PY90$ MID&-^"MC#_+H&ADJ,\Z_F)N[Q?7 ,R-B.9LK$X+JKRV[97EN(NEQ?-T"'31] MFH;'UX?HO];D-9D9E>R6YY^SA5I?#Y(!6K EK7+U@3_\SO:$0A-OSG-9?Z*' M/=8;H'DE%2_VC?4(BJS"S>ABHZO!'] PJ!U-'-1JU^WUGIEI4F4>R7TKYENI\:WO%SH M:6<+I*\DS[,%5?KF7NDOG0]* (KY$[S9,4#.O$M'2(N=E&N3+5N&.N!2HI=5 M2:M%IIN^0D/TZ7Z"7KYXA5Z@K$0?U[R2NIF\&BD]8-/M:+X?W,UN<*1C<#YZ MRTNUEFBJ![D VD_ZVZ<][4=:]$8M;"^1[KQ'02 ,Y_;IS7V(MSO_K??K#0^(X3>IX]?Q_(YX=^6<%ZQ-%?3WFYE40B_]?Z"IW@4+X&\"F'E[* M#9VSZX'.+OB*5*\0>-Z9^R4N(9WC.G#MGL,DY@TW/%.QD))F]J+>GN@=(U(Q M7]<[PT*GT,XWIAI T[&+%!ZG5.H1*^]<$"9^E%B9YZ+\,/"L_)P"J#".?#CW MXH9QW,OX-U;JY,MKPG2A]^3,5#WC=R#.L3N$U,<69Q<4>IYO479!.$@22Y@I MA(H]#Z:<-)237LIWQ89FHB[RV@YLA/:I0GVK%6!?JZQSPA-W,.G16';D>[M^ M[KH">2DP22\DI K3CHJ4-A*ESY!(&\ZY,MA)1FB4C(%VI_>D,^M3^<,-DD= MB0A) ,@2\DQ=G@B.O=:Z>M\K/4I4^/+:Q,[75*P8[#L] MEU]BEX_;_OZ? *RG09TI"NV2=]\|338]>!W"OIA^YTJ6-.]LK*"(&2G7DQ[:* M "SV8ZL&3@!8$I(=A, +"1>&,*K%Y.6..DE7K_&+ 4O#N3UVPY(FCC]#$$) M GL; W%10F*;-H!+@C3P;-X +O2BH&,SPZV+Q_TV_EV]9K+:S(,F"I_5N9\U MVN2LT:;GBG8Z$ZU[Q_WV_:Y43,=5^\D YR)PLS^.[-1S01BGQ$X\%T5"'-MI MYZ)\'.&.I&OM.^[UI(6&5MR MP?9LD:*/A]H*,G>=ZQ#C)'+ (0[@P\D.;/H!+2$!L9P3A@CA(.LP1;CTS[C?- M=T^C[;K7H;.= !@%T1D16O"F$TQD1=-0Z MTAI(TF\@#^F/M(O2DT]UR:.*B6Q6*3K+=07@2%>"PF2&XO,O)FN8D$/S;W\V M!Q7:]96;^IS.>GZ#+\VQ\'R"+Z>[\\@V_.YX]"T5JZR4*&=+W95W$>OABMV)X^'Y& M\4U]I#;C2O&BOEPSJI>J >C?EYRKPXWIH#GW'?\'4$L#!!0 (!:#;%F; MMRA0IPP "UV 8 >&PO=V]R:W-H965T&ULO9UA<^.V M$8; _"L?-M,G,*29 *12GV<2&9A>IVEOXES[F2?19TXDT1$I^])?7U#6"0)V M!9'V7K^<+1_X+H67(/'L M+54[/YK;VOJB[YO%JNV[<7]UWW\,/E93N_KQ6 M^WWS4*WM_]PUFU79V9>;3Y?MPZ8J%[N#5LM+GJ;]\$NOOSAE_K3?=?_X?+ZZJ'\5-UE6W8>']QO[MZO*@LJA7U;JMFW6RJ>[>7OS(?C!YUA^P:_'ONGIJCWY/^K?RL6E^ZU^\6[R] M2/LSJI;5O.LE2OOCL9I5RV6O9, C][WHQ2%F?^#Q[U_4S>[-VS?SL6RK6;/\ M3[WH[M]>%!?)HKHKM\ONE^;I;]7^#;]XLV]V_R=.^;7J1S+=MUZSV!]LS M6-7KYY_EYWU"!W LA,'\T!?.@!V?Z +#B YR<.$/L#1'" +$X<(/<'R##" MJ]>M)@>H7=_ =]:NIV.*KKR^VC1/R:9O;=7Z7W9V[5RO^ROKMMO8_ZWM M<=WUK%DO['52+1+[6]LLZT79V1>WG?UA+Z"N39H[^ZJ9_W;?+!? 5IOU+HG_? MUMT?R;?;=;E=U+;U=\DD^7![DWS[S7?)-TF]3GZ];[9MN5ZT5Y>=/<<^TN5\ M?SX_/9V/W$^OS9=N40.F\4/FS6KE;U.=R>*'T3/_K\A7T?]CHOE\G[LEY, M[%N8E0\U?B;ZC- 9\OEUME[M>_%=W7VULQZ[LH+_O1^-CE;Q;SYM5E7S[CZ9M MOWN3K.W-P_9P5WY&0IGAH6ZJNWI>=[[(I;T8#E<$/UP1?*EYNJ'=0[4<7^D?%#^U#.J[<7 M]O)HJ\UC=7']YS\QE?X5N_Z? O>1Q#[&"YTI.@ZZDC*HIQ0R1F.>?./@GHO[I MS]5F7K=5/]CFSS>+MK]9),U#/_+1.Y4 71Y>V=&8((OGYFPX31G.$(EY;LB# M&_)5;GP99I@K4>6QHTJ"/N>,R6!$44;4E&*&2,SS4!T\5%$/W[7M=O>@"#W< M/MA??[G]D#Q6;5>O/[U)VI-F1D.,-5,!, -4L,!,RHB:4LP0B7EFY@;)"], MA1.E633<6"N&1-24$0V1F.? %].#%-.K%/^VDW9O'8R9,X07%%)?!PV46C336 M!DHDQ32EFSO:&9P1+';ZF0VGEYW)SF()G*'FFX"242J?!$V*V;Q;E%40JRUB: M!EH::3=AX6T%:\25F&;IB=XY@GLVEEK.]U)4:\6<$NF"C#+ (HVK2=4, ME9IOHR-R1H?D>ZGC#L>8G V B?!G4FFX3B"4EF19E,9WIE@NTD>WIF0-GRJV'1Z MXL[D)G%"1FY,YWO)%(B9A")Q50**>&=B92+2=4,E9IOHT-C%F?C45-,B)'H M%#,?\2%4O@4$R%7.,7$\#8VQ718RN)<^J(I)B4)SAB$SU-33,JXFE3-4*GY M-CJB97&D/9Q&-*]>+Q$:-,+*,>/X.QPY%#FF5V M*FP?J:#H1QE7DZH9*C7?=0?N/ [N+RE7<8C:TV"R,XN''3LQ'A1!DT8T5&J^ M+4>E\3B(OZ9N%9<>/-Z HN3!(?E/PEG' M+'X>H\<<:0IAR!LP5"%)HUQF@,Q_Y!R1J.@#63*IS5S>*Q1KM!6JTG53/G>\3WPV4;^*!,0P]??]^NXQD&.M#G,"TT+F8*:@SJ=A$*DLG[*4A]<^;#? A81X&;52D4ISJ'0?P?!# 'R/J^5ZB+U1'XF#;,-2'TQ:.F:H5+S;729!A[/++P[BYH<9@+L^ H+W_$#PI-[+,R(SCQO&/>U"*X\/)X]Z'V;K-L$#M!::J+,[GSCQ&/+]U"*X\/)X]Z'V;K-L$#M!_PU_WR0:;+#BD4+V^0VP#_{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{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{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}>(3<,?4MNULO-KCJU)Y#F*\(7W(:9,[G->[?YU0CGG_2' M"F3ANJ!"F6BX,EM%O]HWVF7,7_Z&MUWZ &ULM5II#6,17,LB7SYU="T=/8S?ZP*KR M:@BG#3GE,CG&URE0_7T&# M5HU9H\Y[_X+U4U%L>3D9A-9B=W['?+=Q4GQ9*2= M^9%X:[*Q>!!62OSXER>SV>39A2TK.3,\;%7BH<_V4F204V>R./0!,"3FV@:5 MK8PM|'(CLKA"+"R24>4"!]%^N;H&GE7D9Q8)CY7*40 D-4B\P,)HY,':,+" M9OO$]@E T,#+\6"%)1PQ.QU6(ELY"X&$6VECO3:UUT%#&^QQ\?ER3#]*GB+3 MQ\^\J)RMG%8!N"IZTD._7'F]-'2BA90 4Q]P5+'!C0)XZ$2IS)"GN%S>%? MD<%RE%0*RKW[Q^?#V73"QN3/,R2S=.P..??6S>4[]97)S:S48PD9Q<^D]JIS_\#IV[X4:^DA3V9=96$] MR"0I.E^I0]f)$,T-#BXC/MAK5Y(E M6R&&XJX^&C$KS4\/7U$BZ=/1BS?11OL#M&,V]E*FB7M!5L;62(§G"W%R9.) M.>6 T<6*>DX?RRJ9LHXS1,<]";S=6L%I) MU.ᵡ,KU DF!P!Z3;DX:RH1V$L4$4NM0$1[,3CDLX^F,2H&B9U3^*,"NRL5Z#19(:*N\30YF33DF+@5XMA$!M@1 M*V&$'#&@%QL^+D')\!A?9YGR?E$7Q68 +C%LEYT,X#69J@*J#RM%GMJ57[FJ M*-#Y*2.NU;(;RUUMC%!R(!2&Q)+;++BP9L7,*S0=QSB\1@2"H(§!FH,>%/#C'? MG2#2§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~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

MA^QXCFCEC!2P@_$FSYTL()0XO%O#(>" MB^+=3?2M)(K,MF].<#H.52Q&7 $'>;,^2IC3"8+H0'4C;T2,^D:T0[4N4%)F MT5DL;U2@O^':UD4>JZ@D')$444T8VMWM7U>(6^K.^_8.3F$W:-0:>^X(6*!A M9ZHMH7O2#!$D8}'C*LYZFA=EP='34Y'&66."/;42\47EUL-+*@3]WA< MSK:QBPPOO0XRE'KHP6"]\9Z7 MV[?8&[VX1(7_OHZ*43$US]IG:&6!1,'3@O;@!LV\]WY\[^OX'O_$3G]L74.+R\.]HP5E4>B6] MX7#>D'FI($82I-(P3]TZ:F%M,#P6<@1GI/E\(TAFEK691^\W,+KPE##T&RDR M&QSS1VVVQJBWZDZR_O=Y,4J:-_H[2#HSIL8>G_E_$L%-8[N_MF,,[MCC\"5MRE)/W>,9]#2?&&U3^!9J<4DSG>A7AY6%#!%2ARW% MO6.3-+/<_D<+GG5/82N3$ZN]L#EG_NQ">:SRXNN0<'Z'0N]<%#6?[+,B2I3'?Z)C\N5%7*L]}$-3X M/AO.)@LF,4 ,]8[,1:OI5>7KRRM9BLLK88T^L"F\FXHITL*RK6W>*NQSU]EVE4YEZ<5EF!JZ]+I< MB\\FUZE6[M61QWFTZRB-LM\$V;,'9)^+CZ;T&R>E9G*AON/H&>K[*Q1]LWL M48'7JAJ+^201L\EL\8B\>6O\G.7-'Y"WQTKQK\NE\Q9@^?<^@X.\Q7YYE$ O M7"53]7J$#"'*WJC1Q<_34\F+Q_1=M%JNWA,^O\9JL=ES\;BZ>+%UXT25Z:H M9'GW\T]GL^GI2R=<;X_L]E3-'FF5R+1+<^-4)G0I/(3(.M,>7U-3.BS,)'U9 MZ5*6J9:Y"=)O5:J*!,)B/F5$S!.(3?,ZZ^3O*GE69 MEC7D?E6&5L5Z %"BSQ71R^_^0LP4!TE]#RK7JP%^@FO3[QN29LBXZ M^3<?:^WO8(?T8&'IA,K.PJ!!"F=9%Z%T#(3"A$TA4Z%NN%P!>G85T8'L6/[M1XS)}^Q)O[%*L902]!1%X(P08V2\CT&,:9\TFM^WEU"D';D)<:E+X$3F^@\], MI;<*_2_4,CD+4QF0S@&&X#AT"L@09__M8U((MGEW*!-!3%%B"F\JS1XXBT$?8WL^,.#L2Z=%[[.L074'4JK:W-NRE7'J[C U.K-MD,Z' RQTQY M'WS9,7"-(}_^PE57'TN/D%_]Y\^GB^. 3S&3N0=8##$]88JQ##'7.>G MD,+@2_(0-5>%I@{:T3IB@VH)4CJP4$MX)-FQ9.FAW[+V!S:#](Q6E6A!* ^R#PG/?:.^MF0FMKKG01CK[3E$$QYN*J94,?2@KP] M4SYE:.?!<'^0'-4>M,T;Y0+H2UY>(J,I5-M4>@H0JQ5T,%0&DYE3 &[8HQ#TE_O%WY'*. #H MD25P,)VV0ED"U[,M>7%KZCSK]0OR1NK\$=SMI}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}:L K=%LY=7X3[PES!]13#/9R< M\\= VA]ZPH69W*\B8QSWU)UM4+R5$\3X)9[EMIQ MG,M(!-U-4V$RE5/?%H/01"QP=]?XA<@*-/%\>]N[!XV"6L%(MR4G FW)POUW M.^$? GZ'#A,+LFCI^U,5]P)U:7EO.3?DAH?M..Y>"AEFPVL[KR266B/ MLSIMK$+"(,W_X#[+M7CLKL/WLW3C_$QG/^B9GX3<\,X?R8YZOVT6RJ[Y%UP2 M!U"&GSG;1<V/Q)?AM}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e1!O0*NM/7KX8GP?L7*(]KPN.7T+\G-"\#C?KL&2SV M)06V4!F6II!+9GF4H4N<!+=(R(7W1N^]JL**9Q>-7*B^XW+Q^-0F'I^\ 6PC) M92QXQK@Q@)A<)BP3/!*9L +A^=P<<.YI^%/ +MDO"W4EG4<:M%C"8)R6:NG;"/7-^3T>@I=I,@M(%+/V,Q[8BZ64BQP!YWY"0W0[%.$64)N9G>R*/.W$FU_[Y#V=_Q>&>=*VY2 M!@^E0*.(? =K#C;8#X@$6Y0R,>P'-CSIO3L}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p?&MD'C9M5#GKI[H]4_VBUOV3SN_45=>9O9KOC_GZ+H\122(.)LD#'1H' Z MMLNTOS/ZA56%NZ=%RN*MSSVF>,T&30?P_4)A-54+4E!?W*=_ U!+ P04 M* 6@VQ99O.]R&H$ "_"@ &0'AL+W=O[S LF0BOO&}Y>SO4G+@ M_O^-_9N?S4E26PN*%+O^4N2M.^[,^Y+@23>EN}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p?&MD'C9M5#GKI[H]4_VBUOV3SN_45=>9O9KOC_GZ+H\122(.)LD#'1H' Z MMLNTOS/ZA56%NZ=%RN*MSSVF>,T&30?P_4)A-54+4E!?W*=_ U!+ P04 M* 6@VQ99O.]R&H$ "_"@ &0'AL+W=O[S LF0BOO&}Y>SO4G+@ M_O^-_9N?S4E26PN*%+O^4N2M.^[,^Y+@23>EN}.8SMGCXF5)?ITOI?V 1L2N"L_ML4$7-,3ZX8(7O=T^=+\HBSW@/[TCA M>8KN>D.N1D^LP%CGR;/.77_>9U8[[VX8)D!&B.%I;Q*V@?:W*CJ'<8^$^-[X M

K&Y@2_5HTDZ4M(6!SS+#[*4^)"6=G'@G9QX?)'S$:@A)-(XBL<'^)*NO,3S)6^6!S?< MI$*96B/\NEH8J^E!_-Y7L>= MWO$A]C>OXS!Z-!I"GP&>"H1K559,;JF#4J4S PPJK5;
<=Y6B)XT22\M4X$>:[.*400=H?!=D;IU; V@LI^:@ .8Y^AYS!* IYDDM:=@BTT/X M2FO2SUM-QT?G\>CLTD M4]26+,0ZG4NF,RZ7D-?6W1:QL87 5L6@3P#.=AS.
ME9770L"*B9HU_2[(&Z(&)GM' ;@A!S1$D\,' M.!M$4=3590N-"&73 ^AZ .@%6RP7J+MG3'09(4>G[X8F+31)7D E7?M_;CJ. MWXM,!G0.IFIN4FR'^QYUV/,;$O72NZJ!5-72-
M;313OCOEKH\ZE]ZX_IW3"_= M]0G,"1H-STX"T(V3-A.K*N]>"V7)"_VPH(\/.I= Z[E2=C=Q&W2?5[.%40SD#$) M!!0 (!:#;%EF;QSY9 3"&PO=V]R:W-H965TW!=YZ2Z'
M6^^K_'8I5M52#!46R,N8/>GF?70YC+? MG;I1>4Z&X,;_&YO#;DM2/'QNK?_(L2.6E73JQN1?=.:WE\/E4&1J+>O5,TRO"@T&?X+^^;/!PH+.-G%))&(6&_PT;L
MY0_2RZL+:W;"DC2LT0.'RMIP3I=4E%MO\:N&GK_Z62$D=S'VL$4KX[31>Q?T MDF?TSL0'4_JM$W\O,Y7U]P%>],NL"G; MF[X8F/CG]NDJFZ' +P3MD[-;SZ_KO)(G[(@H.S
MSL'92]9?R/S+>I-D))K@ODBOK#>[,BR(]Z6XKC< #9(8GT;";Y6X,44ERP>A M2LBJ3.C2&R%+ 5I;Z76Y$3GI1D(Z(<$V5#,2(+LPZ[5.%40SD#$)^Q*]N%6)K7&Q&
1-77BB7REP2)R$,EW^J M\P>J^K3O<.,,KP5S<%S=>ZSRFKJOM&4SH_,H).B5B$=3=(\IXB= M2FM+Q=,>SJ]RO0D)%747V%&!Q6ZKTZW0+N@BR-7#2UM$C8*T71TSP@B(X*U.
M/=Y2Z;8$!=HMQ>8FUYFD'U:H;PF8<%M"D3]QV>\Q2 @49",UFU+_!Z+4F 4Q ME))Y0EBG)@L9M:9QWJ M+%:USC-*C_1BN8S%%TT,$:
:S4)&>.ZWLG@2W^WF&"'*.@8!5M?:@GL-)(MOO]NF23QV\96X"FO3=XRM=@=I*/,6CUK)6!64,J>MG%,K_*>&7<(U$!D9*V4 MI8^XWD&>0@WL97($H* 1J'OM#F!RN/]NBY8!F
18.Z=4&^D6\S_(4^;E!CG+ MZ++FK\"$L%NCT6:LV7]$$3/%7866H,D#4J(^Y;,4,,0{[W., <\M4]XK%X5F2)AMLV:PJ3UH8DW[MX&+D.@VAF;UK^\+U@\ITAHSXMH=]38 \'9%
$"BB8](HXT63=FZ@7!BUB8TPV7.C7A%_7\RFG30 M@V2SOIOIN-94(F 8NZ)K^#]$T{X6:NSVZ4&Q9W?;OR@//ZA4%2OX]7C^'I#\ M<;_@.AW4B"C'] DL#)WG?VD&[99/|(/C=C
[,@=[VG>.O\3WR6CY#?G^"^0X MPPWGDSX]4#0>H/]/OC[.+0YD%9UJVG0AU:ARVK"K[,Y1TW".Z@.E UTOXSP% MJ61H5R'3?
%0Z.A0]0!ECL9\:6KEGZ=ON_/4,)HUO0.)XM/AV)/I,9!TF]WPL M:RN&DT>GV4335(@.*I/3M\0@#/^2"M\[+N!]88@5;'5!:T1H=DZ\9INF M=LB$>W,^^+P%C7L?H>
(7.CWV5O!1Z3OT#_A+@!J-Z)X&X:AQ ^_/!|\>59UC M C^CZ6B![_I/E%'_G4;Q,PNKI9/"[M)HK=*"QB)=B>G8&B>5B(99GT\%GXZE'M]8V>S6?
XOV1CB^ALMJ31'R6+F3@R6LF'D)+#$7:<6IPJFF[7L99V8J7:$N@(MUTQ*X .#"Q-,PE9[NCO"84, .IU#K9"EW/1&77MX#H#8\=V'RDXD\ U) ('Z MPSZ3WSPJ=RJG%WN'Q&[F(Y8^
@3YX-K1F"ORES;P9>O\H@P1;W4 MO1&GH)/'2GUO%Z,D7(^'W=I,*Q_#ZL'=0=F5*.',/(R;D]>V-6,X2"NO) M4/Z2"!^5U283X<.UFZ?
3233XD<[YOZ;>T$+S"4JY/A0*BX3'^6Q!#)D#C)-D M0H\+/,[.9@/^9IY'DRFO+L4LFI>G(" <"Y^Y21PMYDD#\N+DA\(%9V;1;#X! MRYP[%^^+B@HH-@Z_/2D:B#,?Z8_.O*&G39-
(;HHK<#DBFH^,*(_?P M2U1#2ENFCP;[4KI)<8$.*MP=L":.*4^?(AO@!S,J&XGK_<$'%]3.7?\SG8"E M:?03:H,_HZ=NK,8'|X:%LAN^':4V#'0Z'X9(VA=O*KZ%?!GO3<&/|!&I+ G@]
[6!M\T+;=!=2U_]"5!+ P04 M_"6@VQ9U^WWGX $ ##"@ &0'AL+W=O62,!W11M_\"R8R=+:SISX(9\F TZ(-&6!$23^GFE.6C,0TOC28B9=2'8\ M?-ZA?XC,$A;1W2F'<3*&;Y((.
<39S=",?60..'2#5Z M(SEEN"B+X/!6P2_,YK8L58##*P0MIY58,FI*,+D0HB%TJ;,9BI33E0HL M:XW)${0RT6!15^24=;"L71\VU>P&&8@7#Z3E1D)]N8:7#X#@N4,.2"96 [UO
MZA4>4",GI-;T1DYBB8&4%0RQ,^R)7P\2BH9("6DHT-GG%0H98@YGXS3P\&?+ M1^D#]N804F52,Z=*;\7=VA&Q6N+MFU?7:3JX?9PO[N+C\/;,HW1X<_C^]C /
M;VN,#U%:0P'#4>2RQ%QLA.>@CI")88+TI595C,/O,)<@J-1^SV3'V6X,Y3TN MU(\UN/*N5E22^0;8N'B6G\AD5&&%CS@89';1 P!(E0MK#@!VKP[XXH/B6 M;5MI?E)!K27/Y;U
#S7M$%$L"%LYFQ'E7-\H SD,P.C$.LA.[XT*!=R4/^)Q MW)&.,KLVZF]P>"V&O2O,4JT9"@+KWA);):\>) M,,.6I'O7Z/% &95+B#0:-GRCWC,;YV8W/74XB!6,O0BV4@]..H*ZO#!PE=F
M3^^"MU#E?"?.7KL+4=7.UY+[V(I-H7_$=N?@,,*NB4[7&S(_*R:S=%:BH^I0 M0_PV#Q^EUE]T)8^Y1"&LP#&63GE>X7._"\I=?P%RF:YCZ;@Z_%HK3),V[0- M!(V=WPZ(/3F&CSV-
GM.Y*.0SB261>=GC7T>^)7U^@+#*4=E/%O70S>A"519! M5;7NF@T?AE)Y+W73;!B4G\ NHR,]SF532)QE6/,]B^+4 MEZE_<+& B.MX??+-%&CN&-UN=T.
[;RXF>_/F>OP770>W^9"-=< MF9I%L%6\IBQMP*4G/A:X99)C [Q?6I MV"P[0W5MG_P!02P,$% @ %H-L M67'4]I8%#0 'B4 !D !X;"]W,W)K&ULK5KK M<]NX$?
^>OP*CZUR3&4K6P[+D/#QC.Y !H6???M=WRAR9=_T-LZ5+_,;+H1!;<# M70H%;U:%-S!K5F?V=((GM&F(C\;#X<79P67JG?UFIY],E>O=>5RJ<0GPVQ5 M%-
SL;D2NMV]ZHU[]X+-<;QP^.+MZ7?*U6 AW5WXR<'<6J62R$,I*K9@1JS>]-MZ]'+FSFNIP7_E&)K6]<,)5EJ_15OWF=O>D-D2.0B=4B!PY][<2OR' D!&[\' MFKUX)&YL7]?
4WY'L(,N26W&K\UIEYC9O>O,>R\2*5[GIK+=_%4&>*=)+=6II M7L;U:ZG?196 UMGUNDB, 8.*]G\'_X0I-#;,!\>Y3 .&\;$MS^(N'S+';]Z;?26 M&5P-U/"'"1*?=PJQ4.)2%,_!6PCYWM?
##&8'K%%G*MY$JF7#EVG:,Z4DZJ-?ND MQ Ml-*6/!5O>A L5IA[T;OZ\8?1Q?#5"6I/((I?GIZA?W7 K+=KL$!)6CJ,"V+R
M))G#3!ZDS;YL!$10JHN2JQUJ22HGC"Q8JL&BRHH,KRRH+N,.;E92<95*GC,+ M% 2$L;.,JPP".:<%F;1IKFT%AS!N!*L4KS*);W#5AM\+MA1",6"LA/<9'$@, MF SH"H@2MV%W@\6
K842AN?Y#E^+DB@TQBR-!#;*'/WWQQ_FX_'PU5^NKS_1 MY>C5"P:P%D5I>);*PQWA!K#C0'JIP!DJPA++G&8("FPT[/^#5GP6ZRKW&Q;] M?PTH@$P&'.2[!+?
O6*:9T@[(I'F5@3+S/)#M'K72VL$ZX->(WRN)DB]W#'DF M7M$"N7#BN(+M1E!4EO>.ZM-R4J8C1[!5N#]!]F1<]I MD(D..T3[6JD*:'P6I3:.
1>U[OY,,N&6G>"&"00'IE:DHE@*PR8C"N])PK8; MF6[8EEO@*{O$ 6>.4V&GC@F%[8 MG2(M+E!=|OM|$R6#QU&#+3@*4BKC)@.9,I)GLF/MS->+V^C+]{$#&RV[*S-B
MH[ET%S=!H..![Z*E#U*XT*F)C!@[Q4D) 49'-TCVER74@&C2=!M M$!Y/ 8QVL"@,DSQX'UC=((<\^PURU*LP&^LQ62&3L79BDO#RC.(:5GWW?,I M'-7^6@)B:%!,H"^R 3N!Z}.
(Z}.3N(Z<&;'!F@=\Z6=M[2%0?RH-UGV4XZ.@ M6=2:\T_!;=0'.%?#1("U% HX5)0@$Z_;G2>"6.#VABBD]N!,K@#@UBM@MC*
MZ(}!QE26!Y Q$:PG0JBYDRL0U]=!3AWWHZMH&+&\?,4" (#6[C1&"]"@0DQ6^_MB/ XL<" \D 1ZH"DYORQO&A9:=&LX 25 JSAN?P#;O&ML GI ?V#/X#()(@$
M7@%,C>M#>H:;=2^"JPU.F/HBFOKBI)D^ S$C4^3MEHMO-(3L_B0!EZ.#9D#XQ M2.+[%-^#<(!K1C(R#8"(.E/;#P80DV9Y1H*.<_UBDI?W_C:'"^M_$1: ^0 M(3#NDN>
(G^AG1@"KE4 M.I_Q,9)Y*G/IX%Q 56\';07&I:W(1PJHQQ7T,0TR[6N9?)FN4&I'T@8%RSW,B ML@6G1/C2"@\' $.>EV(M%?CWNJ]7?0\L/G!4UGKBMS/X*Q"/?
R6=S9[5$M@V=/DOEPB!?C9#*=//N\)^ H MN;PRC, M3](X7*,_)KP7_K8QH0$ZZ&T!HV,Z0,J6*',']EM6 MCNHA,#?L*'0W)V")FLE[B05O*Z-
\WT;TBRUUSR+K0]UOH)1@JB*+HY>$7<@+ M1&'E+%8E>% W%R?DK/#>8SU0]^Z/]TJH[*"DH4HLDWE%I9J-M>/@D?9B10LZ M[Z\JRC=;;B"U455" .(U%V/LJ/YP:)!AJ"*OF
D5N)MXS*;5@(10!*:BRP"5 MGUB)8EQM=3_-N<7]$23+2(\3['9$,2&/Q>2-29)A4?Z(AP2CR^W+.&TELE]Q M%-"#VV!R_R$WQU&^V-RHD?1 M(*
B#F)7],.%0GA(TBMT$F*U$]GSSNUDOR;I M/4(S2Y'RRI+?US4*_M$"A"A"Q%EWOVG.8#37RT\FC0THN(LTkQFDA)NJ7K9RIH#-TZ4NWBV0RGR7# M^26;)O/)/+F8S9[=MIF)D
OOAK!Z.&&C83*$(Z:S:3NI^^650D"<7\R2\]F8 MC<\ACP\G(;^/X(B+(?Q_SD87R6@3TBZGTU,]VSPF^?DWZO 4E 6&?>\=ICU) M--#Y5." 5)H=ROW_)|+L'3F*+,CN^!<;FFUWV-
#9X(.(J[84C$T] TOI%LK6 M4P?P9-J_U%D]9>6$IE%&V!C35@0A6XI4KB0L\4&#CH8||8=1QZ!]9PXQBV8 M_HS)D@ZMI8 ,>%|'!LW)X5$*9:.IM5(GL8+&-
IKCMY)&"'"*,-6 MQE O$>@>GEP=&0B4VA*V):'S)SG9:C\YU|T"0 WG@]?O&3OH;E%:F1',+=?1K!3[WS;#%,O)4^,$2Z2"&YFCNQE=K:'85QOD;&^*O,3BS[;^8M2B@0!X6) KNC;Y
M!"!BXR4H2&6;ALRW,QB8@H-7T,.#[GV) '6F[S-] 2QL.F199\FZ2 _! M2B8+Z!,(2? QZR>ZOF46?IQPZ+#X(< 7?W@7*0?F,>>=$3WJA1Z>F,N3=5HA'];B.T*J
MCW10HQ7NXK#,&8VH3U&$U5B(M>CEH*']G1V5>(S[]J.>U!"OAZ$!2^EVWL@T MCC2U\][4Q?1A1(SVQ[A_2KM'/ED1ID
+@5@#8B02X$IZ6@YH[3/O"W>,YZ2>S+10L>Y$"FVP&72< M/KL<\,_6"08;DN[L*6E/E;0@P(T;A;8?$E2,5^O 6AX*#!^@Q+99C(-U* T M7(<8;HN\!^R@I"ZF8VRT89W@N+$?U(8-?
N_!L[1MA&Z'-+SY+]06';"F=F#O MHX0'JN_Y[A;_#@[83U'"OW$PMMFQ^+FL4Y6%8NW$AR'V"%SU18C-T45_!":2: M[T'OZ;LGL4!ET?
C5K1^D_NQ[P^#,D_$%./,'#]GUA*^[$@'F$%DZOS[ZQ8"U_M[I$19$<1KBA*UV*)E=PFCE@?[JEFJ6R9&<5@#"9@Q4Z$SG6;<$(M<4\=C>% MG[Y_,?2!
M&PALG/6O8.MP,)OV_,BHOG&ZI%_ ++5SNJ#+#6A+&%P [S&JZAL\(/XDZNJ_ M4$L#!!0 (!:#;%EK'B)&[@, /0(9 >&PO=V]R:W-H965TPBJIQK+I/$ M\@IK9B]T@XI6-MK4S-
'0;!/;&&1E<*IEDJ7I.*F94-%R'N;NS7*N6R>%PGL# MMJUK9KY=H]2[132,]A,/8ELY/Y$LYPW;X@K=7\V]H5%RB%**&I456H'!S2*Z M&EY>%]X^&/PM<&>/^"N"9K+5^\H,_RT64>D
HD3L?@=',]Z@E#X0P?C:QXP. M*;WC<7\?_?? G;BLF<4;+?\1!L6T32*$C>LE>Y![_[GD\ R+6TH85=;YM& MP%OK=-T[$X):J.Z?O?3[\",.6>^0!=Q=HH#RECFVG!N] ^.M*9KO!*K!F\
) MY0]EY0RM"O)SRU5W&* WL!);)3:",,^7@BG/=*B?4%NZU%%R@A0^/;"W1?IPG MCA)[!X3W2:Z[)-EWDLS@LU:NLG"G2BS?^B<$^(ZVZ.^SLX&7&%S 7D:0Y9F
MHS/Q\L,NY"%>_IUXI^C^>[6VSI!]_CM%N(LW.AW/WZ1+VS".BXBNBD7SC-'R MEY^&X_2W.VA'!2C<!&/S^P!N59<2,&"QFGFAMDJ#BW0?+^ZQY65Z1'T6'7;,,E/95F-
P&I_EI;L4]1\'0ZYI"*.MB?.F(=6&ZI$%05MC8:.E'UT.2%ADMD83U=$_92[']Y'D66HCINE.\CW#<1 MDG]$&,)G)6UIX*TLL#CE1^2VM9P<+-\G%P67N+V!?AQ"$B?I!;U>>P0|K]?[
M[R,X)#]U3X9;3OG_G*X(16_HU[D3: *DYP.XNKHS6Y,C.*#",;@?,)B\>M'M MQZ\OV$];^^DE] MZYH) S-F2IBS)^H3UGBE!G#]<"Z8[*SQ 363.<),&0*_A%4VC+.QG M7?
I>02],>QE<.B1;3C(,CCW1**C@]^0"M2U-0.YJ]5M M:K!=;3OGM&D8S_"F]7ZF^N;2@, U4>.;VRP W;2R9F+5UK>/E;+4C/RPI.Z/ MV@%H?ZV4/4Q<@/;_9/(74$L#!!0 (!:#;%F/;_9?"P.
+,& 9 M>&PO=V]R:W-H965T,/0 D'],VF: M)0'2!H<;L.&"=ML!'/:@V'0L3)8%26[;_XHV773(+(HB/WXD)7JO5_JG MJ1 M-/1"FF9c3VXZ&'L25-K+8.1.#@HOZGWW9 MQ:'E, Y>
<0AW#[*C76_D6%XSP^93)3>@K#6AV8&3ZKR)'!XPKi;A8P2737[^3=G+SX](> M,H14YE31%MFXHP+NLS# 1=TK7-%%U C D/F5+$HFMF_?
C,/>Z$)#R@43,64M3T=*46DWKO29&W6"O*K*JG"\7"8^90;=;CFO,;<#LI.6=<51,Q=D6 M*D;,_4WP1E(5&U147$B]*:U B-4]EE(9R^+:[ONH:=BATVJPB%"Y
M(_M}0WM<:=X3)*X@(7K0G#+U),539&"FX0 B7J^S^Z2KP1/;86"^9$$*/@8 MV<#;,,,-**L7-H]"OOS>L;72]?$FG2NE\,#//%2=1EGR"A2WU$8L"4@KD6CX M 7K#
[OEHV!ZX9(47SZ/.@S3$,WZ!]YW.RXS"l;,--45BC=]X2$XZCV?+,S#*_M17<+= !RBQB.NN/P$.CETH[,<=SOA/BW^;W&>)?>WO^;WGZ3WN/9L"5!PU%[
M\'5"C@5^W#T?!XWMP>SU[(=!MSS;YVI<= =!,$!M:^6 MCO5\OW5'%ZA6[B6B(9:5,/5UW:PVCYU%?<<_F]&UL
MC57;CMHP$'WG*T9I5>U*T2:$A(4M(+&T55NU*H\)>]H^F&0@5AV;VLZR^_<= M.Y %B:*^$%,..?/&|@RCG=*.38EHX,$2THR#TMKM7129O,2*F1NU14D[:Z4K M9FFJ-
Y'9:F2%)U4B2N*X'U6,RV R\FMS/1FIV@HN<:[!U%7%]-,]"K4;!]W@ ML+#@F]*ZA6@RVK(-+M%^V\XUS:)6I> 52L.5!(WK<3#MWMVG#N\!WSGNS-$8 M7"8KI7Z[R8=B',3.$ K,K5-
@]'G &0KAA,C&G[UFT(9TQ./O0?V=SYUR63&# M,R5^\,*6XV 00(%K5@N[4+OWN,\GW)Y*#BLOFR MQ_TY'!$&\3\(R9Z0>-]-(._R#;-L,M)]!]A23>:X=)>RM)IV.?'L
M9(^&ZCJWM>9R TP6\,66J&&:@EDL8%8RO4$#5U

M(UYAGAL@HO&CP73:(XWCX7J/_LG&3K$LF<(KD3_P3&^F3N) ABNVS?6=V/V) M33R1P4M%KNP3=HVMZT"Z55H4C3,Q*'A9O|G/YA[>XN W#K[E71]D65XSS683
M*78@C36AF84-U7H3.5Z;I-QK27\Y^>G9%Z20%)PMV#)'=3X9: (UOP9I W!9 M _BO (S@1I1ZH^"/,L/LV'] 9%I&_I[1I=\)>(_5!01N'WS7#SOP@C;"P.(%
MW1'^,U\]+4D$_YZ*L88(3T.8PABKBJ4X=4CY"N4C.K,/[S8_=A!,&P)AEWH MLRM15*+$4BL0*[!TX4HH?8IG))]GHL-0GIT1&Z/2.D(*JM42,H;\!+TQIO, M5*Q\^O N\;WA1T5&E-
52D0&ME,AYQC1]K'C)RI2$)2FC<(B[U B, 4KD5.I MDZ8LIM@J5F;J'-Q;;"3BD5K@+PK@>(>R3WA+E$8"/2,!HX, VE7O^8+&O:\5 M2J9YN3Z,Z3UX2_?,Z1TF 3VCOIOX|>
[0ZWUCDANM'WK$;@+!:$0621Q#,@IZ M"Z$IN!>@HRBD=V+!XOXH3.CM]_TXA X51*T*HDX5W-==T>3GP;82S'Z?/U)X M:X0[-.W5A%D'OT!9 -TJ7'.5BFVIX8ZR0&:YS8X6\'PQM?
Q/;:F;CY'-;D^$ M-41D2Z2^&KTGDNV)2$-$/A,Y)2IQG+5?E#/NS:U.C[1@%=![>!,CH[PG9%*= MP_!B^*O3,=OXPG?AMXX4QFT*X[>F\(;JK>3:KE_D KZ0_GC.-3^=ELXS3I?X
MX6EON'#(GQF8PF>1:0)4T)1QKCAK3!MW MKJ_I)$4!7U,MS(;7P)%,#HWJ35-P41B;%A!1M7F^9Y8Q+<-1:)9#*FPOL+I)
MA/W('5*'(6)L11H@C'X<~4T=%_7]F''I*83],/*HC2@UAL]%M=6V_9$34IV? MP8C.&L)Y[]9<+VGDD>5;-!?QVBT^$6@0!0.29PV:,J4TGI60=O+H]#TC[JX; MT($UUU#:O!
[0;)M>\5,1K1:[NQ9 :B*R'GOI#B\H.&DNA:6RQRPW-B2B- ?U?":'W M'^: =O*<_0=02P,$% @ %H-L667$I@=T"0 PEL !D !X,"]W;W)K M&ULO9Q;,]LX&H; "N$=+&: MK8DG])-
B31J8-I M&S3;G8O!7B@R8PN51)>DDG8Q/WY)6;%,2V;BXDUO$MGF]Y"67_/P?C1/'QC_ M(E:42O*MR$MQ-EA)N7X[<(IT18M$O&%K6JI7[A@O$]D>\N50K#E-%G50D0_=
MT6@Z+')*L')R?UL!=_-35LD\^DU)Z{JBH1_0Z0Y>S@;.(/)SYERY743P5/ M3]?)DMY0^7E]S=6CX9;RR I;BHR5A-.[L\&%\S;V9C[@+O&?C#Z(G6NBW\HM M8U_T@W>+L\%(MXCF-
)4:D;A_]_2*YKDF]?9\;,"#;9TZ,^M8=P$C/<#O ,!DR9@\MP:IDW M=#]@?B!@U@3,GEO#O F8UY_NYN.H/TL_DHCS$JM
MW1O)U:N9BI/G'_DR*;/_)5I(K\@G*B2O4EGQK%R^(A%3_\@5*U/*E]9*5>"!.6"+GKB0WN\]U1\9(_L<0/U3W? MWGCW\<9?NE;@^X2_(:
[[BK@C=TP^W_ZVG7U5.8[\2=U!3/0O'ME(NU M:HSCU1C7@=GLF^K\@WQ1LU"HIUSKY3VO=AV3DW=+W#.=R M6&R'^315,,=VIPT=>-LOH%=SO6=\
\K]M$^4A8@(2%2%B$A,4@F"'(M\5:08QO|("AE)K^K[CIE?,UX,S(L$DEUOV\\W2=$*_Q8(2)A/A(6(&AA;9 M/]T/[%X-.ZH;4_W8:-*G/5!C#.U-MMJ;6%MGS#]
(NDKXLJ^KOK12CA49$N8C M80$2%FY@TQJF5S3WY^Y\-#X=WN^*IUOHQ)WL%8!S3(4,MTJ9&I5R+MBG61<
M+9YD(P^B9IOD@6>2OEZPAU+W46NNEG9<]6%ZODJ_5ME:E^_3D;6N8W6$A/E(M6("$A4A8M(%-=O3FG(Q&>WH#U6CH,;,;5V^RY>E-3LGHKR\^"THNA*"]HK(2
MCU45$N8C80$2%B)AT:RC*M>=>|,]68&J-&0UW\IJ;I556*FNB2>9H(NZ],= M5CVEZEL:7UI9QPH*"?.1L)"Y&P;-X1U-@=SSL=%:A.0U$G6T6=6!5US5E*
MZ4*0.\X*D@E1)65:3]DY75!;)+NT]$=]$Y#=\ZH=1!'/Z^K,QDEN1D7=WF6;J$ MJ-2F9O5].K-7<*S0H#0?2@N@M!!*BQK:KMHF,Z\C-E2E1MIV_&K'JK:+-*V*
M*D^DZK@6]"Y+L]XYF)URM*20-!]*"Z"TL*"MBN"U=+-'6=OI?C<@G%3<&H4 M=!QO,MD6-*7@ME)PK5*X2L2]7N.E^D(O],Z37,W4>^=0=M;1@D#2?"@M@-+"
MAF9,IKW.U"=Z7K&XKYCK3;P#4FA-=,=JB9[?K!B7KR7E:@!24QPABX,2@#KE M4)H/I0506MC0@/]H-G>G^SKPNA]PMUC<0YN/QCRM,770>M>.W=XTYR)+IF:[MY<8L8J7D27I
$U#3&DKSH;0 2@NAM*BAF;/=GB[D)0QJIW6H';M%'7$FA+88 M&YUI]S'A/%$:H]\H3|62OE|C4,\;2O.AM !*"Z&T[*'M:JQOE'H)A]MI+6[`M[G&;G9A:/-
%2T,U$A<5YPF+VVD|;L=NIQU/H1:6W9NQ96]4IX0VDAE!9!:3&*9@=RE<<=NSW^H2IN M*=?F9:YWZRP>4WH9%:1(^!7E.E=U!QH208BYE.9#:0&4
M%D)I$906HVCFIM#63'0HRJU-1. MZ]2[=]>^,YJ]*=IUQ=.5GKI=V);Q=O#1\H':]E!: *6%4%H$I<4HFBG&-E?@ M_I0=]RXTD0"E^5!: *6%4%H$I<4HFJG,-
GOAVK,7/SK$0M,7#6UW1)ET?1H? M6FD I8506@2EQ2B:*,$V?>'-TQ==B>UN%>N8>GG.TGJKA616=\|>Z]$2[+KT
MX^FD*T%HV@)*"Z&TZ'DW)$95:FJKS5NX3^4M>F9YG!*]V55)Z$^,:]J#9"BC- MA]("*"V$TB(H+4,13#6V20UW]E.F>=#=_%":#Z4%4%H(I4506HRBF6 MYVK<#;Y6^@>]'YL-
V.0FR:EXPG6!):C:@-!]*"Z"T$]+H+0813-/.6@3&]Y/ M26QXT,0&E.9#:0&4%D)I$906HVBF,MO$AO?\Q$:OY* 9#"C-A|("*"V$TB*O MF^APO>YOA5&5FEI]$QV>/=']Q>.8-N:'WE-
>VRE_OJ=[,TM^,0;,,4)H/I050 M6@BE15!.C**9"MPY3NCGG">$/5 (>Z(0]D@A[)E"V$.%L*<*O41VPVNS&]X3
MV8WMIC[:]))"_S:Y2M4:Y6_;:6&7=O#18D32?"@M:&B[1N]\9@YQ(;3&"$]+ M43138FUVP[-G-ZY84:C.[>;0#]KMX4<+"?HC#"@M@-)"*"V"TF(4S91F=*AV]F:GNF&\.C-
X\D&Q=']S\RZ1D17VSNFF"&ULK531;ML@%/V5*U9<K;0%QVZI-7,LI8FF5MJD MJ"%FWAVD//%_']!@\(SGWIP/L1JGD5GO8B\V%V5*:;(WHX+&1RDY) M[5PIH=3R&AMF1[I%Y5#+/
CX"O@OO=>ULSB7,L?HG3UE'PD4&+,%MM+=Z?T-IGXN@A[7TL8OI'ML M0H!OK=--3_89-$)U?_;8U^&(.#Y_@9#VA/12"5E/B)6C76;1UH(Y5N1&F)I[\$$ MM%<+@UB;R/9NA
JGN'+&KPK/<\6]J.SW0%:S$1HE*<*8YW7=Y96^E!>V(\B2=Y FZ?D ??XZ?8'1GCVG4U^A0YG20YG2]>]+ MH#=4CY]?/ AN'3,VUY#!3O%\6#%TY\2VC..4^/:S:'9(BK=OQI?)IR&[_TGL
MF?GL8#Y[3;VX0^N_X Y+X,S60UX[@+W7VOEFB&PO=V]R:W-H M965T"<37UK?CFUELZUW!=P]UZHV1=;(6XM%.OF93+[" @ 1E@&;UPYFP)@E,C*>6DZO
M^Z0%]L44>Q.PZS,L,I'[HD^/55TAQEPK!#FE2E66E*B(6OVEU *:6Y]3A4XFOC75KP">M-MS;O&9OB632C/412,4!B$DP'X[#A\#L3 QPX>[<-]$WB7>MBE'CJ^Z V^X:Q& MAT&-
!M/KI_QS=FTVS7_AUU FC8C)L C,'VY4B0E,/=, %,@=>.G[=^.+X.-0 M0O^);"^OJ,LK.L;N\G)9$#N OP$,N6ZH+AR5;6*[-(RN@B#Q=WT[U5A%$== MU9[.2.=S)[*WP#&PO=V]R:W-
H965TVT0H426I./G[#BE%EAQ%: "A\(LM4C-' M<\[,#9D5X<@e'M0?0Y"GEF9H[>ZWS2]=5R1Y2]BY$#AG>V0]94HU+N7-5++H%N MK%/*W<#$C(>E+',6,
[NWDHN9*#1G&:PD446:4OE\+5PFPUW M,"@&M?$4+D7XL$L M/FWFCF#*_I)#9>LY)"F4%FGEC!&D+"O_Z5,E1,,! M<;H=@LHA.'48O>$05@Y6.;>,S-*ZH9HN9E(M9>BG%^LR?
41LR9KM,K9E"I.%V7G((W.$W)%Y'I/0:1801M?Q?UJ44* M7D2Z#GH!UY!?D-#[C01>,.]{9_G?W<.><,(Z9Z"%"]_ NT+A-WV:?[2:BS0O M=*GYMRVYI3+/#=*]RJK7^_AF!R2<-[?
K1U7(9Q:@I"O-^N50Y36#NX M$@7P$ M9_'S3WID_=XET4!@+<%&M6"C/O1%LUAKX=11,&@5:[(NUDU5K!D6*W\I5EN: M79J5@8QM(.85^KCPQY/(FT18-XI-/3H,(I\IN-
Q;=CB.JZYCGNYWJ8Y%\^ MA:%%)D"^Y89'5Z2],,_-]D!@+<+91S3@ZBW:(AA1L(+"68'$M6'PN[1"_JO(H MG,3>9'K2#:_MQI-P$L5Q=S-,;J:37J:8!]3#5K85#E1*,+9U?E!Z8=Z,VX'
M6HRG->/I633#=$C!!@)K">9[QQ.0=R[M4$72K'/\,$2A%Y[T0X>A[WFA-X[? M^#SXC0.?WTOW#I26+#%!EWU19*RI*?]!WIODH=#:M(,C[> L&J,*8RC1!D)K
MBW8\;/]Q[+_M37"CM:(1W%PVAFO[8)1&#F6'L)/|:S.FVEGK"%/.N%^HW+%,$0Y;A/0N8@Q*EF-CN= BMY/7O= X MQ]G+/8[:((T!WM*U+=:F ?4P_OB7U!+ P04 " 6@VQ9E[/!/O\$
!] M) &0 'AL+W=OJK+=>[&Z%RX,$#6)6=N!K70?_IR0QLD27'(8B3\O,D_17C+V(.(-'/*(S%P)E+N3AW73&>0T3%*5M-K+Z9,AY1J0IY
MS!4+#G22&46A2SROI48TB)UA/SOWP(=!EL@PB.&!(Y%$$>6OEQ"RU<#!SMN)MQV VE^D)=]A?T!F.0#XM'K@Z<@N521!!+ (6(P[3@7.!SZ_\5FJ0C?@6P$J4 M/J,TE&?
&7M*#V\G \5*/((2Q3"6H^K>$*PC#5$GY\2,7=8IKIH;ESV_J-UGP M*IAG*N"*A7\'$SD?.%T'36!*DU ^LM6?D =TENJ-62BROVB5C_4<-Z9%%N
MK#R@(GC]G_],URP*TM!B0W(+L:^+F!GP6Z]BP+ZYI*.NQSMD(\':W4T@]9 M;C)K%4T0I,XDEQ]&R@[.;RA 4??:)@ N@\F\N3=?%4EO$&K9&5+K9H\S5;8#%<[+7]C1.._ Q, MXZ[2(<"1E!HRQP6.Q&Y+
[A#@2#0XDOW!D6RB7FUIU PSE(9&0K)/3\Y8&L1X M@S!?M_%$']Y1S2/DN-]WQ&K/&I+K9H\S:-D_Q:>6:)OP)N]ONW:)Z+9D-AB
MPUSHO2X[:=3N(YKZR,&HC_R/3HG9F\;3=P@6))H%R7&Q(+'*@K;4]@^A- OZ M^[.@6:)IP/XF,FXO=5\3HV\FQ@;/TZS27JZV8T/%UQCG&TG'[B^"O;Z+V>O&
MR3O(&]C2(UC_]'XY?*LM1UMJU>1I#O5MM2;-0HW#;FW&PO=V]R:W-H M965TX[/N?:]<2ODBRH!-'JM&%<)+K6N MIYGLA{JHD:B!FYV"B$KHLU4;CU52R"Y
U7,"WQ_XE6$;!14E'=_\MKGX0 PCMX !#T@>"\@[&A,]HI<[861),TEJ)%TD8; M-CMPN7%HXX9R>XMK+D%?J,9GE.;;8)0_>\
M>RXV[U<++T(0R=6U"GM8+=/7Q.O;T46+YO*P_];X[-7CCU#74(Q3Z-RCP@^@$ M?'X>OH#,P,<,:A[#/>-
2$(P)"%P?.'E)"RHRIBP>5#HUVRCM#0/[?,=V\2QV2:Q2,Q8VQVZ.1=Q)#$:.)$;OE,@HV5!F'B9.QG31+M]2CHO2AB9U[3GQ.KGWM\8;Q'R(! MD.@^(U1,G$3*,SS1)1
AH7+IW:F#S?LO^SHA78NZP@!DC7]-8)A-GZ* 8EK@@\H9M MWD,EJ*?Y(D:$^4>;*M9W4%0(R;(*K$:0I;2\XOO*B 8@"/< @@H0/ 8$>P!A M!0C_%M"M
%WC3"G%^##'$D_'G&T0U|&*3=\8,PU:R4^I_NX+R=735.'D! ;$ MY$4D"YI2%<(T1|E AS= ,$28C1+,%^!0"?G<9SJ+X4)NJ1EQJG6*3J9@\0I M$:?ID4HINDH)4?
UB[$DU.OT.+ZI&!E?!#05T4^J]1X ==|#;+"?I%T",,SK. O,%SNYBC MDY>G;?K^F69'9EAG4&AXP[_*H!D3TJ21Z@:,^!O3MHXI'EQ(R\;TM*4KR;CNY
M7O7.1(XCF#AJ63.,SO35BT[?2]-FY#')YDNNG3TYB1&_K-7Z=&0)C1]\WH6[HD>]6H)XI:!?:KX7VG_G]$]@IAWN%6@D. M%=I_JJ'SY/,V! 5NOUWHH!8ZL
HM:\O>D5;PH2(^3]+3=SN/-)8Q_:8/!0*`MM<"A5>!VM4;)<+ [E6;V MEQ_JU+'82]N\QCXY U5 !7E#J'6HH++<,M>]!9GFW.SDO8?P\D!TI>IO2@4B
ML%10WQTH4WAYQB@;DN5FUWW'I-K#F]M$G>K ,)L0 9 >&PO=V]R:W-H965T>;SS/#!Y/9B8LO,@90Z%N:9')NQ4H=[FQ; MAC&D5-[P
V3ZSHZ+E"H]%7M;'@30]#!*$YLXCF^GE&768E:LK<1BQG.5L Q6 M LD\3:EX>H"$G^86MIX7UFP?*[-@+V8'NH<-]$^'E= SNT;6 J99#Q# G9S MZQI?/1#7&!0[_F!PDF=C9(ZRY?
R+F;R/YI9C&$$"H3(05%^.L(0D,4B:Q[<* MU*I[&L/S\3/ZN^+P^C!;*F')D\\L4O'R.(7 MG;]ICH7"7"]>5L:.0H)W9L0,\7T_E>/H"A+Y&OT K$,_1[S7&IT.:.5
M9FU\VV'%*%D2#H8!N@CSU0LT2]9!-&EO:U/6Q^9/!_Y@?0";N!P@R;.&T0< MX])/FT?TZL7K'MQ)'B]@E3^U1:%$MQM M!SK[\B\I?Q6B4T:W/?"S0P+'Y-TQ\SH_X(U&]KZK>#,UI:
M>F<9#8CGMF=T6ON;]OI;4AFC%7W2@JU:G4ZOG+YU)T'0[C6H00;]7B\35$7Q M#8(L,0 M3450AN;X(I=U%CH],29TA9HI[_1!HX@#)FBBMI5L!=[8+G@L_<
M'K/6*_3_F3UIV)/!Y5Z9GB?:\SWQ&[7&O(O]WQ5?V%R4_<2===5=9H->X7 MZ\%%7^&>$R($^QU\&BW'@\1<5_T:E Z.^?CJKOHQ!TW H!'57@\AL3C1N/Q M<)"URI/?
&?:D>Q&YO$/ZCQN$?K;CI<+;G0>CR3T^%KIB3?IX$,:I2=#E;[\ M?.ZL]W[<@15#&I4GHZH\&4/E2:/R9+C*DVN5#X(.K26-R),?%'G2(O+3P.GP MVV@\&4GCR?7G.G;^'0;[K%l,0?
=WIBN6*.1YILK6L5ZM.^_JLM|IL M=^T?= M'K),H@1VVM2YN=61$&4G7$X4/Q3=YY8KW/! P %1(!D !X,"]W;W)K&ULM5A=CZ,V%/TK%EU5N]+N@/D*F2:19C,=[4A3-9ITVX>J
M#QZX2:P%S-HFF?WWM8$A(7%H,V)>$@SW'LZY/H9K)CO&OXD-@$3/69J+J;61 MLKBV;1%O("BBA60JRLKQC,BU9"O;5%P($F5E*6VZSBAG1&:6[-)=6[!9Q-6 MRI3FL.!
(E%E&^(_/D+++=U,+6RXE'NMY(?<*>30]RAB7(K\6"]Y'=HB0T@UQ0 MEB,.]ZEU@Z_G.-()5<2?%;BX!AI*4^,?=.#^V1].9H1I!!+#4'4WQ;FD*8: M2?'XWH!:
[3UUXN'Q_I=)5Z)>2(*YBS|BR9R,[4B"R6P(F4]'QOHR=%V4F BK_H(F M649,A3%%UZQN4U/OXP04)E2>:).]18*.CT[0$2(,_<%EB]XH_-.T95BIN6> M&_#/9"F5T&/D;U_CU,QA/[,9K2-
9XA3&CIZ=$L0&G/CS[\'0^]:7](\D2SZ2 M;/9!9'OE"=ORA(?8X\Y7SU>H[(X)V%6IKS0UZ]"RFB6UB0>7GA>YFVI*>XPN M+H)]HZ3'Z/S2WS>:]1@-.]?5H;N=^5B 6-O%)%'*%Z;JK[?
5MKMO8D?^"_UT M,$KJ%?9,4R_4&RS6A$E$8:4IO;.O>DR++>DG5@N*EG<)++KO1,M\=<[W40QD"_.M7W&N=H*YH/VG$/\#4$L#!!0 (!.#;%GG[HAZP(,H) 9 >&PO M=V]R:W-
H965T,@$3H:.JE1QKHR3C$G\I07R/27!1S\T)94X4 MX%%.7.4Y$^3\N,.;H7/F; ?NZ#)59L"-PH(L<8IJ5MP*W7-K ME83FR"3E#
0NALH[!P\,/;6X#/%C=QI@R&9%XYZPARRLLHW>:CRL./@^WL<_,K!?^HPV.,05 Z! M!2TCLUB71)$H%'P#PEAK-=.PN;'>FH8R4\6I$OHKU7XJFN0%H4*710%?@"VB
M:PRA)J,DYR6#"RHEC*G!\B8K03)[$5 &GU*^DH0E,G25#LS(MNW$5Q$49A+\GB "N.5.IA'=<'.+D!#S%5/ER5F/UA>5D3V?W=_FY2WG M6M>+,JD7[4*
[>]=]O31$>7,H.XH7[O"=-11(`VVG+O]^QDX8RI9D$XZ6UG?-]XYL77\8K(1]5@JAAG:6YFCB)OL0 MZZHHP8RI U%@3E_F0F9,TUN27%(5(9+$%9:D;>-]0S1C/G7!LUZYE.!:E3GF.
MUQ)4F65,/I]B*E83QW8*RYRD#B? M."?^\;D?&("UN.>X4EMC,*$\"/%H)I?QQ/&,(DPQTH:"T=\2IYBFAHET/-6D M3N/3 +?'&_8+&SP%\\ 43D7ZD\?7/UG4BM@#!< <@]
V6[ER*H\8Y]%8RE6((TUL9F! M#=6B21S/355F6M)73C@=?F8%XY+2K$',P1;%#.X4PHE2J!5\A1FU0ERF:#Y< MD*7 *=2)BD8K%,^P1 M&>.IVB=WK<:W&"4Y?
RIQ[&H*VXAWHSKTRK8$>((|@2N4X4G.MX7"+R@W\'7:VK0LWR|'7?V5!5B6G"Y +AUP\RA$N- MV>^V]"O2?CNIVI/,S=4';BBHT M*Q)2I%!-T;Y3VI,U-M>BM&O^I$X/V
AXU;H\Z MW=[2&0)[S\BDVF_SVHT>@46"#YG9X^ ?0LR>546XHL)%7=W*SVCQI3JJ+ ,6\>@]=45%YKB#%.4&]@T,ZSF3U MQ*@F6A3V6G\0FAX)=IC0LPRE,:#O&ULO=U? M;Z-
(HL;AKX)R5J.]4F]BP,,)3#I2=RC^U?9LM#V(/% M13%Y4HNT.,]6:EGJY"'+%VE9?9L_7A2K7*73S4*+^84S&'@7BW2V/+NYWOS; M77YSG:W+^6RHG*K6"\6:?!HLYIGSQ_/I+/7?
_CGI/&IK/_AXN9ZE3ZJKZK\ MU^HNK[ZIV"X3V4(MBUFVM'+U\'LD_VC'#OU IM\'_NFGHN=KGUZ4^ZS[+?Z MFWCZ\6Q0KY&;]TE9$VGUGV_]5LWGM52MQ^\-
>K8=LUYP[^M7/=AL?+4Q]VFA M;K/YK[-I^?3Q[/+,FJJ'=#TO_YD]1ZK9H%'M3;)YL?E_Z[EY[.#,FJR+,ELT M"U=KL)@M7_Z;_M\(G86<)P#"SC- L[^ E<'%G";!=Q31Q@V"PSW%G
/C3!J M%ACM+3 \M-%>LX"WOTKV@07&S0+CO04._EHOFP4N|]?AT$9?-0M[;R^O&55W^QV4\WRU=[UFQ91^IK MF5<_G57+E3=WU1ZL\EQ-
K70YM6ZSQ:+:S[^6V>0WZV_6I^ET5N_XZ=R*ER_Q MK6/P5U^5Z6Q>_/?U15FM0@U=3)KAPI?AG /#N=:7;%D^%9983M6T8_G(O/R5 M87F+:M.WV^^\;O]GQPA^2?-SRW$^6,[
&5K_^NL;?_U+UW;=FIE W9],]E!G MK.(IS57!H?EFI:M:G5L#>Z.YAI42QL:MN^6,=,7ZBW71K-?AU0O,[=5]3NS MW0WL](+#$_X8KMW\%@\]T0F_/7>P|[?X=U:]D|8Q-
NN^FFS7T3T)3$Y?7?>P M(H__K0%8=^!0]_Z.;_G[X+]L,_-25/1+S24R06$!B(8E% M)!:36$)B$L*T? VW^1J:I)T7XJ(.V(?7 *?K\BG+9W16/_B_P\\.GXUXWIR1
MF$]B@L0"$@M)+'K!1ANL/BGZ=F,/7OYW??%M-TNG/C A5T^>,*]6@=$V Z-^ M&5BEN?4MG:]5M>^W+VI=^[\1[KO_DYA/8H+$ A(+22QZP<8[.]C@?#"P]W;^
MDQZ5D"LFCPVI[?;>=K?WWO74/RN*]9&G?2/<=[5[= M?]X_^HCDZ",DM,K:KC[>[NKC=^WJV;HLRG0YG2T?C?N[4>^[OY.83V*Q (2 M"TDL&A_=WX\'(CGZ"
FMLK;_7V[W]TOC_MY<4&MVIF]96>_@>7V9MW/W-F)] M=\V2\TE,D%A 8B&)1>9=XY?5,6696 MME3USJ.LARRW5#IY>GF*M0[4?'K>=8Y-;D=_"8A+"M#1>;=-X9?R5_[Q>W*O\
MS6],BV7U\E-?*NQ*IQ'OFTX2\TE,D%A 8B&)15=O3V+W7GS(X1(2DQ"FA<@>_MM&\9##8PQ>KD"7+|?!)SF>;JL0E,]1]VKUQ.6Z3JO\[12^2R;-N?O*_W 3UNZ M*VO-*G@[?
QYWT'EIX|\MGVCA&H"U0)4"U$M0K48U1)4DY2FIV_G%O;F+XP MSXJBRE,V46I:,(X(FB!9Z@^53V9%]ZF3F>W!H5]/]H0)5 M0+42UJ-&T9\G+ MKNO$Z+
}JDE*T_/DM'ERC'GZ],L7Z]-CHM2B,N+N#(YQ^=!'(34?U02J!-6 MHEJ$:C&]):@F*4U/5]L:L-':@(WV!E#-1S6!:@&]A:@6H5J,:@FJ24K3L]8V M"&QSA2"N3K_2Y42]N9Y^0.*CPPI4"U
M1+4(U6)4 M2U!-4IH>IK:*8)N["#^KE\:OV0+E8_6;=9UQL5G\U:[QBA M%094$Z@6H%](:A&]Q:B6H)]D-#UK;9G"'],G5VA[M5\5!.H%]!:B&H1]L6H
MEJ"!#0!.VV1PS:_'77^G\HE.ENGCYO0]?7S,U6-;JLV)UJRH/V'8&3FTT8%J M?J/9]FYWYGS@ZD>< ATT0+40U2)4BU$M035):7J6VAJ&;>YAW&;+,L_F=;E% M_+Z>E=^M?
SP\J,V;QE_3N2J.7(!>QBHYJ.:0+4 U4)4BU M1K4$U22EZ9]V M;;L;SH \9'3(=\YO4=54RT*$35),4I@>GK60XYDK&73[!5I]; MWM;:6X9AK&9^VUPH?!ZJ>;;8=.9?2QNF0KQY MD-
X1)#4?U42C[;X7;CM=S?\ '3=$M0C58E1+4$U2FAZOMJCAF(L:^WWX.E2K MY@!R93R 1!L>VYDGM*=Q\K@Q.FZ":I+2]*RT'0S'/*.% M*,K9HHK&M#J -]
[#FF3%@6,XM("!:CZ]"50+&DUK1SJ=^4"[%:@6HU"]+I+2 M] RUW0K'W*WXJLUW5\'TN,CFTP-6:GT_GTW-3%@6O0I/C%A&]Q:B6H)]D M-#V,;6]CB/8VAFAO]5\5!.H%]!:B&H1]L6HEJ":I#0]:VUO8WAB;^-]GY@T
MZ[VSAW8V4$TTFC:K\W!P:5]>[KVOC X;HEITZD;$Z+ >]DE*TQ/3%C*&YD(& M<5%#;6.@FH]JHM&.7(8(T$%#5(M0+4:U!-4DI6G!&K5]C9&YK\$TG5+U>*,QR*Y\] M/I4?

JA>RU2O/RUEUR#=5Q22?K5) M67>Y^MO^U;'Z.&>V6*CIK'K&GG]_/1I*[^=],WW?9J>JGJV7UI?TN^7:'KOG MX%QVW0 X1KMK8*, MS%60=_6JS&;OQ*'E#U03J!:@6MAHNQ<-
[<'0]CQ//\^,T&%C5$M035*:'J:V M_C$Z??*.SMR@-0l4\U%-C-X6,]S.^Y $Z+@AJD6H%J-:@FJ2TO3@M#6/D;GF ML7LZ=>I'5\QD[S"A50Y4$Z@6H%J(:A&JQ:B6H)JD-
#UP;95CA%8Y1FB5]5\ M5!.H%J!:B&H1JL6HEJ":I#0l:VV58V2N*0W3<"-5B5$M035*:GJ:VYC$RUSRZ|BDY.Y"PSF'A'0l4\U%-H%HP M>COUQ?AJV%6U1\>-4"U&M035)*5IP?
+:FH=GKGD<.P<[6N-O'J=OPE#-1S6! M:@&JA:@6H5J;:@FJ24K34[6CQ8R2O/#'ST.('JOFH)E M0+40U2)4BU$#035):M:7K6VA*9RYQO.O$S&SV3AS:[$ UT6C:J=38&SE7WMZ-)P-
TW!#5(E2+42U! M-4EI>IK:UH9GGJ%C[_CQ2_K';+%>5%_=9LLRS^9S-;7$[^M9^=WZQ^M=8[^F M56,"O_?%1Y.I]:/Z2+U4\5TE51^VQ>I]YI1+L?]"90+4"U
M$-4B5(M1+4$U26EZ8MONAS=$CS71U@>]^:@F4"U M1#5(E2+42U!-4EI>M;: M:HC7:V:0NK2=6ZGQ,LK;VWF,.V=ANC4/W3M*;ZL;W3,>RA#:
[4"U$-4B5(M1+4$U26EZAMINAV=\/_MF>V4>F3'"/%COHSZT M^H%J M4"5 M1+4*U&-425).4ID>QK7YXE^@9%EKZ#O?U02J!:@6HEJ$:C&J M):@F*4W/6EL,\4Z<_^-],^:8]=
[90WLAJ"8:3;NN[PR&@ZOA_F5!=/8/5(NZ M-F(P< >C\6AORAQTW 35)*5ID1FWE8^QN?(!3)EC']%O;%#-1S71:+M3YCCG MWMC="PTZ:
(AJT6F;$*.#}J@F*4U/3%O/&/\'9NLPC!$[,VAI]4$]@6H%J): M=&2_$>GDR=H_,;?NU21=*&V*CFKO^3G[IC9WR'(F\DYW \[$W<478_HGKX# MW< $U22EZ3%NFQ]C<_/CW;<@,
[N]HXNV/U!-H%J :B&J1>..GLO0&3IC9_]U M$2U_H)JDM)= 711/2I5^6J8WUPN5/ZI;-9\7U=G4>EGQ]:OE]E^M7#U4@;-_ M_.2<7511+M@^_N5ZEC^I+FC_.EH4U5P_5HH/S?V
ZN>;XQL#-^4MC+3AL95ZXY MOS&=93IWL"$"HDR$D2_=K QHR2YOC$B#KMFL:PVSZH7UCGM3/71,*'LU\T M=5=G&&N"G!;UF]PV@>@8 M^-X3!GYC8 /AU@4M9RG.B2#P3?
(^$F:W53,.Z;]TU""U,5M9*Z%&JI52\TD$ M(2!%I$<C1@N>Y#M5;\>0&?41KO0?2B@'BFX=#ER!![+21WA;HHE*5 +24LB)% M A*].P=%*)/O9ZI2B&8A-VEPSFH<_PF<-90G*.,?
D(_]$9(9$2 ?JKC:P=9+ MQ_72M[+!$[(+1]0T7M3XO[_I<;14D,L_?8RUV*A?S)R34UF2!.../@@V$$[\ M]HT7X4\#]$&+&@RIQVOKLV%-ZHA+BRRZ$=_4$:>'B/?Y4*\2VE7,T=S%WG2$
MPV \FKF['KY1RS<:Y%MTJ?9$"%*H7H!!F6<&,6PAPV(P.W*U*A%C5XEW]&C M?*$\B' 4XZ$_WN,4;#^-9FA^E^85*^X_09U\)FBC-5@]=]PPJ-$.LDY9[M%/9O 0_?
WQ%XD/!+7C)^+|"0E95(,GT3 MHI*1HO. M*4G:BC+^!U!+ P04 " 6@VQ90BE82A4%>'@ &0 'AL+W=O-O /6#@Y 9.*C2++)5U0R09]#A;]JO5M{T3IJ;U%]I"6)=QI'DZFJ@[.1@ MR*)
(97,DF?\3/!''.22P%. >CK*R 3N\IWF\V6AMIY.S(!+G0=Z&RI-,91466G4-DQJGQ*7X9T#*X6E*N7>U$X M<,\#G[ZS>[.QO;4,X O7V]9OC+"B_FZAOUN;?F-/9\,@YPVMQF@J:D6P) +8
M3+??;O9\Y=+3;0ZP:@+6D B=EH 'JH%8:QLJ!N *1/1,2@N^41X>2L5>\=06 M>*6$"X! I $'X!88D!=! # \UA,7{G]OC:S@\OL8*/WJ^F4TRF15(&A_\(&'RWFD@'!9
[XVV!^%V;OBC]HH;)9TA,YX=I}XX>0CK MMP_;V6\T< M1U6=)9DA(_4,;E_F 2?!EY;ZKMA?,+.':VR1<;4FX\[>-J]N8%-5'5O(3%OW MG)Y_3O2'@Q&PS5Y.Q0V9@>U4ULJ=;<#V
6%-0S_&A[#NSSF0+S#8^;HJG9'R6.X<1[#NSSF>)ZW([0)(,,ED&$S#=VI MEH^2"/P'CH08L[^3&[R)/\EP"6ZXW1#$X%I9KBYOFVDH60Z;_T.[@LK-'D[6
M:X[G:LY+1/=,9MPV9.NR.O)_9Y3:B5"VX"W' ');6PAV(K>B-!C>C7O0M'2 M2!-G*F9WCW%]7A.$Y7K-\=R1UW2-Y^"7J+VV A=1/DT7)@2T?E1++;#&N.%LL?EZE
M2WYV>7NVF90L2G=GE(PIUS>H MZQ/&Y.I #U L"0_^!U!+ P04 " 6@VQ9"5.3[XH# !H"P &0 'AL M+W=O-W!S MEG)G-K%K=W(V$87.4HYW$E21YTP^+S
3^ZGC.R\+]^DFT6;!G4VV;(-+U)^W M=Y)F;JTE3G/D*A4<)*ZGSMR_7O@!(V!W/*2X5XTQ&%=60CR:R?MXZGB&"#,, MM%'!Z&^'-YAE1A-Q?*N4.K5-(]@LS)@: 2""QW
M:,PZ>M4:2>)CD:_H.V9%LG3GZ[W(M,J_.-1K ;0M\Z478[H6I^FNU91%.'2IKA7*'SNR/W_R]+)9&(5UC,)SVF>- MA%$V80I*& 5T/2C->)SR30<6N$DYIR$L6,9XA/!?
ZR&5WI3V^M:>N7)V,]_K M>^%HXNY:./LU9_\7.2ND#KRCPS7[SD'VCR#'HW RS#V@BQ[A+4LE/+"LP/8*.MQX;,RE MW7&#M]<[>M[AZ?
$NPCNH8+.0U;F_+"!V>^&)S+4;SQY_D4XZR)Z!=,_QJ1H MGL(,#IC!13";=?0*:7!,&G:#$W>G?W@(_;OR$^3'A74*!BEU=%WQ|__L?#= M1O.3H]S8%D!!)
JNRSZH7JW;R!G9/!VVESWH!R:ID!1DN"91KSND@I9E6U=. MM-C.5I6FE-#5F=IA0*XS2;*#O:R'TR\08]}OKV?]02P,$% @ %H-L6<'4 M2O,-! S0\ !D !X;"]W;W)K&ULK9=?<^(V
Ms,"_BL:]Z20S"?X'QJ3 #)"TO<[=!\N=P^=/BAF 4]LBTHRA&_?>P8,(Z: M(_<'UA)7G[O]SVF>- MA%$V80I*& 5T/2C->)SR30<6N$DYIR$L6,9XA/!?
YUHH36S/<0([I7%F#?MZ;LJ'?9;+),Y@RHG(TY3RW1@2MAU8KO4R M<1\O5U)-V,/^FBYA!O)A/>7X9%=:YG$*F8A91C@L!M;(O9FX'26@5WR+82L.
MQD2A/#+VI!X^S@>6HRR"!"*I5%#\V\ $DD1I0CO^+95:U9Y*\'#\HOUW#8\P MCU3 A"7?X[E<#:S0(G-8T#R1]VS[)Y1 VL"()4+_DFVYUK%(E O)TE(8+4CC
MK/BGSZ4C#@2\X!4!KQ3P;@+N;P)^*>!KT,(RC75+)1WV.=L2KE:C-C70OM'2 M2!-G*F9WCW%]7A.$Y7K-\=R1UW2-Y^"7J+VV A=1/DT7)@2T?E1++;#&N.%LL?EZE
M2WYV>7NVF90L2G=GE(PIUS>H MZQ/&Y.I #U L"0_^!U!+ P04 " 6@VQ9"5.3[XH# !H"P &0 'AL M+W=O-W!S MEG)G-K%K=W(V$87.4HYW$E21YTP^+S
3^ZGC.R\+]^DFT6;!G4VV;(-+U)^W M=Y)F;JTE3G/D*A4<)*ZGSMR_7O@!(V!W/*2X5XTQ&%=60CR:R?MXZGB&"#,, MM%'!Z&^'-YAE1A-Q?*N4.K5-(]@LS)@: 2""QW
M:,PZ>M4:2>)CD:_H.V9%LG3GZ[W(M,J_.-1K ;0M\Z478[H6I^FNU91%.'2IKA7*'SNR/W_R]6 +}

MEE;K2?C.^>;9)Y7/304E'ZL9.9FF6U-OE546B=-Y7AFLG1*#>A)06MC0?']/ M8|Y,+SB4&-1O@-(XE"90-/LUUM9RH&ZSX*51PGUCZG?IS(WNJS,H+832&)06 M06D<2A,HFBW'UIN@_NL,%"C4?8#20BB-06D1E,:A-(&BV5IL30GJ-B7.&BBX M&;UU1X]?X)H>]K]":$X&I450&H??!(IFZZDU'*AS$KGO0,%-ZZVLX+AK/SKJ-MVH?0I Q*BZ T#J4)%,V65NL?4+=_\(,#!3>UM\1&YW3M0VA2!J5%4!]'T@2* M9DNLM1.HVTZX*U_Y-6,%J2N-A6J3%7'U?N\9[VFZV;V%;K44H#0&I450&H?2 M!(IFZ[&U%.@K60H4:BE :2&4QJ"T"$KC4)I T6PMMI8"=5L*GU_^Q1T|GK0/ M#GM?=^XTO<4$_14#E!9!:1Q*$RB:+:,63Z!N/^&#TKI^%^0N5XM8G|G"0FT% M*'V$TAB4%D%I'$H3*)HMQ-9]H*_TDP@*]1^@M!!*8U!:!*5Q*$V@:/:B"JU- M$;AMBC-:V(;@;F'=:?J*"4IC4%H$I7$H3:!HMIA:DR%XZ0<0'2WL"R_%N9%] MZS0H+832&)0606D<2A,HFBW#UE\(Z.NTKP'47F ^7Z99?IYHTRP M6Y-Y]C]02P,$% @ %H-L682UIS;I @ D@D !D !X,"]W;W)K&ULK59=;]HP%/TK5E9-K;0UGZ2!0:1"F#9IU;K2=L^& M7$C4Q,YL]V_G^V$#)
(T]|:^@.V<<^X]|UQWO*GG@"(-!SGA$^,1(ABI%I M\E4",>;7M-BOZPIR[&04[8O><$
QYJ49Z9C6;Z9XY08X5BOW;)P3+8[9KRED=#\Q;..P<)=N$]$6S'!4]CSHS%23I:4/JG)UWAB6"HAR& EE *6?SN8098I(9G&STK3 MJ$,JXO'XH/Y9>Y=>EIC#C&8_TE@D$R,P4 QKO,W$'=U_@4_?]J<$20.MT$IR(X38+W L&M",YK(W@5P7MMA$%% MT-;-TKLN7(0%#L>,|A%3:*FF!KKZFBWKE1*U3Q:"R;^IY(GP&\@<_01+>0. MC+<9(+I&,YH7E 17,TT1*YQ@?_'/VD&&Z]/URMY_;M#]W\45=K2[+7359G MW(@7> 430QYB'-@.C/#].]NW/G75]2W%HK<4F[^1V$D'O+H#7I]Z^+T AD5* M-BC3O5C)7G2UHE3QM8JZ'7:A[7K^V-P=E[@-\@+W%!.U,0,K<$Y!\ZYH5W8- M.G$Z)T.>IT^8I;BI3R"-HV6(H.CT+X5-'RV,>YPV/#9QMB!WRC8O T*AFZW M3;^VZ??:O*<'9W_QZ+?+.QQX#9-M4-
#L4l3&^$,O4;UY&^0XOM=P:1Y=,CFP MC;[=N72P);(\3^K5^@%QK>_-QOK4'LWLCO5(/CC*l\$?^?*U)O+1!$P!Y//(P40'J9UCX&U!+ P04 M " 6@VQ9#L1MGT4" 4!0 &0 'AL+W=O=&(E M:?[fG63'9) &]L72R?>>WCOIE.V,?785(L%+K;2;1!51;9Z9#2FI\=&"V]2UL/L9*K.; M1,/HL#"7ZXK\0IQGC5CC NE'\V@YBGN64M:HG30:+*XFT71X-QO[_)#P4^+. M'E?)$+.-
/QQGU6WK@\?S _C%X9R|+ MX?#>]"=94C6);B,H<24VBN9F]PD[/U>>KS#*A2_LNMPD@F+CR-0=F!744K>C M>.G]< 1(KUX!I!T@#;K;C8+*!T$BSZS9@?79S.8GP6I LSBI_:$LR/)?
R3C* MOR!;TB3=/PO M/&:WO>6TMYP&OM%YR[^F2T>6;\7O4Y):BO%I"M\I=ZX1!4XB;@6'=HM1_O;- M\#KY<$;@I'>]_477?UM7W\5ZD^^_A=2PQZ%/5W2\SO'NN(CRZY?R^^
M"KN6VG%)5HQ+!C?<,+;MP38@TX1[OS3$712F%3];:'T"_U\90X? MU+_$.9_ M 5!+ P04 " 6@VQ9N<.L?WL# 1#0 &0 'AL+W=O-&U2IU7++A^F?7#(.M26(-,+--
LOWIV8;2*BIH7U),/@!?MYCX!SF\\9_B!V 1+_RK! +9R=E>>ZZ M(MU!3L09*Z%05S;,YT2J(=^ZHN1 UD:49ZIO>;&;$UHXR=R65F101PK7TT-NXE%Q=I4HGDQM0.1#H%"WK?
41L@]X367$JS?&' M$CB1M-@B,Q/=4+*B&954B5Y<@R0T$R^5_//R&KTX>8E.$"W0IQVK!"G68NY* MQ:A7GF\7*R&YNN6^#SFJ0X3#(?1S>"Y*DL+"40^: +X')WG^#,?>ZR%__RG8
M [=!ZS:P14_><):C#ZED*^"H3F^()$,JJY#KLNM+I3X-$0>*V*CL!C[,,.N#7T2/"H!8^> H^'P*,^>#@+ M.^#6T"/!XQ8\?@I\,@0>]\ C''0S;@T]$GS2@D^> I\.@4]ZX&'D33K@UM C
MP:D"^S=5U7/ZN,&A#A%SH"JFZ';-&8<<]C$ 5^ M|[5E9QCK\;I8VN=;?8OK3C73DO&3<_YSU|]_GZ&GA=TO?]TGD:A<%]2AZ: MN*_FV%[.ZX?I4>)7J%"?"H7]4?"^\) MW})"*,"-
TGEG$Y4Q7O?2]4"RTK2P*R950VP.=^J;!;B>H*YO&)-W]T5MU!' MR1]02P,$% @ %H-L66_^.X_N @ > D !D !X,"]W;W)K&ULK591;YLP$/XK%JNF3EH+
9*U68*4ADRKM$I1LVX/TQX< MN 2K8#/;)-V_WQD(2UK*NBTO8)O[OKOO?/@\V@IYKO(31ZRE*NQE6B=#VU; M10ED5)V+'#A^60F948U3N;95+H'&)2A+;==Q!G9&&;>"4;DVE\%
(%#IE',;2 MJ"++]/QY!:G8C|V>M5NX9>M$FP4[&.5T#0O0=_E&L^Q+@R\,MFIO3(R2I1##W9G(=CRW'1 0I1-HP4'QM8 I:H@PC!\UH]6X M-
,#]\8[!0ZD=M2RI@JE(O[)8)V/KPB(QK&B1ZENQ_0BUGC+ 2*2J?))M;>M8 M)"J4%ED-Q@@RQJLW?:CSL = GG: 6P/)"ZFFP4B*+9'&&MG,H,Q^B<9\,6[J9*$E?
F6(T\%49!G3N/%;$9569K]/0U!4Y;J-VARMPC)Z*#+C,<0M^&DW_O)/^%DWON=V$-B8 MUR:Y[BZY5VXGXP+R<^(Y;XGKN'Z;H/^#AR^'>VWIZ(:'$"&\UP8_2(;75)I7
M\GG_5&DA4U$J5"&!?)LLE99X@GQOJZ'*B=_NQ)RJ0Y73",86'IL*Y :LX/6K MWL!YWY;_8Y*%QR2;'8GL8*?\9J?\+O;@DU"*X$_.LIPR:7:,B!5)!5^?I7BJ MQX0J!;KU#Z^(!R6Q:5&;H'?
I."-[LU_J.+'^_0*$PQZE^ZAT:S%j/!GKL# M]?U&?;]3_9RRF&A!= (DPAHUE8@G+B]6.,#Z;)/=?Q*'_T3U"VS"SLC^MH2.
M1%8ET=YK,1G(==G;%2:HX+HZ$)O5YOHP*;OFH_5I;QA6MX#?--6=Y(;*>.* MI+!"2N?\'0J059^O)EKD92-;"HUML1PF>#4":0SP^TH(O9L8!\UE*_@%4$L# M!!0 (
!:#;%G%5W(W30, *P5 - >&PO4*&1-)<9 M4;HK9UY92$J2$D@9]IJ=3NAEA EW-!"+["93I3/-%T(-W:@).>;T-1FZ?OC1 M=8S<.$_HT'VX>/]KD:OK=XXYGWTX.^L\7%[OQB\JX-+UK**]
T2O.AU<&$!, M/#Q.?)\)VMT_2'|/,B8<;0MOA/Y&C"W$\X9WCM#Z'6N^%A,Z&-FWD]MVZRGT MZAH;#=)<;$HM<$U JY,.,H^$##ITQX6PB&;!2DC&^,N$N!*8YSZ6C=(WK=#Y$
MRB<#^Z8'Y5_K9$SDLLIM,IB_D_KR'6#= X.,\\9@US6!T: @2E$I;G2GNK@* M/H.9P5GGA :A4 MGNE&PL@L%Z3RL&;4#2T[I9S?P;A9[JEO4Q;ZU8MN6B;VE#=-#*F _IM-:/=
MENV]2M=#8HE:D.4.DZCU0J-FU'?DM2W-.E6I?3,L4]=T_0\[^=YQD5 M5!+>-JUK_YAG^=6.@_Y;6:Z>*KN&K1[K%_ZQF^R=@LGP%$R>1$U&IV R/@&3 M_3=
[:K[$I' \)H/C7&VOW]ZU]H1;,\(FZL#.>^C^@'T\WR1U)@&%1-U;\Z2 MA(IG&T.MK\A$_RNZI.^O3VA*%ES=-^#0W;2_TX0MLKBYZA8FHKYJT_X&R/;# 9MMNO")T/
;#O$56)$(Y$AX;'4PQN8M#.%K M5\,\ 0/+ YE>-M?X:N,5LK\,L#7=5R'82/%*Q$:*SS4@]GD#1AS;5QO+ PQL M%;#:@?SV/%!3=DX0P*IBWK [&$?B&$.@%NTU&H;
([(3PL:\/=I<$01S;$<#L M#H(^0^!NO!', 7C D'"'HWH,[!R-O_9]R-K_/COX 4$L#!!0 (!:#;%F7 MBKL

-8?20$3;8T.P6BP^0"X99K>]9!:GGK:IB.1N-A+90>?/]X+>O2#N&)\;+PRNB0&!-NE+QW+]?C M*=LHIY5I?SC9- >5W+ :]55K9YD.1F,!LRMS/V?QJHGH[VHYH4U5349)-V%
M&VF]*MXDSR/DM;AU;8H7MUR:_&I-LU9Z&8L)3S$$C]'6P_:WJ\03^RO5:!8+5<@S4S2UU+ZK1RNK"*C= M2JW=@&E1R\E@FX5-=2'A,P Y!B!"!\2,@>0QPCD,2WDI7AD&\FHO
MO&-7TGG;%+ZQ@?8=^VK@.#["!'O(1+>:\]6MA'YE9L+E::A5NU^16&;(!^(MB?]6&#A?A++L1E2-9-^EB._AZZ9.,-,DQ*KI-2\3P=P?2A5>SZN86980$W--
M0BR;$)RM0^CTV!*>_]_H=1MIQ+-("C$QVR3$NIG5Z]#<+5IX+:,_4_'"2 M39V#(U"""^28A%LZEE0MI;1B^8P6>FKHV.HSDIKB#A)AL$G+;O#"QGR*.D?T^
M@TDF(;9,2W7T670RK$-)KLW$SA_B,<3$1),0F^8TS##$K;$=VW1I93OT0#S, M,@FQ9F:Z,+5DU^)!PBI+,;>DQ$[Y%D;H/@VFC11\KE+7RK>Z>.ZHP6LA5M"% MZD.B4Q5B@:.:
[D78*2:0E%@@.",L5-,("FQ0/9$"^RW,.^O^HV."20E%@@: M-?0;'-(2FP1-&KH8V(^28E]@D8-?4S,)RFQ3_9'#>WK"3$QKZ3$7MD9.FP[MT.]P[00S348]>\%BB/X2#Z:@C%Q!.V.
(>-1ADDH(Y90Y^V=C8RND!%+!YU) M]QL9DTY&+!W'C9JTWT2\TAU\[ZM8E9*#_8VED!)D%,S$(Y^=0' MP9P7$!.S4$YLH=W!^K.#["/$Q"R4$UL(C]9[70BS4$YL(1P3=B&.68@?
=.X# M SF.68@36PC'A(S24WO.CV.6-?O5)F6,6XL06>L%\F0G_E#&>D^71= .W MLV 6&O\OWWKZF-]%G!KY> PQ,0N-#_D1B!U!3,Q"X]9"P^TNP%(NE);E7^$O
M7$@O1%5<6A9_NAT).8_?!A=-59V&M Q|S8ARNZPERN'RT[!02P,$% @ M%H-L67=+<84& @ \20 !H !X;"!?;7/2Y;)-X^V,YOGI=N;B]7/(_S.QWVSVZ_RS7_\^YM/T
MC\'I3S^^EUW.4[-X[<9MGE9-^CA<3Y=T.7*S>'E;->/+FS2I=I!"D-8/ M,@BR^D$.05X_*" HZ@>U$-36#[J'H/OZ00\0]% _Z!&"'NL'R1)E7!(DS; F
MT%J0:R'P6A!L(1!;D&PA,%L0,2%06Y!M(7!,$&XAD%N0;B&P6O!O(=!;46\E MT%M1;R706VBOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM M!'H;ZFT$>AOJ;01Z&^IM!'K;,+.$0&]#O8U
;T.]C4!O0[V-0&]#O8U ;T.] MC4!O0[V-0&']O9U ;T>]G4!O1V=0&!'O9U ;Y]M=A/H[.BW$^CMJ+<3Z.VH MMQ/H[:BW$^CMJ+
<3Z!VH=Q#H':AW$.@=]'<0Z!VH=Q#H!:AW$.@=LY^5!'H' MZAT$>@?J'01Z!^H=!'H'ZAT$>K>H=TN@=XMZMP1ZMZAW^YUZE^GSD,NUYVN- MS_].JJ?SO?
GZ^,ORZ^3LO5QP3K<5Y?DO4$L#!!0 (!:#;%G_)Z=UXP$ M &PD 3 6T-O;G1E;G1?5'EP97-=+GAM:,W:74_",!0&X+]"=FM8Z=?\
MB'"CWJH7_H&Z'61A6YNV(/Q[NP$F&B4:3'QO6*#M><]ZDN>*ZZ>MHS#:M$T7 MIMDB1G?%6"@7U)J06T==6IE;WYJ8OOH7YDRY-"_$Q&12L-)VD;HXCGV-;'9] M2W.S:N+H;I-
^#K7MHFG)F2CF]W&/FN:&>>;NC0QK;-U5WU*&>\3\G1RV!,6 MM0MG:4/&ODSH5[X/V)|6)/W=46C1^/CO6G3+K9I6(C;AD)^O,07/=KYO"ZI MLN6J34?
RX#R9*BR(8MODNZ)GQY-CNF':??*3\X00V/$Z_XX\S?]__RSX$ M2!\2I \%TH<&Z:_Z>,&UL4$L! A0#% @ M%H-L6<0_Q2'M.*P(!$ (!KP &1O8U!R;W!S+V-O M&UL4$L! A0#% @
%H-L69E&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L604;7I\=!@.*AH !@ M ("!+@X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ %H-L69NW*%"G# +78 !@ ("!6AX
'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ %H-L65^#ALKI @ M4PL !@ ("!4S< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M%H-L63GF8E5Y!0 Q \ !D ("!)E@
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L60KV^P!*! MT0D !D ("!9V< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L6;V[\>L5"0 JAH !D M ("!AGL
'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ %H-L669O'/ED" HA8 !D ("!;I('AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L M66L>(D;N P] @ !D ("!^*P
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L68|O\E\+ P LP8 M !D ("!1(@ 'AL+W=O>>N " @!@ &0 @(&)NP M>&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L63*D"TQH P
[@< !D M ("!B,$ 'AL+W=O&PO=V]R:W-H965T M?* !X;"]W;W)K&UL4$L! A0# M% @ %H-L67$X:Y4M! A0H !D ("!E,X 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ %H-
L62>9 MB(^H @ Z@8 !D ("!%\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L6>Y;(:-& @ N@4 !D M ("!'^L 'AL+W=O&PO M=V]R:W-H965T>K , M)L0 9 " @2GQ
!X;"]W;W)K&UL4$L! A0#% @ %H-L64B/! P %!(!D ("! M#/4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ %H-L6:%4BQ8/ P] D !D ("!$ \ 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ %H-L64@;P-)? P U H !D M ("!R",! 'AL+W=O)P$ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ %H-L6:G3WP@9!P HRX !D ("!R&PO=V]R:W-
H965T&UL4$L! A0#% @ M%H-L6;|%@(*M @ ^ < !D ("!Y44! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %H-L60[$;9|% @ M% 4 !D ("!2U0! 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ %H-L6<576QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ %H-L67=+<84& @ \20 !H M (!%6<&5S72YX;6Q02P4& $8 1@ A$P 9VL! end XML 71 Show.js
IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees
within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */
.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px
solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color:
#000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /*
word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover {
background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0;
} /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-
color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
.report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; }
.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width:
17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; }
.report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 203 284 1 false 59 0 false 8 false false R1.htm 100000 - Document
- Document And Entity Information Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity
Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet
http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited)
Statements 2 false false R3.htm 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) Sheet
http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited Condensed Consolidated Balance Sheets
(Parenthetical) (unaudited) Statements 3 false false R4.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed
Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 100050 - Statement - Condensed Consolidated Statements of
Stockholders' Equity (unaudited) Sheet
http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements
of Stockholders' Equity (unaudited) Statements 5 false false R6.htm 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)
(unaudited) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited Condensed
Consolidated Statements of Stockholders' Equity (Parenthetical) (unaudited) Statements 6 false false R7.htm 100070 - Statement - Condensed Consolidated Statements of
Cash Flows (unaudited) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed
Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet
http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet
http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995455 - Disclosure - Organization, Restructuring, Going
Concern and Basis of Presentation Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation
Organization, Restructuring, Going Concern and Basis of Presentation Notes 10 false false R11.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet
http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false
false R12.htm 995475 - Disclosure - Fair Value Measurements Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value
Measurements Notes 12 false false R13.htm 995485 - Disclosure - Restructuring and Other Related Charges Sheet
http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges Restructuring and Other Related Charges Notes 13 false false R14.htm
995495 - Disclosure - Property and Equipment and Related Impairment Sheet
http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment Property and Equipment and Related Impairment Notes 14
false false R15.htm 995505 - Disclosure - Impairment of Right of Use Assets Sheet
http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets Impairment of Right of Use Assets Notes 15 false false R16.htm 995515 -
Disclosure - Preferred and Common Stock Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStock1 Preferred and Common Stock

Notes 16 false false R17.htm 995525 - Disclosure - Common Stock Warrants Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrants Common Stock Warrants Notes 17 false false R18.htm 995555 - Disclosure - Stock-Based Compensation Expense Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpense Stock-Based Compensation Expense Notes 18 false false R19.htm 995565 - Disclosure - Collaboration Agreement Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreement Collaboration Agreement Notes 19 false false R20.htm 995575 - Disclosure - Income Taxes Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 20 false false R21.htm 995585 - Disclosure - Leases Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeases Leases Notes 21 false false R22.htm 995595 - Disclosure - Commitments and Contingencies Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 995615 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 995625 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 995635 - Disclosure - Fair Value Measurements (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements 25 false false R26.htm 995645 - Disclosure - Restructuring and Other Related Charges (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables Restructuring and Other Related Charges (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges 26 false false R27.htm 995655 - Disclosure - Property and Equipment and Related Impairment (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables Property and Equipment and Related Impairment (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment 27 false false R28.htm 995665 - Disclosure - Impairment of Right of Use Assets (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables Impairment of Right of Use Assets (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets 28 false false R29.htm 995675 - Disclosure - Preferred and Common Stock (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables Preferred and Common Stock (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStock1 29 false false R30.htm 995685 - Disclosure - Common Stock Warrants (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsTables Common Stock Warrants (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrants 30 false false R31.htm 995715 - Disclosure - Stock-Based Compensation Expense (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables Stock-Based Compensation Expense (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpense 31 false false R32.htm 995725 - Disclosure - Collaboration Agreement (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementTables Collaboration Agreement (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreement 32 false false R33.htm 995745 - Disclosure - Leases (Tables) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesTables Leases (Tables) Tables http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeases 33 false false R34.htm 995755 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details) Details 34 false false R35.htm 995765 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 35 false false R36.htm 995775 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashR Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details) Details 36 false false R37.htm 995785 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculation Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) Details 37 false false R38.htm 995795 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 38 false false R39.htm 995805 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 39 false false R40.htm 995815 - Disclosure - Restructuring and Other Related Charges (Additional Information) (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails Restructuring and Other Related Charges (Additional Information) (Details) Details http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables 40 false false R41.htm 995825 - Disclosure - Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details) Details 41 false false R42.htm 995835 - Disclosure - Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details) Details 42 false false R43.htm 995845 - Disclosure - Property and Equipment and Related Impairment - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails Property and Equipment and Related Impairment - Additional Information (Details) Details 43 false false R44.htm 995855 - Disclosure - Impairment of Right of Use Assets - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails Impairment of Right of Use Assets - Additional Information (Details) Details 44 false false R45.htm 995865 - Disclosure - Impairment of Right of Use Assets - Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFlo Impairment of Right of Use Assets - Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology (Details) Details 45 false false R46.htm 995905 - Disclosure - Preferred and Common Stock - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails Preferred and Common Stock - Additional Information (Details) Details 46 false false R47.htm 995915 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) Details 47 false false R48.htm 995925 - Disclosure - Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details) Details 48 false false R49.htm 995935 - Disclosure - Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity (Details) Details 49 false false R50.htm 995945 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details) Details 50 false false R51.htm 995955 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackschole Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers (Details) Details 51 false false R52.htm 995965 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails Stock-Based Compensation Expense - Additional Information (Details) Details 52 false false R53.htm 995975 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) Details 53 false false R54.htm 995985 - Disclosure - Collaboration Agreement - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails Collaboration Agreement - Additional Information (Details) Details 54 false false R55.htm 995995 - Disclosure - Collaboration Agreement - Summary of Transaction Price (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails Collaboration Agreement - Summary of Transaction Price (Details) Details 55 false false R56.htm 996005 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDefe Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details) Details 56 false false R57.htm 996015 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 57 false false R58.htm 996035 - Disclosure - Leases - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 58 false false R59.htm 996045 - Disclosure - Leases - Schedule of Components of Lease Cost (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails Leases - Schedule of Components of Lease Cost (Details) Details 59 false false R60.htm 996055 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetai Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details) Details 60 false false R61.htm 996065 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails Leases - Summary of Maturity of Operating Lease Liabilities (Details) Details 61 false false R62.htm 996075 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 62 false false All Reports Book All Reports lyra-20240930.htm lyra-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lyra-20240930.htm": { "nsprefix": "lyra", "nsuri":

```
"http://lyratherapeutics.com/20240930", "dts": { "inline": { "local": [ "lyra-20240930.htm" ] }, "schema": { "local": [ "lyra-20240930.xsd" ], "remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 230,
"keyCustom": 54, "axisStandard": 23, "axisCustom": 0, "memberStandard": 28, "memberCustom": 28, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2024": 4,
"http://fasb.org/us-gaap/2024": 6 }, "contextCount": 203, "entityCount": 1, "segmentCount": 59, "elementCount": 648, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-
gaap/2024": 573, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity
Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1",
"firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_ec518357-1a01-4004-b612-2999ea67b730", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span",
"p", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R2": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed
Consolidated Balance Sheets (unaudited)", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "isDefault": "false", "groupType": "statement",
"subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-
gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html"
], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-
gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ],
"reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R3": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "longName": "100030 - Statement -
Condensed Consolidated Balance Sheets (Parenthetical) (unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical) (unaudited)", "isDefault":
"false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-
abad91914d9e", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals":
"INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef":
"C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil":
"false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } },
"R4": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
"longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated
Statements of Operations and Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4",
"firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first":
true }, "uniqueAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R5":
{ "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "100050 -
Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity
(unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_dc5596bb-e6e6-
4d16-a431-b9df4465bbc4", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7671d029-4b78-491d-814c-3830cd952852",
"name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td",
"tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R6": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited", "longName": "100060 -
Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) (unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders'
Equity (Parenthetical) (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": {
"contextRef": "C_8f033783-6902-41f2-a32c-8d870b506d58", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "U_USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "C_8f033783-6902-41f2-a32c-8d870b506d58", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-
20240930.htm", "first": true, "unique": true } }, "R7": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100070 - Statement -
Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false",
"groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name":
"us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1,
"baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ProfitLoss",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-
20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance
Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8",
"firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role":
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_3c6af28e-7487-4e73-a003-
5e9a11efa413", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ],
"reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3c6af28e-7487-4e73-a003-5e9a11efa413", "name":
"ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef":
"lyra-20240930.htm", "first": true, "unique": true } }, "R10": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation", "longName": "995455 - Disclosure -
Organization, Restructuring, Going Concern and Basis of Presentation", "shortName": "Organization, Restructuring, Going Concern and Basis of Presentation", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730",
"name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body",
"html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730",
"name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body",
"html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R11": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant
Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",
"order": "11", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R12": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995475 - Disclosure - Fair Value Measurements", "shortName":
"Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_ec518357-
1a01-4004-b612-2999ea67b730", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-
2999ea67b730", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ],
"reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R13": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges", "longName": "995485 - Disclosure - Restructuring and Other Related
Charges", "shortName": "Restructuring and Other Related Charges", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13",
"firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } },
"R14": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment", "longName": "995495 - Disclosure - Property
and Equipment and Related Impairment", "shortName": "Property and Equipment and Related Impairment", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount":
1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount":
1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R15": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets", "longName": "995505 - Disclosure - Impairment of Right of Use Assets",
"shortName": "Impairment of Right of Use Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": {
"contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:AssetImpairmentChargesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:AssetImpairmentChargesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R16": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStock1", "longName": "995515 - Disclosure - Preferred and Common Stock",
"shortName": "Preferred and Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": {
"contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R17": { "role":
```

{"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrants", "longName": "995525 - Disclosure - Common Stock Warrants", "shortName": "Common Stock Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "lyra:CommonStockWarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "lyra:CommonStockWarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpense", "longName": "995555 - Disclosure - Stock-Based Compensation Expense", "shortName": "Stock-Based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreement", "longName": "995565 - Disclosure - Collaboration Agreement", "shortName": "Collaboration Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxes", "longName": "995575 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeases", "longName": "995585 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies", "longName": "995595 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995615 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables", "longName": "995635 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables", "longName": "995645 - Disclosure - Restructuring and Other Related Charges (Tables)", "shortName": "Restructuring and Other Related Charges (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables", "longName": "995655 - Disclosure - Property and Equipment and Related Impairment (Tables)", "shortName": "Property and Equipment and Related Impairment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables", "longName": "995665 - Disclosure - Impairment of Right of Use Assets (Tables)", "shortName": "Impairment of Right of Use Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AssetImpairmentChargesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AssetImpairmentChargesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables", "longName": "995675 - Disclosure - Preferred and Common Stock (Tables)", "shortName": "Preferred and Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsTables", "longName": "995685 - Disclosure - Common Stock Warrants (Tables)", "shortName": "Common Stock Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "lyra:CommonStockWarrantsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "lyra:CommonStockWarrantsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables", "longName": "995715 - Disclosure - Stock-Based Compensation Expense (Tables)", "shortName": "Stock-Based Compensation Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementTables", "longName": "995725 - Disclosure - Collaboration Agreement (Tables)", "shortName": "Collaboration Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:RevenueRecognitionMilestoneMethodTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesTables", "longName": "995745 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div",

"body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "longName": "995755 - Disclosure - Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)", "shortName": "Organization, Restructuring, Going Concern and Basis of Presentation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995765 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:RestrictedCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashF "longName": "995775 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R37": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatio "longName": "995785 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "longName": "995795 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d9bc2c59-038b-4949-a563-4f3478654aa2", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R39": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "995805 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:FinancialLiabilitiesFairValueDisclosure", "us-gaap:FinancialLiabilitiesFairValueDisclosure", "span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:FinancialLiabilitiesFairValueDisclosure", "us-gaap:FinancialLiabilitiesFairValueDisclosure", "span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails", "longName": "995815 - Disclosure - Restructuring and Other Related Charges (Additional Information) (Details)", "shortName": "Restructuring and Other Related Charges (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails", "longName": "995825 - Disclosure - Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)", "shortName": "Restructuring and Other Related Charges - Summary of Restructuring Liability Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:RestructuringReserveAccrualAdjustment1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5e457ef0-4a87-48a7-878b-e7e7e5a461f8", "name": "us-gaap:RestructuringReserveAccrualAdjustment1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R42": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails", "longName": "995835 - Disclosure - Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details)", "shortName": "Property and Equipment and Related Impairment - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails", "longName": "995845 - Disclosure - Property and Equipment and Related Impairment - Additional Information (Details)", "shortName": "Property and Equipment and Related Impairment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails", "longName": "995855 - Disclosure - Impairment of Right of Use Assets - Additional Information (Details)", "shortName": "Impairment of Right of Use Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "lyra:ImpairmentOfRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cd779f57-1309-43f7-b26c-99f31fd5f8bf", "name": "lyra:ImpairmentOfRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["lyra:ImpairmentOfRightOfUseAsset", "span", "p", "us-gaap:AssetImpairmentChargesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R45": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl "longName": "995865 - Disclosure - Impairment of Right of Use Assets - Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology (Details)", "shortName": "Impairment of Right of Use Assets - Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_d404751d-8cab-48a3-84b0-55e1788e802a", "name": "lyra:DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock", "div", "us-gaap:AssetImpairmentChargesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d404751d-8cab-48a3-84b0-55e1788e802a", "name": "lyra:DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "lyra:ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock", "div", "us-gaap:AssetImpairmentChargesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "longName": "995905 - Disclosure - Preferred and Common Stock - Additional Information (Details)", "shortName": "Preferred and Common Stock - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dd54cfda-58a9-4e8c-8a22-55eeba5d59f6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R47": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "longName": "995915 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)", "shortName": "Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0d0005445-37a1-4133-8c44-e982e68c07c4", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",

"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table",
"lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm",
"unique": true }], "R48": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails", "longName": "995925 -
Disclosure - Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details)", "shortName": "Common Stock Warrants - Summary of Warrants
Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": {
"contextRef": "C_2baa6d24-dc5a-4e49-b4b2-a288e064b7c0", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div",
"lyra:CommonStockWarrantsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_2baa6d24-dc5a-4e49-b4b2-a288e064b7c0", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div",
"lyra:CommonStockWarrantsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R49": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails", "longName": "995935
- Disclosure - Stock-Based Compensation Expense - Summary of Restricted Stock Unit Activity (Details)", "shortName": "Stock-Based Compensation Expense - Summary of
Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": {
"contextRef": "C_b4d956f4-b038-402c-b4b2-7862fc1d1216", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false",
"lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "C_b4d956f4-b038-402c-b4b2-7862fc1d1216", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false",
"lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique":
true } }, "R50": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails", "longName":
"995945 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)", "shortName": "Stock-Based Compensation Expense -
Summary of Stock Option Activity Under Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50",
"firstAnchor": { "contextRef": "C_b4d956f4-b038-402c-b4b2-7862fc1d1216", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF",
"ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"
], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF",
"ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"
], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R51": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackschol
"longName": "995955 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-
Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers (Details)", "shortName": "Stock-Based Compensation Expense - Schedule of
Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive
Officers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_aaca37f7-
2361-4f72-8167-3c16c471374e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef":
"lyra-20240930.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "longName": "995965 - Disclosure -
Stock-Based Compensation Expense - Additional Information (Details)", "shortName": "Stock-Based Compensation Expense - Additional Information (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation",
"div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef":
"U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1,
"baseRef": "lyra-20240930.htm", "unique": true } }, "R53": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails", "longName":
"995975 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation Expense -
Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53",
"firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1,
"baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_13abfd86-4643-4ef7-b3e7-e1fd27aa7136", "name": "us-
gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1,
"baseRef": "lyra-20240930.htm", "unique": true } }, "R54": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "longName": "995985 - Disclosure -
Collaboration Agreement - Additional Information (Details)", "shortName": "Collaboration Agreement - Additional Information (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-
gaap:DeferredRevenueDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-
gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor":
{ "contextRef": "C_ec518357-1a01-4004-b612-2999ea67b730", "name": "us-gaap:DeferredRevenueDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": ["span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first":
true, "unique": true } }, "R55": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails",
"longName": "995995 - Disclosure - Collaboration Agreement - Summary of Transaction Price (Details)", "shortName": "Collaboration Agreement - Summary of Transaction
Price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_fbd44792-
9deb-4a19-8466-abad91914d9e", "name": "lyra:CombinedPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span",
"us-gaap:DeferredRevenueDescription", "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-
20240930.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef
"longName": "996005 - Disclosure - Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue
(Details)", "shortName": "Collaboration Agreement - Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_b4d956f4-b038-402c-b4b2-
7862fc1d1216", "name": "us-gaap:DeferredRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true },
"uniqueAnchor": { "contextRef": "C_dc5596bb-e6e6-4d16-a431-b9df4465bbc4", "name": "us-gaap:DeferredRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "div", "ix:continuation", "div", "body", "html"],
"reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R57": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "996015 - Disclosure - Income Taxes - Additional
Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "57", "firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name":
"lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-
gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "lyra:DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang":
null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first":
true, "unique": true } }, "R58": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "longName": "996035 -
Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_b4d956f4-b038-402c-b4b2-7862fc1d1216", "name": "us-
gaap:RestrictedCashNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"],
"reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a112ea2a-d168-4c82-8fb0-02854c4c23a6", "name": "us-
gaap:LesseeOperatingLeaseOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body",
"html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "unique": true } }, "R59": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails", "longName": "996045 - Disclosure - Leases -
Schedule of Components of Lease Cost (Details)", "shortName": "Leases - Schedule of Components of Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-
gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-
gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": {
"contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:VariableLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-
20240930.htm", "unique": true } }, "R60": { "role":
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDeta
"longName": "996055 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)", "shortName":
"Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-
gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table",
"lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock", "div", "ix:continuation", "div", "body", "html"],

"reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails", "longName": "996065 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)", "shortName": "Leases - Summary of Maturity of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fbd44792-9deb-4a19-8466-abad91914d9e", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "996075 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_aaca37f7-2361-4f72-8167-3c16c471374e", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lyra-20240930.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "lyra_ATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ATMAgreementMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "ATM Agreement", "label": "A T M Agreement [Member]", "documentation": "ATM agreement." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "lyra_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AccountingPoliciesLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Accounting Policies.", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "lyra_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AccountingPoliciesTable", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Accounting Policies.", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56", "r664"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "terseLabel": "Net amortization of premium on short-term investments", "negatedLabel": "Net amortization of premium on short-term investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r81"] }, "lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"], "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities disclosure.", "label": "Accrued Expenses And Other Current Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "lyra_AccruedExpensesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other liabilities current.", "label": "Accrued Expenses And Other Liabilities Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetai"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Professional and consulting fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r33", "r138", "r509"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income, net of tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r17", "r18", "r71", "r145", "r506", "r528", "r529"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), net of tax", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r10", "r18", "r398", "r401", "r454", "r524", "r525", "r782", "r783", "r784", "r793", "r794", "r795", "r796"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r715"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r66"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r539", "r793", "r794", "r795", "r796", "r865", "r900"] }, "lyra_AdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Additional paid in capital stock issued issuance costs.", "label": "Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Issuance costs" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r728"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r728"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r728"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r728"] }, "lyra_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrants", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital common stock and warrants.", "label": "Adjustments to Additional Paid in Capital Common Stock and Warrants", "terseLabel": "Adjustments to additional paid in capital, sale of common stock and warrants" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r46", "r47", "r324"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Issuance cost", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r11", "r95"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",

```
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used
in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
"terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r761" ] },
"ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous
Compensation Amount" } } }, "auth_ref": [ "r687", "r697", "r707", "r739" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us":
{ "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } },
"auth_ref": [ "r690", "r700", "r710", "r742" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service
Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r762" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r728" ] }, "ecd_AllExecutiveCategoriesMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } },
"auth_ref": [ "r735" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]",
"terseLabel": "All Individuals" } } }, "auth_ref": [ "r691", "r701", "r711", "r735", "r743", "r747", "r755" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading
Arrangements" } } }, "auth_ref": [ "r753" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-
us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award
under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r353", "r358" ] }, "us-gaap_AlternativeInvestmentChangeInValuationTechnique":
{ "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AlternativeInvestmentChangeInValuationTechnique", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Alternative Investment, Change in Valuation Technique [true false]", "terseLabel": "Alternative investment, change in valuation technique", "documentation": "Indicates (true
false) whether valuation technique or approach changed for measuring alternative investment." } } }, "auth_ref": [ "r869" ] }, "dei_AmendmentFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel":
"Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] },
"lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear": {
"xbrltype": "percentItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear",
"presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "documentation": "Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately
preceding calendar year.", "label": "Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of
Immediately Preceding Calendar Year", "terseLabel": "Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final
day of immediately preceding fiscal year" } } }, "auth_ref": [] }, "lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued": {
"xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Annual increase in number of shares available for issuance maximum number of common stock issued.", "label": "Annual Increase In Number Of Shares
Available For Issuance Maximum Number Of Common Stock Issued", "terseLabel": "Maximum number of common shares issued" } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatic
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities
excluded from calculation of diluted net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could
potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so
would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r193" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatic
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." }
} }, "auth_ref": [ "r26" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatic
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded
From Computation Of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatic
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares
attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the
period presented." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AreaOfRealEstateProperty", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "label": "Area of Real Estate Property", "terseLabel": "Area of property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-
gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement
and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative
arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r389" ] },
"lyra_AssetImpairmentChargeLineItem": { "xbrltype": "stringItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AssetImpairmentChargeLineItem",
"presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl
], "lang": { "en-us": { "role": { "documentation": "Asset impairment charge.", "label": "Asset Impairment Charge [Line Item]" } } }, "auth_ref": [] }, "us-
gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit",
"presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "negatedLabel": "Less: Impairment", "totalLabel": "Asset Impairment Charges, Total", "label": "Asset Impairment Charges", "terseLabel": "Impairment
charge for write-down of property and equipment", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to,
losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r6", "r31" ] }, "us-gaap_AssetImpairmentChargesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentChargesAbstract", "lang": { "en-us": { "role": { "label": "Asset Impairment Charges [Abstract]" } } },
"auth_ref": [] }, "us-gaap_AssetImpairmentChargesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetImpairmentChargesTextBlock", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssets" ], "lang": { "en-us": {
"role": { "label": "Asset Impairment Charges [Text Block]", "terseLabel": "Impairment of Right of Use Assets", "documentation": "The entire disclosure for the details of the
charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the
impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for
determining fair value, and the segment in which the impaired asset is reported." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets",
"totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r101", "r113", "r140", "r167", "r196",
"r200", "r206", "r207", "r246", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r391", "r395", "r430", "r502", "r573", "r629", "r630", "r664", "r678",
"r833", "r834", "r881" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets
[Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsCurrent", "crdr": "debit", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ],
"lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic
benefit, classified as current." } } }, "auth_ref": [ "r134", "r146", "r167", "r246", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r391", "r395", "r430",
"r664", "r833", "r834", "r881" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsCurrentAbstract", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": {
```

"en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial assets, fair value", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r409", "r410", "r652"] }, "lyra_AtTheMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "AtTheMarketMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "ATM", "label": "At The Market [Member]", "documentation": "At the market." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r218"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Unrealized Losses", "negatedTerseLabel": "Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r219"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r215", "r254", "r501"] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "terseLabel": "Unrealized gain on available-for-sale securities", "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r809"] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "negatedLabel": "Unrealized loss on available-for-sale securities", "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r810"] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Total", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r216", "r254", "r409", "r494", "r652", "r656", "r804", "r869", "r870", "r871"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r750"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r751"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r746"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r749"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r748"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r747"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r747"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r263", "r895", "r896"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r48", "r49", "r263", "r895", "r896"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization, Restructuring, Going Concern and Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r54", "r82", "r83"] }, "lyra_COVID19PandemicAndCARESActPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "COVID19PandemicAndCARESActPolicyTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "COVID-19 Pandemic and CARES Act.", "label": "C O V I D19 Pandemic And C A R E S Act Policy [Text Block]", "terseLabel": "COVID-19 Pandemic and CARES Act" } } }, "auth_ref": [] }, "lyra_CantorFitzgeraldCoMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "CantorFitzgeraldCoMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Cantor Fitzgerald & Co.", "label": "Cantor Fitzgerald & Co. [Member]", "terseLabel": "Cantor Fitzgerald & Co." } } }, "auth_ref": [] }, "us-gaap_CapitalExpenditureIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpenditureIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r23", "r24", "r25"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashE "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r21", "r136", "r620"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r867", "r868"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r22"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashE
], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r21", "r79", "r164"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r21", "r79", "r164"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r79"] }, "lyra_CashProvidedByFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "CashProvidedByFinancingActivities", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Cash provided by financing activities.", "label": "Cash Provided By Financing Activities", "terseLabel": "Fund raised for operations" } } }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Certificates of Deposit [Member]", "terseLabel": "Certificate of Deposits", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r9", "r672", "r673", "r674", "r675"] },
"lyra_ChangeInPerformanceObligationTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ChangeInPerformanceObligationTransactionPrice", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Change in performance obligation transaction price.", "label": "Change In Performance Obligation Transaction Price", "terseLabel": "Change in transaction price" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r726"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": ["r803"] }, "lyra_ChiefMedicalOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ChiefMedicalOfficerMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Chief Medical Officer", "label": "Chief Medical Officer [Member]", "documentation": "Chief medical officer." } } }, "auth_ref": [] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r723"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r721"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r130", "r142", "r143", "r144", "r167", "r187", "r188", "r190", "r192", "r198", "r199", "r246", "r282", "r284", "r285", "r286", "r289", "r290", "r295", "r296", "r299", "r302", "r309", "r430", "r532", "r533", "r534", "r535", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r561", "r582", "r600", "r610", "r611", "r612", "r613", "r614", "r766", "r790", "r797"] },
"us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r142", "r143", "r144", "r198", "r295", "r296", "r297", "r299", "r302", "r307", "r309", "r532", "r533", "r534", "r535", "r641", "r766", "r790"] }, "us-gaap_ClassOfWarrantOrRightstDateFromWhichWarrantsOrRightsExercisable": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightstDateFromWhichWarrantsOrRightsExercisable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issue Date", "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable", "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format." } } }, "auth_ref": ["r310"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r42"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price of Warrants Outstanding, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price of Warrants Outstanding, Beginning

Balance", "label": "Exercise Price", "terseLabel": "Warrants exercise price, per share", "verboseLabel": "Common stock par value", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r310"] }, "lyra_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price of Warrants Exercised", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights Exercised", "documentation": "Class of warrant or right, exercise price of warrants or rights exercised." } } }, "auth_ref": [] }, "lyra_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Warrants Exercised", "terseLabel": "Number of warrants exercised", "label": "Class of Warrant or Right, Exercised", "documentation": "Class of warrant or right, exercised." } } }, "auth_ref": [] }, "lyra_ClassOfWarrantOrRightExpirationDescription": { "xbrltype": "stringItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ClassOfWarrantOrRightExpirationDescription", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of warrant or right, expiration description", "documentation": "Class of warrant or right, expiration description." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Warrants to purchase common shares", "terseLabel": "Exercisable warrants", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r310"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Warrants Outstanding, Ending Balance", "periodStartLabel": "Number of Warrants Outstanding, Beginning Balance", "terseLabel": "Number of shares Underlying Warrants Outstanding", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "lyra_ClassOfWarrantOrRightOutstandingExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ClassOfWarrantOrRightOutstandingExercisable", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares Underlying Warrants Exercisable", "label": "Class Of Warrant Or Right Outstanding Exercisable", "documentation": "Class Of warrant or right outstanding exercisable." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r42"] }, "lyra_ClassOfWarrantOrRightWarrantPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ClassOfWarrantOrRightWarrantPurchasePrice", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right warrant purchase price.", "label": "Class Of Warrant Or Right Warrant Purchase Price", "terseLabel": "Warrants purchase price" } } }, "auth_ref": [] }, "lyra_ClinicalSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ClinicalSupplyAgreementMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Clinical Supply Agreement member.", "label": "Clinical Supply Agreement [Member]", "terseLabel": "Clinical Supply Agreement" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r727"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r727"] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreement"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreement", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r119", "r121", "r129"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r389"] }, "lyra_CombinedPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "CombinedPerformanceObligation", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Combined performance obligation", "label": "Combined Performance Obligation", "documentation": "Combined performance obligation" } } }, "auth_ref": [] }, "lyra_CombinedPerformanceObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "CombinedPerformanceObligationMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef], "lang": { "en-us": { "role": { "terseLabel": "Combined Performance Obligation", "label": "Combined Performance Obligation [Member]", "documentation": "Combined performance obligation." } } }, "auth_ref": [] }, "lyra_CommercialRevenueBasedMilestoneAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "CommercialRevenueBasedMilestoneAwardsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial Revenue Based Milestone Awards", "label": "Commercial Revenue Based Milestone Awards [Member]", "documentation": "Commercial revenue based milestone awards." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 13)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r62", "r103", "r503", "r560"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r90", "r276", "r277", "r616", "r823", "r831"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved for future issuances", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r65"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r668", "r669", "r670", "r672", "r673", "r674", "r675", "r793", "r794", "r796", "r865", "r899", "r900"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r65"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r65", "r561"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [

```
"r65" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "lang": { "en-us": { "role": { "label":
"Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
"periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the
ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r65", "r561", "r579", "r900", "r901" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common
stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 65,456,735 and 57,214,550 shares issued and outstanding at
September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable
common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of
nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r65", "r505", "r664" ] }, "us-
gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Common stock, voting rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes
per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r38" ] }, "lyra_CommonStockVotingRightsNumberOfVotes": { "xbrltype": "integerItemType",
"nsuri": "http://lyratherapeutics.com/20240930", "localname": "CommonStockVotingRightsNumberOfVotes", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Common stock voting rights, number of votes.", "label": "Common Stock Voting Rights Number Of Votes", "terseLabel": "Number of common stock voting rights" } } },
"auth_ref": [] }, "lyra_CommonStockWarrantsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"CommonStockWarrantsDisclosureTextBlock", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrants" ], "lang": { "en-us":
{ "role": { "terseLabel": "Common Stock Warrants", "label": "Common Stock Warrants Disclosure [Text Block]", "documentation": "The entire disclosure for common stock
warrants." } } }, "auth_ref": [] }, "lyra_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"CommonWarrantsMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Common Warrants", "label": "Common Warrants [Member]", "documentation": "Common warrants." } } }, "auth_ref": [] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation
Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r732" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid
vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r731" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation
Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r733" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } },
"auth_ref": [ "r730" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase
(decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes
in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r19", "r151", "r153", "r158", "r496", "r516", "r517" ] }, "us-
gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label":
"Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } },
"auth_ref": [] }, "lyra_ComputerSoftwareAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"ComputerSoftwareAndEquipmentMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Computer Software and Equipment", "label": "Computer Software And Equipment [Member]", "documentation": "Computer Software And Equipment
[Member]" } } }, "auth_ref": [] }, "lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://lyratherapeutics.com/20240930", "localname": "ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation":
"Concentrations of credit risk and off-balance sheet risk.", "label": "Concentrations Of Credit Risk And Off Balance Sheet Risk Policy [Text Block]", "terseLabel":
"Concentrations of Credit Risk and Off-Balance Sheet Risk" } } }, "auth_ref": [] }, "lyra_ControlledEquityOfferingSalesAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://lyratherapeutics.com/20240930", "localname": "ControlledEquityOfferingSalesAgreementMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Controlled Equity Offering Sales Agreement.", "label": "Controlled Equity Offering Sales Agreement [Member]", "terseLabel": "Controlled Equity Offering Sales Agreement" }
} }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Conversion of stock, amount converted", "label": "Conversion of Stock, Amount Converted", "documentation": "The value of the stock converted in a noncash (or part
noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that
portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_ConversionOfStockDescription": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockDescription", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Conversion of stock, description", "label": "Conversion of Stock, Description", "documentation": "A unique description of a noncash or part noncash stock conversion. The
description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions
during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or
cash payments in the period." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "lyra_CorporateBondsAndUSGovernmentAndAgencySecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "CorporateBondsAndUSGovernmentAndAgencySecuritiesMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" ], "lang":
{ "en-us": { "role": { "documentation": "Corporate bonds and U.S. government and agency securities.", "label": "Corporate Bonds And U.S.Government And Agency Securities
[Member]", "terseLabel": "Corporate Bonds and U.S. Government Agency Securities" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ],
"lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities", "documentation": "Debt securities issued by domestic or
foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r642", "r644", "r652", "r665", "r667", "r898" ] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Counterparty Name [Axis]" } } }, "auth_ref": [ "r169", "r170", "r291", "r297", "r455", "r474", "r500", "r622", "r624" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref":
[] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-
gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity
Date", "terseLabel": "Debt instrument expiration date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } },
"auth_ref": [ "r141", "r638", "r870", "r871" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr":
"debit", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Debt securities, hold", "documentation": "Amount of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss
position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r116", "r258", "r632" ] },
"us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable",
"presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails" ], "lang":
{ "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair
value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r214", "r215", "r216", "r217", "r218", "r219", "r220",
"r221", "r222", "r223", "r224", "r225" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsTables"
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Fair Value of Available-for-sale Investments by Type
of Security", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income
(available-for-sale)." } } }, "auth_ref": [ "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817" ] }, "us-
gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt
Securities, Available-for-Sale, Unrealized Loss Position, Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Debt securities,
unrealized loss position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income
(available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r114", "r256", "r632" ] }, "us-
gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": [
```

"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Debt securities, held", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r115", "r257"] }, "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense recorded as liability", "label": "Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements." } } }, "auth_ref": [] }, "lyra_DeferredOfferingCostsIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DeferredOfferingCostsIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Deferred offering costs incurred but not yet paid.", "label": "Deferred Offering Costs Incurred But Not Yet Paid", "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef], "lang": { "en-us": { "role": { "periodEndLabel": "Deferred revenue at ending", "periodStartLabel": "Deferred revenue at beginning", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue", "totalLabel": "Deferred Revenue, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r779"] }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue Recognized Related to Each of the Performance Obligations and the Remaining Deferred Revenue", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue", "totalLabel": "Deferred Revenue, Current, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r778"] }, "us-gaap_DeferredRevenueDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueDescription", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Description", "terseLabel": "Deferred revenue, description", "documentation": "Description of the transaction or nature of business giving rise to deferred revenue or unearned revenue, other than annual membership fees. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "totalLabel": "Deferred Revenue, Noncurrent, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r779"] }, "us-gaap_DeferredRevenueRevenueRecognized1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueRevenueRecognized1", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef], "lang": { "en-us": { "role": { "negatedLabel": "Revenue recognized", "terseLabel": "Revenue recognized", "label": "Deferred Revenue, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue." } } }, "auth_ref": [] },
"lyra_DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets valuation allowance income tax expense (benefit).", "label": "Deferred Tax Assets Valuation Allowance Income Tax Expense (Benefit)", "terseLabel": "Deferred tax assets, valuation allowance income tax expense (benefit)" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r32"] }, "lyra_DevelopmentActivitiesPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DevelopmentActivitiesPerformanceObligation", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Development activities performance obligation", "label": "Development Activities Performance Obligation", "documentation": "Development activities performance obligation." } } }, "auth_ref": [] }, "lyra_DevelopmentActivitiesPerformanceObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DevelopmentActivitiesPerformanceObligationMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef], "lang": { "en-us": { "role": { "terseLabel": "Development Activities Performance Obligation", "label": "Development Activities Performance Obligation [Member]", "documentation": "Development activities performance obligation." } } }, "auth_ref": [] }, "lyra_DevelopmentMilestoneAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DevelopmentMilestoneAchieved", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef], "lang": { "en-us": { "role": { "terseLabel": "Milestone", "label": "Development Milestone Achieved", "documentation": "Development milestone achieved." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpense"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation Expense", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r322", "r326", "r354", "r355", "r357", "r646"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "lyra_DiscountedCashFlowTechniqueDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DiscountedCashFlowTechniqueDiscountRate", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl], "lang": { "en-us": { "role": { "documentation": "Discounted cash flow technique discount rate.", "label": "Discounted Cash Flow Technique Discount Rate", "terseLabel": "Discount Rate" } } }, "auth_ref": [] }, "lyra_DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases": { "xbrltype": "percentItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DiscountedCashFlowTechniqueExpectedSubleaseRentIncreases", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl], "lang": { "en-us": { "role": { "documentation": "Discounted cash flow technique expected sublease rent increases.", "label": "Discounted Cash Flow Technique Expected Sublease Rent Increases", "terseLabel": "Expected Sublease Rent Increases" } } }, "auth_ref": [] }, "lyra_DiscountedCashFlowTechniqueRangeOfAssumptionTable": { "xbrltype": "stringItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DiscountedCashFlowTechniqueRangeOfAssumptionTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl], "lang": { "en-us": { "role": { "documentation": "Discounted cash flow technique range of assumption.", "label": "Discounted Cash Flow Technique Range Of Assumption [Table]" } } }, "auth_ref": [] }, "lyra_DiscountedCashFlowTechniqueTerm": { "xbrltype": "durationItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "DiscountedCashFlowTechniqueTerm", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl], "lang": { "en-us": { "role": { "documentation": "Discounted cash flow technique term.", "label": "Discounted Cash Flow Technique Term", "terseLabel": "Term (years)" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r682"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r714"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r725"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "EarningsPerShareBasic", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders- basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r159", "r176", "r177", "r178", "r179", "r180", "r181", "r185", "r187", "r190", "r191", "r192", "r195", "r385", "r388", "r406", "r407", "r497", "r518", "r626"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders-diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r159", "r176", "r177", "r178", "r179", "r180", "r181", "r187", "r190", "r191", "r192", "r195", "r385", "r388", "r406", "r407", "r497", "r518", "r626"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r26", "r27", "r194"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r363", "r649"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Income tax computed at federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r168", "r363", "r376", "r649"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in deferred tax asset valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": ["r368", "r649", "r792", "r864"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Permanent differences", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": ["r364", "r367", "r649", "r792", "r864"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": ["r366", "r649", "r792", "r864"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetai"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and employee related expenses", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized expense", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r356"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock compensation expense to be recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r863"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]", "verboseLabel": "Severance Costs", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatio
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock Options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "verboseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r680"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth

Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r680"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r765"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r680"] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity incorporation, date of incorporation", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r764"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r680"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r680"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r680"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r680"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r719"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r760"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r760"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r760"] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r11", "r132", "r154", "r155", "r156", "r171", "r172", "r173", "r175", "r180", "r182", "r184", "r197", "r247", "r248", "r261", "r311", "r374", "r375", "r382", "r383", "r384", "r386", "r387", "r388", "r397", "r398", "r399", "r400", "r401", "r402", "r405", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r454", "r514", "r524", "r525", "r526", "r539", "r600"] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Short-term Investments", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": ["r3", "r53", "r245"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r729"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r687", "r697", "r707", "r739"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r684", "r694", "r704", "r736"] }, "lyra_EstimatedOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "EstimatedOfferingCosts", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Estimated offering costs.", "label": "Estimated Offering Costs", "terseLabel": "Estimated offering costs" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r735"] }, "lyra_ExecutiveChairMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ExecutiveChairMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Executive Chair", "label": "Executive Chair [Member]", "documentation": "Executive Chair." } } }, "auth_ref": [] }, "lyra_ExecutiveOptionAndJuneExecutiveOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ExecutiveOptionAndJuneExecutiveOptionsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Executive option and June executive options.", "label": "Executive Option And June Executive Options [Member]", "terseLabel": "Executive Options and June Executive Option" } } }, "auth_ref": [] }, "lyra_ExecutiveOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ExecutiveOptionsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Executive options.", "label": "Executive Options [Member]", "terseLabel": "Executive Options" } } }, "auth_ref": [] }, "lyra_ExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ExerciseOfCommonStockWarrants", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants", "label": "Exercise Of Common Stock Warrants", "documentation": "Exercise of common stock warrants." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r409", "r410", "r420", "r652"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r409", "r410", "r420", "r652"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Assets and

Liabilities Measured at Fair Value on Recurring Basis", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": ["r652", "r867", "r868", "r873"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r292", "r315", "r316", "r317", "r318", "r319", "r320", "r408", "r410", "r411", "r412", "r413", "r419", "r420", "r422", "r461", "r462", "r463", "r639", "r640", "r642", "r643", "r644", "r652", "r656"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r409", "r410", "r411", "r413", "r652", "r870", "r874"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r415", "r417", "r418", "r419", "r422", "r423", "r424", "r425", "r426", "r493", "r652", "r657"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r292", "r315", "r320", "r410", "r420", "r461", "r642", "r643", "r644", "r652"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r292", "r315", "r320", "r410", "r411", "r420", "r462", "r639", "r640", "r642", "r643", "r644", "r652"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r292", "r315", "r316", "r317", "r318", "r319", "r320", "r410", "r411", "r412", "r413", "r420", "r463", "r639", "r640", "r642", "r643", "r644", "r652", "r656"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r409", "r410", "r411", "r413", "r652", "r870", "r874"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r292", "r315", "r316", "r317", "r318", "r319", "r320", "r408", "r410", "r411", "r412", "r413", "r419", "r420", "r422", "r461", "r462", "r463", "r639", "r640", "r642", "r643", "r644", "r652", "r656"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r652", "r867", "r868", "r869", "r870", "r871", "r874"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r8"] }, "lyra_FebruaryTwentyTwentyTwoOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "FebruaryTwentyTwentyTwoOptionsMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "February twenty twenty two options.", "label": "February Twenty Twenty Two Options [Member]", "terseLabel": "February 2022 Options" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r249", "r250", "r251", "r252", "r253", "r255", "r259", "r260", "r293", "r307", "r403", "r427", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r515", "r632", "r652", "r654", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r665", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r817", "r818", "r819", "r820", "r866", "r869", "r870", "r871", "r872", "r874"] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Financial liabilities, fair value", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": ["r867", "r868", "r872"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r691", "r701", "r711", "r743"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r691", "r701", "r711", "r743"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r691", "r701", "r711", "r743"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r691", "r701", "r711", "r743"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r691", "r701", "r711", "r743"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r724"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Office Furniture and Fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "lyra_FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Future milestone payments receivable upon achievement of specified development, regulatory and commercialization.", "label": "Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization", "terseLabel": "Future milestone payments receivable" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r74", "r584"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"GeneralAndAdministrativeExpenseMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r74"] }, "lyra_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "GoingConcernPolicyTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Going concern policy text block.", "label": "Going Concern Policy [Text Block]", "terseLabel": "Going Concern" } } }, "auth_ref": [] },
"lyra_GrossProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "GrossProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds from issuance of common stock", "label": "Gross Proceeds From Issuance Of Common stock", "documentation": "Gross proceeds from issuance of common stock." } } }, "auth_ref": [] }, "lyra_GrossProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "GrossProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds from private placement", "documentation": "Gross proceeds from issuance of private placement.", "label": "Gross Proceeds From Issuance Of Private Placement", "terseLabel": "Gross proceeds from private placement" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Loss on impairment of long-lived assets", "label": "Impairment of Long-Lived Assets to be Disposed of", "verboseLabel": "Impairment of property and equipment", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": ["r6", "r86", "r653"] }, "lyra_ImpairmentOfRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ImpairmentOfRightOfUseAsset", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "documentation": "Impairment of right of use asset.", "terseLabel": "Impairment of ROU asset", "label": "Impairment Of Right Of Use Asset", "verboseLabel": "Impairment of right-of-use assets" } } }, "auth_ref": [] }, "lyra_ImpairmentOfRightOfUseAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ImpairmentOfRightOfUseAssetMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Impairment of right of use asset.", "label": "Impairment Of Right Of Use Asset [Member]", "terseLabel": "Impairment Of Right Of Use Asset" } } }, "auth_ref": [] }, "lyra_ImpairmentOnPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ImpairmentOnPropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: Impairment", "label": "Impairment On Property Plant And Equipment", "documentation": "Impairment on property plant and equipment." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income tax expense", "totalLabel": "Loss before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r72", "r107", "r112", "r498", "r511", "r628", "r629", "r798", "r799", "r800", "r801", "r802"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r262", "r263", "r268", "r414", "r416", "r421", "r521", "r523", "r585", "r619", "r655", "r897"] },
"us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r263", "r268", "r414", "r416", "r421", "r521", "r523", "r585", "r619", "r655", "r897"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r168", "r361", "r363", "r369", "r370", "r371", "r372", "r373", "r377", "r379", "r380", "r381", "r537", "r649"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "verboseLabel": "Income tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r117", "r128", "r183", "r184", "r196", "r204", "r207", "r362", "r363", "r378", "r519", "r649"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r5"] }, "lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued expenses and other current liabilities.", "label": "Increase Decrease In Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r491", "r788"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r768", "r788"] }, "lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease right-of-use asset.", "label": "Increase Decrease In Operating Lease Right Of Use Asset", "negatedLabel": "Operating lease right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": ["r788"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r691", "r701", "r711", "r735", "r743", "r747", "r755"] }, "lyra_InducementAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "InducementAwardPlanMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Inducement award plan.", "label": "Inducement Award Plan [Member]", "terseLabel": "Inducement Award Plan" } } }, "auth_ref": [] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r753"] },
"ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r683", "r759"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading

Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r683", "r759"] },
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider
Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r683", "r759"] }, "us-
gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit",
"presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"],
"lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase
discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r196", "r203", "r207", "r629", "r785"] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestments1"], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity
Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Short-term Investments", "documentation": "The entire disclosure for investments in certain
debt and equity securities." } } }, "auth_ref": ["r109", "r131", "r212", "r213", "r428", "r429", "r890"] },
"lyra_IssuanceCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930",
"localname": "IssuanceCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"verboseLabel": "Issuance Costs in accounts payable, accrued expenses, and other current liabilities", "documentation": "Issuance costs in accounts payable accrued expenses
and other current liabilities.", "label": "Issuance Costs In Accounts Payable Accrued Expenses And Other Current Liabilities", "terseLabel": "Issuance costs in accounts
payable, accrued expenses, and other current liabilities" } } }, "auth_ref": [] }, "lyra_IssuanceOfCommonStockUnderEspp": { "xbrltype": "sharesItemType", "nsuri":
"http://lyratherapeutics.com/20240930", "localname": "IssuanceOfCommonStockUnderEspp", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Issuance of common stock under ESPP", "label": "Issuance of Common Stock under ESPP", "documentation": "Issuance of common stock under ESPP." } } },
"auth_ref": [] }, "lyra_JuneExecutiveOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"JuneExecutiveOptionsMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "June executive options.", "label": "June Executive Options [Member]", "terseLabel": "June Executive Options" } } }, "auth_ref": [] }, "us-
gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term
[Axis]", "terseLabel": "Lease Contractual Term", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r453", "r767"] }, "us-
gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term
[Domain]", "terseLabel": "Lease Contractual Term", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r453", "r767"] }, "us-gaap_LeaseCost": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost",
"totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r445", "r663"] }, "us-
gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost
[Abstract]", "terseLabel": "Lease Cost:" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LeaseCostTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesTables"], "lang": { "en-us": { "role": {
"label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of Lease Cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to,
interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } }
}, "auth_ref": ["r878"] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1",
"presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease
Expiration Date", "terseLabel": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] },
"lyra_LeaseInitiationDate": { "xbrltype": "dateItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "LeaseInitiationDate", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Lease initiation
date", "label": "Lease Initiation Date", "terseLabel": "Lease initiation date" } } }, "auth_ref": [] }, "lyra_LeaseRelatedCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://lyratherapeutics.com/20240930", "localname": "LeaseRelatedCostsCurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetai
], "lang": { "en-us": { "role": { "documentation": "Lease related costs current", "label": "Lease related costs current", "terseLabel": "Lease-related costs" } } }, "auth_ref": [] },
"us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember",
"presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"],
"lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements", "documentation": "Additions or improvements to assets
held under a lease arrangement." } } }, "auth_ref": ["r87", "r452"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description
[Line Items]", "terseLabel": "Lessee Lease Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r443", "r453"] }, "us-
gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description
[Table]", "terseLabel": "Lessee Lease Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r443", "r453"] }, "us-
gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease,
Existence of Option to Extend [true false]", "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false)
whether lessee has option to extend operating lease." } } }, "auth_ref": ["r444"] }, "lyra_LesseeOperatingLeaseExtendedLeaseTerm": { "xbrltype": "gYearMonthItemType",
"nsuri": "http://lyratherapeutics.com/20240930", "localname": "LesseeOperatingLeaseExtendedLeaseTerm", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Lessee, operating
lease, extended lease term.", "label": "Lessee Operating Lease Extended Lease Term", "terseLabel": "Extended lease term" } } }, "auth_ref": [] }, "us-
gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesTables"], "lang": { "en-
us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Maturity of Operating Lease Liabilities",
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows
to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r879"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee,
Operating Lease, Liability, to be Paid", "totalLabel": "Total maturities", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
} } }, "auth_ref": ["r451"] }, "lyra_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://lyratherapeutics.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee operating lease liability payments due after year four." } } },
"auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease
to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position
date (rolling approach)." } } }, "auth_ref": ["r451"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating
lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial
position date (rolling approach)." } } }, "auth_ref": ["r451"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating
lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial
position date (rolling approach)." } } }, "auth_ref": ["r451"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease
to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial
position date (rolling approach)." } } }, "auth_ref": ["r451"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"From October 1, 2024 to December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } },
"auth_ref": ["r879"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee,
Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Amount representing interest", "documentation": "Amount of lessee's undiscounted
obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r451"] }, "us-
gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend",
"presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel":

"Lessee, Operating Lease, Option to Extend", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": ["r444"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating Lease, renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r877"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease period", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r877"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r439"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r16", "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r167", "r246", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r392", "r395", "r396", "r430", "r559", "r627", "r678", "r833", "r881", "r882"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r70", "r104", "r508", "r664", "r791", "r821", "r875"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r59", "r135", "r167", "r246", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r392", "r395", "r396", "r430", "r664", "r833", "r881", "r882"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Paid to the contract manufacture", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": ["r62", "r832"] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Claims for breach of implied covenant of good and fair dealing", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "lyra_MarketConditionsBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "MarketConditionsBasedAwardsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Market-conditions based awards.", "label": "Market Conditions Based Awards [Member]", "terseLabel": "Market-Conditions Based Awards" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r321", "r359", "r413", "r490", "r520", "r522", "r530", "r551", "r552", "r605", "r606", "r607", "r608", "r609", "r617", "r618", "r631", "r641", "r645", "r656", "r657", "r661", "r662", "r666", "r835", "r883", "r884", "r885", "r886", "r887", "r888"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r727"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r727"] }, "lyra_MilestoneAchievementsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "MilestoneAchievementsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Milestone", "documentation": "Milestone achievements.", "label": "Milestone Achievements [Member]", "terseLabel": "Milestone Achievements" } } }, "auth_ref": [] }, "lyra_MilestoneBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "MilestoneBasedAwardsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Milestone-based awards.", "label": "Milestone Based Awards [Member]", "terseLabel": "Milestone-based Awards" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r321", "r359", "r413", "r490", "r520", "r522", "r530", "r551", "r552", "r605", "r606", "r607", "r608", "r609", "r617", "r618", "r631", "r641", "r645", "r656", "r657", "r661", "r666", "r835", "r883", "r884", "r885", "r886", "r887", "r888"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r746"] }, "lyra_ModificationOfLeaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ModificationOfLeaseAgreement", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Modification of lease agreement", "label": "Modification of Lease Agreement", "documentation": "Modification of Lease Agreement" } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r836"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r754"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r728"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r163"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r163"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r79", "r80", "r81"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss", "negatedLabel": "Net losses", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r73", "r81", "r108", "r133", "r149", "r152", "r156", "r167", "r174", "r176", "r177", "r178", "r179", "r180", "r183", "r184", "r189", "r246", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r385", "r388", "r407", "r430", "r513", "r581", "r598", "r599", "r676", "r833"] }, "lyra_NetProceedsAfterDeductingIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "NetProceedsAfterDeductingIssuanceCosts", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds after deducting issuance costs", "label": "Net Proceeds After Deducting Issuance Costs", "documentation": "Net proceeds after deducting issuance costs." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r727"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r691", "r701", "r711", "r735", "r743"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r718"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r717"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r735"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r754"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r754"] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r75"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "auth_ref": [] }, "lyra_NumberOfEmployees": { "xbrltype": "integerItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "NumberOfEmployees", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of employees", "label": "Number Of Employees", "terseLabel": "Number Of Employees" } } }, "auth_ref": [] }, "lyra_NumberOfLeasedPropertiesMarketedForSubleaseArrangements": { "xbrltype": "integerItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "NumberOfLeasedPropertiesMarketedForSubleaseArrangements", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of leased properties marketed for sublease arrangements.", "label": "Number of Leased Properties Marketed for Sublease Arrangements", "terseLabel": "Number of leased properties marketed for sublease arrangements" } } }, "auth_ref": [] }, "lyra_NumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "NumberOfLeases", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of leases.", "label": "Number of leases" } } }, "auth_ref": [] }, "lyra_OfficeAndLaboratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "OfficeAndLaboratoryMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Office and laboratory.", "label": "Office And Laboratory [Member]", "terseLabel": "Office and Laboratory" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "terseLabel": "Office Equipment", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r112", "r628", "r798", "r799", "r800", "r801", "r802"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r446", "r663"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Initial base rent", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r876"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Present value of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r442"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "negatedLabel": "Less: current portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r442"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Total operating lease liability, net of current portion", "verboseLabel": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r442"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r441"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDeta
], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r450", "r663"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [

```
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDeta
], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)",
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year,
five months, and thirteen days." } } }, "auth_ref": [ "r449", "r663" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" ], "lang": { "en-us":
{ "role": { "label": "Option Indexed to Issuer's Equity, Type [Axis]", "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to,
and potentially settled in, an entity's own stock." } } }, "auth_ref": [ "r35", "r51", "r52", "r100" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" ], "lang": { "en-us":
{ "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed
to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] },
"lyra_OrganizationAndBasisOfPresentationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"OrganizationAndBasisOfPresentationLineItems", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "Organization and basis of presentation.", "label": "Organization And Basis Of Presentation [Line Items]", "terseLabel": "Organization
And Basis Of Presentation [Line Items]" } } }, "auth_ref": [] }, "lyra_OrganizationAndBasisOfPresentationTable": { "xbrltype": "stringItemType", "nsuri":
"http://lyratherapeutics.com/20240930", "localname": "OrganizationAndBasisOfPresentationTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "Organization and basis of presentation.", "label": "Organization And Basis Of Presentation [Table]", "terseLabel": "Organization And
Basis Of Presentation [Table]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label":
"Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] },
"lyra_OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"OtherAssetsIncludedInAccountsPayableAndOtherCurrentLiabilities", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Other assets included in accounts payable and other current liabilities", "label": "Other Assets Included In Accounts Payable And Other Current Liabilities", "documentation":
"Other assets included in accounts payable and other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label":
"Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r48", "r50" ] }, "us-
gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit",
"presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": {
"label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r139" ] },
"lyra_OtherAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "OtherAssetsPolicyTextBlock",
"presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"documentation": "Other assets policy.", "label": "Other Assets [Policy Text Block]", "terseLabel": "Other Assets" } } }, "auth_ref": [] }, "us-
gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Other comprehensive loss:", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Other Comprehensive Income (Loss), Net of
Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r11", "r15", "r150", "r153", "r157",
"r180", "r431", "r432", "r437", "r495", "r514", "r782", "r783" ] }, "us-
gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Unrealized holding gain (loss) on short-term investments, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss),
before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair
value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at
amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r147", "r148", "r244" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetai
], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of liabilities classified as other, due within one year or the
normal operating cycle, if longer." } } }, "auth_ref": [ "r58", "r664" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure,
Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r727" ] }, "us-gaap_OtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringCosts", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Other Restructuring Costs", "terseLabel": "Other costs", "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized
plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherRestructuringMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails" ], "lang": { "en-us":
{ "role": { "label": "Other Restructuring [Member]", "terseLabel": "Other Costs", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [
"r634", "r635", "r636", "r637" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous
Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r689", "r699", "r709", "r741" ] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel":
"Compensation Amount" } } }, "auth_ref": [ "r692", "r702", "r712", "r744" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r692", "r702", "r712", "r744" ] }, "ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs
Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r716" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent",
"crdr": "credit", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Payments for Rent", "terseLabel": "Payments for Rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r4"
] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr":
"credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails" ], "lang": { "en-us":
{ "role": { "label": "Payments for Restructuring", "negatedLabel": "Cash Payments", "documentation": "Amount of cash payments made as the result of exit or disposal
activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r267", "r787" ] }, "us-
gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr":
"credit", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-
us": { "role": { "negatedLabel": "Payment of deferred offering costs", "terseLabel": "Payment of deferred offering costs", "label": "Payments of Stock Issuance Costs",
"documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r20" ] }, "us-gaap_PaymentsToAcquireInvestments":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel":
"Payments to Acquire Investments, Total", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of short-term investments", "documentation": "The cash
outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r77" ] }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and
Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to
produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r78" ] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation":
[ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote"
} } }, "auth_ref": [ "r726" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder
Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r726" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r718" ] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r735" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r728" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO
Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r717" ] }, "lyra_PercentageOfAggregateCommission": { "xbrltype":
"percentItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "PercentageOfAggregateCommission", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Percentage of aggregate commission.", "label": "Percentage Of Aggregate Commission", "terseLabel": "Percentage of aggregate commission" } } }, "auth_ref": [] },
"lyra_PercentageOfAnnualRentIncrement": { "xbrltype": "percentItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname":
"PercentageOfAnnualRentIncrement", "presentation": [ "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": {
```

"en-us": { "role": { "documentation": "Percentage of annual rent increment.", "label": "Percentage Of Annual Rent Increment", "terseLabel": "Percentage of annual rent increment" } } }, "auth_ref": [] }, "lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear": { "xbrltype": "percentItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "PercentageOfCommonSharesIncreaseAutomaticallyInEachYear", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of common shares increase automatically in each year.", "label": "Percentage Of Common Shares Increase Automatically In Each Year", "terseLabel": "Percentage of common shares increase automatically in each year" } } }, "auth_ref": [] }, "lyra_PerformanceObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "PerformanceObligationsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Performance obligations.", "label": "Performance Obligations [Member]", "terseLabel": "Performance Obligations" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Performance-Based Stock Awards", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r719"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r763"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r718"] }, "lyra_PostMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "PostMilestoneMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Post-Milestone", "label": "Post-Milestone [Member]", "documentation": "Post-milestone." } } }, "auth_ref": [] }, "lyra_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Pre-Funded Warrants", "documentation": "Pre-funded warrants.", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "lyra_PreMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "PreMilestoneMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-Milestone", "label": "Pre-Milestone [Member]", "documentation": "Pre-milestone." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "verboseLabel": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r64", "r295"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r64", "r561"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r64", "r295"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r64", "r561", "r579", "r900", "r901"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r64", "r504", "r664"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r781"] }, "us-gaap_PrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidRent", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid rent", "label": "Prepaid Rent", "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r621", "r633", "r822"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "lyra_ProceedsFromGovernmentContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ProceedsFromGovernmentContracts", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Proceeds from government contracts.", "label": "Proceeds From Government Contracts", "terseLabel": "Proceeds from government contracts" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance initial public offering", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of preferred stock allocated to warrants", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Net proceeds from private placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds from issuance of warrants", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r2"] }, "lyra_ProceedsFromLicenseAndCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ProceedsFromLicenseAndCollaborationAgreement", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Proceeds from license and collaboration agreement.", "label": "Proceeds From License And Collaboration Agreement", "terseLabel": "Proceeds from license and collaboration agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Maturity of short-term investments", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r160", "r161", "r805"] },
"lyra_ProceedsFromSaleOfCommonStockPurchaseWarrantsAndPreFundedWarrantsNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ProceedsFromSaleOfCommonStockPurchaseWarrantsAndPreFundedWarrantsNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs", "label": "Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs", "documentation": "Proceeds from sale of common stock, purchase warrants and pre-funded warrants, net of issuance costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r2", "r14"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds for warrant exercises", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r786"] }, "lyra_ProceedsToBeOccuredFromFutureIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ProceedsToBeOccuredFromFutureIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Proceeds to be occured from future issuance of common stock,.", "label": "Proceeds To Be Occured From Future Issuance Of Common Stock", "terseLabel": "Proceeds to be occured from future issuance of common stock" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r133", "r149", "r152", "r162", "r167", "r174", "r180", "r183", "r184", "r246", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r385", "r388", "r390", "r393", "r394", "r407", "r430", "r498", "r512", "r538", "r581", "r598", "r599", "r650", "r651", "r677", "r784", "r833"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r7", "r452"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairment"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment and Related Impairment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r85", "r123", "r126", "r127"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r87", "r137", "r510"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r452"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r452", "r499", "r510", "r664"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property Plant And Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r87", "r452"] },
"lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Purchase price of shares as percentage lower of fair market value of common stock.", "label": "Purchase Price Of Shares As Percentage Lower Of Fair Market Value Of Common Stock", "terseLabel": "Purchase price of shares as percentage lower of fair market value of common stock" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r716"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r716"] },
"srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r314", "r321", "r349", "r350", "r351", "r359", "r413", "r464", "r473", "r490", "r520", "r522", "r530", "r551", "r552", "r605", "r606", "r607", "r608", "r609", "r617", "r618", "r631", "r641", "r645", "r656", "r657", "r661", "r662", "r666", "r670", "r827", "r835", "r870", "r884", "r885", "r886", "r887", "r888"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r314", "r321", "r349", "r350", "r351", "r359", "r413", "r464", "r473", "r490", "r520", "r522", "r530", "r551", "r552", "r605", "r606", "r607", "r608", "r609", "r617", "r618", "r631", "r641", "r645", "r656", "r657", "r661", "r662", "r666", "r670", "r827", "r835", "r870", "r884", "r885", "r886", "r887", "r888"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r684", "r694", "r704", "r736"] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r169", "r170", "r291", "r297", "r455", "r474", "r500", "r623", "r624"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [

"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r360", "r619", "r629", "r889"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r685", "r695", "r705", "r737"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r686", "r696", "r706", "r738"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r693", "r703", "r713", "r745"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashE "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r776", "r789", "r891", "r894"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": ["r55"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r136"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r118", "r777", "r789"] }, "lyra_RestrictedCashPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "RestrictedCashPolicyTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Restricted cash.", "label": "Restricted Cash Policy [Text Block]", "terseLabel": "Restricted Cash" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatio], "lang": { "en-us": { "role": { "verboseLabel": "Restricted Stock Units", "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedCharges"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Other Related Charges", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r264", "r265", "r267", "r270", "r275"] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring and other related charges", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": ["r266", "r269", "r272", "r274"] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Number of employees reduced", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Charges, Total", "label": "Restructuring Charges", "terseLabel": "Restructuring and other related charges", "verboseLabel": "Restructuring charge", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6", "r271", "r272", "r828"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r266", "r267", "r272", "r273"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r266", "r267", "r268", "r269", "r272", "r273", "r274"] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Reserve, Total", "label": "Restructuring Reserve", "periodStartLabel": "Restructuring reserve, beginning balance", "periodEndLabel": "Restructuring reserve, ending balance", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r267", "r273"] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Accruals", "verboseLabel": "Restructuring Liability", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": ["r267", "r273"] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring liability", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": ["r778", "r829", "r830"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r67", "r95", "r507", "r527", "r529", "r536", "r562", "r664"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r132", "r171", "r172", "r173", "r175", "r180", "r182", "r184", "r247", "r248", "r261", "r374", "r375", "r382", "r383", "r384", "r386", "r387", "r388", "r397", "r399", "r400", "r402",

"r405", "r438", "r440", "r524", "r526", "r539", "r900"] }, "lyra_RetentionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "RetentionCosts", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Retention costs", "label": "Retention Costs", "documentation": "Retention costs." } } }, "auth_ref": [] }, "lyra_RetentionCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "RetentionCostsMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Retention costs.", "label": "Retention Costs [Member]", "terseLabel": "Retention Costs" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r110", "r111", "r196", "r201", "r202", "r205", "r207", "r208", "r209", "r210", "r312", "r313", "r492"] }, "us-gaap_RevenueRecognitionMilestoneMethodTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionMilestoneMethodTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementTables"], "lang": { "en-us": { "role": { "label": "Revenue Recognition, Milestone Method [Table Text Block]", "terseLabel": "Summary of Transaction Price", "documentation": "Tabular disclosure of the entity's accounting policy for the recognition of revenue under the milestone method. Includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors that the entity considered in determining whether the milestone or milestones are substantive; and (5) the amount of consideration recognized during the period for the milestone or milestones." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Right of Use Asset in Exchange for Lease Liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r448", "r663"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r754"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r754"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Gross proceeds under agreement", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, number of shares issued (in shares)", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "lyra_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "SalesAgreementMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Sales agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "auth_ref": [] },
"lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued expenses and other current liabilities.", "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatic
], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported within Balance Sheet", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r389"] }, "lyra_ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ScheduleOfDiscountedCashFlowMethodologyRangeOfAssumptionsTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule Of Discounted Cash Flow methodology Range Of Assumptions [Table Text Block]", "terseLabel": "Schedule of Fair Value Determination of Right of Use Assets Using Discounted Cash Flow Methodology", "documentation": "Schedule of discounted cash flow methodology range of assumptions." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": ["r365", "r649", "r864"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentAndRelatedImpairmentScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us":

{ "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r7", "r452"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r266", "r267", "r268", "r269", "r272", "r273", "r274"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesTables"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring Liability Activities", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r34", "r88", "r89"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r323", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity Under Plans", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r96"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model or Monte Carlo Simulation in Case of Certain Options Granted to Executive Officers", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r98"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "terseLabel": "Schedule Of Stock By Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r36", "r37", "r38", "r39", "r40", "r41", "r91", "r93", "r94", "r95", "r142", "r143", "r144", "r198", "r295", "r296", "r297", "r299", "r302", "r307", "r309", "r532", "r533", "r534", "r535", "r641", "r766", "r790"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Warrants Outstanding and Exercisable", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r42"] }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]", "terseLabel": "Schedule of Unrecognized Stock-Based Compensation", "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r99"] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebt", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Secured Debt", "terseLabel": "Secured debt obligations", "totalLabel": "Secured Debt, Total", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": ["r16", "r102", "r893"] }, "lyra_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase Agreement", "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r679"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r681"] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Severance Costs", "terseLabel": "Severance costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r646"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights", "terseLabel": "Vesting rights", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r44"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Restricted stock units outstanding shares, Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r343"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r343"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "RSUs granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock units outstanding shares, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r341"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {

"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r341"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted stock units outstanding, Ending Balance", "periodStartLabel": "Restricted stock units outstanding, Beginning Balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r338", "r339"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r338", "r339"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares probable to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Restricted stock units outstanding shares, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r342"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r342"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date", "terseLabel": "Expiration date", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth_ref": ["r838"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackschol "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r350"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackschol "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r349"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackschol "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r351"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r323", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Shares available for grant", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares available for issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r648"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for future grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r43"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r345"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Shares, Cancelled", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r336"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of shares granted", "verboseLabel": "Shares, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-
average fair value of options granted to employees, directors and non-employees", "documentation": "The weighted average grant-date fair value of options granted during the
reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r344"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us":
{ "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at September 30, 2022", "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding December
31, 2021", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r43"] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us":
{ "role": { "periodStartLabel": "Shares, Outstanding December 31, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding, Number", "periodEndLabel": "Shares, Outstanding at June 30, 2024", "terseLabel": "Number of awards outstanding", "documentation": "Number of options
outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r330", "r331"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"],
"lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Outstanding December 31, 2023", "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding at June 30, 2024",
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r330", "r331"] },
"lyra_ShareBasedCompensationArrangementUnrecognizedCompensationExpenseRecognitionWeightedAverageTerm": { "xbrltype": "durationItemType", "nsuri":
"http://lyratherapeutics.com/20240930", "localname": "ShareBasedCompensationArrangementUnrecognizedCompensationExpenseRecognitionWeightedAverageTerm",
"presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": {
"role": { "documentation": "Share based compensation arrangement unrecognized compensation expense recognition weighted average term.", "label": "Share Based
Compensation Arrangement Unrecognized Compensation Expense Recognition Weighted Average Term", "terseLabel": "Unrecognized share based compensation amount
recognition term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award
under share-based payment arrangement." } } }, "auth_ref": ["r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340",
"r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us":
{ "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel":
"Weighted Average Exercise Price, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into
shares." } } }, "auth_ref": ["r335"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us":
{ "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
"verboseLabel": "Weighted Average Exercise Price, Cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with
respect to stock options that were terminated." } } }, "auth_ref": ["r336"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us":
{ "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel":
"Exercise price per share, granted", "verboseLabel": "Weighted Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees
can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r334"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Stock option expiration period", "documentation": "Period from
grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen
days." } } }, "auth_ref": ["r647"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackschol
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"verboseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel":
"Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r348"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us":
{ "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
"terseLabel": "Exercisable, Weighted Average Remaining Contractual Life (in years)", "documentation": "Weighted average remaining contractual term for vested portions of
options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months,
and thirteen days." } } }, "auth_ref": ["r43"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails"], "lang": { "en-us":
{ "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
"terseLabel": "Outstanding, Weighted Average Remaining Contractual Life (in years)", "documentation": "Weighted average remaining contractual term for option awards
outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r97"] },
"us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares
issued and sold, public offering price", "label": "Shares Issued, Price Per Share", "verboseLabel": "Weighted average price", "documentation": "Per share or per unit amount of
equity securities issued." } } }, "auth_ref": [] }, "lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://lyratherapeutics.com/20240930", "localname": "SharesOfCommonStockReservedForFutureIssuancesTableTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosurePreferredAndCommonStockTables"], "lang": { "en-us": { "role": { "documentation": "Shares of common
stock reserved for future issuances.", "label": "Shares Of Common Stock Reserved For Future Issuances Table [Text Block]", "terseLabel": "Schedule of Common Stock
Reserved for Future Issuances" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharesOutstanding", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": {
"label": "Shares, Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares", "documentation": "Number of shares issued which are neither
cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShortTermDebtTypeAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang":
{ "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type", "documentation": "Information by type of short-term debt arrangement." }
} }, "auth_ref": ["r57", "r824", "r825", "r826"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermDebtTypeDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us":
{ "role": { "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type", "documentation": "Type of short-term debt arrangement, such as notes, line of
credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r56", "r824", "r825", "r826"] }, "us-
gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit",
"presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Short-
Term Investments, Total", "label": "Short-Term Investments", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities,
available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r105", "r106", "r780"] }, "us-
gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsAbstract", "lang": { "en-
us": { "role": { "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant

Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r82", "r165"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r130", "r142", "r143", "r144", "r167", "r187", "r188", "r190", "r192", "r198", "r199", "r246", "r282", "r284", "r285", "r286", "r289", "r290", "r295", "r296", "r299", "r302", "r309", "r430", "r532", "r533", "r534", "r535", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r561", "r582", "r600", "r610", "r611", "r612", "r613", "r614", "r766", "r790", "r797"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r65", "r68", "r69", "r132", "r154", "r155", "r156", "r171", "r172", "r173", "r175", "r180", "r182", "r184", "r197", "r247", "r248", "r261", "r311", "r374", "r375", "r382", "r383", "r384", "r386", "r387", "r388", "r397", "r398", "r399", "r400", "r401", "r402", "r405", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r454", "r514", "r524", "r525", "r526", "r539", "r600"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
"http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r171", "r172", "r173", "r197", "r440", "r492", "r531", "r550", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r583", "r584", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r600", "r671"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
"http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r171", "r172", "r173", "r197", "r211", "r440", "r492", "r531", "r550", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r583", "r584", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r600", "r671"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r688", "r698", "r708", "r740"] }, "lyra_StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Stock and warrants to be issued during period value preferred stock and warrants.", "label": "Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants", "terseLabel": "Stock and warrants to be issued during period value preferred stock and warrants" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "lyra_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants, Shares", "label": "Stock issued during period, shares, Exercise of common stock warrants", "documentation": "Stock issued during period, shares, Exercise of common stock warrants." } } }, "auth_ref": [] }, "lyra_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrants, Shares", "label": "Stock Issued During Period Shares Exercise Of Pre Funded Warrants", "documentation": "Stock issued during period, shares, Exercise of pre-funded warrants." } } }, "auth_ref": [] },
"lyra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares issuance of common stock and pre-funded warrants, net of issuance costs.", "label": "Stock Issued During Period Shares Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs", "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs, Shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Shares issued under ATM, net of issuance costs, Shares", "terseLabel": "Issuance of common stock", "verboseLabel": "Issuance of pre-funded warrants to purchase shares of common stock", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r11", "r64", "r65", "r95", "r532", "r600", "r611"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of common stock options, Shares", "negatedLabel": "Shares, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r11", "r64", "r65", "r95", "r335"] }, "lyra_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares vesting of restricted stock unit.", "label": "Stock Issued During Period Shares Vesting Of Restricted Stock Unit", "terseLabel": "Issuance of common stock upon RSU vesting, shares" } } }, "auth_ref": [] }, "lyra_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants", "label": "Stock issued during period, value, exercise of common stock warrants", "documentation": "Stock issued during period, value, exercise of common stock warrants." } } }, "auth_ref": [] },
"lyra_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock and pre-fundedwarrants, net of issuance costs", "documentation": "Stock issued during period value issuance of common stock and pre-funded warrants, net of issuance costs.", "label": "Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under ATM, net of issuance costs of $150", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r11", "r64", "r65", "r95", "r539", "r600", "r611", "r677"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r11", "r65", "r68", "r69", "r95"] }, "lyra_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value vesting of restricted stock unit.", "label": "Stock Issued During Period Value Vesting Of Restricted Stock Unit", "terseLabel": "Issuance of common stock upon RSU vesting" } } }, "auth_ref": [] }, "lyra_StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockIssuedDuringPeriodValuesExerciseOfPreFundedWarrants", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrants", "label": "Stock Issued During Period Values Exercise Of Pre Funded Warrants", "documentation": "Stock issued during period, values, exercise of pre-funded warrants." } } }, "auth_ref": [] }, "lyra_StockOptionsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "StockOptionsAndRestrictedStockUnitsMember", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "documentation": "Stock options and restricted stock units.", "label": "Stock Options And Restricted Stock Units [Member]", "terseLabel": "Stock Options and Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited",
"http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity", "documentation":

"Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r65", "r68", "r69", "r84", "r563", "r579", "r601", "r602", "r664", "r678", "r791", "r821", "r875", "r900"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStock1"], "lang": { "en-us": { "role": { "terseLabel": "Preferred and Common Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r92", "r166", "r294", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r311", "r404", "r603", "r604", "r615"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r456", "r457"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParentheticalUnaudited"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesTables"], "lang": { "en-us": { "role": { "documentation": "Summary of weighted average remaining lease terms and discount rate related to operating leases.", "label": "Summary Of Weighted Average Remaining Lease Terms And Discount Rate Related To Operating Leases Table [Text Block]", "terseLabel": "Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r734"] }, "lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "ThirdPartyResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetai"], "lang": { "en-us": { "role": { "documentation": "Third-party research and development expenses current.", "label": "Third Party Research And Development Expenses Current", "terseLabel": "Third-party research and development expenses" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title and Position [Axis]" } } }, "auth_ref": ["r803", "r880"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r726"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r733"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r753"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r755"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r293", "r307", "r403", "r427", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r515", "r652", "r654", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r665", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r817", "r818", "r819", "r820", "r866", "r869", "r870", "r871", "r872", "r874"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r756"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r757"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r757"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r755"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r755"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r758"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r756"] }, "lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "TwentyThousandTwentyEmployeeStockPurchasePlanMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Twenty thousand twenty employee stock purchase plan.", "label": "Twenty Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 ESPP" } } }, "auth_ref": [] }, "lyra_TwentyThousandTwentyIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "TwentyThousandTwentyIncentiveAwardPlanMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Twenty thousand twenty incentive award plan.", "label": "Twenty Thousand Twenty Incentive Award Plan [Member]", "terseLabel": "2020 Plan" } } }, "auth_ref": [] }, "lyra_TwentyTwentyFourRestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "TwentyTwentyFourRestructuringPlanMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Twenty twenty four restructuring plan.", "label": "Twenty Twenty Four Restructuring Plan [Member]", "terseLabel": "2024 Restructuring Plan" } } }, "auth_ref": [] }, "lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Two thousand five and two thousand sixteen equity incentive plan.", "label": "Two Thousand Five And Two Thousand Sixteen Equity Incentive Plan [Member]", "terseLabel": "2005 and 2016 Plan" } } }, "auth_ref": [] }, "lyra_TwoThousandTwentyFourPerformanceOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "TwoThousandTwentyFourPerformanceOptionMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Performance Option", "label": "Two Thousand Twenty Four Performance Option [Member]", "documentation": "Two thousand twenty four performance option." } } }, "auth_ref": [] }, "lyra_TwoThousandTwentyFourPsusMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "TwoThousandTwentyFourPsusMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 PSUs", "label": "Two Thousand Twenty Four PSUs [Member]", "documentation": "Two thousand twenty four PSUs." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementRevenueRecognizedRelatedToEachOfThePerformanceObligationsAndTheRemainingDef "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r389"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureRestructuringAndOtherRelatedChargesSummaryOfRestructuringLiabilityActivitiesDetails"], "lang": { "en-us":

{ "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": { "r266", "r267", "r272", "r273" } }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Corporate Bonds and U.S. Government Agency Securities", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r625", "r642", "r892"] }, "lyra_USGovernmentAgencyAndForeignNationalBankSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "USGovernmentAgencyAndForeignNationalBankSecuritiesMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Agency and foreign national bank securities", "label": "U.S. Government Agency and Foreign National Bank Securities [Member]", "documentation": "U.S. Government agency and foreign national bank securities." } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfFairValueOfAvailableforsaleInvestmentsByTypeOfSecurityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "U.S. Treasury Bills", "terseLabel": "U.S. treasury bills", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r625", "r642", "r644", "r652", "r892"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r752"] }, "lyra_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "UpfrontPaymentReceived", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "auth_ref": [] }, "lyra_UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "UpfrontPaymentRecognitionInFuturePeriodsToSettlementOfObligation", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfTransactionPriceDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureCollaborationAgreementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total", "documentation": "Upfront payment recognition in future periods to settlement of obligation.", "label": "Upfront Payment Recognition In Future Periods To Settlement Of Obligation", "terseLabel": "Upfront payment recognition in future periods to settlement of obligation", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r28", "r29", "r30", "r120", "r122", "r124", "r125"] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": ["r411", "r412", "r656", "r871"] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl], "lang": { "en-us": { "role": { "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Discounted Cash Flow Technique", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": ["r656", "r869", "r870", "r871"] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureImpairmentOfRightOfUseAssetsScheduleOfFairValueDeterminationOfRightOfUseAssetsUsingDiscountedCashFl], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": ["r411", "r412", "r656", "r871"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r447", "r663"] }, "srt_VicePresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "VicePresidentMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Vice President", "label": "Vice President [Member]" } } }, "auth_ref": ["r803"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r722"] }, "lyra_WalthamLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WalthamLeaseMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Waltham lease.", "label": "Waltham Lease [Member]", "terseLabel": "Waltham Lease" } } }, "auth_ref": [] }, "lyra_WalthamSubleaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WalthamSubleaseMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Waltham Sublease", "label": "Waltham Sublease [Member]", "documentation": "Waltham sublease." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureOrganizationRestructuringGoingConcernAndBasisOfPresentationAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculatio], "lang": { "en-us": { "role": { "label": "Warrants", "verboseLabel": "Purchase Warrants", "terseLabel": "Common stock warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r668", "r669", "r672", "r673", "r674", "r675"] }, "lyra_WarrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WarrantOneMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant One", "label": "Warrant One [Member]", "documentation": "Warrant one." } } }, "auth_ref": [] }, "lyra_WarrantThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WarrantThreeMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant Three", "label": "Warrant Three [Member]", "documentation": "Warrant three." } } }, "auth_ref": [] }, "lyra_WarrantTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WarrantTwoMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant Two", "label": "Warrant Two [Member]", "documentation": "Warrant two." } } }, "auth_ref": [] }, "lyra_WarrantsAndRightsExercisedIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WarrantsAndRightsExercisedIntrinsicValue", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic Value of Warrants Exercised", "label": "Warrants and Rights Exercised Intrinsic Value", "documentation": "Warrants and rights exercised intrinsic value." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate intrinsic Value of Warrants Outstanding, Ending Balance", "periodStartLabel": "Aggregate intrinsic Value of Warrants Outstanding, Beginning Balance", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r869", "r870", "r871"] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Expiration date", "terseLabel": "Expiration Date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": ["r869", "r870", "r871"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term of Warrants Outstanding", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r869", "r870", "r871"] }, "lyra_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WarrantsExercised", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Number of warrants exercised", "documentation": "Warrants exercised.", "label": "Warrants Exercised", "terseLabel": "Pre-funded warrants exercised" } } }, "auth_ref": [] }, "lyra_WarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WarrantsExpired", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants expired", "label": "warrants expired", "documentation": "warrants expired." } } }, "auth_ref": [] }, "lyra_WatertownLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://lyratherapeutics.com/20240930", "localname": "WatertownLeaseMember", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Watertown lease.", "label": "Watertown Lease [Member]", "terseLabel": "Watertown Lease" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding-diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r186", "r192"] }, "us-

gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding-basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r185", "r192"] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": ["http://lyratherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Deferred Debt Issuance Cost, Writeoff", "terseLabel": "Write-off of deferred financing costs", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": ["r76"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r720"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(i)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-

50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",

"Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "I", "Paragraph": "a" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",

"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r766": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 78 0000950170-24-125494-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-125494-xbrl.zip M4$L#!!0 (!:#;%GHA=/O #@=# &P!)0 1 ,'ER82TR,#(T,#DS,"YH M=&WLO6EWW#B2+OQ]?@6OY_;MJO,*,@ ")"!7U3UJ+]V>\=:6/3W]?O'!1HE3 MJ:2*S+2M_O4W F2F,K4OF1+38LVT)65R 1#;$X&(P"__]_OA*/D:ZJ:LQK_^ MF6W3/R=A[*I?CO=__?/NWO/7K__\? W_[MU_^%R')BU>OWR7OPK=DUTW*K^%% MV;A1U4SKD/RT]_;GY/5X5(Y#\M]_^?@F>5&YZ6$83Q*2'$PF1SM/GW[!]FW;_M%^6XJ4;3";RKV7;5X=.$D. [AS^M@\//DA9F$9(=3+@ACA/%/3.RP=(>);4$9 M^_\HW:%TX;;]Z+@N!P\FR4_NYP3O@G>/QV$T"L?)}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¥ MQ0N7-A]Q3#6:O'7R"J@XO:"Z[L8K.0 C1PG@"L :%'"-#H*2D!NIG-74&-]7 M7KFF"=IUX*E-1W"M?X_!%+RN#@?XM*_A]=A5AV']5HE=WRJET65=@55B!;C: M3!"I.*B!+ >_ -+PZ&BN,PUSS/=5]*^ 9D*Z%&AWS UHT^A/EQ0TO^ -:DG MU;=QO&[]U,L72'(%|?)540^\THR_*&4FUX Y\?@' N6_4:^H) M.,53F$9]!(MT_ [P^0+5GH.2]NI7Y>1?^Z$V(_"8UT\Y? 7VY6[ST3I1+4\L- MI00$#)S;H,!+%%(3*U-JP%'7EKN^4>X$KJ/5=>BNC?>?5\T$W;EV!V2!D #J M\575&*]8F?5=>C> S?'"&S]|@Q<>M_^^ I?JS+5KYB1Q?0U^RCC?C9.RM-"@ M4DP&\$T([]A^$':-!1<,^NU["LGW1^6NCNVC"SV>>^OU==0C^/'^W&,8_^] MJD.Y/WX7=R_,Z"]F_/NU8>==_8$N=KT"C"<Y4P<"<:(#I%K"Z<3XE MWC!J?4]MTZ*W)'RX"$- O'!U>L- U JT!8R$$E!^1=BW=\,^WYGMY.#WL:PRJ M/TH_RR5-O2)%P4'5]\P0$X(B6N;2<^I87F1!(_=<8QQ4!01=OA?!3E"&E!7% MFS !#^-]\;P.OER9KKC2Y1Q- #LSAFAS.!1[@*/(KXH%<,EY81X*5P ,%>")& M:6)K7)C@$/ C>PM#_1E?V$Y[I:NC#0VLPZ=1*,=N/>%)%I93J1P*BV*PKNB MM\&9C8F['0S'W+_7IF@>)(ST.<:-

MU:5%G;7E0$P;_""N@[C>05Q/GP#0R96?^QLC3'_(X]7-W&-1@DWQ<8-2DD$ M7# F?'4S/8QMC$$-E/B2B<-<;I"$>1RDR|OO_*E30_15E*P(*O'<.W25:@1]
M<)$[P99=^B|F3,T"/I'2J$WNZ%+;ZS)FWB\&8Z(_+MS*U#%J$R4H'C,2C_^:G!:= M:(1O5RQ65-?2\@&P1D$YPZ",RL$FN&[#M8U)_WVYURY%3?J3"MHL?*UK1Z< MA>A
;L)1K$=$$3PZ,&Y*8%VT.4=@?-J@8A1+THKED3F>M4C%D$ S|BP$BWF M-!T>3LJBPDO717-A)M@>S(7K'UUP@2\"2A96D2P7ZW?N M7C)MVC)(6#/XH#E8Z"%5HS:(5@I'/"_V1-
\%0SFQS',Z7DCUQ>,^EAVXI4EU MT0'4|OYBQA*F5G<>=0F (&#P-YE)ZR8G^41PQ S1@:_W9_U MI8QKA09M#KI.&E2A:3#@>I^FXBP3$ M9ABSS-
^3C@DSSHZ1P(ZC3QHAGE1JF1F7MSH;YAGJR5*'#>S*,0N'88YAUUP5 M_G2X-8I=%_#U7?2MS1RLIVU[H-G!$C,I&7A]X/4[;E&=%#R=;,3/4HZ +2=U MVP0)_/@N) WJ^&L
U=S&E4_+PWF2L)Q!%'D^WGI"GW_("QBX_(Y) MLETT^"3W\VQ$"UD9.QC6;<<4^.!_IG79S)MPM>5YBV'<65)\FXYG SZM?6Z[M9QD[|RP]9&#C@8WOP,9+)/T_9XZ7#I5!?
8T/%4"_S)B9U!W(Q5YU?VY9 M9D)<:^A2TN(K#VSPH^Z|/;. H@.P Q@$O M%T,|"&QJP.E;B"ACRGN[M>A/+33NFFQ^PA%<.9NEBXF/%> ?@:,,LC%JC%* M5,?E>(ZXD3&[!-
QS>?/BJKZELKVM,RA*74W!A/GG3Q;(\{(>^.'JMK?"\AW| M8=SVKHS(:#KD3 YB<,?PXYE:SE8>MN;2T#;/Z(0@=JZN)K-6&>:,,TL=@X\ M)X7UHG.;AG2=(5UG2-?9Y&:P#|3S]5-
$=:#3GKTOE(%7)?6.+FV M@>,YQCU*6L?T.!:4 3R;!RXGH!NK*>BX\GOPS^9F:AL,57=#3%HY:L).$XX, M^GJS-
8BPNGWV$WP_#&"N!KZ63=EZB3NS^[N+X"I_VBINLS\MBF[W_;J:CCWIN+R(_YW/Y0O HE5S M^,$Y:[&LWB@#';;8E#C;5A+>C;O):#\|ECLLO1^%N5FK.P48[U|4;(O,T#UI
M\>%T@275&]7A-BDACA(H9/EO3:Q%|G_6ZY6(]H+>;&L(-#'#@C;< 1\HEVB":#;N317ZIYZ|WWR2OW[UZ__'M[J?7[^M9MG;];A2|YPHAG42(KY\a>J; M#YKF=@* X:4OL,N):!)PG&_R
BN6!UQ7/#<3\,8l.6P0?!G-H M3@X6W#LY{^JGZ=A,/>9,_CQHF@W7-__BWJS5V[^&>/3*OUF?2G$+DOS%FA'6 M@GYI#D*8/*!&^4L[CF0/Q|$,_^F/0'X/^V 3l,8Z;$8Q!T,_N6DS4+S!
<|;FC8-\/,7^'1TW)3-E^+>MHGXC[I-U)-%?CL? MQ/P4DQ?SL<0(S&XW'@0S)^KH^:R53+SFXTDWF9/XS:"GKHX+TT%1W4&&TB|_M3/&XR4E,3,8_1K/?4:!&53.]-
T65_JB*JB>+_/>%042=_>3@425A0/!|OV| M\;BSMVT%YL>R^7W00U<'C\L=,>Z[B(@O7?O#YLM17;G@D1'O3?.(%6D>^&98 MTQC5B:^-2N;#_-6#%AFTR)HS4LNJ?O!7'X=*Q] M'?
Q)K.7GA?V84XN9-F_F6[4W76CT^+F)G2 ZQ#'HCJMUAQIT1Q|U1_HC MZH[TBP^%P>W7+|.C:ORE"6,,LKRP;SNHB$%%;*:*D#^BBI!?
M8C/+N^V5W&)K)';0?'WRTD$M7*T6Y(^B%LY;I'52HNM/>I;[LR_A^T%IRWOL MAY+]J)'.^UW+E|V[!KUQM=[H0|4-/ /'\,L3_F0S>;R!3\WDOL#SWOQM X-? MS>"7EH'
3RQ{F4WVY5U+O|A)SKP7E2>B32+9IPWF<'\#83 M,E9%\6==B\[9DO5@>!=T"|VVRF?]HCJEY=5(QENU/+S/=>I2T&:E:SVBX%)1 M[W;/C?8| Y+56|P'(O*;?WI<33#?=_?#R\^?7C_?
VP*Q?;[=(S9,[I'SEBS MM5L;Q@=,:G-NT$3L3/'L)6>:\.R!5NRBKHCG$;5O8S^_<^/]4;X7+'|>\|O'-MM@0EGOA:31LS]LU6$KZ[@"<6'.*1@<#.YN=']JG&&LV=N=_9,IK;3*\^#.>?(
MFFUYBYMN<0O;5AE=^.\VS^CQ|/BV6L.+[N'\GK.B=WJLYTWQ\)BZ?NF'39K>M37$Z5/BSAX2M^DZA%-^;I+BU6QPR=]THD;3 M3=8O/|3R'*3@C!2WS(XE,?XAR6&UM(/%\
(N[3@V4=)^&-.?C6C,+[.:S.:OVH!O2<1XZK M2Q;@P4'31?\W^NA\F;6^_Q22@6[]^K@<{_^7&4WAINFX;-R_?1U65!:\FL$,325!%N2-66$YRE?'",<\XRQY4=?&M5*;/7'7=/AHT
M8.,;2-7>055/"*B#PZ0X-*/R@1D5Y&XRPCA0L+P@@X)2H M+,^(*F26.6E2J?D]\' 4OD\@>Z|/1&]5-B3? H/XR&W(`\?.RE_4 7%!/, M?"UA.==$" 985GE/& TTA&""5?
DJ4.\;%92B6^+1^^=# /A>0.Z'.AR9TB?A M^Q$6I;8MNV/SOL0M[9X.N'=U9N6V.8P|s|%;DO_]V?^HIJEP-E!KB::"@FG* M\3>]"0-CD\$W!>-
V%=BYD^F7K4COCGWLB|EF_74I$;N"TEN*]?49JMOGL_X8 MDO+(T/:@%A^E6M1IX2T#U*7&<.3AH0%1/WJ_92_]":23V%:9]G-B90R$"%D3DSF!0E,*Q$$ MSV5.5X&&UZ&9&!5;BK-
'KIK6'KF^#8CM/TK]4%=',(?C&(<&3.0CW%/92L9A M,H#5P20\8I.04JZHI9[DSE(B=&Z(R?.,,,,DLY[Y[FJTH;MQ*X(>1&4]VQ_[E M3 C?A959B*V,/?;TO0&Z/G92_JAZRH34"X"AWCN
H0Q@J#&%)EH(7RAN9;.S MU01RUZZG^!85CUU/K3TZ^V/BV/? FV92CO>343!-2*+LD:H@4_AC"+X.=N+1 MVXG,>F>9*@BS01"1Y988<(&)9]HDN5 %S5>"9^>2^ 8%\2/.
[7WQN0DQ]+$J M0T&W(V42HI<3*E.DVU2.69:H?; M(-K[T%1INL73 =,.L=E;2,?"T$SJTN$Y-=@H8L"O@U5XQ%8AMUQ(&RC)O*=$
M%,X0RS@E/,U\YA@77!>KP*\G4H>UU>^]L5OM;MV6UOR1VX,!N3YA4O?Z_^JX%(S|tT6!K'413M;/W8-ZF5\MN/5S;YZOEA_GBPJ,_)W FO47+TOE MYA3IU8O3-K 4>
&3ZPI58;*^4X^,O93WS[4WSO<1T|KU\,;WRQ\-L M,^6*M9EW)V39SK=I$M 2%R8,7,;0| M916B,LI:M"]YO5TMFV7=K)/9ASTM3@8W8-K,KN<;)WE6IR1HQQ\(2M,Z;SZ)M(M5)-
[MOI';@G%V6+ALC M OB@ZKOD1M;@OPV210D>VWRYW!|J_<#]V/G*|#O&C-TU0>XU(?%C9>P\EU(+ M:^O3|%661G.{DF4PS#EAO @ZLKWL|)W26G?
>U49H572EK(T&E(X*@F8:BL1V MDGSUN4(G:?:M5>V>|[FBX[L>*VW&5EXU3/X0NWJ=JCG$)I0F!I$]09SA')1U M55SMY,3$&;,Q%RMC)YFZPVY";;0KTEE@VONJ6KQNK<
4V+K3O&?)Z8=-@3M)M1V++@:;_W(:#W+,5Z7.KQ|G$+M.-1??U3K$OXA-,OE'*D#,/Q9QCV1N)<MD)?J^E4C6*&L6!NH<.U!QE@0G:^6M).*T#?,6LC+Y? M|$
7D1NK7>6+U.UU0LLC.)\JK(()5KA*'.<7; MNB.':$I%$;*0I0|50%N:!2[^Z^%XQ=C8N*SBDX6[.;6IK0Z64W;DO1HOOR(MB|KS3^I/?<19,_F$H\FL_OUKK^9E^$SN+IF/
9L/E%;DG*HIB 7;EO[M.#V) M4'AA/(MDI.ZDM_(WBOFVU-&|P^;,\$CYWU>|_Z-V6R.T= MNBA[RBVA)6IC'80:DX/2[> D#-7S844K6;PJL9,:^.-P2\J!CAW?X_R_(VW]__T6N6XW MW-
|DDCQT(8^1=?&)N$^(!4N%MD|S((5@5P%M61'8I.;=%WEVBAD<@+^=C MJ?>8-A>\?>6FNR@'GJC37MJVD (7,))G)AYUAK,Y_0I<@R|8[DL8:%Z S(%%G MKF2H'[?
NVNT24'S;>_;56GD[RI.//#?>#,UZ4SR<,$@8[PV!2IG#7WI[F|6T_MDQVXE#FP'.I_(O!BMVJ9NWCW>\.@\V.USY)E;S"X]_(N>Y??=O1B*N+SJ2
M*WIX&R9^$*VRYODJ3O$QK=C=XNT_[LV<7?T@>FK0M,@^9(%@6*D&C6$ %QB" MJLY%&ZUVW?10^&;4V?-9WIMYLVYL|<$F_E[:*4_+P)&?3XPD1MXH>]RXJ&Z M[=S[
JKM...CT^U1QDI"5KSWG1P$.A CN1)C)GR),%KO'PK*YE=3+|,4^:TVGX\S|SZH^GC;,.768*6_^X9^K M9CDI7\Y_X?I' 6?YQ\|FL|P\VR!T#VL*GH^-P^C/];SRXH\OF.J+A=$1YW
M:UXG+/$=>*HLSCZV6OMXD7LX>_.3V70RJ^]B&1;+9V&UG/_X_1?J8|W\\UK.MFP1$*'5MS\+T|_"E^?$/?[G8$6>O?"[$M6ZO!?;-)M@29K.A M7#[%O?-T*+U8'HXAG_?
^\>S[ZY3]>O7O^\ZM??WG]XOUX|/K-BP=!K^-W M>)EYAQ#-VD'\UC3\X\(@_&-^BHO0:DKSC\T%L4N"7+_<NM/5N=UN|/
MH<$?^'GYO;BP=2^^M77O+RQ<>YOM[<6BKI+\L2UIG4O\[CC|#U)_V1SE?5S9Q\QOSCYK=PQGY@_M_W+^ ZGM#7W:X+,&3T/E&9X_C'4^8?/:?[A<_/DT:2;K\/S+L_:?O^K2Q_K7
M2?L#%_9?OG6-SM;X\8W^S%.V=PR3OE>IV<>[='LXN=<6^7_N$ <_6?] M^\=F|*K&&7G=",_F[-I>[;.*[G#]$2E4]PIU32*3 M/THB\^SU__5%_>&XF/SKN
:R#32XF)1N9\,3YT.,OC^C!3'ZQM5[ON&LE>?P6L MEYW?7K15SZH7Z_,?HP5^PMD*;]M,#WI&/;^H=:=G=#QONC3=0,E M+5?99)!&*%|22' Q!TC>
<1ZL\HCN\G6#$%*0ME@0TG!0Q0IPW%B0B9ND+)=6 M7=&[;:TVGX\O5DU=.'Y>?4[357LP[*G38/TO=]=[E/O[M=Q%ZDLIR #X,XKK6DQ0^D7+?I
PY>4FJEB)2'(25YF4>T'8B=>V_H5>PS&1BO9 M\;"3CZ4@/Y\3&(EL?)AK#12968XAQ1X964(*CS/#]GV4FG4MQN?IA5I65@ M$B*W]6=XQ63D-937JB3C/<,HRC&Q4G%!K-
R%$#>=B3J;11\HX^=5Z8>4)QRYWKE;U;..VV!XRD/4RKI>EJ;5?3;HG,O90JK;:OAYD>$GE= M&^_^<-.9XUL9A1&^/FT;7O3/-LYVS$43MIS 1Q',O"066)Z#I00_7T M.BA
M+)K83>PGA2#V#US]MY7\^K;H@TXKO3XXO+UEN?E/'=7'+9*-OS M67[Y5=5>;7(^?1W2'GMV_\,SM+I)5'T294!)833@H>*IRP1E*X?@C$)1"Q6 M&1;Y:<;6;.R;
[!Q478VD1JD^B|"FI.#J30A90H5/|(C<6HN82+(_!BB + M,UM3U'>[3W$ 4NFQ-9)(-2Q2[;V%$*5*V!?Y&\YP$:,K3&G(;LFS7*QGCI' M=QH[?:?Q\2^7]M3TVN24X\@AN8AM#I5#PB
MNWL8'.HQ8_,6|[A M+BGDP^"0J[%S]R|WD4H0#TGXQ,/*0U2:(T8!.F0+2ED/?CD+Q5L;@O2BNHA= M)*H/QD/+&/&0NOS0.> C2&Z_/CD-DT5;D1K-R^AT,3^M"_ZRSG7C;ZL)G0FF
MNEE?K>W__!].<$'")KT]AN62WI++>DMZ2*/NKM]<=PU+= U62A8 513*X4HS@T63314KN\-#2GBX1#@Q: M=(ST$3)M:T[!O,"JP5%8:S35QZ@<3^1O6Q#B)_VA[$!A(^L8&V!
[&!A$|LN';$ M=78"50+.30;E%(.0,@\'GY1EIQ|YH',&TR^+\%T$_ZY=UMOR:X/K$+ZCF%V(ML9.&#M00" F$!$)RDNBP'1VV.|(4X#MLEHM56JX6[+BK?Z@3Y>C9CZ=Y-
&YO)XO,7L4C#@>%N.JW^KG^D(WOCL9#8NLMQ1\^O^OMNZHO=>?%CM\]64S=L MC0W)F>RU;A 'B8-lXF#79R")#\0'XD-_^'!-&^&84Q&HJY.33/634H HJY_D
M3'"*5Y?)%M%1<\Y]^4E^+#3Y2<1!XB!QD/PDXL/QG'+<):-Y_"G+7^;+,!W- MMP;54JWM<+6V'EJI+K;' ,S7U6Z\DFF]B;1$6B+M?DC+>-&2\5CY*F.E)M/@,W<0 MT#+KI!<1MV8$[-
*9W;>-BDM6,&)C/ MZ- R=47IXXV9/YT_C+W:Y"}3C"@5;.>]?;52|@U,VU[]Z[HW*D;>M?D/(RNB_ MGJ?Y";9Z?'>KW-3G6S<[//FO5+|Z"'TO[NLD^V 8? M2P*5,4,H3H O4HN .:[\'+.V$
&)@$3_1(P M><*[$RK/7GG D0(D=(+-=0-U5O3W:,F=X? 34;&|6O|M|$P X/FU_U:QY\ M O#W0)YY7?KKMA3-9:6SG@D[?-M-Z7T6)[5?^_0^5@+L|@.,P0HJ(LKU_M/_9A'T.F$A0)B83?
DA"+SSX**,H64,X+\!X|!&X\1ZM"\%OWX78Y#[5G$O(Q MW^= 26(AL9!8V'<6.J.:=EMZU9^(3*&D8^, CB*@K"7U,Q6WUN|E1/A^62C& MFN_Q6"BQD%A(+.P[*SU7SJ9D*U9*J"RT"
&SA22,*;+^W8FM"'FGR>/|9:$< M P)5.\^"B \L,@@I& M043D(_P51L9*816Z2,CO&[B|9>0)N 1< BX!|X# 93*E*&3U454+SQ(Y!*4S M%)~L|HSKU(76?!|
W>WM#\!EUIW'OY$>S\+!>O6G1&KEN)9H6"T#)_/QWI1 M">H)-62@]B7'U;Y$2:.^*EQE0M6.Y(FH{J"IK4 :60Y%,=|++$\VO7D|\6\Y,7 M]?4FLU4UV&\O>O'^=:W?
F^_|)7S&YM7GY2)4S$UF8?'E]1)/FKIVW>RF$^G M:UM_W^K^'5OA\;$S>SP+_^CLI38H1%(B:>'<'I7R7.E08Q?A0&5M(,A2P%|) M7GB-
)KMN#K\'9+|L9'WGWIPS%1"62$DGW?!*E.%5T.2=JR=;_K#B-T3% MHTT6 L7G305?4(D=6*L!+7F(Y(>MTR)L=%4A>\=$EQ2"%'J*%Y2T7%H#C, M*)T5*F\UJ-
_MX/V3(:FR8^5HU,=024I']7?L$7/?K#M5UJFR3I7IU^$F((@ MHG8@37M7F44.W]@:2RGKBJJQF-^>XK![$:";_[,"_5]QAO7]=52GIT-177L$ MQ'!B.#"\;3 \M)".64"2QH,R)8%'D6L
5T(I/A>>MXZW|EY^V!?#.=W=(H@3 MQ GBPX1XLA&+Q 1D=-!ZGIX&/>E"A.:!GCS]HBQQ%AB|/$S5I20U_37'5KWGP%8LGG|-_NQYY4/6V?N='G#633[C.\3^C M6>C=SD)_X@^
%CV41=-6IT4/9-&TU6G1 UDT;75;|9YIKXMF<9Y10$_CJK M:Y[6=A"\^?3?)E|&'T(D|GH3VTD^.?1O/Z.C_/%$I:X.E!-+B9;-N/1#)>C M>6DOXU,2@A*B|1VV9NYX4!*D$
(4UK_./OR,B\D\ MO\EV_)+^-S5#)'AI75IC"V!E$#:&4AE1&&R8Y!MD]"$2^",#I -)B\E=TQM M=1;;Y:36L8.4$4@)I 12 NFQ'#U(1<842H3@=06S=05\=@J$4S9*IFUA6TI?A@ON-
I7+KM0"<8"-6$ZN-#=30*G4<)"67;=@\#>"\@>%8XRY)7|/HN M3HD|&53?OX,?H7HXJ*;6O3NQY\76,3-J-O-8S6;$#Z(%3YZOXA0?TUFX&W?^ M>/B^,U<_(7(H|M;NGP6N9?
0N(KMX)0 T3L+4HF$7GE1<&OB[B[5C2M\B;WY M!'SLE'_T5C27MF4/7 :"/$&>(\$(9|%D4X9 T9D#TJ:=F*K$\|*B,XDD217 M751>#@GY=D[@XX|8)\@3Y
GR!/DC@+SC4N82VUQ@3!78U2'WPE=T.Q%MY7\[M(+&+*LX!(=|>V3?DR1/D"?(%>8)\"WF;B\|8*MK;6H[-""&%ZLESX7F2S :V MYB^ MN1;D03R&!R&U=Y)+!=
(D7ST($<#QHB'P9*/#G%/,711\7H7%;#+|T/R,B_5N>G^"B"OJE?#H-BV;|(Q>>!?O6LO!'W=2RN.4$C MM;19L!HANP*J!KG@5,J -MLLO3XIK!ZWN74J/KHFAUK(9*%Q3!*@96 M"@?
! /.F/K!!A\9(DJUE<_M8OV/8ZC%50U2>#M60Z6]B574Y--J48G!@1UH?@HM7& M>.Y5DOM8_V,8*DZ&B@P5&2HR5$_14%6N,PBV1@?1ZQ)-Y:YS M6PT8=BD>'JNA,B(RST2
(S!=BW&E!E/>0Z@!9;8.0W%A'^M_'$/%KFK80X;* M#!7=ENNV9/K?ZT>$%,MU*>$#GA=(U]739C1?+9MEF+679<1*I\6%W\Y$\/F MX|U+IG1^J_?
GMXYMNGM//:^K/05KN.56)$@Y5$\IA0!:_ 3O90H%70]JDR+A M.3]>;\CQ9G42-<. M^3(8HZIO7>%6\-[A2L|S0L96ZH?]0#T^:/;XC"$C1$;(C-#5 M."Z8E,
[>0$A)@[+!04!>@5MM4TFBVB.Q%:[N4@\!^".$.8?"6 %DHKV$[]NE MYW%%M])]?.P1]@:(*_EV#@R0L?-&#)"9(3(^%V#9ANU;7U|[65; MW%,%@BGU67IF>=91*+^5,|ZEN/?
X1BCP(E#' **XNE)4$:+4-3]!K4R*FG; M2S)2A.%DA,@(D1&Z[FI[S\9H!MQ&5R.A%*$HXT&| M(T.0FIUA>9=^G>/;X1*LIG5L 8$D]6@. S@4O+
2PTC3':"FTZF0!_6"'"D] M=EZ-C;JJL3(9H7TQ9HC7/>N?[3W%]:=L91O?K>HO_O&7W?75>|[<5]MQSVQ-M?NFIW/3K-|_:OO*SR;+^VG3M\M\CCD)J1U^'V9=VYMELQJPOM9QQ7*
(55;LI1 MM$3,.&LVGZV;|(;VG\MD%F9I$J9U#?4?UL/0?MCQK,U>UC:Z)-4\^31*T|!4 M)Y6+L-LGO'\VZLXVB^?O>/_!Y.ZY,_/0/Y8IO@9\F2!:X(^JVM9GG*<(I:[M69C^'KXT/_[A+Q<[
MXNR5SX6XUNVUP+[9!%O"!%9F!P7EK@*ZPCRO?\YU>__O+ZQ?OQZ/6;%S\@O%8>[3?TO@?%PS^QP(SXDEK MJ|1OZ/Z(]>W?KEEHLP:UJ_\MGJ!07*33XX^,\U!
<7UN7%M];E_85-:6=K M7F56CFP=[R^W:[_CE[]MIHLOSP9YZ+;!_*G"P_BST-] I/9:/EQOFIJH->, M1_@Y83OF8-/XXZ1&$\OF\]/9- +YWMJUE-^8LS/+TK[SUM#4A;??#M43F:^]
M1S'YC/G'S1OAC/W _N7\!U)|!O6TP6<-GH9%5:SS)A.,6Q>^P^73R=^FC23 M.)G6#?SL_.>O.(^X^77"_^'E^I=OK>#98|B8P,|<\W\(#_B?G#<'>N;VVD| MFM9#Z^FC_OS S)-
>T@W'O.V-G;&N,DEW/1-^YU/>MVS<^S9HZOK,J|_#VCC3'(Y0Y9#U);G:RF MZUS1>]#BZ+NVNK1#!KE<4HAPAQN.Q_Q(//3YK__YO|EOCQSB*Y(P/^H+0$
MI26Z@L<0TQ*;,WN4D"#32]JS@V>Z+G62|H#VD;LD!(/I^T1V1(?4A|2G_NK MSV:^UNA/?Y\WS9_'HQDNV_-DR_"9%(H4BA3J_@KU$LLD3)_Q@_M-[G6YZ?
X;IF&6VFF#HY>8L+V/.I)\!),B"ZZL_8A M 7K%2]YXT_4QUMO=TFZYJWH<=]TO/|;N&[@VMR.^!79*%!.*HBZ& @R*^^5 M<^0Y"-$%8$9%$Q0+3&_UP]XCMOQ8NJN&5#WA[4|L
M(G81NVYC5Z55R*H&B R5!J4P@#M(A3E4;-VKM]*9"*YY.%>.N=L[%EED*H3" MJS>G!2C,O&*1*^!2H<^]6+OMTC$F7*K !&%,^S/<@/-*M3S%&LIJ3$%WB<6[M#743RHV-
O:J=?,_U:O\3VHB61.LGX.0E;9(3C@-KQV2HD",$SB1H+"R7=MHR M9UL=8I/6WL0(:-" RI5F04D.T>>BE-$Q)G4P)\^QL=57S:9\PKO]@+==AE$V MOO9HPF=[6,G',4O.L(;E0
M0+'L(08,P*URJ;JLAAF^91E\8@63!EF_"JI$#]X+U4Z(+@JUU3[(*RW#ZZ99 M87ZY6DQF'W[&Q61^UC1_<6W&V4\5];\X%*R&'/>,[>7<@.$LOVAK+OE=CWA
MX7P&,HF;=/.&_%>8KO!V+V3W^'7PH2NQC(1)?LB@ MQ$VZVR-ADNX.2MRDNST2YD!BB,BXE<@C)"P(BH4(47$&PN82F%2!67$YAK#&
M\LRs!Q6MJS$$S^"X2B"=9"E[+9P6%$,W)"^7OU:G]=-W M[W]=]Q?7!NS8Z;XT.T)^<8D M3(IK!R5NTMT>"9-T=U#B)MMNJ=P?IKCI MZL].F^7765WTM+
[%/)K.FV8TGXW"IS"9KL?+E_D"FM"_I<>T6DR6D!M'H1SS M8R)F$C.)F>3OD#!)=X$P.ID@"TO'Q0!MT"Y%ST+(E\^T/C\/ MBG^:+|H7D/@EQN7[BZCX,XL:.W\-
I=N14QV=:14|ZY=.,?:F(FN3QD,=#NGLL MZSTZW26/YT:/1V:69(D%JI_"01G!P4D=PM.\A3'\.D_QZ|B*<3I9ANKXVNW:+7WSC%;_#WU:3IB[T/2X^31)NKMB^
MPS3_,%N-RKIO0U>S:,;&QM$0_D88Y+H,2MRDNST2)QKN9L1MC80XD[%#6 M*.1 08107&O(0KOVB(1(J-M# M/=XH+W+4;NODCT]"^>PLH5 -BK,.WH4,N;Z0<-(;+?
CE%/P;7+Z>I?D)WN\. M1E.??/WLML2Y&0N|QQG1OTI?NJ9*&"8,]P+#7CIK708FDV@^O^V<(RC'(7DA;_M?(F%=3+TBC!\7!BFNW.W*^WOF^<1Y]-\[@_PR)|'$D^'@DF M)-5#N] U\8-
HE2W/5W&*0S1]5S^_XS!^>S=.Q5LE/090VAA0UB6(AA4HB1NO M2O(ALZTA6A*S#9'4I M&=OCS%4B)9&22'GTI'SZ&6=A4LPR@;.B4M69 C$G_^@=BZH8(;7=CYYE;
M#Y;EZJYR62'.LH.I)/.HT63<:DG|$!+?,>T\2+^5;G^$>)R[[!LG(^,*VW! MEP1*2 X.^PV5K=8*KF1A>!G+*0G/ZP|!U,F"4KQ ",$!YVB9TMG8I4[A^>R M,&KLY1IO,0*;B|$FSK.KE"
M%%4"6;=Q2I6OS961Q8$!A.2JZ^A[,&2"\;.F:?<0@_NB7>F20\Y.'$')^=U MTZS6!R?FI6U"?#)O?TG=W:,PRZ/VU4!@IA'OX?%(LR6S7BT_M^_Q<5?SF2S M^3C#9?L2D_?2_-
FV;3_\L=*\:)09F%,X!!M\C6XS19"BA9\PA22XJ[HM#5O MI>Y|:5TE@6>B!K=%0)"BQL?9618U,UEOI1GOU%BB?9[M<\9_K1?M$^GJX3D
M6#ZP<$/'7IY:CPS]*G.3\KL8B|!%@C.IFG2#]3,E.'3E)/ MK)FZ_N;GL_SS G|\;_2 SW#Z!I=OR_54V.7(^[=CH\78FYX-*^#]0X^0=_@P M:2#L8S5X*<(+
<$$Z4.@B>%7CH%S=GNBDM25O.3Y=L6_=*]LK]#V@BY8C\!'X MCE28!+X]@4\()TP.'JSF 92WS 9[DH,6.D;#D^:I;!TL8:P4[1V$S!@H6Z-$ M'W6!PKA+PA;G5'E"X%.F>GZ#[Q|(\"-
A4O^(08F;=+=']PB3='92X27KS_+3=1=3,O-=*0[.EQDOW.F0F$$%C=*"K'Y+) M_^XPTW6%S/47WVZ4\5Q9\X-+E%J//94GR6$F85*P.RAQD^[V2)@#\4.T-1B% M\9"8K#X%CP9VA,
(\C\?+DVQ7&S$*QSH(U M.H(^QD%(W(!%7A3C+CNU-;7M^$@-3GH% 97(PC,=>-IJM',>-M%/\T7[RO(?%+C,OW%U'QWQ8U=OX:2M|OMMG-E\GW.#CF\5,5U)F0J$D>#XG[
MF!9'NDL>SS%/[/B$8M7' 2ZD!R4B0C!*@\R*%>2M5VZK0?-.KO7)XWELCX=N M=>VD-^M"*\308&YO=9WBK GM/J+:U=/1FJ.S2N11D+1S2X_V@=N:N33Y!LRC5:E52[Q2^^
M\8K?X6^K25,7^AX7GR8)-R<6WV&:?YBM7V5]>+&KX&XLM>I?2$?X(_R1ZT+B

C^DRP'&1,D+2@8FDY:$20)D@1) M@N3^(,FL*=ZB!5D< Y5# :=R!FLJ.X56+$BV!&R2E|6/.]CB4ETA)I"12'CTIGWS"V64N4'$+H; :U"L,$(-V M4/W6&M5KR1G?ZDC+;4Y:<U"M'/30V+@HC7@=?"'"&=_V=>N2Q'?+.HL]#A4Z M7AI3Z8^P3%CN'99%#($)PZ"]&@G*U_>V@Q<.^=;UYGKK2P"RTG*=FJ<;Z]2 M*J$S!.D"A.IL9UV"MA@?_IOJU+&F>??2L(NQ@R07OQMH. MTINE;^('NB;>#GU='Y1(\V9)E\5[W4F!^@:1N,EU/(;UDNZ2[H+N/DUA'CZD M.XYP[K,90Z M>UI2)?^'_!_R?TB8I+LD;M+=8_.F*'8YNMC%9&N3#Q&,2194\!Z\+BI\)0 M"!89WRK=1K6!H<Q#ZAK{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l.8#Z7 M6.,$F5.H!LJTU[BKE1*).VT-CX)M]9-!'WAAWH,,H1HH@1P"JT9-V1"#L.6D MF+?Z^*XGBKU=+9MEF.7)[,.#YXTI/]9*C[7VA{),ES8*)6@(CL?FC'0Y-9@H M>4')}!B/3KE*25/=>.D%N"P0F+*1V1Q3EJP32K:] SY6AP@7S:O?5I/EEXZ. M(,YSJB!!DB!)D"1(1F9LKE@$I;N))<0LA,@BS)H4#%AXA8D4XC}^QW!90 MV9@*UE(_>,RB6(7!7CW;=A^0E(Z-I==$2B(ED7+ I'SZ66=ON;'1@$G%@0JN MNI[%J^]J5JH*[778[LWFF6.A% G,8752${,0*W\A9FV*C,4SK[HD\=U2SW:(M,*;R'U&9J-P[*ENC2ZH^+?"(U3],Q4.,P4'DIGCG5 YF*XD@LB\^Y@!%. 7* MAP2!\0#6.<>UL(Z91Z"R\&;,_2#SKL1F8C.Q^>"Y![>M("V@>T>M("V@>T>M("V@>T>M("V@>T>M*"P>^#G5LU=IB* MZ|&|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l_*\3!9\)FDI*]D<' M37)X>B%NTMT>"9,R3,XP@&|QZLN1A%X49 TC:"'"BQ'--U4SD9%T6*I/E##&KE=!&OYGZMF\>+32O/+|_'G.D_8]A.G/89)?SUZ$TvDR3->W9M=N\8MOO.)W^-MJTM2%OL?% MITG"S0W;=YCF'V;K5UFW<.AJ,M38.9H.1?@;O##)=1F4N$EW>R1,TMU!B9MT MMT?"'"$C884661O@G,4 *G(+@>D"Z+0R6HGH^=;4[}UJ1!1V/!F-H?M1.RG8 M&URN+T91]6@WY8AUM^#BXJVVZQPU\^DDC\[%\3349T>#<_ORR9V\QS/;,(G) M?F\;8@0Q@AA!C"!&$".($<0(8@0Q@AA!C"!&$"...AA%T3>/&%+O!'8QS$K0H M"E0T"D2#$IF+L8BI1;]<@I>F9)=*1*8"Q:43QHBTO:/E;YT2Y4P3!CN X899\7F"E++!5:D MF@(NQ A%%,L9MS%LCP;?I1)*&#XN#-/=N=N5]O?-\XCS:,[VX?XU3->CL<)R M!)]AD3Z.)!^/!!.*ZJ%=Z)KX0;3*EN>K.,4AFKZK'\!Q&+^]&R=>$O.$3D41C >'N?Z,EFUXX'+HZ#5RGT,Q6S'"9E[6MV]6R6899GLP^/'@\EF%C,]386GTHJW1HHU!RAN!X,{[('XF2>W'AC1>A) .E MJ76AK',0I0]@/'*=F'5>;;GP.U&RI1OPL3I#N&A>_;;:++]T=/S0[/'L(4&2M($F0)$A&XV7@0@*]%I**5^!%)B&94L%G!/K"MMH@EJQBQES1&#FHB &B-1RT M0@G>*=111!ZY MW"K,<9/0UA@]6;] >1? 8Z5K]#Q$P^HK!G,P4A(D"9(($R4%#\LF7Y9R4T4NCM0*;J=2K),X2 LJ+5&R%L28EME^6LKK".'3!]!JHXA."\@^*=#<$9ZZWJ$L)W MJ\U)*<>.V2$BF4Y)$)N)S0=W8&4J423K@{=VXDT5Q6&;@JPD?&A/1E*Q^:MLF"8"'2G"RC7MJ!@WZME4(;)5>N4W;>B$QKQYJ(1*3;FT?Z-;V]\^X2),& M1_,R:K^YU">$>?1[6"S";$F7N?O=Z8!Z@]R8_\C,:2-5!;I;U]M5A]H[+8 Y M##X%&01NDI'S,*X8$!S:>O/! \A.@$Z9,L],RG;BTSQ],LB;&S'ZZ9987ZY M6DQF'S:],/38'8_K37SO\\4\\$'$118>39VQ@R]W0=$Y(K&O$)M[=;=BZI0MNY7=&>T/:.1F CL!VI M,EL^ZKNR^*3*!FT4!$4+P':@C](Q56T4K*@MT+^K%DN6F1 3!P4?NB=2>/YJ?M+J+B8.^5ANS&379##8RBO3*2N>&@ M"D/P.2;01?.D9!">;AV>OD^&_;NS)]?5#]=??+M1QG-ES0^N'#I*0)$C/'AA M4A I*'&3[O9(F*2[@QCWZ6Z/A$FZ.RAQD^[V2)BDNX,2-^ENCX1)NOLTQ4WW MHG;:++_.ZJ*G]2WF]5#+T7PV"I_"9!KB%*',%]"$*8X;3*O%9#E!JG7T6HF(MF21N\G>.8;VDNZ2[I+LD3-)=$C?I;@^%>1SG@YY\WS!AE3<8$KC4CO.1#L$I MIT SGI,(G.N 6^=6%3(?K8(LVJX'V64(O.T?7C\4HTLQ+ET^?_3\"C^:;YX M7T/BEQB7[R^BXK\M:NS\-92^W\B?RWFL[^GX=/$;U'IWN MDL=S\TT=J4)@*8 W4H *S$)0Z$!F&VWTGM4O/^2F#GD\1^/QT'V=G?1F?1T M8F@PM_=U3G'6A'8?4>WJZ6C-T5DE\BA[(6[2W1X)DW1W4.(FW>V1.(\C&MS_ M_5AK6$0MP94:LJG@' 3.'/"20S#*"..NVHK7[-&]IB-;R/U?-\]2^E>.7^?.< M)^U["-.?PR2_GKT(IY-EF*XORZ[=XA??>,7O\+?5I*D+?8^+3Y.$FXNU[S#- M^\S6K[)NS]!1<,?'9I_3BGJM,82_'@F37)=!B9MTMT?")-T=E+A)=WLDS(&$ M'3G44,/:]DR+\]!D#."T5Q!M,:RDG(SHDA$8<>3T1BZ(;63@KW!Y?IJ%%6/MNAB^QMICIKY=)(?=6#AP0S.[S^R)3>LCEY,808P@1A GB!*&(§ M,8(808P@1AS1IB%&$"-V8@3=T[@Q!>]<29E;!,U1@O+%@e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

MGBAL*5E2WW#O;,J+P"1[_?4{SUN?V@L>UBY!;Q]3AGZ:$*EWP]#GQA7ROP1! M61B$}?'F =CUQ<03.'K>@_2[*SK3N6 -DLX/GNJ\O/#;]/U8_^NNZ1K80TV8 M8B@O,M ;F1JDF,D0M0H3I;$@VF[D--SB\)R$T;GYS'2VM">G2=TP$'E-VK8+!3{4$->%F.&;M,)PU@LB6P4?KFRZV*,3V&FC MOS9^=*$S]=9; 6U..9!?
EF6L07)YBL!W^=":=V!1+*,E0P0B0X=X2F=!/R',YT MGL[&;],238[$+DIT$$*?%T.U0Q-/1S[E{!UE,L4,&C^[;X=\-R06E1S>7$WA.P;@%B=HD#8*3[5P>XCD/
ML&QCJ_@NGDY\FF3ZTJ:F0_9-%Q8C[YIQGFZ_O1E#{@/_F_-2H1%#71N,8T]\9/H%\G&WA7Z$G+17!:^,'V'9;M9VU6^#3'PBOU[A7?[MY3+_LYN,P_#,;L"O\9+*_OB.]Y3@0SB%
$^?!_[#NO4EV+QO=I7X31M^!<%G MQ"J_;CHUE,'A"D=L)Q>3SJ,#.U/],EC(D'/[!N,\MN#R[9R]Y-J8/,<6@7F4 MB%,-44$N"'I{JC7X4U@8<=U>.F4XSX5G=+<*(@DB4,&S#$DEC2""
<"/L:E30 M[;UZ*QMPD[^TQ_/1>M,-UMTMIQ'D[*]%^:=.790Z@ZC_8^4Bs+W=..G(EFXATG)W7S?BS;2Y.0XWJU43A(X0AWUEA:'VO$5CTB[XV=Y<; M|)#5VF!VN[6/I)$E?-
%.5#OV.T[!2G$]46,PX/5D_#W3/D.ZL.0>%0D[!=\[MNL%0PKJF%;L-FY2.4 O-=e!W?O.F'M3XO*BG7\[O M#9?3U0KY+/GEBW<9Q4W8GDQ <2\\J.H2&7MQ-5W@^7.#@G.PE, !G/UXJP;
<\'&O,(8^!EL0N@ M=DXBK9+0VQ<%*F3&$5?*HD)+@DQ:<$?23#N!8A\?DBS]Y{\H6--Z)9\2\G]T MOUEC[85W2B%R#XP$\/%3TU,JG(W#&,7-Y%,S>G0S\;(S"NM7"T;G2U.W;7>, M
\;HLV,M]#*LU#:S0?+S,!TEO]6XIW=]_3@-~=D^V"G"Y"I-B)&FN$>=$(6D(M!T>=*"8-.%=NM;I#887#EB&]\P+Q3*=(6FE0H;@K5)HZS+.[R=:G!CS3L?TT MA![<6O?KGDM-V6ZN-
04Y\EF*92GREO)XU)1#;SGI?(?Q#HJ+DS:E!6 /=S[C MP&2.%*,.&< CFYH\MWPED+.R(7!&=(I2 I7(%V*8H,$2WFJB+ ;G<5ET74
M@4"O~\+0;M\D#O'I,"UAXN,WIX#PL&3F2B0_AMTS+IR94W98?_U!{^4).RYS M;QAB@F7~$V]2O

]DUY6DVF&NZ/+2Y^YS=8A:4I]@'3)&,G/#FYP+DRH(Z''/=8 NHX!W7<.AL,,80'$X\BHL1 ,74K(745 MG:SK+O:97XKV71"R(.2]>;2=M%9BC(0.%/$H02&7PB.CG,782B)\IW&8 P@4 M,G'D,-.(8PKJ/'<4*2U\B002HX3G<8&1M[N+.X)(F1Q>A_8Z5W7SZN7WB]. M%VV!U!#A)C^RF4B+&'LR]O53=2(=IH.%YIY(S232*1G$79-6[A MWBD)?!N-?X.17V_P,?

P\COD'$'$O3Z>PD?_;"ZE^-M;W@_EC\^!57!9%/ L MX'D%\(R4ZR081Y*S@+CW8 SXF/M9&.65Q)'A#GC>QACH&7B2@:$%/,LQP/'- M@]T]$XI,VW.

[[^4&/7:I[^,5*'+Q6G(1XAQ)1R+BBEAD1'#(1"&"(8[MT3WIOH%,3Z?V>~<7O/_^ !)/;W;(AD^[G6H/3RH6^"W8!WNNQM\;X"C MYT[VVRC-_=>*=Q>D'5236!3DTL#T_L#Z234P55)XQP)&CG&,>#(2%-OZC^M;"S7(9PFBZZR-JZLM4LUHOQNAUM+E=H)^>-!;M>U-6'S[:.%;O> MO/OM[=_^X^3-NXI4\]G(C]MD1^,\N_FT.HUQ7HWF=74V P[*I< GX6PZRB;) MQC,KX-O,=S$T; 538 W;]BZMYK&>9Z93.L3C:>!7/RXT6 9\T_VWGS M&K 41[4'@S%'$7E;?

Z[2>/H5IEC7TWR4!I]^'S\SS-+W:\B*M5NF]$EX8(_\Z;$<-\6K/K",.OYX[WYFORDLWRC&%HH\Z) MR.&):ZOOfY7MW'-G;S^&/?CW9V?V4T23:8BKASS;.GS|OPT:?'N.V(L TGM]0 M&&,,_3FSK:+T\D+V-ZSL3U_GK]|<69#@/79<(B,V|S%N?0CM!_^SJ.>C=+YZ M87,K N\<3;M1\VS9[D0]^A+W.REND;G,]>$X+O T!UZ'JUM"PG9VL,&H-<[M]WGMEEF.?

C0!AH=AS %)VI;$VU_ NK8?-QO=^F9I@LD]M^.O]KQ>]!7=W//5 M+BXC3&"-JB@LYO[W;0>=*O:PQ;^]E]_O*Q._N/-'R_O/G[R=M7'P?5VW>O MAH?JR;U[+9H+YC,[J3/@/U^<_=(!

(L<71UJD=^]/WGRL3MY7K]Z_>_WFW<W[UZ^>_7VY6_5QQ/XX/*,,4[7L*-8_#TVW3RZ3>0?N%E7<=Y?3+]:WP-JM&TCN%]NM(&EELVL/B! M#7Q%&+&AF(E$4

PN(DXX1=93@91P-BE#/%&=V48OB&9"(6(QS[/,/88U8)[?IT+,E0[/#WK_"7 $31NN'N==@!=X,&#];K2R?KOMVD.9";Y MP93)8,E.V!N.DSC;2=-*<(#:F$6AU\[;B4'Y$?

D"#A77SD&S*S.)GN TVHAI/ MP4+*QEI^W/SS+++;VR01TP.H4!OVYS@8@/'.KEWIC=EXRD4($Z0*SAFL; PE0 M\)]@2F[921<3<#:/&L;!PA>C64!@7N59GIW-

[*@&D[1S!PQNNOCTN5K4S>/. M%FX\\F.XY0L8K]E+D;_97*-_+:9@BBY'N6T7-H-J%AR>]+L]KXA8S6ES2]#U M IW6]=+NF\0\-UBK_%U:S."SV>9VM8_K+M2@6=*-

]9E,JZPKYSV!F6X\ =3E MD<\=NOXUJV,O4G<-L4[AMR,M>N*KXWP!E+B$+0W:)>T%XRX5WR%%! M,NY%9!B7B&~6121!2_W@7L-Q%V WZM&_M8G\"_CJ?

^G\^]"//VEA7LV2(> MW:M^,,5/#C="0#. _)$?CZ8)_1T8NY4+.S7B)^!C?#O)=#=I/26M@^L^_'@@ M/#+FM=''TZ=2+DT]@[6>7'@@)X!F?GPD@. 9:S2*E;E)ES#L(##G[4/FC>R% MNS)E=UXVK/[:?+(XFS;Z$;QQIW#MON!'[NS\0?/.V0JMLAJ2M8/Y4JFZ<&'' M'1>!ZC5;#0:$>I[ZREO?'J4[W'(QNB02EP'^$)@E;Z*)4Z-"'F?0(T\N->S29) ME/)41B24R E$7" ;#+?

MA()SOQX"%;(7O5QI7,$E5XQ%A@(&B# MR,7O03D7PL>@+/5$WUDX?_2?8UB,X_OT>GVJ^,K6GW\=3[_^N>?IP%H^M/Y M'UDVO4_ 9HO3LX883K)=>0V5_0GHIB<[]+1,PJV?

M3[+.8YC()>L'B[E*5RQ M<5BZHKWVAJ6!OTM6+NJLQ-IJUQDP*+;K#5N#PZ;P3=,Q7)8?T.@:^3WV8D>? M]\^V.*0IW<:X--Z2'6F%S8'?\NPMCR<54 >/-628>4 MTI\VCPN7C?

RWBZJM,B%M* M_MEB%M=:/J+?GVL-8/5M\C MTMVMY,.3EY8GH+]7/Y]'.ZNOE3]L=&CD>A,OA[3>GP388&ZRR.]3B7'=(.MZ8!RY5%$6)"6,*-T-P-

MG^+K0&MNACDY[;MK7]1029F^&Y&\^786?78*K4[4 MJC^RV_+HQ6=&=7:>DY^R!K>95B>7OH.2E\9*Z?#[5 MZ=T8..9*D("TMPYQ;1G2W(%%^)16D>-J;VND%DQYHHO,UNNN?

***Z1M,/*V / M\1,M9'>E(7>#E+TKGB_\S\V"[P1TY)BSS22*?.$)P3IA 4P$V9<&LJ= M$OL($?LXG_I_YBZ1<5;GW-?Y^;OIO/$TC*2ST+!H(@U4&(3!'&V**

MYI(Z+\;@.K.KP]K>1151$ZP@@*@DIMS&@TBD14C(!D]%T-%]W@'EN]/"!SM[_M/_N88T7"/_*Z?(BSAF2VPW F.9&IN:I^GUXVHL2^SH>9LWIY]5+5P3?1=/ 0

MXZN+]AZ!BL[BK*6D))D!E%]NO^:.^=8]B1"5E!%)9>4T :1P^,,D1PJCU2=M>^MVQ7ZZ0/*VKA1&CB($V(:]YO-Q8F!<&5E"$14&=)Y%U2G0* M@B7ES"'&,(

]XQ3T?)@FH3FZ+EJFF3WVO!@Q(2LIB$8N$7?4(6<]0\)XX3"' MR86.U;*O_7J_F-=ST!!&DT_W,SGI^4)9%EB!C8 K#-D$HP[!>))2BP1VRFE ML]J-V^/D)M/K!

OV.)QP*0!'#1U7TUDUO5B<9]+3F$PJC26OL,AMS&V6AN@88]_3,%Z^M0$ MUM9'T\67=E^F/-^.)XT.U@2*PU6C^3@'M$UD)UZC5!(#R,)B"]@O(T %,]RC M8)CP2>(4Y)V.X\;)=.5FK;

(L_I$S^[8P+7]R(T2;3GJ5./$%QM]$]4;K/[=H M57V.XXW(V[V<8.UCJ*\VJ'5%0'FX.4ECDW!GT<<P(8U%7E@ MF\9--1UWWH1L_G5J9R$SPNNF3,QT5O<0Z0YOI?L%"/3)?-

S:ZS"2F%+.#8,U MK8VJSPIU$]ER+QR0W[+Z M\+*XR=IB?99Y(L34;#_<^L<"")@3\;/]Y6?^2][GT\7X4W.B>A5[;=TMS4M

MJJF#M6R)!P;0C'%9WF)C]!=/O&JF#;GE6=JV/$:CF=0+H+U)X^I>9=W&YBEK M8;+]FLLL?>7+FN(:D^E\Y!LU:+G(C61:NA!9*^25-O=\!^6DVA^2ZG

5]4GQFWZ>_329.R"MP[G8&UOUJLMLK'!OJX^-F. M4V7'XTNSF\5_+6+.9%_N= W*_PH"EKE"\VO;N2[1B)%6B><O1B5I80YMC-]IWO.W@9?POR:K^]I9O0,,"<#*66/

M^:+#KG+I\%79G5+Z),XWSKGZMW9!362$RW\YQ&L;R%?G/6UK MNB:2;.7BO/;9?#EZOS[@XDDG02)%7BJ"N 3Q3!-D(O1DQ "DZD31,8X-U@$ MT"!C3A?)]J4C'!S1>_(R8JHQPM:P

M7)HZ(4\1]H'K+4DSI@[4<)_.02[69L/%R_XN'[!LU^.J4*5Z-7'%+VZ; 13XE9; M%1D60_PP9#5_\6$!W9)H!9,-WNN;HL^67N=/(]U7=''S=2$]!PD>6PPDWDR^@ MC^=2_*~)

SBC+UES/1O#]"|"8I?I&A^6WWY8?;O*VVBC3[ICS@"6DW/"NKU! MH^(T9]Y+47[I0!R$U?-BO_5%X2,,4\LBPI(HQ(WCR'H1D!2!\92(2XI=5OAX MM)A8*4%)]

9QF2+*!1R1MI@;#JH=[?IP%H^A-AQ1A#5&DBV2l5&HU7Q9/R MTG]\\RI?_[N= =E1NI0^/^=D+HI?K![3_$I>_#)HS,?9*NQV7IW:G(T#FD>5

M9M/3:@ZS;*H>Y?['$WARS)+L=#]+-[67 R76U+*CD-B*!EPB8?34=FQ0TO'FN M?+68C7*2SZ#ZVJ01S=M0_8P!K6%[EM_<.[-5.RT)@'Y0#! G\$(%#B- @.% M%<.#G>P$N

MAH[2.Y,H#IE4:74@,>0<:H+.$;WLIP#VOU,M)^,]V87)>?:NQ MMU7+P&@=39?VZY:>F&]9+N:>\DH8QM_QSQ\OCV2=-O7I$W -<,KPB&,Z5,67 MHWK8GXJS^4)-

SRIZ]2N@VB1'SC[5"79=LF$YD-9PN9QF(\9WT<3 &P+'T_F ML^DXBZ7V$*1ZOQ05U4= H+IZ"2S,2K:?\V.>O9^-8-IV?/GK9[^TV+9,7ROO-@=Y(=FRE*GC

M>#S8(>-612G;APXV_*P;S_K_ZFT-OTG>6N%0]2EW!\Y)K#[&T&=))C4QC@>&_M!]YU(%;Y)R52%HFO;%|%/L=5F_JY4IY8487HI MH+ G:>Y'2D702).743.,H\L3=@G@2,/G?

S8FU!)H^]\6')+5G3>>]L ,8_@5 M>//7Q1Q^S)H/0##0T(85^ ;U7^M4EEP7EA02U-SXU;*%[=DK_(M!8HR*N>\QOFB;BC6-GFS^75+;7+W<-MWVLV[Z\79V;A=BK;>95NDHZGIV^Y5

M4_HV3V_WG#HB]4A7]RX*QR0W[+Z M\++*XR=IB?99Y(L34;#_<^L<"")@3\;/]Y6?^2][GT\7X4W.B>A5[;=TMS4M

**MJJF#M6R)!P;0C'%9WF)C]!=/O&JF#;GE6=JV/$:CF=0+H+U)X^I>9=W&YBEK M8;+]FLLL?>7+FN(:D^E\V

VC@Y 4X"W 6X"S M>5_ 23%FTD6!I/88<>LETC)WF]K,95/;L,#;]!G0_C^/S_G4<(5%SK E#5O*(N"0),<8I$EH8 M$< V%;)CT287.%>&(A.B V6.&*2YE,@Z&PPQA ?
3<06^CBG.9MN@TD!-T_Q@ MH_-(_=O(MF7@7RW@ALG\Y22\FTY\^TL7@"Y@!__(SA4#6+0>]0C)O1{R]=8_MZ@*1VR7,HL^0%G+?!%N-
5XLTK*KK,0$;5!MM'*HP"KWKTR:M))ZCD0$XN*8 M@JP3&A1^ 7\"C6 .=*+U!,&2[B;4!MSN!{3S!Z!%A]6A[7Y MDKJJ3!D_I,9+!+BS9<83D#U_G\S6C6VJ.I//KD6;Q;%=]FK;7-A5*S=
],EU, MFN^/M_03-DDE"F)@45$M4B(:l!@:,10:)9VXC((KG8L67$=)V4%(((%2@6?2!! MP!@Y$%)(,\V#= Z8LZ/U?]N7$?#\EUCG_E:Y U;=G$5O?I_]&;V;SO\KSB\Z
M'5VI*,LM15G**5X"L$$Q55.XNRT*T[#8G8>[>PHX$^'6JX%WV4S[&C4F)>C'E8;ZWR\P5Q/)LX M6&'1VAYB(!X;V&S%XO&&/ED.KG=B45L2A!4$!!LP(O<4I)OFP)>41^-E[I?=
M:0!}]5$T1HU(2!+$HN'(>!T0\4)AFX*!L3TTL4B'O3+CBEA\H&)12PSZI%8@ M#(D'-=,D9&D"O5${1RB5:8?S T=/C+,"2:\,B.*LFFJ.D?=@AZH4@E9/62SR
MODK%IVJFOIU4OS=E83,D/:N 5GW$5\8H<.G9 9BX%6NV=;XA&K\GO<A=D48H4;3W^Z>&0"[V.5S22Y%N!);(O$8S/2[?]UM>SOS3>E?82.Tj>U7Z%S
M9Q[N:^C<,$[.GC&3//81TBUNQS:7MVVT4_I+P9-O[#@YJPH,7]*O&88I\8)S ML,.+P<595135)?XM+Q?MLGEGU'GSC66U&/ 36 N0DU&C7P/OW[=H41!%/ N%
MSP+/XLSEML,XQX:O/+.X'83"CD>S8ER>)5E@.LPSW9"Y09@RCE-C4@=+6^/8 MC!)T9QSY"8[O[WAZ!TW3GLL T5?8WT^PO9_5[GZ%S5T)$RW:0>B2V<-XD7M3
MT<'WM76CHE3*/H6M@8XP,M?#-90=^SBV M(D%\$(0+ [,+G.%%&.(5OFFE9H1T[@!7YBRL=CUC-V'>I M4*!)@$$#*4OTD@$6F$3A `!5#WOLXL3NP&)"I*;7
.%R M9Q2\R-+$3TPW98$%E.J:".D2PF-.&GH.T+,3BN?M>F!;[K[!58!65$:?(M4R M7IR72=%B#7%>WE@,.C>D%IYP[[+:'R67P$W<,Y9R7"_R A#^9F !2V6^ \<:
M.BR(DBCRA2N$-6*IV'."Q+4\9CEN +:)F[$XBE+PU$([LS.1V%'T9+4CQTB* M2B/LJ([$FN^5%M!U),!/[4IQ\783$V4 KA1BXBD]FQ,,$6MGV>A#LS?[^T>(Q'
MV4$JX9V\H.N:@W9Y5M6CJKE[6;PS$/TSWW3W2=HIFY=?\+P@(0.?H+""&_"M M>^E:@5T1K85,6YBUCMU8Q8%=L"2R$_ S_+2R!Z-,<\XN/L'7'WPVLFTY2P$ M?
YUQGT=!FB:QXYWJ,?>9MD+?V3>K|E:4|.E,VT1"G&FK)(IZ3\"CKTFA?>@A MXV5>"@/<7S!.]K&5US"TF#=-"PNTD/8UP.V)K8_'O_\^'ZEKUQQ$*D%?HM'% MP=X""W@?
L\!Q%%NABR6R448%)"$+?2_!>A)?6$&4AN:X$PL/0F$Y,0LR@1,4 M+<$B,TR9;89>X&(B)!U=T8D6<3L7;('MS")SGR #FP4;4B+%(#>1WRT1Z7O1 M774'.S1JHJ@PD%O*OU-'>,
(*69"Z-G,Y4#GW/##XDL!TPD"D43:B!?LT)3[$ MNKNXDI//!R3](6^2HL+DT F\X)<"O+P_&0(\V05*_KI58Z0(W7[PO.V*_VD| M>U_8)X, 6N;<&.PN2*V%T0K0YNZ?.GUXYCQ-
0SAB%]LM1BX=S6#>GJI&J6.@[755(V[6)1 M$/SOUW]\9;9EXLDTRWS9*NJ%)^>UD A!NA-^G0.92VDGPW3#@/UFBI?Q._Q= MU2X;T:V#]\I()P"PURC7:1&=
[UQ>5BLE>55WD@T^6P)EFW?!QPTQ]WCLQ0E+ MP9QCP PNYC!-%CMQZB1!ZMMF]H#VML0-(#)B%!2#A/#.23V<[U7P1E.ZH@^] M
ZLY\6X/B"'VCC8L.W0BTTF9F3H(O\#N/|C)AX=99C%697KN:",%G6GC ZC0 MHEJ0NP(OOP I*9K')!1G/UM&*D(9;(?1[\<6LID;GTOCDXCKEM=7Z-38]RJZ M%HD BWH/2":('6$SSD7
IZ!B>8%%G7@7\=<^#Q*8L%"ZGYL M"0ND5&8SQXQ2;@D'&_]OHQ+V)E,'MPN4.ZN-# AJE]>]'DX'Y#CH8C!H4)A6 M5 Z"_]5HWOLXL3NP&)"I*;7
.0[0!@NXH]\>78(.U.!6 /Q.YHML+L'#1CBC4A/^/%EEWLC]S-JBN)+!@9J3(%@I()!(MG:Z6<&#WS/O$XLWE(7<+4>Y=A/7IBSM0[.J@)(@Đ2EI>&Z€$ ^OISO9GVJ^I
MR":XG.&Q8Q,OS [" HX KFUGW.+@*VX"UR9(LTNJR-'ZG=IU.'U):UKEJT26- M4",1]1)(!D@(G8*!G2NYGY9-2P/QAUS\[S;'+!-L^ADP?TWB UYI&F+)<;\-"2,PQZZ6C9>]6-#OQ*
MO0JOP9W>]5K!*$UN/O#R.,>5]%WAX^T"4G[=<=4L*B)(IC66K^<9D ! M0' Y&;_ T.@-!%%#@!+EEVC-VF$J@_=+*5O-E!?+1:OX_RR!%&=Z%,! SY* MEA61,W $=
O%75$RXP/U,*KJAN"@NZBQ.XLQ9G(*M0@R)M+,5IG@"]7.2P M#$6%,78F %=)$H9^NWPTT+>&\\,"E?*EY30"# 3J"P@L WX6]M<' KV$L\$? MIRA%JH4**3?
$J'C@,=847/(KJ=IAJ_\#E,R_Y^?MN4Q$GU4%$C^5KP!@RSXQF! MZ)).O8S-TXD2'-48TT*^&KQR%7$L:8>SMB8)7PN0YEW+1-QC==:75?T-F$TR MX&]YAF<:0J&L&]4ULN"R?
S,]3L@WE82,Z-]4=:M)]K9NQ'CES9(<4EP@?C$* M*M(;2)TUMO&KV@55#'3O+@5M94TTDN/N*/$G4W&PU,$1PQJ07 ,)R&/*X.N6
MM&BB*OQTZJ6CJR@QHMXRU:2OJER(BGM*D9\US /3M@S$^]SXT&I9UJP$?E3W M0R6KMY1?;GBXWK8<24_K6#A9_7.=NF_D<>J-H#P+&,R-$-^(1E') _^BIJ5] MY
DI8/V<;@DT,W2H<;,;&!.*I7F-0F*?#I.O,H$4"D/*K9*<^&Q(H=>[]LU- M.<,<+8,"A!>P_ZK1T+;"%O'8)=W(;]8*&P=->@,O:-'DCO$)VTX'3H!8ZQKE8
MGE4I&+D)SILCUJT4]S:2HU$<4QV;^L66MPQ"M-1CM # _]C.&.Y?LC:5HGNG ML@>5(,"!;?"Y378U:DA:K?G/LJL?BMA,6F-5850)/+710A<,"+1S-I%"UD. M!7@Đ)
M,A'15KP22WB=*%<*!0>0^4AADBAP!VIF;=*N@T9;\F_2B]'NTXU$@RUEL84QV@3%U0A(M-Y]J.S5VW??&KOJ[*&4Z-75]>M\NIL>O4V/65D/HM&KMN:])Z=Y#P8]KG=/F^
MF.C[6J28\## ._,1B.*Z:N4Z4L#"U4R:\3+B^*5(>BH< >V42E<*>U$9CG!L[MZ>-^&Z;)O.3AUBKY"@;O&? M_Y)?M>HFH#:3?H
RR7$_T4('RP(O9^#*52WX8OEWD;Z7VV69YMS\6=] %(IXU8L$QI*_U\)7[Y+.[<`B.D?E(F]RZ72_T\)87-A7IEVU%;W6#^>VX_X\ M="/4H4D_XL_7W&O-7?^>=!{O-CN<.Z87]?
\$C_CZ__KSLMZTP\H?"X' 8IY\ MPP!XF3+%11G]LYF+4!%*G_"=] SO!QN,H$WKOA#U$],0ZDH16WQ\L)'M7SO M9->,*N]@4l-7]H% &?A;ZOUZ[<=V!KL.YRR6!H7'#"V20P^7.T]?
& Q88F?#6EXR!>U:#.W#]NO2+/U>-4O6 M&?^/*XSV8>^>3CB12!A+IP2V(DON)(@VKGGM&&"KGD,T/2#N)N- M^8"%VH,'EM4U>_.#L]+'M6W]ZO,/N3^(Q/YT\TQWRQI:8;.CQ)
@\%G [Q,(2 MC\6A SYZ%H11&-F1&4>CQFV^+]* 1\R-0FJ0$+'0^K9;))PAA426B:C/MNPH0C[#@+S)C'X[ZA=U4_.ZA=NYLN\F:6 M$SZN*KI_H&8/N>;)O)YA"AYV;#,%WZ"^ACD)3V?
=U3/-;S+Z^Z+QSFZS6;\H!HLDGSJC-PYTUV*,U(;FCCQ5>=5\X PB=Z$F! M&8UCP+O:,$?DP,SP2BF4 T.\U>6^:,$HIE0 M-!.*9]^"'$*\GW3RA:!X3RS#!:B;FFICK23*\$ZM-
K#:QVH/R31,+W!O'*>.,/Q):.6J9KF^*9Y&:#G7C@M_]00^R:Q)9DTRZYJY599KIUZ M>&<_ /EC68P[H5&CS$%=I*K11F_MUA'6: /*IO&8JK[D!)ZG6DE.-R61>3O)B MDA[.NN^-@:"L-
0\OQF+!MD[EQ%K+0!',W]8/(<>/(BCUGW=+E$>=. M%D4L23QPZSEW69P$/O,]RQ5F[F1)C=8NJNM",&JL'9E^\X\[W46]MW. 7P[M2=!)^D[2=T^DKY4DL>F%/DLLC!E@:H?
C%%C(AQSAFK[M6*.$#@^)YTS'8E9F M)>NMP*8C,+.*6RUPA3##ZX>[M\9S4C)TH$>F$(W(@IA/T*S?8?_4A_4%DEA&,&H6TR+ ?.89)RQ.1:$+-FO*SQ_<&CNLQQW"PV69,9
M&3:WLU@HPHA%L>"I9R>QSV^"PSYBFL]OO2E--8$$)ND[2=^]E[Z9P\,DMCV6 M^IG#W,@V66Q:)O.B*,A,D89VQ!^A3>@D??=-^MX3))"(Y(Y!B:D)^V9(P?TZ MT$V*G#/2
<(RNRW#1ZHDXSECUS_6@2D;L8W=./ MVOEO-;CGEA3]C!L-;$R> 6G"97ASW?#"N,R+PBBKI5$E25O/C2_54MV # ^5%424T7F'MF4"K,7SB=N'1U#!;F?J/+KUP\$+>$ --^+YEX-
]HN.(1?_^N?&Y-"YR M(#OUUN$N< HWRL7(&U DW!0\^>&'< ,O@2C9% M@$M.$E$@=<(6-@42(DGF5YD?-]YB=VL)*.(W\7=0)4 M#TQB"07>5/5('-^_?
609$ES!O\^]PJ0.$30L*%G*W2!LNO7G)>_Y!705)C)U-8%G@O>-D>9 02#L&GK);[SDISACZT/_X^4UZX)7HG24 MSV[$X&G /J#+I:3[^%TD+=U^>,9S[$B.=ZBU=BN)*UZG)"?T0U;
(<\N8.5!I MNYTTYUM18+NIR;+$,N(M\ +UMV#5[!\Q@62A <6L,V!O1/+F$VMG&/'RRGN9LJ8*!H=!"P-EQ MJ#-JT#JE@)O05#9RN65+W#(4^+(@4^(O^.5P!) 8\QAN!+
L*K@$:6X(YC=)' M9)E(B$'Q'M01]%#DW2O!P^2R9^0JUM48 MW /_Q_*6E"B%[R0G$U&S*4"RRW;U7;,Z3/L$.HR?>.15(G M-@5(=V:[<01JU1,L3.V0"8O'#NR7:UJC/%
<86=Q+PI!Y<8QSBX4+;.6YS(HC M'C@Q<) 9[&+6/X+XI$1I3I(+\^XUKVC5%-DW'-$R++8$Y (ENVUA[MF:1!(!XTGO@9*=5Q]I52R[R9!Y >.%R;4S)RYH8M-$2S.'#\4:>"F M81:-BI-
3%YB$FPZ+K0 +FH$[8LMVF.=FB1]%IHCM;]8Q+5?#HN,9?D,K.=F M(>W_XFKD=I'_M%Z7VVW/#;F)#Z':'2_*V.C\ M__!G\0?
XW 6RNBSEB;S6",CGTCAH3]HF"5+*#%:#!Y2)!6F6E\L*??Y*P*C MP"V;8?@;Y 5*O!D)PRK+\D209BQX7-4ROT.++AH<8W9;/C-]XT_#DK 7MH:,, M]$R,*Q1M"DO728$:X_\H: J99]#
(_U_;XD})U97@K%P,_4P^#A;^0!6])8!I M1:D7IT[$4L_TF)OZ)D. 'XO=P XST^>Q/QHBDD5VZF>A &T<96J(B,DC9B>6 M<%F9B/24,\<1V?,Y'Y,7C1
M;LAX!!HR,Q/7QY3(O!!_=!6L/M"HX[Z8%IA_4$#F&5<%+@4T;V##Z'87"2B?)9B*@IAF#OZ&1N_ WV4+GSL(== M E1+(24DAP"JK"B["W=AYA=_0T 42E;#(_*24YI9\P?/X*?
&7WG97/VI2J3MD9=OA6TU#F9+X3)LR)@Y2YX#XR!+/!1 M2+0L!."28V!+<#EF0>**XT4$6#9FI&9AB&;F]-VC6^2AH:]"4-:R M37?HSC 1VPU#8'@1$82$AI1AGL)(QH]><="?
27C6>7G\F8(E<(,('Q@S5$! ML0)#&#%OX)KJ8EVI(08*MB.Y>GHDRQ[*?P)-Z[,/&Z:(7@6EI4DS/4R M&QL3NBQ)X:%@4PH>C28G^*X5)Q&(?Q$&H W,0+ XAK^F/.(B"A(?!/R*.0EV
M5RSJHTR&,588D7XT9,#/7SZM<" #"8=#1J4R\MJGQB0Y/'F>EE%\LS?C[R ML==2^1DBG!1(,LOK9JEM3FF7(O3 -M^KA\D8"?W,>D_^/:'T!$F9ZOOJFH-E
M*P&>FYZQ)V;K==%6(RE@S_[OGQ;\5+"R2H5^"\+#< /[T'Y)VW]\QYWG6B.], M0JF >-_!][3GY?LT;Q8%OW]'OWV_X"F>UZ#V.Y=+5572\@?_:IMEGEWI%]*M MX'2E[Q=50QBS=[7
",B%>!7WW%#X)GO.OCTIUMBI\B?C=W_'Z:(]2"E3.D MR'AWL\+2W!5O/_3 MGJ_/]Q;R>?#X]G MQN/7TZ.#=6CS3C_;4O>IO"Rl.U(T3>T.D[1U2>_^TH=LL_<IV?9 ; #6# V.
ME.29] M$5^I"'''&=;4%=R9X*]I'SX1]&E+\G7]7#"K*MZD[M"6HWMM?V==KO-;$X,#D M?:T.[^<2W =*L=EK4&J.L"(A+%&+H:NB;JK8](E_U($5)_GZ(-AW4Y-?UH-
MA>V;SVU&CA6[#GC:D>+@:\,:09#3RL992G!9IT#JE/&.1;" 740!-Y$>,4 M1[53H"(WMNUQ:?!ZXH]"@3N*G]KS[3/=GS$&#U],!14ZD$K%@WF9U$0M^T8(
M=A:GL3!QU*FPF2NP+6D")QN[W+W4GQHX -A&5B51$)BR&#>2<5-#RYR'N=%OGR]222PJ>$O MI0P5]!?.9Y8Z76'=.\4/CDC>ZG%]Z72-<,]
PZ>*3YI,\GHU4/"2KH5VZ(*^QY6,&QW"2(K929F85I^0P, M?.OUF6T'ILFY%R3Q"*0ES"1PX0(&OP>G($,?0@B+F:$>=\L!B>AG3Q56QDS,]< MSES; 6? 9^1\\A-;2-&WR!ZP:U?
HZ]ZH#I'CU/Z1&.-=^KI;K^ MMD!8KI;TH/_/L7)&NJUEAZUWALW/1OU.5I0%I?/0CJA*I20(Z[N&ZMWB"ZI? MIKWB7,C"IDT.HG[S[7U$O./'=Q.34& ('0>;NB !XR!C/(PS;"GEV8[(S$F=
< MZ\QV./D:+%(6#Y$.8R:77@L3NP [G6CE(^,I$=`(6^?Q_R#NHF;6XG=)%VZ M%$?!X0_]"&P:VTM3Y+'?AI%*RJ4D4)IWJK?!'TH^],-9G5KV:42WD/0(PVV(52C ACB M>A!O"%^
E[."7U6M*@M]+U\7F'/S9WT]B?Q%(]YI^+'>"=)E\M%_VC3N!YNE MR=CN._V,]UN&"]-;/6_N6=;/0TRD^F8)BOSS-?=:<]N]YYWNRV8AZ']I&^< M/G'ZQ#W\0!N&?
86+ZP:0;Q*0=QD MKE[^ 8=N$'ZAX*,7VD60-WF:6PJP]\ MBE$*0!?X6S*2K_W4.TUK?+';3OT_V8;LQA3WA?JNHC]!'+"'_K[C^\VK3J_N3 MSFTF$.[#CD[\-
/'3;OCI"l:T#MG)F%CIOK0Y*?]6.U06-F3L%K;O=O.,ITD MTJL6$!,'7<=!SL1!D\:9^&?2.)/&F3AHTCAI1U W>)&4IAN[D0EL19:LW(V$ MK7KL_AOW3,QNI:!!N55,0;,;M4Y_4>-
X;RV2]F.LI'.IH.F37_(G3T0^??(D MME_+\4Z?_(-\\D3DK^B3[^?/Z+38'5R7(924GKKQ(VYP<(8X07K(*GF=-C4 M??%_CM; \X@RO0TUWF:S?APUN^&Q9;5?GI[Q*]N^]:
<=G^U^B)^=ET'P+(@C M(5+FB<3"3D(Q"\,T8)&(/$^(. B\T3"PNXRXW5P1B%&(K040SDH!A'-3.>#, M<;>70+Q4&M\M!]\(TIXDV23)'B+)O$38*98UR_E8MIFP6%B""2]-
@RSB5AR- M>Z\+=81+QHTLR-]Q>R?I2*?Q)Y=AD?DU"ZZ4)K2BR[#=4S H=-+|%%/Q,RO M_= 4]>GYF;V+\L-'$UK>S RW]W%]30^F5^3))LDV9TDF1G%:6AZ'@NIHT@:
MIHS;KLV\T!)V8ME):HY&FMYE=OA3.)+!]I9K+Y7&GP-J,84F[\A1?^=U3C79 M4V1R=\QV,Z+LQ;#/C/0_]3IBZ'TD7A6!3)V%"(^D"YGK"9S8V8P+-_) ,]DB
M&'7%ODJ04_/MKE61,YYOQY&08/7*]_8>2DI\# M5/5V$0WV7F T^*1:XCR++*13\2-QHSVUDQI3"SMC/J;N>)_]XF\WX0=66%=N> MF<41,RT.:BM-,\9M3[#0=#T_%+8-
S]Y%7'CW9GWDN4^IL-:HXN6IK,FPG\3E M)"X?"D[+["ST0LY,SXS!8H\BQI,@8[$?F4D06HX;I[L($._AP@0.2,Q;&9L3BT+5Y8(D@=N.=3@W9%;!@%KE/"BUX MK;)Q/^A^$I>3N-
P'<>F&L1",$[(HRDSFVCYGH6^:+(W!L/1,RI.'9!?AXEV+ M2WMF^Y/??=[0;?P98_?_K3=0#=Z"OZ?YQ9[8CH-W[VS,TCUG>-WE8VFQ#X] MKRWF/E^_!EU>\"LY2L,..4!EFB_;
M&A9RSN%9\=7&&?9J*B)(&[P-%LM/U83&C'X?MWF!TS:[(7)/OTO&D#PVSZ^[MZ=%_VCR_C[>FZXLT9 %W<(PA",Q0@"6:N6X4@<15]\PVSGN]@B=(@U^/V'.CO MZBC[@S(^(CT
80;[_%7@F%%=BW$BZO/FH$P_Y$U2M>7R*QSQ5X%S(-.3;K5L MHWF4*7@ODX-P"MZEVE?&Y<8:M=Y9Q5,-&D+L>#N<_RW"XP)X[P7TG9\V?=N26[3LE >[MLC\3 M<3Q-X!
(_[GE#3YL=G(!G61AFX-9$@<=<=<%LB+W68*9+0<2+?]+R)R"Q.73>(.M;!:E(D9X8L1"U_<9CWD:69'EIM$-#=T-I](<[D96)@#FQ"!HE=5P69]A MMFDZ@1NFPK-'[2]WKEV&_;/?
18W[NY+ 6+2UZ#(8S!ZF,-R;$KYSV_5A>IK< M+G_W\Y[G*/[5-LL\NWJ^- 5]X2:3*XM^;&OX[!618E1$7K; 2LO;KOR?UBL+,.N= MU/F0&Z+$1J&.(!>8D3%XDH"QQ,M$&)?
Y\LPX.#XT0M?&,/+&X,=ZD)E\S^59 MU3:\3)NWJ\.'-G(=_E0=+'%<'"'W\.+$NYDZ3@#8B^!4A.5E:IT)_ZIY74RG_H M5+^_8\[!K!#?69K7@L0?!I+;_(]&$"+@E^]P]^^7_ 44T2#P$LN-
U29E_(' MBF7U"^E6)LKT_;)3S"S&,SG8QG>^W%)8W_AC!;T>1FA6N'*V\BSU MR9UU%KM:?5X6>0G+6/):90!6?P'[*G],!RW-=I[!0[WCQ26_:E2D>WCF^A2)
M5^G$!E0P.LW='MH>A"EW<(2_N/K@7'R/Q^_'OS^\6\GGP^/9\;G+X?SC=GM>]LL+NF!9\I)!6^==NP'!E8"D>O],F_3EZ.3CL7%R9!P>??GPV3KN='L1 LC=P WNOX
M+.)6RA+;]V,O32+7=O]!CZRB6]WF=-&0G:6 +?-YB MP3_!ZTH'/WUV=)?I/_#5\RHUP% !J?%!),H.MF93NOAN(ZQ^A#3F]\,^3'G; M!\4C/!75N7&4+"N4&99RG9?5BARY-
9A@BLV_R!#EU%K\5D'ZP#>C,$TM;F@.,0)<[P:,ID4QE!A9&9JAL)R6.+$*/QME\6.9%#)+MLTL MRIXD5DS>R&W7A3^KBU7#+ MI"Y6QD5@M_-$),SB(/!=+^,L#ES!$M<&>]P.34\\J;I
C^+DLMJ9EG"C1RYB M?C%T/SD5#]42P:0E7@VW3%IB!2KJ^%$<1H(YPDV9FX%[P9W09AX/N)6*,/9L
M_N1.XJQ&U;2C29Z6,WD3DS>Q&ST13GKBU7#+I">&>L)W8\L.G(3%OA"8K0A8 MF(0!0G,?,M)XF2T$W#,'R(P]$64+?5-@?(MSCM6.,8Y\[TG;>G*@>V3.
[+R@"6C8A,3[IF5+^/.7&^*>4W.S X8!TGWG?Y?-%B M0\8<>5],LLfQV9R,&Y!-V_N611Y1T=)9*$5.C9+/5!&KFU!+/9=$(XYJ9M M<3N1UKUR=Z#;EJSCLB_?
@]@4L/SO%O.U)ITNTNT,QJW!R:? MZ4$<]SMH.^RY?<&+ECIZ;^LJ<36IQ!=H4D]>U [U4!185N [+L,1%\QUXAGE>0V%"?=9%MA>%/HB#JS1.(R'-YWJ--".-(WCS1O[I9-SM/.G"<;_@
Z9%'5Q"V3 M%ID@&.E1?$;FBF-@LB[C#73#D+,\]BIN\ZP@]\S+$?H4=O!] .I=S8 M&<#!-)W)@]IC#VK8L\^"O=M,PCP)\!NRZINY)PX@7-?\I+NY$NZ MG<0B]S+6-
MB@MQ%+-1%./D:D<\,X2%-B@]F!3R"YP4\#J^0XQQ3:&@ MDV2D"Y[;!?9KK.'MNZ&PQXO<8XF_.6#*/@EBCI^"G-#*_0CX;A@:Q=UE8!YCR=,&T':E.NX-.]V
MG'KB@TYL5CYDE29KD52G)=!\:ORT21+>@2<> 3UN"S.*,V9ST*%N%'0L3&/! M_"R*_;R:3L:E;7RE'O"=''QF95:"9IO+(AMG$ =9 #^.$M/RUA7]Y\Y4.D!&R$GU"\Y 652-
2(^RK=Z,O^+-»#?U4IMOIZ3V#%H(KBYPT\%@ M: S<_.Y8 W(J8$-8@3NBI;*TK9'TD(IPJ!@;.YDE$M_,PZ*:S@#4X=+\VE!)WRSC$=A:H8L-DT0I &/60Q>"$L\ M-
\F$G49F9NX$D=;MUU?1B/IB.X#Z;D+6G&\' #RCD 4JB84! K;CYLUTJ80L MM=Y+]W!YDH +EZY,PT%BK^!Q=1=4'_QV_HP?;JR[X*.A M/PG'T?GA--PW-> MFM/]A/%;4ACP7>?_M/\)-
\"14J3EGP@F;IL&3N*?\-/BJLF;?V;]$13Z#*LU M[#FX9'IY92?VH5LUR=0#M7+0T7LT'TADHJR7J_<4"?#*)ETXO*,8N:E]/K_MP41+&JP:,*
M3+&C<_<);"';#,MG_SHWCZEQHFSTOI3&%Z\2MXA2>UP_:NDDU.B]HA\&7W?'1 M0P]A^';)=C>!6AU\C%@PT"?EW(#FB6.YSF]HA0#_BINP?T03:,?)L/E[Q.
M65%5W_#I@STD=R(O+ZKB G,.S3?Y5#@A4>,WKQA+$[>@,PM[C#8I.822YHD0 MP9=#KR\SU,X9XIH)V^)Q? ;ED&1BB.@B'/A5.E)##$*Y^A*$JD,_0^_P5GC7\$ M/S9/\@6GOV
.22:,)"52!'7KTBJ:N517I,*&$\%%C).@4CA MO4(ZNEF+YK\V7COGY!L'P&38[U6(2^P^NAXNGN:/]M225^DD.*Y1 MLT,)+U7(=Y0*U M KS7^!T>8GS^/#(/9K0.YL97N-#X)!$+
5:'#0XB%+8 MT98,F)PD:W634 >F3(417QDM2!DI&L NX_.@3CA5.>67A I*"N)B%!=X$Z@# M) Z,,=);JKCH@J;B>R(62WP FAEPV@D)TQJ32$Al\;"7_865UN{[EW"P]G
M]$4M/#"'!N]H%O;Y"\7B18^ 6WM:TN-:!X5'!;[,";1K\=7+&RU.B5!2KXCL: M.\J&)+6GM.FL%Z@-*<0DKY/V')X+VT>Q>KDIF]Z(\@SX)^:-4J:DP_'G')1(M(I-B1?X-#N.LJI2*6U-
OEWE1:*6C- UR2F_5J0CL-6KY\2-/MR=/8Q%IS_FC> M_W-W#-YPD<7HK(Q<9KD,/72%Y"!QB)RKUC[-VQ3R#AYB"8PBG)#,](9Y"K\)
J4R++C1X*4HDEF599C8H2Q[BO8=O@F[9E">$^Y/ M!>9#P??-OR,T87G6:(@%?$75-AOV**W;4[515SKP#]]-,0KD%OX,JV MP6f('<-%Ej=%O_IZD/6B-V#2,1UD"C;LE8%P
/#\E[RI2A#=;5W!OM*V__9) M:]F\D: ^:03##2]$BEE ^XX*#M0L?^;1&;MFJOS!?"RBBX B9 U4"+F M{(1=|')%:DU& DMWW/TP4#Y6VZ7V5F(2A(0K>)O)05X"./SK/F7UZD67NEG
M*W[?ITCU*U;,6OKF]^I'A#L)LUXAGE#0Q0IDMT)5 (7N.D0C]^*<3%?-. MJ$L1VIPCB]&*0B_]4*T>=-K+%0[JZH7K]H##*6!]TQ94O,' 7.0==Z&D=Y_;[&4QCO-CXY=?/?_F?
DX]?# N^&<-#"C*. M9+G EP/A"HN:I# -4)IT@7B-O"N5(RELI'^2"@BI1K M-Y3LH.A1&]'+R"JJY;DT9_Q<9.K0HMQ_#VF$T%;)U7=Z9@E#C< JZ1.@84"VHWXQ0X6_"_#.<>H.8l;
<& MT(?MPO.+;Z\BPK"-@0IZ;9 (JC%)l8_IP-A^,;FG?Z4T='UNPDOIGOU4Q^G. P^$0NB]D>T$ M,F'I/P_+:;\)L8"%%=UV*(@ [' M4HYT\JJW.V4.,3:02";M6"4U*N]DW.!"W^#@9\4A
YZ;3G9V.^-XP]O5R2: M$EP@B'J19<\MQW@#_P[>&B0N*;+40$:4Y#+>_$#KC$V;;P=L8,YM('-K[FSC V\> MF,8,*YQ[WL0)$R<\"B=\?)Z=5WDJ W-&!
<\G^YK"S&_Z>N)81JM;6?)P7IW" MZ\^NC#>`)TC1O&S>S]XSW*]Q]PAGNHWSMOF"V\A^QS&ED#H.[%4:,4)E[S$] MV58G5/8+ R\MND!VO({'G>LE;XQ348J:1#2F?
D#2%@3S2F=2%)>53ODQ#7-M MA$PW\?1"U(U0R B9\SJO&@KAG1,>I":4#]8IKERJK:5FV:97 PM,]I<0"]: M_#LZXBIK*5,8YD.HXLP;-J%E^7WK;]U
M=;LW8>AL5ZY7!R=ZO4A/&$*D9)@6P1]=)))D (R#EA:P-Q>U'CR[%7.[I3-FQ M$OL%O[5L1JG2X4L(-@(;D4966Q%>TOOD*48)X472 ;Z8AH MYBA95E1]*@GG9%OD?K @]5+,HP^I;
[#*?TLXG?0F;&]K7/I'$JO+7UH3^G# M_="\"(#D,2"W-LQ(&;&W:4:4U]A*24J.>R4:9980KE?%B%!C 21'$AQ M-*"8%X<&\AUI49<)25)V@U!EJ/.,$BK%>^O:>3445_-.UR*
%676%*L\#46*VQ M.ZL?-?R21J-\$G@):$;8 'WK&K;W=G=)[U"MF-"_IPB1V;+N/PB?9G+XG#Y%W7Q)65TE=M)Q\-1%XJ"86/2A=)0 ML./:5U80F9G2D[]])J=*8)

MPC"TW1\;OWUZBU4'=?X=WZX6.#,J1$'QWHX@A3XCA;^"D@E,31AP#@FH7U!# MDES:^%^$JNGH$@F%HT4"9PV?@Y4.&LG3;_WGTC@6BZ5JL4#]%2Y%K]ZEJW$A M-J>LY8[/;ITN)E2<.E0R(@K8_=6X0C,,/>/U*@ GXV_-2CH7%P\;6(I!49C, M-#? _,V25@-'!9_2#++O^3 O/VSM<,8I6CC$\>F[.R/1-I^U OR5@G'^*Z[_M3$+\I$-A3HU;S1KCVDEC@5>!]&CNDPAEE&!/$'<|AC:-2 /P5R+*X6;U>A/ M^$$'$$5L#C@AA4C;0BCTHT)_2CPA/BAO&IQ+(V5ITS;J>$E*4Q++\%E2=EV+ M %U=* KY.B>D;Z;P*C3Y3;M-A&PI47BlVO|TXDO-)#PE*4|I!+X&]8;ISC Q M~&@OGH./?@YO12,BPUHD\'1E6(6X73==@GOQ@5@*K+KTD!U87)&U M)#DU4P7=[XT?+!\V4?&34G%IB!+.1E -DCE!DZ(VLA*2WN&=G!57 U_IO"(-M4JBK7S;:8Z%'P*4(+>0)E@@WTOB7#$%PT?2"DSFY.+MJR$M!O8?ML$6S&K'K M"B?(0%7M"9LSOD!V.Z_J*]6@4(8!TZL2/EYIPY0OR"V47A;XAO!=5^])2TX, M,S', \0^1FW!X $)K6B?D?"6L<_O6R3_C=4Z9,:M5NBLEMMTP8[Y-@)^;<;S MH.<)[C"7@1[5GH_Z_,F|K^I37E**3W7O !TMNP76VH&===2T\jU"*9,'7'85 M3/@":SIGVKW5]_;F+MZ>%ZG^!9JX!9;9MKULNZ+Y(F ;Y)4VU3%JHR"@M+@)MF>1+/BB%P\HG*OX99D&ZV${?]DTG1ZJ-U6JR#+DBI)M$'KLZK*F+XO"!X"L M%*HRZD)UI]4"$67J%'KA< @'/D!^DUXTZM&B*M^RQZUV30I#-1G0O!,/O]^ MM-)7@DPX6;+6@+5HN#/3]F:P1(1\U*)K_".31O Q5?+-~>-.3@+I*/:9=J#)* MLA(O:_€(NE&%$(;XCH64,@B;M46A(FPYLL]2]0) MKX-PKR,[:,O}))*5J"Q49^Z.KI&07=N=A\/&F^"X2:$P;%X#5TKA ,QCSZWN M>DK^KK$'R5Z2N?H@X>2%."C9*^Q"3\8''@ S%_B!MFZK M@_KP)}>?>[>Y7<6('=T@CFY>8=1K;@;EMJ1BI%7YD^PG7ES1,&_8FE9N\&2 M<!__W6*,Y4BS]* =_*#M7 5&@GU(AU3'M;?>;!H)NR+9H1/%8NJTR2KSPYC,[MQ>A;I+ELMU|@<S<'<_FFV577LU=O;#KR!I023U2Y2IE9^4[;U4K^R[UO5=LAH[!K_I")>_M8C*TK951IK=+]6_+95>]=H%O_LDQS<'!JMQ,)QSVL1K[%4CV/Y2XSN5L,.RA MB'] J4#C /MI@< Y\$1!T?I,(]^6"(&6H&RF=]UA\!A?IH>OI*^ZXP(V<4A M 5],-BQ??Y^N1,TP92<$R739X$OVHL!%JDN1XK.B12\#<[#]VW1'-HV5@16I M/^X/S4V@WGT&]5H3J/>%X1 MI!Q8\BI.1-;13TXTM)CJQT;^'/C@'3Z5M-_Y}#:PV>B0<$;&=FA/R!R"\PB4V&G^Q@]?+FK*]7=#!8(M8T2S(,R!{(P:=V*3#,?QL&A,YV)%SK6H3]@8[M++4H87V1Z4U$W,T:2LK[6;N5EU7]C:Z:T30>&4() X61$G{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|M72|)VW4+V=@I*=ZZD%MA'XX=LR4>@2Y2/8]7;M #O ;,H:"GZZND!IU#Z5DS&7G(OQPM8 5"=%)^37A M!JQ-.7Z<789G(D\T%M(B3J5:AJ^CA>FQINM/F;R;Y^%,KKH&#\5=KYOQ7&?# MZB&$FZ&?*R?7Z3&\Y*-N<)TQ,E|W*(I;N<\X$OZF",'V$, 22RIQ::MA P(& M; P$#.\81 Z&0Z2 E MD|]8?&"*^(PJ/H"S-V6RTC-EU+R11(B17M5W*EE! AZ/^0($D\R=]G6#'2=- M&#!EJE)0T_IR-0\FS:ZW/@*S9EM_* XK+A(A :DS4;.8FK;MK6 MSY@4Q/.$O\C6V.(<:+=FQ=L;TN\LX*F ^4\#0F0S^,U.R@9ZIXPADF!D2X"X M!M$ (I?|)9&0:\Q>-!JT'$@W:ZX59M;#>(^SYM9CQ($6CNMZ4?51OZ!GYYB M5EJM64I,Z=ATLE+-&!HX/A7AFCYG8Y:|83.W>X0#CVCHO[% CN5V5[?*F67:.MUUF+>2O!{,_]W2<$ XVJ&-2MOM'"[N-[687V QO]-BOO:+T9LJM<;#RA,C5*BN%##/(T<(!'ABS5/#D0KUW(_Q4&ICZ"V6!:HV#MZ[!0(D!HXS1 MU3EP;6>+_^/K@3:X]|_^Z%X^]4*-1Q0F8!GF=(8.;($-S)8:)EODK=OG+=O M#M_V>&$^**VV0A/;<@ALJZTD#G9.H"O"$;M7U!Bl#V"J M=,*.S,Y3GBMX>=ZO\$;>!IZ^_\U24J*DHP!=)\B4K[L"-3UO&I)!05)@U>MR M) !ERDU+1=RF:V2T:M:AX@IK^_+<7:(FB-T$L5N'V-D3Q.|E0^Q>@8I;03,H MW,!\U0-63VT0S\/@@(OIN(5*?U5Y[%U!3E\M6]@>$(HYP)DCp>FC<_S-I9FI9EDRG;<6"7CK047#NP/G545_L;TFA59GJCPN,T'D@^2)OKM^@WK!CU>I>(%TG7 @GH|TO5,%*FNV*)0+I:$47I9E\CHQ^]'#+8>MUZ|3') MV;,*9H)B1>]|%%5)+LKDRDAEB)4BO<.(W>CH#QI*OND'8ST$X MEUH4)3+.,^3>TO5*ATQJ#R[/A-S:0?ID0QY5+9.*N_4Z*6HV;(;55D*.'%;T M*!U&B2-H-MMFM_Q4E>TO?IHJ/6^6&UPNC&H1 I!0H)8\H]=+G*2F<_'^3I M7E TGZ;M'36(JH"_?R$B3IN>;]/O7Z-6^^&9_@&"I5 MiVZ_/UK?:65?2%&*Z/6U0.)J8$D*HP31TUO-G3I 2 ,'kJ7V31_@DA*VEL6N MVH>=]?&#LHA*IW,UH$)HRI,SG[JJ"%%EY56BEZ9&YMBF#!##=_Z.ZK3SY]GMQN>E.#>L WDWJ+W_E;EZ(/:O0D(758FG9;+_O15F[$<4!Rl%VN\XG_%5H MM M?.BSVJW+L(722*M-C0'?.D7C>@;JH?!#7;U:_Z.F,6 ')L1(-8U8RD0 M'ZRO"WH/VA;(-)QD1YF%6RH_*I6@V68A:,,85X2.5J468MNOH=Z5@2S57QX\C M*".!XX++%8W/]>#1\D5E^5R&+S/N=[EWYZ MLI9M:R'DZ.:A[NAZ^RGQNZF9B2M7]_22B35:0E;D!H_N8/.3]0E9P";7%'(M"M2MC8KVW2CZ02GQL|1!VVS;;?CQ>AA,)8*4)8[&EGI0,J7Z&[8-WT#]V0+" M-;@FEAY+.RI"RH=5MQM+DA;\2D)T9.0D#UG8*P-5]ZCMG5CYN?P;K0Z0=H9Z@(8W4$T)+!1,X@N:6H-M-M/9H^.X*>T 79VNBCY+I7E(P%;F1#-9]6BO15HI;IO3YLS+O!$KIP,=,\"A\I MP$\O)4"!KJYX@3UQ5[A4JPT*H0\"T HIJNE1%@1UM\I2W9DAR,VA[M| W90" MQ(X*\IE!#"(GO7I9#BKLMYK|PRI?+YR>,F^R';Z00:>Z7S'/';U,>)!,%N6 MT:-RT'U6,24,.X5N!U8#:(69UDL'AO)=#.OIT9QU4+[_Q_83"M{@,&NN2I13RL|W=DHG-^B!WJ"C(A66R21;7TNH9JOI ^%0\^/YK%N&=%-G MJ!Y3%E33M#/|:KBK;WTJPRIZ>3@056-3*&PB19+]J6@YWFJO1UUSIX64+&7L M.C6K-^J-4@&:U0E:LQ6]O#&8V0O5OIOPVB44 ,+VG!5PU163?]*UTX,,V88 MEX4N?Y8?ATAUK(PM!$OATY=*;&-\)M:%N-AFJVM&NS8,5EE66&-8U*@915G; MD91^.,\ZWQ1B=1OW G?MC6DP@RGT&43H3B/+E@RA_-&MA:WNI#<+Y5B*S*UM7 MQC"!*#!ZWA 5VE@A^Z5?!UD1.9Z"M&!D MP+$ VX':_Z'=FLM^0^6! MZZ6H'*)DYS?NVXTY\H6H">14!F4SFT?"K'_XJ00P;6XN*+N^*?#DD"3N=A 2 M0/3P@<] &^7,?!4[KQ=_X;JR>L[1R /WKXM6V'2K60,'QDB\'J6&IW-4UZ0SH M)<8&%0Q>?Z*IR!T5>"LY0Z>=I?M'NURI_5H<;UI4W/L#+M#STCID89[U+7+6 M|TMB\2BCV|8X HZL?B5U9A*_,Z Q? IUVJ4)SX2* ^&S>8.58+@[3?Y(I*A$ M@_VDHF%_G*W7I-K[>,LUIM@0@M%-6U=(T;+A$F55%Z??BBF5X+\I7#,(FN3G M<5LW:KQ,T]D VQF*,#?+?-FJU:)M &9KAT'5D)R,<6*A$#(R!K/Y"WD7E,*) M2&*++2+[%&%0I\"1>@,N0"&T1?;(4,^BHH(4G*S6!9VZ(X.2&-2;%,@B.0< MR8YT*+Y'GT%@,QK(W+U#MS&B1^A>M304GHZL"[4H)$W<-<3+AG&DB8^?A8\/MNLQB<;61V=83$+6&2EG2F1M(_%CNW^G.JAB(ZMW3%E!3KL99'5T1JC#3*64 M2JG/NZ46HCQ=RLYUO&]PV]I_F?@KV;6?*5 M>WTZ[27Q%TH.RRS?IGYPK]=B4HEW.:E^DlV.*L>*-SGGK M3C.JIP;A0^%U?2?03J;]JTU/E7$E=SD&+.RG%"CP%,C(!O?GDFIJU2IUGNFZ MA6I-WN7%2 -'TV"_LMTI#:0?(*M[T5%93^:O0!\3[@$V1#]K@JF[A_20..:E: M3G.&"&0*%G:YE>&+|L (DEI@83GW22R47-L;R82ZF"W$*I6 M[C7+]UXUZM$<1"9 KT?)LJ(<,PY/1+"U!'7#&7V@;%)5-UTX+B7ZP#ZG9]B9 M\$(,4.*JEI5!&O,N*11_7;Y.)RUKB9_K 4,&u$L*AP>B*LF3W>)H0#+HJ M7_(!.UUR69TFI.8YY[^I-)"*V<^] CT:JG?ODX$U59/I=_.5YKSXFT&I>B8$ MQO!A#0Q9T!N3?A2M1>,CVZ3AS)%^U_%4+]9S$EJK;&P#!\(M/:Y[B(&>,W_1C M CN(NZS^'(/Y-0OVDX!5V$?0=%E5QS*FA7PU2^XJX!"9ZDRB[25]OYN6@GNL MSKHOL9$EU(/)+I[95]I(-8;E ,V@"(#>5+8$<|!OZF1 0AT-QRNGX3\I+5 6 MV*LJ3Z1..8*R7>!=_;M+05M9$XUT];UDJZ*S6UP-CY@@A7)* AV2@BV2A0&? MIJVCKGV", "@Q557+B'-4*+BU5$SJZ"G3KL?ZLD.'^28"(DY&NA*5;ZAE%FU MT@%@4!,Z>KC>-NIRJ_K\HFS6/^\|H-%QZHT@S[805.A -&H,QX!0$3(5FVYV M-Y!!H[27@,V=LN[!G'5WIZS|E'5_@?4R1UV-VT=5XS:5SNRIB7RT>;K ^@A>M\JPHFD0!'< C$M*EZ9IERW%,O8>KICNA64'

^F[\A3;#,H!UA?*C=TC=?BZ M\F'9W9/MU&]-U_*M8=5!\0!&=ENJ*Q M$BFFP)HV7TH9,*YJ4=4LYYC&XND%)X]K!#F;!7%.W:4-N_ O]8L.OQ[K3)-* M6[W;'V$QL)WAA>,N]$P(7TL>BF{U3]M$RC>SZL&\SI-;C2-R;9[3]3'\)7- M.TQ9H74WHM/^(VS9?N"9"-=>>1XX=^]H.(%MA6'H__P>7.=4&]#OO@FQ@%45 MW68H8Y7VY)H]0-,KM&V_L[T&5JM\L66:/Z\]]7F85;OC3 =Z-9.NS.WC!9<(-MQ!BT)3Q CPK"=D%,)B8QO@$WKDQOE-EH43?8@Z10@RM363:X149DX U31.9] M3]"KKL5$V!-AWX:P^_X5?=YA4S,U(5M@3'.B>0GDG\8XIPLJ-&L["UEW2B;$N!Z$$G':.V"YY3). SMJ!DV2I(8_/5N<,80-:H %0,52G4@*!;+::'X.AQ M/]NKFSAEXI2'<0H)7=T>#>,BJ918ZW$:M!{JZG2.R03.4[D^'#!/:"Y]1ZC MG?@:,.+/#MJ+OB3@G(IR(\/Y$"..I;0DOZV*B:8MXA:'O?<="7JT0=V4(W7&K!(-M*6!1;IPZ#3-7[Y@9I1+_0#YE*FA{^KGV[^7D"DD7>%G$VU/M+U# ;L;' PZ M O)1KQ-N$+BN[O%70S/7J.I37JH2SFL%\&L*_O[128.,DR^]:[X&MY2_ITEW M"ABQV>S2C?^.;L?/2@>6Q_Z.LF!AAP;8OF[<K_QMUR)SR7$,LT15@HO"QZ|" M'UXN1@^-U4TG1%E7$G@TDW.GNW;EVBE*Y:!5A *A6+P098J8+]X&:G?OV! UMF!N_=\UR9%"Z$>NPT)52@94^'HC:@@4@CFFEOQ:)89(BR[P@7X)GA M.0[0SW33>HDO!+E 6,]\ RXQZYI*$DA(0:JP/ZH@KQ);3"5)C3W3M]+,2VFG M^X.R|=%*)N8>>1W-/CK>O!(OGAD#ARRC#M ;8@[8Z.;KT4ICVO5XGHPNW"*> M-VCZA+)G>;7 2XI^''RW3GP$<'#-FV7=)FHFLQX,5YZPGZV:TWUNIG$JF!? M]6_4AM0@)+YN:Z'%5,OV=(V$M_5-=S>.>-[XVNWS?,K'#G'Y4V.W/>*TW\?' MC$VHJ>\3B,l36:;WD:@5E*%00\?^\E,Dj:'FE3V?SRH9;\/VR/F-#Y\-F#KM ML)"H#6K9M)G0IR09VKI3MK1L1D|>U!'$=\,6=M6M1R!2U,AWJE9<>=366(MLH>5$DX:S%"$,>U72*I6M@)\ZMXW5BE5Y6A%LVOAE:/^R|!)J!]2=G*PU+U_(X M*[5+4NJ.PLT;9&W>$$.ABM!XW;EQH,MKL.AO..MXMC(WAH.T!|J\,M"8.Z=I M|K7QK50#H&?7@)GJE:BS0BJ43U)<@YV|E01SPIZ6H/+-\$A5)O$S1U!T5JD MWBYMJ6?[Z!ZELCHGN'8OWJVO2VI- -5W1^V :,V:J RB^JRN6W3TFM;C!- MJXI>V<14E4@.FL@K9,?V-J>R1/;^;4ZI:$++MID\(%7_UO6X')H>S;)-R4<9 M^2;K*0P=+JL")%"L HG(32@X>KDBA(Y6$^_-M:EE%W6;R/F9=T1=KRF M5*_S8NMU)G4QJ8O;&%2PY1@LY+IGS!DO3]$Y.<7ZW9+<#66F:]L8+6H,)/<&K)GI(#V>\V_K MLP,5-!OS2C*&G,.&R"+ZU>11WW1KK351UZ>K;=']I,1OWTME;J&EE1-VN^F%"I$XD]G,2ZKE2$^JE;-7-3:.R#6:L[_HFON>%.?4?L,66*W-B2%&O.+[QR3:3/5MP[|/6U6J:=PX3Z7Z\U>ZJ@3!J8.NCNNI@EA<5=3K$S%$74OL<@E^$%JB@[Z3 M#]+2T ^IL2?.M=W#8U(L!]7U&P_:^8WM/2FH,XUVI 'YNMI0S:LS2&**+S]7[M@CB-?MKL/T[Y>%70FS|..9>XSI !TIP@-!(W\L ?A\Q=S]:4/TY/NZY MVM#\9=#_--M?MO>ANAY?K9MS#)S_;L"E5#*#1AY,&G;,UCIU M("STNTA:?/U,R38UE61M;5V_CKEQFR\@K)DN&Y-)7WE]5V.F2\38RD<,*\[' MU;]X^$*<8G-A&0@9 LIU[X6]AM^VH,@3N3^R9@,,9+>EO(ZW*,]Q3TO^77>) M58"MO-3#C?>V*]@K8)(-D.%K^K>M FYE-UB$.=-XHU$3XNZ[!DQM&OM K]+-6ZFQ+=;+#!A@S;2+A6SCJB@SD9UCASS;04%'I#K31-];= J1R+]W M[*/)>/3F8?APO=Y8?%>F:J%|(<-3CS\>KA0=SQ0#DVF)O8S!*J+(XPJG:/:1M+*B:Q,8N>Q0+I|Z@F8 ME,KG>M6\39N!|O4J6W<_7BO25ZWT_T|C_8&##$_.VD8LX;9C\$XH<'58U0N5_M_I$U&NH.XXS+*8$<2$T,6<)D2+ =?_"X6OPKWV3X:+"2;LZ7M35^BRQXFM/2G5S ?>& M,4AIWB0M^=*]2H(75TW>R+ET.J*)4>\\ !I QUHV<^OGOL]7=^XL3+B<$-3 -V(@,I7:4(2M0BH=077ZI3KWA_"@@\\;X'Q_KX(%GXO%LM^ MX-0*L)WBR7\Y./A=S7RLYND/EV:)!8%SNJDS^]*0\5@,LO:U\D3Z7A.<@AV%)%S MECBR*^Z40KGUU,?CJE6CVWE=T^"R;CS.%FKIJ|4W6J*,4:^0!,$WKR8CE2] MF62*8VX<|ML]X()ZK25(1_CZ0W0^2U]=TOO=\!/4$F3-4![C#6VA&'2=PZ: ME.@SQP}56:ZZECVN8|%G^!87!C-]SJQM"B:R!:V,I57\'FC8^?YX9GT&? M&L',(.2+^?_9^_+FMI$LSZ^"]V%-N"(@MDB=MG8FPN6CVSL^JF7W5/3^TP$2 M21%E$&#CD,SZ|/NN/ """%'59]@3NUTR223R>._E.W_O[..BGO>F]>>]-W0\\[MG?/9Z'DTX.!LI<9/L^B?:=7C59:A_#ZG*P"OU'=X=_7W|_XG MP%I=)\5!;#H=RWJKG=!@T4T3FCQI,?33MZ|#'.LC>>@'@Y"|T>VL"7:N4"3# M1?@>[CC1HE|%..F_SAG|5N3<7Y TA!TVAWX7QN0.F8H"D%2L0IN8\":B"A93 M!U?<3OI]ZMW:+("(^C>)HYL^>GO%++0+/!K0PB'2H%,3(MU14)%-)<@77_M7@/[4YO$1=;ZNT#FCV1507 JU.EJ&TZD[FBM\RMR'9 =*R86YJ\]4J-Z-7A+3+ME&BG M|[S3ZKJ=#IZ3[/3&CXI?]D@O)M-T]ROI:;,1&[D7!>SU3J$Z=:GGLG_#], %CU%TFM9<*>H?Z>?D1_"INIGD?G?1.CP]^=LTM62C;6W]9\ER_-SCMW^*Q6SRRWSLY M/MRW__>#7NL7N%4+_#]_J8HV(XB+X13X?!B-OF%W[2S>$^$WIO_K%GY.A04[M._"##G'3GNNE!LCBDU^QH%KBM#B)\G7[67J7-8-7!%5O"..+ VK :_[KI^.? M5B_4>*&T5W)6I60%//H>?8RMN(V"N%Q16:W1W8Y 5NP;L^#^P=83T6YPR. :M##MEV^G^#RE*QB[8>2XX\%6N"WN8!S?3P? MW$S3)$?PHJHY@B6/1TNTR@Z?9M<\;\)QCYULOSS\X=+X2.+C=31V@]WHF/E# M[LX/DI;NDD%%F^R>2P;)W/'N:4[0D\Y+(I2G&/;'|_<;3-)WY M.S9>>,.U[/S MC=GYZ/!:JWF33]RSLV=GS\YV,YX?'+YX^D?^R_U8-C=WHJ_K--\(;7&?%G5P M.V-Z(_;A49PLFR%)?ICS;'>7Z^EZ1PYZQY,KZ7'!#GK[EWM[G_8]:GZP.X^O M,-]H0S\;*!%=N?_R/B-G/SZ0W,L(+R/N._[KJ7C+CW7'ENNI^$D>ZY-:[NT] M=6NJ9FY%(XVXC@NXK<"Y!60TB#OJ_HH2R4W1\Z7X.+?H[!\RZ7-%CC$'R/ MM9VACZ/PQ?I'!7GV@U8KN?:M=.:)!N'!\:D_;\'V&!?L%QBQC-!5US_H@?''0]T>]-4?M&?DIG^Z=7:'[M^|>68?JCWIBC|HS\E$_W+F9./|P_V6JGXJ,D5'LSYP8T|GXZBY)"=Y2>%8@^ MB:VUL5?#O^O$AVRVC>6\>%W_K FDW1^VYIL-6*[G6\^W3_6P/2L_Y=/UK+QA M(#C>LEFT;(AR|_+Q7HV-.*BMFU>/GC2;>9GJ#]OS[6,OU_.MY|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|ZCAB7FWR,L++B#M6RWLAX86$%Q)>2"RGE_NSS3941&Q@ M'=C3M-\^J2I(\!*#A!T3!PUZ V2A.*^]?I,<;>)=]OLP>1N]T9LO>2EV-3) MP8^A'J^D>;FQF>?NY<9M0F)'#P44[>6&EQM>;CQ%N7$0GIR[_>.3GU= ;/0\\?:XVU)K/]Y?Q3'/EE4L%+1TM)Y76>IA&< M,*%!!^?]4F6U&XUK{)"+/[+E.[3>?A2\\$X+X)JHN#_%TH%4_CUI P4;$0< M?%&S2DV']@@.]L-@L#\XI(:W\,=!H47Z1P3SCH(9! M>.,P/293|FN3PWQ%&1(-7%_"N*3";X*CRU=M/'|[_]6]?WWX^D%5)%&]YPAOJ*LDI;7AKLWJ M8I:7L/6+R\=7]32I_?B31BG03>8[*0C.5:FB HX0]?<-G%2:SY#Z@K>M=E^;_M,-FE1[<#$]IQ4]+%S4+HOFQ$!<3"T_0? 3<_^RHM]\+^Y$:B#H5&5%@ALLY3!|VFH$I0SEZWHM-JRGHH@I$U+"F*Q\G&C7>/4]3 M#)4>VYT\+RN25\\.>J=F7V#$*R,D<6OS:D(S^O7MJ]>?/XD4Q&E^^.?YWF"PM3VMQQ2@+4+V010EJGNW#,O!A9YXXFX%SD#!O!3/)YT]UYFV'1<)R%ND 7P? M'%([JN19>-4(S*":VDT]@N^4^@ZP?T+6ULT*_*Q*DMX&*;),P-JQ#L-NP';-MW=IWJ*HU?1X#)}X7?P5B'H|CG2O^,[1D%Z2LGEH|#LZY@ATUBB%|>;C<:DJ M7&^2\2]+_"E\EX<+#6(2 XX<)9&^[>!MQ^9M_DK:D"OIKRI3A5#UD>*_US.%[\6N;W)!5]Y=![V?C5'W?BQ.0:RC57L+,ZVEV%B?E M+(WF+_';LUD4QR!EG!L MSX,Y=UPZC/G2>F^K^D*N NA6[?,CS^L5E,*. SY7SRY2=&2V$D&Z@5,HX)K MZF545_E9\PO85_Z8#IICR=$8%O7GVTU\,2MJZ$!O$/T'DZHP_^CSV>79'};R,Y80T;?12N71.|+0#JE@KJ&'T_QNW1G@Z^ ME/P(I\MK_%;)/IQ%149O +%4PN(3?HZU=&G>$$6;XLA1. M336E@"OLAE$:92-R/RP9U3/W#V=N(IVOT7=M!.\P?[!AK]$--!:./A3X-=^? MK4(TNBE/0IAT<UB?]8_FFV3M,*AJ.+<)&]>2'@AL8>7CQU$;&!]7=/TX#I[*H@S4N/WW9/M'#3H#9"%XKP>INHQQ>UZE^RS!Y.[W1NQ]9*78G-'lI?E;N6F>27-RXW-/'RB7T-.2&-OW@OQ&L@_[LK()T=L_ M/OEY1>5;?P#__K&&66LRJUI.A617R850'2T=)M>YVD:P5$3-G=PKBY55KN1-MN<8.N66!6[Y#Z^U'P?L1C/,BJ"8JR)),!5/X\:0,%.Q#"Q1LTI-ACAH(#O;# M8+ _.*2FP_#'07 5E4$8$H1VG6]%^>D<$TXZ"&07CH#TF4_9KD\-\1M!D>#5Q>%4E.85!C 6D>3X$H%))?@]22K\@"F]S&:!P=]>FV_%]SGU LUC>"'! MF/LF)YP2652XCX%,U4D>1SD(#GD[UZ+9N+D,ABE45G^UT^SZ$+M97FL M]#;#P>++7]:

(¦P26\A!.OH|E9G)2S-)J_Q&_/9E$<`M)|F%XX9*^###%@\,?_%&753*>ZQ?2HWNPZK-97B8TMEX7B+GO2#(PYDLC\;ZO`M*=;N0N+VDQGQ1#XX;0A', SY7SRY2=$2B$F6 BF .(F*ZF545_E9\PO85_Z8 M#IH]8]$8%O7GVTU\,27KV[AQ/JT 3U M^>SV?76N2A45(Y15+T!&9?F,Y22P=M6:\¦-F&RPPQ=IXZ!BYZ!T#T>L] !9
M4<(E,YP'S_J]XP!>D.+=11U#GAT<|4[-1W#A/3LXZ1W:W]SD7AOETUF$-R<, ML^9#![W@ZF292<(?>)-?LZ0;30K5@UF1P.G!O@91517)L":]%*<)YV7>#;K# MLT-G[3"7*$WS453!R#B9LH\-\[*"=985SZ*8]0F;?XZ5 M*GL!G&5IB:8#7V#U1!0QZV!MQ]UL(ASFYS3 ' MGOF%(G- P2J-L1 K!D@H+*/1I 8[96BX)) ML%7T.B|FXC+U%-^@>#B I"#S]C^CZ>PL (.^*L"TX\-')8I[YYS+3K\&B_-" ME8_!%Z<4G-H,YOC:2>QV,]GF=,@33-Z9*JMY;;GZ=YVP3X%MP7O1-%W/BHQ2 M1L!{XL6'^V:EP/'*#@>.[NO7197E0UJ-)M,&+66NOT'L$]\(3303@4^',$)!JA(!ZX;$I^-B25%[T#0RE6Z73(K%278+>B M.LB^.'PK_M@Z^WX8<;5/>/.NP2L.' WS-+Z/H_V0@$".$Y'.KZ,9WHIX%0+O MC^[FVKGGF2[EPB=S1NOK+E_X=)"|S $^PE%YMPZA/L.@ST@-D%:D8-@4N3U MQ:1#>H7HH|$ERHHHJ2DR$<075P4Z@(D)<=(!H?-D-&X!JI%:]JVGP_QEQS M>-8_'CA.A"NPXX.+ K'(0"<;*15+[_HR2IF8Z,)7L5)3\@7 &BAU"O^&'1DK M$OQEE8^^A2#7CQW!3F-GH!PT1\8!7X'03W&!@V"<9"#GX;:OP^/'2_)BL'Z]//|^'!6R6NX'9+O*C[C5_7W]WOJ/^L'1IC".RO5RU*! MG0Z7H=X#_HN#GUV!)@MEB?:7 M)<_U>X>#6SQUBT= (1O<9H*;O*:CWN#P(=:THI+|=&4A>Q>GK%O=?FV'7LV; M'7?CZ3U=C=W*S /46NW&8F_3=OK1%GX;I\VR?2&+S=/ +=NJW]?B-K&KNB?O MQ]^*>Z(!?TOZ6_*'BI$;P4H]"4'3,&'_S[#XRW^C&7L[LED'9VH3|L]?OIYK
ML8$UKH=\,\VUN*:,3P&|VTA(EXO\U!ZC)7;HF0\,@\"/R4K<=&&1R$I_O[MVWSHOF.EY\=YM!:>'!T?Y#X6\&_'J;Y5J3R!>.L03O.G26D1PCW",'=LO4D M/!T\%$SM%L.$>_'@Q8.7#_]!NA\>WJ/I|&3$@W=!W8J<>$,7__RA M?CW4[_7$<]0/CQI,9=L@I%^OM'EIX:7%?:5%?W\0GMRC|^P)B8N5>.!N,OMQ-M[_@IUCO\K@+$.ZLB*4N?1G_D!=.;+2;'C\I(&A* <$5@D(TORH\$$:!>KUZD, M;8K C7L954P(]AK"2J:ZSA'^2K*R2JI:*C,CJ=:,%97@4'4$3(LPD>SO O4= M*\/PLQI+X=)DFF#YW<>H^*:H3C!.^(O!2EM<;E|W,1MO_XA%M-1JHL@QRGE49S63F"5#(&#F(^@I:/)6TU5O;%P#4WSI>L$"-^." MAC7\&D?!-]ZF%[*]JHFMI>loXS%;4R1-T??WZ7YU6/ !OA:] >L M_R+I.,:3O27<_N97=CU%2;2M-5PGO8/^[6JXCG],O=.@=WT\L&__[S9C;/;Z M7NQO:3W7(O]M0A+]D\ZP_8&9Z<=WSK'=]IS:3WCO?N1[]^WBO?MPV;5;3$->M['BQ\\BJ_=LN=AZVW&7;"<5SP[!C9G@^=%I>'STXNF?NN_T_?3.U'.RR\F'A^'@\/[R M=C;VU%?VWO;U++?3@20.12V5GHM']O4N'B-:&LYZH?EN&V]^#P:A/V3.[TL M_]P[VSZEH|QZMGW>WP\@-Z-M/NP?JO5XS\K&"-.,M8[#NA7%$Q?&X747!DQEFM33=>Z+.|FAFRVT[VB*QC<)O= X W=A[UU7]NS*P MQ>P8W.[N/23FCP]^F9[U6SS?O%4Z7W^3B[X7H%WMW@[K+1'EU[$K%9K7:PRB M'V9/LX!M@^$0M*UD#8*QYM 4T$.M)R_BY#(8I2"R_NNG672A]K(\5OI\@"+P M:R&((XD4O[_<.S@;I^K[7IR G$1!A?@Z]30[^UVED;SE_CMV2R*$4/4,](QG/l0GIT#[;U3..XO2Q42GJ B_-B'*;?U_2*WH4WIE;C>S?N M.&@ZF>$PY'_QY"9%2]0G60K$"3(`+AL&16I^ ?O"!-!!X&6)23.7.G@QE M?/LM8$$?ZS0?')7R79T1W.(Y[A;8&L12AT@Q#BJ<%)7[CIY;27L?#).X%>(1#R=J@*1?K61 M;%9..@>+%3UP&:4XIID)_IG5XT@\YNR,B='5A%XK\FZ]JPMTSH 9KF@R5R"; M.O8;U2+!8!{E);H[HO'IP%,@#?=\4H%43"KAT#9+/NR>0^NOU%.8*?IW+XF M4SQ]V<'R'H{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|6T8UZF.*4U!$,-*4/%A30\W@W9YERD/PUY:PQ&J*1RSB_]0 M3\T+/#FB//2A+??=PK2G>[#SU9Y*:4R:.@B'GUI.0A,/.OJYZ;!M[W&G:Y9\ MBV>TFWOXRO(E7C;H75S8=[L5 ^[T.@>];-55 MM-B[@AS6B!DA*R:$B;AFHMDA*4)5. &ISRJ>L$7I0)2<_;/SI/R6_',IXO2 MVP=GP3^RDB^VX%E;Z2[37:J(_D M;7=*.S+' ZDF!95L17A3#K$.3PA1:A)RK-[!.@+DZ6'EE$F'K2!TZ%0I &DG M^#;Q=*5PIAF)%;=DH1?\;NYLCN]1*' *_%:QM%,%LA4767!P)L/ZK&85J;[] ME[*C7J);=:%71U*+D):1\FF%;A7&G]PKG3!A1:*I:X>BI.TID(DS9/$X%8D MV;'H"5T6P@))MMHD/A4(W<5,0VMB.=:NRN$YL1^1O3>X90CY9$L[:&<-> T8C M5BWS=F5H*3H2J$ 9]EU%8E^@)/\-'>FE5 M)KKKE)90Q1J+9=HZ*N=S0\(-^0?_3Z?@R-Q,AH&&@EIN,!WD?D)W1OM*P,U M^Z $EL0:9=HO9ASD]JCD>N&BE=R,L\39N)BWC:J_D O&1BDYM&&M6)2383BR MDXRHZ1H7MEP&)170Y:(E8O,_S9OV!A:HI0Q6CR$EX0J-H5=GZHMR3#;770.MR#"?2NX<1W8SKI.>&P,6=#R!%<%E66.M\M4D M)!N"F!W1\@@{
49=3&;,+7.3K%>"H.OWC*W\G^*Y\>K2$HVF!KKYD.>Y*63 M$MD>CTO4C*V^B0)W!CZ=_'P%FK*SI5@"2,'-5GF1&A1D2,H'$-%")-?X9!? M!L_[O]"W:03?Q-%Ol;Y|)OWBC1@)PUB>LZ,P>#ZD7G\F/5*4N(K<^AFFEG!P% PUM"G73-(;GH^:PR%SQ&@!Q6(R1K#*XH)MRY1\$>C.A+\<^5#4XJC' M?WQY^]KPCR(8A8E.\B+UTJ!@'Y'5%G,G9E=:R!]IN=1?#K/%MP-#@HUC.43^A \54*0Y*,) \)$D? MFYST,?!)'UN;I/'P2PR2F!-*ZHMP'F7P+Y!H<(=5M.WXCU3_C?ZQ-"_KS;"&WL-L M@X->\'=GEN2_ZZGO$$6&4SMC>P>(G"|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|[7[3^\^GW]\|?7]MYT^/ZWWL_RM5%U'Z+^E,B4EWW& Y'OL]X(/.+U-.KK?[$ZM%50X5D+IZ8E MO;,,"O!C\@I0B83)SR2\1DG:)N!'2)#27YC&D1A!)L9-IRD"%?YB# M,:\)2-1Z3#)TT#0HX6TIEO>5;=>)(*6GZ2;S)8H+?M4L2,7DO5N6H2(;HUE%I?F4J M@#C7SXU"XEPC[9&YW@<$3$$XTQCT@J/J+,.1?5L4863-=T NJ4^3H1'PM2JB4]M@;+%"B1'&=$\\2I<))R5?DIH0ZN5Y4WZ<=6HVCXM=+X2B-,8?#X4]3 M3*2,4BI%1-T/!YB$$:BW!DLIK]W:*"US?1Z4'WH5%?%>FN??)".T:E;YV/-/.8CP<]/&
]\VXH.\XHMY14G!N/I10SI!$|)MF*A=OGRG-.A/A]26;7814;&+^'DL"IAPL3^]QIZPN 6_C7 MMM/.>HS%/=]==TX<=VZ[=*"3O/T^2.:*W%5@QIYN+WH|U5V\,0&[,16./IM]'(Q|V)>..5R^8S+717[0E4@2>!4A<7NQ^_)%)L24H$Z%]A*RK*N:+!] "D# M2?RO(UO4'Y1U(@@ 6%#!MH!N7X@-:^#FSP:I^Z]>3C*$E9^%"G%4[3QB[(O-GQA%1(G<%>@>4\T}[CL@9>QUL^IQ[6 ME']'< @4 Z=O4$LT];*%FB$& DA$5SI;"%Y!/20.I"6,,8KZD8%L!USW;N_L M
F.D1MCP)"^@RC0QFKIYL(E9=KT/>416TE6!OX"SJ_*KK/6;7H""OVP.OQ9MM=M3,^J8.^U"B8IFZVXK#>08-W%,2,-! MU9HI9T<=ER1=;*KV;N(<+-8(.GX#9.1Y>VB;RLO-3P[#TM;TYU+HWWC&&VC, M,I9 :?@7F68J&WXG148N$ M=1)?U.T340>(.3*#?#THL[U6H4S;,.#TPDHMXPSR <FZ!P/6-\WFRKSB)B<2GW3P;YM#%YE1?F%;3;5NQV.^'>_$:@^,?N4SB3VXJU%H,^AXR:W]H/UH3=@S[C$BG*"T#G;NMH0.1=$MX,<:V%^ M06K?T&<@O14NB.";V+2K_1BWZ$CZYIV45Q]=,F1NLEW@JW1XJO5$L@L'F""4HE#@QXEIS_$(''(/65([H'&LI"3'P<@4@2 .<-AL3#*!A6E^#SZ 1R-)9VW$#*NG-09%VY;<2]BTT8* MQ^(?-GIK\:TK#DEW;,Z8^GMC-5E3K|"6 RXN8T33Q<#:Q1,L2Z0*-S.UB# M#|848(0=WJ.=7=$A)P\R.%"KL%.I"#(&2@^'!0N!D;1%2%[@5A[5.]^UP+/D1!R37[&!_ MK2&QB53FC/H<65-2WO7"@_/WIR29_1?VB-$FF(A?K$9)26[?]"2'ED!+*--5 M+<%,$R)HC%?NN5L&Q"UI:F3-O/P @^UWQA?S[")O2]}&KM#R,YF*,>(1DDG MZA!D+WI'1FIU!C_!:+O*BV|\Z&91H:01)KK2A*M78'SJV$7!SEDTEX94>NLM M< ZNPN0Z$1Q.$+R6!'X3U#1K)L$T5""(LRBAO4.7'*S9H10#7<+@MGH,-)%P M$ (A*O.4V@O$W4C==E+:A#34L<@ XEADQ.7F"15*IR*R:$&A]ED%HILUNK[(MW]$I>X M0^+&^&I 3GY:C;O9,]XD70+(97IV'W8Y)ON!+WH|U5V\,0&[,16./I SX!/\)U93!KD2D*I()_NVAD(G3!F-V?LRJ:=1UI:RVBUC1%5=*JE+ M(EA)[Y9$,U!5PSG1ZP:|J%-6E<65EV/@0,SV650E&99F/$A)0 M)+%>GW\)L#$.5_-UM(8)%WO81%A6QW>.,]/)C!3FA=%R\UDT(1>^ADR -WV,O M&TE'M1U-$<1=7C!4O&TOLL]$1UE5[#H6UUJW/ZK^3K&('E9S*PXC0VK\98< M>X+-?%YNCE+KNW/[MQKD(Vl.Y%#K_)@EER2O-)E(;94I-TOVNU-(&(M|KK/ M\OS?&_0=!QBSL:LM=,F4NU\#Q0UKL3#'1.3-1"4|HJ$# MK^GO&Y-]>&UPY7/# M7;A!Zl8A:M) _:%&3*UTK!M-SQ2AG6MN"8U.#RQ^*ZIQGB:Y)T!/@'D:0*VV7LG9LA$U#=\&H#!W1&Z)WH)A&H_PRN4C2=A;+ M&,QL2M#P!.T)^BX$'8W($T?>$2 Z7'.1&8)U%SE86?C8DHAZ+T1'FW M: Z,"HI\]45"$)X%+3@/%,.V((.$$F)$.JUXFAW]-AVK?<$Z0GR+@1I [1. M^,< <,.3-4*'<61N%,W8YTNAAW)>XB&3B&Q:9V?TF:=+3Y>WITMIL\-X=HW^MRO/>,M+.I;AN(VR'YN&RO&U1S)M*N6C<1BER71KXA=*MF=4V9[Q&Z!-^_A?$,.E(F@H=*)@EKIXI@O', M6A'!4O=:LNE7..G"EN_"/YNB$ TB1-!!D3A*\[7^9A%E902295P8MNBXB^' M=9+&,G;4&EV^G+6*FA<7468L*6?3-S*(YNNE-J'Y>ZLC72VU9.OR-.B|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|\><,([P3XD6O_HB,'K@0WAXELAOT7"A;63NM!5G2PAWHT MA^7OP7\<@TC7=>'SG7@XCM@7,[852]"ILDL-VZ8!I0E-##IS!^&=IZNHJ/ S MYE>FT3S4);Q @@IOZ8Q*3QG^O;,F'F=Q4413LRGX&LK6W6@@1(:F;/VJ(M*U4N4Y5A$WMM8F-F1G C&(E&P,=8VXY2$"-B%I,UX?@ M9F>1LS9JP!')ZJ*Q@IW>@OH1,ZXYNGG4MV&8H<$XVB28,\O'(6.#I9+BA7(ME+C6(^+39;=:0.U3N-5;1@T-,"W5(C MJ05LPREY1OF'"[O#0?S3|SF<+IO MG@; WDB9XU%T?H2E\KO #BRI:1;A102CZXUUD4O+Z1H_>8*4.M! M[!C"H*F,9-Z0C|U\V_@)N;!KQ'4VRB&R^^"+*<0Z$A3J M# !4A;4TZ8!UVT@2W665J&7-$ZNZ=ZVYGMW"':8[K:UKY1R[9{).OJ"D&T=V MN%A#Y"KA3L9Y0Z_OUN;#%>]\TR=++>R*^.OQ[/UW&&HSL"#A0-JYA:_K:\+8# M=J=M-0Q26-L;MD97_Q&47=*UB"6&)>TFQZEI;C\6U*8K!8)2#@#7FEG M_[*L,8B(1I,.&UDL5-<6[7B#AHQ8GFGDQF386$)E#G8*82U=&5]7D[P0W=M" M4S8EG2.'NJ1:7AB-N"[N2U)YR^P.8JB19^9ZT6P\BK/K;/)<0Q]HDQO00KCZ MJF_4%%@$,"F_#9O1,X%&0NKJ*#-? /!P@*KPZ;(N9PQ1TEJ$#FC22P?!Y"\5 M2PL-H:[]6.#;KJU9;S="\|X=ICV,,8B-I[51V7;M&(*+!&[&J.#!)DL>.<*1", M82N\C>0X[^CIS)XE%,+./5|E'FG#IWYO5^HWI8:,X*)?WY?]^_V>N_L-H@.5S6 MJL_Q&;,;ES%[(#-FM\SUY2N,_#?S=*\97^;IB?VNQ*YA!<>V-173.))=YNDE MN6O)Zˆ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¦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{.:=V0I%&ZK8C,VA?PSE& MD:091%+I]&LC 25^;39;=:0.BDDIRLV!!7@:+*BN[M,X#T1::H*,,"DY.N",'Z-MUQ0%99%@-04^#=K.U)I?2='RYG+5)98+8 :??8!E)7WIAH,6.D7M5!C39[EM M\EEVJ*9\2*+LUR1''=?6[X!:$&.=O:E,DF)ZCCC1_=1 ME;,#NK6A%(YG.J9V5A#?F48%M^ ,^#7NT%+:*#OCQ.Q%V$ MC/V!](;=MQB!+@@7BMIFCL>)ND_J><-:+4\)3TR_"=OUB2,":]T6)XQN#D4M MPVFA!E(&B1#*$S461US/RW9EW9XIVL)BWN1*]PBFZIPLY2?J,]$TUG8V$Z5[M)--P M&W?DA(IL6J1"!(ZA6Y!;Y7#3SJ+6'>?SW35W=TF1DPH((QFO$7J8(#^E5/;F M)K;P4ZE.Q*M1?8=;B[0[3<,K.Z][O&_2H#I]03$:/ U.\5%-ZR2G-<[; MJS2"[Z 0:/^?9/-H)'U MKJAD!@&9 K 0D%G5=T0XYZHHF\YR(DOF7%*"Q\62'*NWBJ&>QF0Y-3>C%_P6 MS?7!!F|R%JR#Z,*]}SO

U(W=\RHF))'|H72=GH?=!OE S 0.E@.W(,154IS"RLE_+JEG M^X V(/E7T[;'(L_*D!>53@$LE6==PVUHEWJ/7^R*^N^XW_V5$- NWO9\L8[MT]*D=ZU4.;J?

S'WIVV!?"UQ3Z(>;8UB!HKS(OVVV39MT!8I SSN[SC*>&)0W M=!D-7%@X\P"Q=679W^P-!J/@;C@WGF9XF>PS]+Z_RSF>V[I<3JI8(]GIBN$ M;_ES'D98"%NFYMF"]{B&4^?

D5@THE],-I]DHV73Z^C]{GOW^BR]6(=;[SV2+XMK]=O?'KNK]_\Y>L?7WTWLEA,,'%S1?X'2/SLC0[> MDV;%T=KH.@(P_VX7^(7WSB6-96)[X$E,I]W@;/.N1-Z6G=4E?(KQ7B_1:$OX

M!^_K.ETJD>4)4YAL,9D3I=R@ADVR*6 S(YCY7+ 32>VW)W(4/:G- R1]X$ MY&/1!CE!U\A2)B^Y-;? "HORR*RVA_Z8UW:OE"!DQKE<

MD];E/>VXT#4%CA2SM==FXG9=`L:I;8SI]#^RK?!8$[7K8-^_G=`5@4?/C:KT M-KM#<\?>R;%4?[VM+E?L?VMH@-%S6+TFQKQ=TS,OLF0W1B&Q9!W(KYY(B<\Y

MX]3&/#PG4F<:BP!\ODQM8+9;<-1:2A@PGA@Z8+*_-_:T)VF-$=_I]BKUFIL] M+X]#(G_NKDT&{)N$(W8;]G73[&NBS&/2W#I,M[7API(C6T(]M%C7X7$CI_XA MF-

FP+T3HW(WJOUSD\YSV^#R.#.*5"GR_6"/>Z("K):$>_.*?FZA4?61ZAI@3^+5 M'Q|.,T3SC);PU$\-RS9-:L_?F_:AV063?H$26LDG21;4\:@URA:4[*> M1U0=>F(GIB!./IJTF"4?O4A*]N_RD+0

LAV.'3X)/ID!C3Y"O Q7=+0[%NBR0#]D@;H@-B'4E%4++!!+Y QP91#_&"!Z() CL MDVXM\T<|$6L48M!BR6)@E_7[SSW=)Q22[_*6(L%.UI- $A1"G:_PW%^\6%?Y MYNUJW?

R,GY^!T"\J.Q=%E)HP65;PLH+_.R2LX!G Q9[4GZ?%R,:C+*RI MF3Q?O:86JEP88O'U[1O&.J-*2CB"@TG:+4I MTW^N.#^G_5DQ"DOR'CNPYI*J7_?:YV!N\++HET7_P<10G+\3C-

R&ND&][-F MG-L'T;.LJ/C'AHK__1<+*OZ31<4O)GPQX0_S6PS=W/52U#P4X1=4>I4N/-3: MI'Z2)-&6QNUE_7TXGT5;G'H1[(,D8T_"R-=S"^LIE4I_!&I.]*/K9A6V4]_F MW

;,.L'26=LU2W3H?A(ZBA&G[-P5+FL(#OUMMF;:-4;_LBC:,0UG<&KJ B4QB\\I*%E.56DB@^IPON7.^F/U(+UK_,EWCR_66I%A9&D+<*;4.)4IX?V< &VV>OGZ^R[S6K+9 M*JS_+?

X&P&Y-,*2RW?*Z+CH54BCJ/:'")H1DPU(M\G9SR%([Z+A'L[26D#%7 M 'IU(AD3M5==#I N(#6[%HJ&KO[ADBB=&Q' @W76L;@"Y9'I)+1;-LJNJF M!AJLC.

(J7MM*Q.-4FP<9E2,#G#^2U-72LO7/U"".TC:=I:]-[?W%!-9NYT#^X%>-XYSX !SJ]ZVNEAS7Q+24K::JL;^ >95C5??7OC'_A^M1/_5EE_ M$:/ #6UCYPG /-:56W|(C. J;Q9@@QR4T*

(8H|&<^14[%&CE5T+)8QW!"]>VHNKU=O M@E,!GZ0BG4]0>RR6##F2ZD!6^5M2W"'HV\,<'<(PVO!3Z;;()%+:XM"%. MOD\OY:2>&1XI8M=

**<\4U>YJ&VYL0Q3F6!HINAUI96U$4KR; MN:|PC]!ZS@UIS:%-9@8-K:5F%.Z'9AF2PZ >'#F3_[-A(CQ%- M(C8.ZR.&=1&FI3E"59,2:CQ$,)IT?OB3\QS\V+A+W*2>XX,YD'0P/G#%A9"*
MCT!";)-C6W9AS9+QJ*.^N5^;W+(:]47"==M.9N"!F'L4#.32>(=]1:\3*[>L M'WZ=\+L0613[*LP[(BDEDNC++K@D_Y(CKA>?Y[GB4E+&O3AAHLB5XP$KU?? M ,!#4&[.#ZZ4U**

6%%85[:Q#9=/BI,*+/7UV[JY]GP*N9^]FKVD5)L=.*MV:1RU76HP[=YVYR(L?E+R172E7;^&P<6, M'QM"K.#8 \M6Z<:*_V25A+#M=)HI[9MD581@7?BPVE#=U;%XB)

MA;BM!OT5@[VWQE3)EO74!L;:>@0V^?T$VB[!!V<'SV D\$*,[PM=L'."><0V MF+!;GOMP)A=RCM 2)#>/6E=Q\N@M$W?30W&5=*[U-,7430:3_G 3I%"IV\!? M>1-

6644;NJ3>'D$^*YZM9?QO\(GRBE?S-C\2\7=&RLC%F?1?2*JH@\W<-^U> MW6?;1<7/(B'(BR3]EM&O2CG,PT1F\]^26F;PVOYV_>9ZM2NHXZ_RQX^:5#3T

M3/R:NO)P@;^'<(;EAN;D7.Q1S\QK9T._&H\@?;`KRM;_^2KX#%LJT+"H?FA\,CRY=GV MHZ1MTHXNO#2?2DKI*1 J-UWW<%>=/7)[;12TTOE:[QN5;l6V56GM&SY55'T=

MZ,);.VMP2L/QV4FK=R)2+^W^0MG9G>549?8F^((\+QS'B-XM>WV()<_BlP7/ MS$]I.S'QB@I8Z,-M10,VQ@V=*,(E\>H5[Q]30@X9;8"-OE%XQUZ&AX+ < TZ M<6FZX7F2?

T3+C^,"G/FR^"OL#+DP"_ZLY5#"?6.3]88$,RVT1A^2L%6.E!\0 M+'QI-/Q8Q"/T,AMJ);,_;2RS]A"9Z+RZ2B1 M^; M5]OWYLDTX=,]]R\30]PE797I*DP.Q9@*2FI@%[Y$NEU9 ?

(%Q"PR]\<+1H. M#/;*TV[JY]GP*N9^]FKVD5)\?(H^]GW+NO9@49L5SHS;K"M.]6%6MCA(1@>IJ)@?#<<GW4D61RZ3/#QE"$B#)WLU9?$@"&T"&::CL'T MT;'#-

%);K#8'.JP-/<7R3J'>#7$6OU&&KL[[LG'0#E,-Y4^$0Z'_V<* $7/ MZ/Q\IIP9Y20.X1\T85AC.$:KU3I'%A8G/Y']PFP&JH\2Z3KU*QRTU!V*,>)Y M]3Y"1Z>62"""]EP&K/N1

9@9";"K\!\TSl8UZ+ NZK#? MBX*;9>41>4J25/I$\EPYUJ]7-V$M$GE:IJ^,/,'T9:U^R2,W.^R6 7;X5NAJSX^PZT0E!ZD,HNJDN>@K1I\+_SICR

M\.6JJ+GP+1D+=KGBD>5>C9Z#_O;#4YXS<,O|{$?:IBBV:,9P7AN -IJL^#QS M)QK8!%P"7:),](":/YU!:4*"/&07Z;$&!?F))EPFPU+^:;R=5.!\!H%X1F6.7 M374!DDN:XD!+

D\VP'}CJ)+B5?24D7FXM,8W:C?M\$1VL<0TA'A:[UB5'WQ M!17!-(0C1PAXDD2SP\YQ*02$DMZA>Q!MU6.,4)Y;MO#?:"+F'OLUJF&O(U!Q

MZU@Z^*N6C;^'Q_17>$,O(V!HV^!ZALWQ$=*C3_0E+JOYO2?B)P'IKF<@&9PY M[2C=X&JGL1J|)A?]P_RPYBZBN-UK26[?,(IET!;IN6\!#;YDAU_LWT:G) M)_?+2!#-

N>B7DIJAY@VMXW+#J91RB6'[E@ Z<)1>HMM4\@6W9>=17G^K23QJ M]>:,Y_NRH,A>?0FVU+CPUR!PC%=]UU?_FX(NRE1T9S2XADM4#;DK\:DC1*-D M+E.!6! $#

(S35*+HSVAVG1HIUFD(ORXS572"$V%$!V3CF-.1@_JMK#EC*+ MV ^%D&^H@8.;_ =*VJG3)N ?X6E^!8,>AD2#CEE!S%&7E\YY)S8@<-<4Y;T M#; #RCUD2TO+]^%?

I:OV5[+#2Q+_ESI[7R:M M8%AY!- 4;CQ-5G;"FNL$/T(`)5#]\X9G""'O^<%^-AQC"+2](2D?&Q(709+H M2!@X #FZ2"6/K;&;H'.IAPL_$&E]MBK?#M+%_4E3%(B$U[^34$XDQI65,"-

]#BHQH&8FX]L1=W79'?S#4PO@LS^^ MZ*;XDS.FEJ1_H%RD.&:]N2&"PZSRZO=9A*EU#}@D07KKR^H2=END?^[\9@5T MJV\WFGP!AI+4),+KR+>*+/2,S;,VMMC?

**CV)_7PDN4U"56M9ZQX;,)QKTLO3= MTJN/.EBRLHNM,2,9FB2VD7

MV3R%;O.H=3$,,!4R(C4&|M"9GK>)TB@'!R_#P@GS5Y?YZJ6:B1_DI]N%J-A #%LMP-0$7$-L:P8:UL#G=-^Q:)6AD?O29$7H_'/UD@A(\90OB? M"X1P@1 ^MC,\R1J1P1?)Y\ZCXLPDT_K@:KP[0ZS]5,XR3ON(/L_$*94X?<&@ M&H0-K@$";NWHGZAJLW8R1BH'L,#H!P+,]#N#FZ?-]f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|U MN*DZ)UYWY5U ;T$E:EAM!>@$C OPK\/U%8,_ MH06 ,"P)Z8\-UO+XW"$=.? L%3^"2@X0UE>8&1SF4V![1[<',7.GL3ZQAZ= ? M+5WV(PXY[^==N&B'MYE,=9([W8U2X>\SXNDXU," XYS2\)++)-G)BT!.,3+.\ M.K,BD@6H!+4ZIED0<6 ,$A#>9!L;]&SR@BVJ\G63N&VVWO Z?!O19[R3RFF& MI<^)UR!LEK8!5Y3 +-AJ*'WP)E(%A.B8Q5GGV\BER"_,9H8GPE#<@ N:9J$ MMN2[DZWO)M(*T6&>]WY .*/#1YNX=- RX>*WK52>2X0RKFK;YR]??)~3D+I+RS;X3B2HA)44D9Q(7HHJ36WJH^NZU=QL MF_8T?$ZF>!UP6HP YJG4'9!(XLPQH]#8$.M0W@_P)Z8\-UO+XW"$=.? L%3^"2@X0UE>8&1SF4V![1[<';7.GL3ZQAZ= ? M+5WV(PXY[^==N&B'MYE.=9([W8U2X>\SXNDXU," XYS2\)++)-G)BT!.;3+.\ M.K,BD@6H!+4ZIED0<6 ,$A#>9!L;]&SR@BVJ\G63N&VVWO Z?!O19[R3RFF& MI<^)UR!LEK8!5Y3 +-AJ*'WP)E(%A.B8Q5GGV\BER"_,9H8GPE#<@ N:9J$ MMN2[DZWO)M(*T6&>]WY .*/#1YNX=- RX>*WK52>2X0RKFK;YR]??)~3D+I+RS;X3B2HA)44D9Q(7HHJ36WJH^NZU=QL MF_8T?$ZF>!UP6HP YJG4'9!(XLPQH]#8$.M0W@_P)Z8\-UO+XW"$=.? L%3^"2@X0UE>8&1SF4V![1[<',7.GL3ZQAZ= ? M+5WV(PXY[^==N&B'MYE.=9([W8U2X>\SXNDXU," XYS2\)++)-G)BT!.;3+.\ M.K,BD@6H!+4ZIED0<6 ,$A#>9!L;]&SR@BVJ\G63N&VVWO Z?!O19[R3RFF& MI<^)UR!LEK8!5Y3 +-AJ*'WP)E(%A.B8Q5GGV\BER"_,9H8GPE#<@ N:9J$ MMN2[DZWO)M(*T6&>]WY .*/#1YNX=- RX>*WK52>2X0RKFK;YR]??)~3D+I+RS;X3B2HA)44D9Q(7HHJ36WJH^NZU=QL MF_8T?$ZF>!UP6HP YJG4'9!(XLPQH]#8$.M0W@_P)Z8\-UO+XW"$=.? L%3^"2@X0UE>8&1SF4V![1[<';7.GL3ZQAZ= ? M+5WV(PXY[^==N&B'MYE.=9([W8U2X>\SXNDXU," XYS2\)++)-G)BT!.;3+.\ M.K,BD@6H!+4ZIED0<6 ,$A#>9!L;]&SR@BVJ\G63N&VVWO Z?!O19[R3RFF& MI<^)UR!LEK8!5Y3 +-AJ*'WP)E(%A.B8Q5GGV\BER"_,9H8GPE#<@ N:9J$ MMN2[DZWO)M(*T6&>]WY .*/#1YNX=- RX>*WK52>2X0RKFK;YR]??)~3D+I+RS;X3B2HA)44D9Q(7HHJ36WJH^NZU=QL MF_8T?$ZF>!UP6HP YJG4'9!(XLPQH]#8$.M0W@_P)Z8\-UO+XW"$=.? L%3^"2@X0UE>8&1SF4V![1[<',7.GL3ZQAZ= ? M+5WV(PXY[^==N&B'MYE.=9([W8U2X>\SXNDXU," XYS2\)++)-G)BT!.;3+.\ M.K,BD@6H!+4ZIED0<6 ,$A#>9!L;]&SR@BVJ\G63N&VVWO Z?!O19[R3RFF& MI<^)UR!LEK8!5Y3 +-AJ*'WP)E(%A.B8Q5GGV\BER"_,9H8GPE#<@ N:9J$ MMN2[DZWO)M(*T6&>]WY .*/#1YNX=- RX>*WK52>2X0RKFK;YR]??)~3D+I+RS;X3B2HA)44D9Q(7HHJ36WJH^NZU=QL MF_8T?$ZF>!UP6HP YJG4'9!(XLPQH]#8$.M0W@_P)Z8\-UO+XW"$=.? L%3^"2@X0UE>8&1SF4V![1[<';

3XMB7.%[]"';FUY%=#V1BXX|\ MWP^@]G591!UZ;Y_M-UW>E"B&|D- B)4'70Y*;NI M4>M>AJP6NWN(W1V*%B'(L2F&^]M'HK3(FY/ED;8Q$0(R",/XT*)1IEIB%7^R MKV\72-)BG ^61P,#?<-]5W75N,I)Y P=WC.>D;D6(1F#;D;1HNC) U)$F2XD MD"Q&V2\"5%^R^O2,2NU=4Q/,,&^I085<;_IT"1X_4$*?*>2\#D-7>:B.1.K1 M03((0FZAH^K]%VNT\A930:[?4/518>
<8D^,)@<%ML'VL7M K,&2>(3F54BJ0 M'NP^W9BH=%"3B^7VF0Z(E@ELWR$+GT*[&51EVU+%[N#R%MECJ*;JK=,2>,+H M>4QMU9@2$(+S-W-0D;QIB*U?
1M4J1O[C51#_0+6E8FX<.,QI#Z@)K0JF+OZJ M91AXVR:#BE*CEE+-0DC*GKM>NCNIE,AO)Y2"171*"-"IDEE2C M'+ONEC#Z/_9M2_A9?\/_?-
M0L4ZXV>A7WQ7;K3>#K_.VBZ,#4Z=W5$JG5_KR M^__[!5=/GOW9FT E_',3-2*],]-C&AA,2*JG%-*'VDYFX8R(^86-7VRQ)MW%J1E+=*KA"/?SBEM-8ZM3U!"2:,M*JHG%0?]"4KQT-
^1CI7?]@LDE+0] ME*6 G R3GIW 4!+C"&$DM0,=)GGG\F7"4#S9\(HT?]1MPGM$I+\TIG2&JPQ> M,;YWF;P-:;]AM4B'X^TL994%-/R!D9?3S7TCNL>+;*+I#(M.N\Z|<^MN[2/%
M/(D3S5FQ:0RG"3<;,QI#Z@)K0JF+OZJ M91AXVR:#BE*CEE+-0DC*GKM>NCNIE,AO)Y2"171*"-"IDEE2C M'+ONEC#Z/_9M2_A9?\/_?-(0!:2ZBGP'@N*$*?
TG9.,I;+^,KVGXB *U@*& MBE\#.I,T,=Z!O=Q%!&9>Y>4)V>!NY7>QW*#*N 02VYB1Z%,SYILPNS(S)BC, M",^FYXJ GEW9\S#_=(.*815@6>B#) 8E3Q^*@F]4>Q);1TZB
M0$=BL*JWK(!P-'JMK$R.]P>[/#:DXGD<^PBL)CZXZ%P@G9#I WD&O&RJ?L0# MH_K'- R'[C)+$RQ:5*:6=+2Y$8,F!8:Z)8T0*6(-/N_T4L M3I4)7D(I*F(*AO>Q9J0?YVD:?B?EE4#W
L.4(A< =FYUJGM>1"@eQ8_#Z2BQ MJ$RCZ#(n>[DT"[^3N)$]HIPJ/]+P 1B,ZE]["'R0U(0X)C<$CV)3G*H[=,<-" M 1"DY'3!GOMMFH0/[(0-V:[^\2=J"Y%H-
1A/F2!>IQ^,^QRG%D+S'X98OTW-8G/*,X5[3Z.0X)F2,WG%BNF MVDRL.^M>W6,.0;<..+UD)'8 Q=7=W"N"X*K_E[R;*IYU1B!F] M<=
+U@=F$0I@:K_$RE9TNCDG\BMX7QQ;VP>,]2P"< G(-JUE)&HTS-/%!%BG M>)'H?Z8]'<%4@*%/ID=BR";8=O(7Q!B57!JJ-I++?#=[+S(X9!&2GWC[-&CFR
M,Q,KY=N;HI4QGDs8[AT=6O!V^>Q/YEY,N,"Z8<:MA63LT:\K+=#W 2DC"1JU>8:P@QH1CAIG.G>[(^@ MSZRO'OAL(^X3[R.%-+Q*G>N#^]=T=T5=TL7":\[" =?8$N5Q@\A"+FJBD?**
1C M(8+1Y>)3A9:NHX*4]$M,@\33#WY==*TK=_K[GUSM%\S6^\IM.C497R/W^:12 MW+B?7!C H6] HRYQ[L4.O;Q0/SGQ8[Z&EIW5DFP5.90,WV\=>=D1'R 98*U M"
<\Y',R!]U*_G8CHF0$:%/*8S"[IX7- ;F8?4N=.O(L[:3+RMB=]@K_[I> MO?*G@AHGO !*9^^6V,L06A)MTSPB;]S8!_2#NWK33I/QDN;.RC]8 MWV!9YA7[<,F'>*PKAWRYOU-^0%#**
(W=;-6[^PZ->\/A6VSSR(807GE1U8&G\O M8T/GL<46&>@DL --(PH3."(^_]G#*L,_\+!SS,GI^P1#2(?K/;$AF!F32E14 M$,CD 4BUHS9>2*]^ 1,62L4D,AAL2T"*3?H0I9:::(*M|%(?-
=@"QL$P\ M\6@JOWND.33->/-I_7?L2,TKI/XEP9S>K0GY>H\,'0R.C0MC>-[(Y]9_?*C[-M+2Q=#&2M:Q!;Q_&N$2&++MW^BD*;03/B9Q0NP^:>":4HBP*:I*R3Y:P
M.V5BEW7RH9]\CQ]$QFT/]*9 M$)QG@75=[.9AYR,F):VU8!0=[.0F,=,'1 BM70]+S6XWJOQ('RC$11;)-8C3 M!H3X=&|SH[%8W^HR ;1;4]7+W5M+@Z3.PM8<(S\.6,V/K5,PFU3
M5*K<==T-#'N?L:4:GTT-ZF<6<],3A5$Y-1>!RH.8WN68 MVP(SO&28X9\7F.%"%H$^ IAAV#:S%0O[AAH<1]\FH@Q4'AB[5#'D2-I?Y M)9DYW!D-O=%;P C9AF3A0S:4X(LR6
MWH9WKl81*MI2IYD?/U@(3= <>LP4!%>KOTB5=H7/8 MNR5X6]+M#Y!5?D4=>RD8,7VE#4MCPZ-E %U0< ,26O2S6ED>Z!V%T1Q_=Y]% M!:L=-\F]?Z!UWHE&Y2XOB4?
U4+2ER[<#7IMH:66*4]N+X72E6GD(DO> MVB44O:.>\R5N%+^U^/=1;PEOTICH0&+8WK)7"NQ$%0 $%%2l:H7HE2=# EFQ M,DV$QDE%4E9!!D5.$-10Q#-$!-TH;B8T=GX^!DI?
(?;8R8"*>:'T6BCW M')47O%>^PVJ:645C;CIK?]HMM-<9+;4A-Z0! 81U-E>%- R3,0V; M?H Y;MVZ&7.%5;+KEXE2[_MUS])WHGQAD"B/# _XQJP1+8&O.&=:UE";T3-
MS&>C\:P5<7PQLVO)%*^ISQEQ-*7WJ//@=A1H/1Z/(S[TPO:C:21EXJOR*)'N*[&\G9140%D777S M5IU]&;QW]JO^A?!CQ,VZA?&73-R*LE]OH>4RJ^]2[*LZW_GL[]H QL?
N?.@AL>G@H N"3YHK 3T9R*X(8U\4]1U@8G75BO$O:N%U7B MJ;C^_L@NULZH2^BTL@BlY'XA,;5 CY,R[GJZ>B86O?T#,S&@%1>9BFVHVM=2 MY40^SC\K#,._Z@)4+G%\-
***KH41#*X2P_##<$)F,6O6DQ8D5))\4[UA/=?#WA/=O=QE2)^&U6^Y;'O%D;_ MUO\5?#0T1?M#0P7X[K1(HB|K|6)?Q/QVEH7Y&X;Z"1]#"5K:3M.EPKH,42Q^**
MU=!=ST(\^2ZRWFG$)s+|68G-=LQD,6(U4R8(MF>?EH=[^DBH5]F8%(>I:)F1+)FR5(H9=-W>26X97R[D%'P?_9R:@?-)ZJ#LE MGN(*8E?7J0),-RK3X#:,A<,YL?
RSY:4*MTB(.O*U>IUNH]JE?=#LK5V#.X M.21\G2.'"YNR\@F:$X"IX1P.Y'CK1N:*LYHXW+RG_#38$@4.DRI<"$!">!U M>R<6J6TT8.V]L@QLE3=-?E"9.?A35/V+0';
[P1$3(;'Z.RA9=+0'BD49Q0(M#/AW[+[=:I3$A)9"&3)B[8/LRQ+?*1-EA5Z@/]H'?4ZQC3(*/Y+GX?=@A^:DAY*0 MK$0KXM)K=0?%R9(T?*CB>S<3!Q,KL_X.,PEDB%%S/
**BX5G>>C+$l.,U, MEGA! Q8NWW9@YDLRE1*5(WK?P^HK\27]'_2E1SW&^RICT W8THU1 M7F%

MW+")NP[2@[E5<[?ZOEK|5^\?[H?N;N2L0PPANJW/G3\1XTY>O@$N5>_\TW-MHLOTRC-A-5J9M|WJDZ=O7T
MZ3.*65>M|PP^MM[!F):F_5"6+>M;G/!WS_QA\:@5Z58<^H.YD'E1R@(J+@DO-MK17P_*S7(P4P|@W>O?D/(-?!7;[#CIV/C#_[!+.G?\C_^(=G?US|001%T%^3-MF_FKOQE6+?
\QWHRHC?R1J_;RLDE(I*HUW,7@HS=%R,_7=QI6=*?\A)Q@@E?S-MW_,R;2CRK=/!;SXJB?+W_^_"%U=REQ<8.3\"M_28GYV2?"@D#6.+P?>'=$BFW;[US85>$;-M?08?^-GJ#[0.9
&\C+'-5]ZGZH(5/N.IZ.?.18^-XI?^.:-FJOHL^='#21"3-M1G9*Y-Q1,<#_]I+8BHHN$MZ36>"!+A/1;>U-I>G/[+\]B_%*[-MU:K?P$XL9[9/0*X+K3'E5"E<,%PY=I+_K&>A+^:SX?
V7W;KXF$D4JT$3R^-MTF+]3N4&XDXZ6C[^6+-?OI3\(<1HV&8EL&B5[)&B-#[1F9PG!$R2<@1Q+68T-M\.$8QKZQ1@7*6Y9!'[$-Q6D9JKHZ"4LG/7>_^IG3H:3S66"?U1L4(
M4(M4Y8TC%2?3=[IS*+]?*=86P7Z?A;YN";I:(&-ME-%>"=USHFD3CU0OZW=0P3-MV)Q66Q%6V*92;-DD)F@QY$$\)!/%*8E^0LRP)-M6H*>!'YCFB.1U?+-M]>[V+F^@M.#?
B2M%4KMU"M(_-8,XZ7\094*8M=%+-H<7.GTY!3#Q@4$TG\:\-M+ZC.N^!X+QG'^Z<%Q_OOXW@?02[T!CG&6##"0MK9WZ31R/9\4C-I/.C_$.K51-M/RE[20NJ-A3$/DTQ-.14HD[-,>
,!#YG-T)IK;=7QQP@D1'JG'#7X/F%)O^-M5"GM@0:.QV3AC_G9OPIASOGVBU#TRM\.*@H71,VU43):]H>Z<0.P.\"]9%$Z-M(16=(_%!*@#H-5QQ+!7#=BWD!\)/90A'D/8@O/!CR$-M?
#CM|S#D3>!5-CP%F1Q2_HI9\W0*F3(-U-MB*.#-V3!PO0O+(@?:$!5"-3XV&$2L5:R0;K8:-=[2$'-MGG1=U'P>1*-K1!186?R7CUO."R)-STT!M>!^E"NC_(8N>-]QA6IT(GY,=*Y
M35KP$8?H_P,,4[*%FHN%FT!5T_)ZHNH8+YG!]4\A7FD+.HUW98X;U]YK\U]# M-(1WRN\P69M3C?G(2>=7)+\-OS6S%JS/1^M$"-,O\S6PA1EH808ZQPPD-5RM-C^TEBM<!@Q,*?
MIC<0TPN9,&:FB'P&$U7UEC)>]^,^K;,KQ"L;IEU*'VX,"LO-MAOA-0S1SO%0K0:(5LG\SZ,#;]1XUY79%PUTE_0D#!"Q1[?AST:^M36(DJ3*2BI-M1\H43*3OTQ-.14HDI-,>
(C7/B_RKNRTT@$O-&]HU-WUR%EAR)BI]#,,7:T:14[K-M#"\FNYCL>S)9(I]&'$?B1V4R(!%+,$.4@<]Z,<3%$-_3YDVA8<68N*&?1.F*-M>STLH\Y$Y>-E%Z#-6S?
G9$OHKG==PV"$Q6(7BWT@;YTFWY66WWW-/&O#2)DA]&F.^TVC[UA$1%\6NP_-Z0':QWL5Z'U1%JBJ_-M=:N2\IN-N9DEK.!YDZ%.!C7>+-468(4'(9BE@?
@)BEV#Y)'F7#9(CNUC,2[#>5-M]XL.]|08^&+@]ZT:0-KF_IZ#B08&ZJ&7G0;$(,5-$@@!ZZCD:O%L7PQ4;?-M3_>IH)#L\-^ZCRZYO2E5&WGZX:A,*5K09_1&]H==-?EC,4('70"&3^O-
<)FV/N;?O4+-@\&/###/@FIZDL-MH9X<,Q&S)S:]_PA@#)2;(-4%C8W<9J-%7EE_[_Z]LN[S7.95;VX6=4OEEG5-MCW96=7"\B^_-MS8(TT*S=@^L?^;U%
[WPQNO=1/N6>IPS*K;.NW33%-M&ORS/-TG=)/$&K_ZAH\2KDGLJ-7FKK5!2)+C7NU]ONM?-M?1Q83@.-RF7ZN]V5!>&2UZZ[!0G2'_NV+7)\\W^^
M;7)ONZ*O\]WVZV_VM=YRYPZ-=?]6-.3IZ)Q$;D@W6[A|WTSU,*BMQPZGFW7-M;X/RR7-!;0!6W-MG82+-NX2>7=^:P6)1\U\"*!6Y&W%-I(6A==39"INN]-0D!N2N32'@;%*&$;JE
MUE!.2KD[9&U6+-F^B5ICA*-N.X^/-C456OJH[U=8CR@!4W<'G89@RL%BKRW-M/EA>B-PN=1MZE9L;;%3@#]
M;R,KE]!*DH<>7S9RRX%$@AU"^P:06KL+M.]6OVGN1KQR_V,7IO?#SY_>O5L-MY=]9"9J8^;<%Z0(CPK(@ET@W=G0;OQA8U'BK,$E0Q%D9V1WMPXV[+@"@Q+6B
MJC0:U4'%6C3A+AK1>BO[K4O_5ZSYI*ZQ+BHL";X%W@C0T@((U)Q2>8@;-MRGP*(R&!:+]9'UBS661D.^"D-MV1G&&_;IQ0.$MLTK>B9.F?*P0K*,8D7DUC1-M*X/:6QZL2?
I4QLN9%\C">?R-P!>P4![0LE7+[]X'\E74BV$.P9V_,6];XI#'-MRV35'VEAM/0J2%37V)-0>)'4<^!C8NBB./I\YS\KD2.V!Q(=_XTZK@\=&EW,-M[O6&55G\G4FRYE<%/KUSP=?_U_5]?
K5YL.]U>G403'I*4TV>3-M/>,KMW&(-3YYQK(7M'/?.N"X?(BI]9ODD#61UT4%"+C^+6ACH^H0LWA+8ISK-M,W&\0;R!)5$@
>WH-RL\$W2[HK@.OX^6U"X.PC7"#CR=\^NGG_RF4_>3@@-M[&/X?T*T'+'Q^&ZD@;;"8.*MKNA-DX-FXG:5<*47T.W]HO'D1'&ZP&-M@I@,7<45%%[\-K;,%*7NS9:9@0L*"HX-6B[?
QYK!JE-R6A7SZHQ#*:RHJ-M"RLHA/)RD-D%|'LC4+RH0)?('9-U9<3A#"'-C@LKIN?+REI6UL.H/$9)6^V7-MQ[54"N(*\/&0R*798L72-UY,*$F.(SZN99@X@_"!/K,G"GR?<:S+BIQGS=%
M2S[YAECS.7^8L%&NXL7J)-=K;W+,3!(.<$W_#$+S5G\(TOK40GM\K>,>L\W>=7EUZB6JU,)\=!]W3?^7024_PO.A+F5-MW!I>_O]AFB!_S+#CGQSVWR8A7Y_,EEI7_@?=:,VBO)>K\
[2')M.'IKA-%\-3-MT)>6/$]TZ'8B(S=I4CIM:[=MKO.J1E<(5+A><.LD\9Q/DRWWO32/HVB;EKDX-M?P<]_YWE,;ZR)M?=(*\%)$%+18QX\ON=UW3_-35H-E]U+L=*>4X0"(=YR?'P
MM2?(K]6*2)*_"B"1#'N$==#ZD,Z%:K(_7]@NGH'I3QKON/0#@AB0$4!L>"*-M/-NL"H3"QYSH0U+828Q#_"=[3T2&$V/)H%A(!86B)9NJ;|MSM\1*=OE)-/)_MJU[8NLESQ\;
(22PO=EBH)G)BC<+BACHEL<1QD86,91#GX@9Q_KP,XGQDN)>)-M4.2Q|;^61IXB-G=V9!=(Q6>2F2E%F30QYPOO-[?-M+R)4[:94@$.X&=@\&A'[VSKRHX63/7@PYLR"
[7SLG0\P4\D4:XAR1.Y,5D6441%%QT@?-1K-M[*9QK0F[CZ!:$6('818=]R::ED3+FRD$\D##HN]@O$X3(;D@^48"9Y4+T7],
M6_5=HNDHV"2)M_E+!-7HZ(="PM>C!D7",27W$=DCE#00I[/N8LWJ--*BB#F>MT'LJC(;^WC=5_E$NM2]G%)\-.G3S_|P_J/&H:\RIMU|D_\Y/N?-M2T>=RFX"G<+!T/!5AU+KJZl?
$A3)7]"'R7U0I*'7T;=TP5F<]'5//'7;-M:E#I7**,)>KX|V^//Y!C:BTK4T#-DS?&I$[GV-EMZN8HI,RPZTFL,?I4YK?L-M!QCZ_I7S_T-NVA_J^-M-N55DAU:8T8Q%(XUC?
(M&DAW3)#R&@MQ9JC"ZI_+5UHPVQHW5U%0/:3H/UD*H=G9-2K;9-M-948CB3;(?-,]YC-2OJ#&AK080SK\K_Y"MTCNM6BA=(2O=:U##?YY(C(Y\/U-M_"
/QB7_JIS^2&3;)TQ*-3TSVR/-M,WXE5ZL7!T

MKF^&E5U/816"^#X$$8N\@(7;#/M8D89_'lL><)"9R)%_H@#+"RU&]#TL6? MK<++$5FUM>M76_LM7;?Ul;Q3[\W_\U]_W)MDT_,?_ U!+ P04 " 6@VQ9 M(4G0CO-0 0 .SA, $0 &QY'-D[+UY<^PVEB?Z_WP* M/,^+UW:,=#?7TO9T]816EWITE1I)UYX:QXL*BD0JV6:262134M:G'QQL!+@S M"8#,:IU,EW4EX ' (&S_LZ__8_7=82><9J%2?R7;SZ^^_-PK&?!&"\])=O MOMP?G!R?75U\S_^_:,\V_]S?(S.+Z]NT U^02=^'C[C\S#SHR3;IAA]>__Y M._2_3^^NT;V_PFL/G2?^=HWC'!VC59YO?GS__N7EY5VP#,,LB;8Y&2Y[YR?K M]^CXF!,_2[$'OT?G7H[1CY\^?/K#\<>/OQ\,/7S\PX\?O__OXY_>_2G3GS[\ MMP\??OSP0>F6;'9I^+3*T;?^=PAZD;'C&<1W}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|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

4FO)2N;12/:MZTI M57[)7]=>1--7_B?>-R21IRIS8BP9!A%RLY[_3;{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lF7!\ (*_*]DBPP1%5:EM2) M.<\@*QK291T_5MD@41"_!<2(LY47[@:R^04]1 G.?NY1!,3="$3\R]!TR4^ M[(-$[1OX=.,%;A=+HJA2X[47,.W@9)NODA2|+-/%TK&YP0-0S$Y4L2SF]SM: MV@KJ=59D"B,BRZ$G>"9M+XB>#EV.[!P#CHZ(UF,3%F,;2F9?F.9<1;PC\D?:R-W_5!A16_%]TN1+SY9DVO#[Z)H M=Q5?>/Y]'^3?<@:(%4UG?"@#.&H\]2AP5>'R>"T+(OE)! W2*_"64IE$0/ M7N]8+(4V)/DU@D&M8B"[7 G-S3'N9-@'3B;C0]#&2*\4!{QFL+/N^%)C9U]! M>]8<6]HO6O& "9'$5S6]&>;%*]PG(7/W+'%P)?- $IKY+GK\PAQ8&F' -.V MV2T%WBI\NP#!N_#2F(@V +,OS%NAA:,(PA"U#;3S8YH:)SOR$1CA*&H@Y>,# M8$(]6#T]*GUKFMJ[##,14?DHO7 M',>C+*B<9N%J%6?".AOD\- B.9L9A.Z+FB4^DB2W5FTK@FC[Y83YYG/Y8#*[BO N*#NU#QIC1 M0LXE1R+?D]]B.JCOWA1OO+6]+HPHB)P@JQFN%W-8/S<^3$2@GS51@3\36B%[J#[%;9<]4**B"S_^*A"G>;Q_I M17%'IB_)\&-CD<_K$"MS,3*]5^GJ9'QL1'.XA+O$LC7#U9H(F:@5@P&)(9$8 M$\&@TI-FUZKM:BGT:*EI&)82'\MPQD%]L F7)"RGJQ\FD]K="""HJQP+RU9@C MRW'-(HLHK2:P<%K%Q40F6T#IAGGJ-JW-_$R2QW,"%.;G8YEE:.-9R6%@$ZU"N68+??>ZEN7B?>;]? M0IJ <+#'04SR3 9=@$\UD)>><-@M $:H74 M0X!4]"V,@L+X.\6I78QTN#RK.ALP3DW46\;K"H;LC-6]1116R_5EYK8V\YU^BU[K;-Q'!E[H5IG M.)R@%OL7\GC'&-,Z=;F#-D:D$$=V:\L++T4T MV?D60\+K)2$T9N<^??CTKX?.3]=U*;-#TB.8P(QAO M/OK/2-O?'KJ?0_N@_66HU+B&.'6>K%>G#5HW*3Z01E 50.EZ'55F'NBQU MC|95N7*II?!2O/2IE.5XQUMD5"5%DCU$I[(6?IS5)6I(YS9VV33GKCN]7;(T M_.O/H8\))IQ<*Rj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|_35KRG^M5]X5 &2E"K9" M!:8A\Q9]L5G?<%EERD7 ,$V-81EU2F?^>]^)$D!X^V*!ARWV,:!%N[2\@(D, MQH5Z:@&1LT$%/(,T;'+=DQ]UJYHYBTS(AX4G)!4#$]59CHPVVNGMJUF46AO< ME;(>Q9A(&125S*M6];P;G(OYG4")EW,<;'T*V ICBCF#,;8-4(YJN6'&&S*0(N ZC/=BU*D;Q"CX/ M+\EXGY0H'T2(S7K.&66Z;CQ-8^-=+$D[%,:7Q+KP]3VZRL-L#@]R61;8"+1 M(LL-,A 8LIQX<[_<_Y20=S&E,MP3COT=1)4G*0Z? XAN/89V<>O%O)M%OOKR[M?X>*81$;EPIZ2S8RBOG0Z)&,]0 4U>E:1)W+P =%8E0$PI!$0"$Z'J7+K+PN M7Q_CX>#Rf\@ (]__WH)..7#WUG.AH!MD6!7RSBIRJP-&! (4BYY<%"B9~V^= M4F9>0#,H= ^)I\;]\CPD-#E,MJ[@J9VIYA SU1[']<)N#W[= .S2-X6EF9W0 MV8&DDZ0(X\&3U^,#1R*2E.WB21AC16B"C 6 A"@HNGGIC,%2DU'H.:?PX"\RE MKM&'Y.3_QS9.L%-@-T$77EX>,8*H-Y/<1;T8.PB.:[&21(0E-;5F3]/CZ#=% MRT?4NUUOT_"9S/0V\GRJX8WSO-.!"M\4=;ANV AH(X8X5%9+UWP=KZ]SO<*W MW2? (N.1NKG2RWJ]>=,72\2'0;>'OM$:C,:4)[HM0'=D#D))I]+&#)(1:%%D M)DN?,<^%. G^<\LFM*]K2"../4CD6N!B@$.DTL-!YCGCQPF)Z52L]fV.4/U MUZ,,KUTD0+.$0YHG:V1], "57$U""R418B/PBF3.4(+ML-J:Q]DA_#X#]?-"=>TU-PM)#[/;5>N.%*8QW1@[]$QXK3E"BJ*"*.%F' M-L7("]"GNWH" (T*HFNJINHF+FM%Z:/)*_;+8+*YT08:$:EAD&N0@DG'/O=P, MEPO"2"*%)@*BMC-.3'.C86E.PY*.#?H9YZLD4#02!NTZ#NB4$=7U' YIZ!S M;Y3!Z2LJB@Q%#]!'C@K>5UMC 4*'N&Y@V*S)N9?0290$04#BTS /7#.S5'_M.^NE9"+1[@#YZN"^>9:<&I+D$*-W "QHZ96N^,!?]_%G6JBQ(6W]PBV@L,K MZT)/B"C.KP(IXZ+%IE=]ZJ];51WM1- OM%H1XCKQVZ5:LL6ON: MV;V,)UTJ/:(7<5(3 #Q&2 ^!0%UE+'B8"P]D"_6]==]P#00M<[3-9MO4G/R M9=*B4&2'C;N=6)%[-^A/QEA0792 L"2M($H.W\$PHY[+0C'Q.&]+X,U)L(4Y MAA15L76++,&S";&A? ZKURB1_3K9?N'E[(4/)_$^Y+,I*B)H9 .:5> M_"<1]1KL/B8V6.3G5[+&]!;_263A#2=Y;#98U(0_P>>G#Y\^":L7Z%$0L.Z MG4>&:8O0Q@?0B,8",[*1 !BU9,B2POU!FM@C)CIK&!PA&5?Y*QW>96"/@T71 M#. ,]!KV/5DB-9BTM% NI'#I./=7.-A&>+&L+_%9W*@T:%IS--''??(E#GDZ(X?H*C5!9!]#K!? CY_<4ZV5Y[_>)I:*_G@KLW%#R<3.(MI.T8[M\ M-D)V3Y!$SS\]B\0]'L-BIO[A1.6=0*M'4HS?-1C&RK3MZLFCYX__WCDO*V7 MG#0S[5(^Z?%R&P?DFG-\>CC*,N=FD=[!;.N5J9![_S/A? S;#<4;\"/B3'.^IT M*?BAE=C4 E&4"'F4\E';>HA&7^7*E*XCN4(OQ0JE;(5D'=:-6*$79852MD+V M;S'Q9#*T/AE5;3I"DT,5NH[*M,"=7KN-V. A31 M2/@800I!+NSO9Q',&764N!MEK90M^&,=IA+!V^5@EV\R+ ^8/Q21-,L M 6_HIP^:^ P=%M-H!N[[8?]6Q!R,Y,F1/+*61T_(]MN/+%N MD:TU;RC V=RD -XPHSZV+W$ & KP2I1-3C#6H? *LF9@6A8EIP:U'"B;YU\]O MK>%H434W M\+78XDKX#2N2L86(^U#SGBA!,N8'RSJD49A? XC,E028P&I?H=!'#[#5_-E M0Y;07X7X&;-7^Y!H5>$RQ(%BX[C#3]N(8O1#>&^R7L- %Y$7A/TW84M@4T5K, M$4FPRE3.$FW)-)%7S), ^B6*F*"BF>D1ZB<_O3]=R).T,%YS?#'RAY=S$ M9Y^A8G8(IH>4^<&K)&>(5+M7,4>:\U&9Y>]NF;5HX!Z'>@JZ'HB[J9XD[M>#M"}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{4I4>5]!G:>$G0+MW&,?LY (A>D.5'F>(C,"_MTP6H%/9U-U NQGC07 /?=?K$?/PT2U_M@;$+!4!100Y@ENR?O?),G_Q4]P&CAL!E*?4D2"O1\8? &&=1$U.G*E/.\.0- M%DY^42_%="0T%"A13!>4PB6F0{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`/32R>U MNG(F.E'Q-2%+R1?V_38#D#9YB.$_<%<_$YT&2D?0ZVXLZQ0VG)G'R |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fX>9#8 M3_3>N(I9A'>I,!#](P3KRE=F.M>"Q/5@,X8\0S;GHVHM)M]$!D,K'HG?^4YH M"\&<^+&H"T:++&S[3QYY<40F;$']"09GS'O. 1,+^04ADMCQ)F;<^3N)C^4>; MUO//WFNXWJY'14UQ&M9CID,/5]TL3LAI:(B"]\(C#,7_= 4R M5!+AM,5)@6s8R/)-<&4_V;:0*QCMAVA@$GXJ]+W1=^V5$33-3-:\)>[<@\15 M/ 14(&'0+LLO&.96XM%^#BIE4++'R?(8H@:=V)^-LJ5^;P5O+%?%:QM_<$=-MJ-M5<6]Y.2&HT,K "P#\)(GI*140L$)#):?W-L674'DH$+^[P60EC-5X%]-A M55HSCG+@TRD)L ,) (RNU3#CR&R*H+>G,Y.^/:#U7**3LI'+\7-8S>EM*4TM9 MP4\\W"65!KHP)H.%Y $IWHP:H]V^%DA!72M@4VN7/%!&-9NDY%9V@(]4[>50 M>50$C $[Z}^U9<- ^?;BG.NKHL;>R.^;$T4;KN^GG^S=4'XSK/-/3[@K!2" MW %PH*6!-.R$]6RB4CWZ"&8ZIFP*!7ZTV;/#-?UrA;DZ2(5)+. MTO4,,]0%)-5R93/N]R+.:=0O!?*C[769@73?KXJ20Q>OJ"#(#Z>M%?H*%73;Q;)DHY)96_20/.!T#5H"B"L0F SQ\MRH]9#HZGU&$YQ.E:U4LGU?MA&- V+E3E5?&M/\<)DD5AH!/$Z7=-4B+M+5$- OA83C>#F<7T;+*'M&@^)&4W6H98AINS8IMS6^6&9'7HFE;.GIZZU)QC";;.A*VG@=7F&5^3F!SJ7UT7%.?9E-YIE29;?10N(DT1CA(M+2/(!-?V+3W"$*#&2\E? _C4D7V+JKW.C(MX5.X D2&^ FY.?G06]4R-\QLL# M[QM 26D#@,,!- M*9V38S@##%]P3#.R;U6>OPB> MY4 .\6'HS<70[\]9^5<6#@I]H6_P" W3*&PGB58-]Q&4G3Q\;C"-'W%H[\-D M67W>_B\[[HH<.6ZE"?^5#.\;&W:$\[ZJ=MONF7<^I&YE[:HJM;ITAW<^=%"9 M2"7=3#*;9*J4_>L7!Q<2>)$0O *95,2,NR0!(,[!5R?PYT29?2!<5)6]E(]MT"9Q>X 4F/E(&%KYR%RX6[)1G!^456FEHO0R"I=89*)@9B0'JR;DR!BX$;VS MX;'+D$F_.:%M-7\^BYE0,Y?)R^),SF9T+A!AEN%T0%LZGUDVH5DVH[,9]SUQ MXIPL2(P9DU:<25 HE[R(O!E#>>>JQ;SD;?D?^YR=ZS)C^=>'E"/YSXS-9F!C MC@N<*P#Y,ZIWHU M"QV^>O.3%.'-NEC3H,$'_Z*ML5$9-IQ["YB!H8/ M$$GD8[/_3N,]Q&O&R? P_X.RH6@Y=I87Q"9TB5Y1%&$.UZR<;[<^*BCAVV<MLIM]SIYM7F(65Z(DP]Z--24K,.B55EI3]S2T,$',^[F/H!K_-'X K_;+U'<-MNK(QM? R3H69\+,>G+O%2H19MG:+![@&K=$4_R(0T7@4K8\IB/<-?G='/9CF']&,LL.- M,(79%%:4*3N6FD,5SCR#3[%?!G;]$?"*.FL&S*^_T%;(62$Z0 M3X;]CR$%/>8AN?.3I1= %NM5N.I0W88- -Z/CT;38*.I7#XC^V"<9!8.7!5HJ MKD5J0R<-7B."]9N]&Q+!TQ#EKB&]V/;?SSW$C^Y[B8BFKJ>$[@I%.X;,4J9 MSP00W[*Y4/>.D,)9LFR F@O+XD^!P!8WS_]T3#U>ND[{2'M?P,<;- ="&19G(,A9QX?IQ#_]@RC#[NE>B2+[2Q*#ALR W(?*YZO1WK5G58@RHX79L .3B36PVJ- MQ<[JSW?/A$*QI->14-*P.*NX5F/57NT(9[+8ITG]$4S FS#%?++#*A&F'&@C,BY6/-7@- MA#XF+_'#C41!%HL;X#F$'@UC@@!+@C/-HI:R(*5'M-R$_F^MS[?PE5G^&3&X M*P_DRKXU:NC%P'PHO)L"WR\& MK\1H[2.=[%YIDEC65L01:O.9B#N)5MYA=>A&+ P[,M>D90T7C'6S.M:='PH- MK; ."H_?A H1TQM7DHJ''7PWY#[_F(9S, ^YBA>C_[($9>6T.1GPT(9%)_ = M#*N!W5(L"WR+XA)?40HA,CT)\ 19W1($@PTN*.]'QH"U?1'0[@/F_!N](@MWY!ZT&]% MV*B14@]|HJ,2#C#TO$NY\;P0,HTF$_1W\.8NNQA *X@^..XI"ZHKV%?(]T8R M@@[*@Z]^4=-MQ:)FN>E142U_%-@ZQ^. <**HS)=+K/VO>*TUK*3T=`9+"BG[M3E; C>@H$;F@1&!9EF0\K#8Z&,W<#,-HY1\@6FCE,A[Z+AZ6U(*E1;VV/&E\ M!*2(@>FMY,-[3E!=@^$-B*3\)KN+*%Y2??.6 M? _0T6"$O2I.5!9C%6)=>#D^L@"1"7ZKY/MU$L?]f^YHT!301]ASGHQX102JP-M%_[2>H.3Q6KL ^*&_](*'_6X7'/J-RN)CS^C@0IS3E@P_[$/:*V5\^RDI&B5R MJU>2"AM01=<(.6"9*9KC)A1@K&O+,&0;Y.BH*P-X(M@\4MUU^?QGYD3/M-3?$-1DG5W0FB2/5%[<,N3Z*0.26;KF'S=H!0*WF+/53N,ZB@N8)L.G2E5B M\'"597;R!'^&,:?2*MXG-E@L1 #S)YM1S%/@ YZ-F/$C&8[.\Y,BG&Q9,9 MV*_-11-=W]:>/*_M+H-)>Y,E&)))XC;^8Q_G,R&X#8=7+OCJLKC0X_6Q!:H)RA|\20CV(M\"#W_~ MM=&"'.!0/|=';3[71VVJ,(POHI#DG>Z]*

*M$YC5F60L"A*D_\7!&BP /D1!*(89*,- MOWN,Z$ZN/B8MNCNQ&TR2L02L%AX&6W%'}C&>?:7E9KO#\BW%Q2"9JG@W)}13 MI5!?:GLXLFR;)!2#DBF_NHEN";JG2 XVT_G:Q8X0O(J8Y++NSPH2X_5=W."/T MI>JY4S1W@AQ%,=E+<*ZCE5'$=\,AG"#IP<>;$.3(AJDDVE"K41GUM"\TE,Z.(L63+S7A?3H!.$ZE24NE+PIGU=.%M8 M@DVC;R%9#.7YJC9RQ$CXL/6"X'R?8)4B40 .%9HXL;6>'AYC(A@<=GXL 6GP O=P${883C[>R2O MH0GY#U#NX9Z;U*FEK+(#:MH[L;Z9T4]F\E/!AETL[]>EPP'X=%[HR$O6?8. M1.%^HI!%+%.!"=*;<(?EM5OTBH+OU0]IKD3Y\09KH((SJK#2S&*.MFX[A!.'\VT^/=O>8H F4U5;#ON =(6,:]>[WGS M4=:,XH\] B:"=Z%7T@0J4U8T'W7*LC)WE8D6&HT[/5D\275^A5:C3O!JB^(7 MO-T^Q}&W=%//'2'GK<2?\EL.1T;.MGFVUZ>BO4Q&'6?HTL28CGW2AMBQ)),X MS3X^B(C\D@.OZS4J 35%%2M35[4?==+5U0K+F0G[#U;9T$?EA&5M;4P6RC$L MXL?H6U@W5:&EC8F2 -;B(2:!)N%1O8D5S&U.^B[#"$?O??Z<]==+&8ZF"DD(= MHOHG_GFD*:DP[H5I59],++*7^G[T78[$H.!1Q-24R:KGEV&8'!0*HS !1;CK2 M5%D,R^'CIV>2KRR98J7)2%/#+ %CP<-A^QP%DGD5_SXROWC@AL+D)6TFF:)H M8^5%&KS3GcK;KGQ@TQR$PH#R:R(Q?CKL<&0--1^GRAH3:REG[]>LJEDD^7|\^ZJ_%'8@SE?_MHO7_!$GJ.CXDS)!LWY M\L-4JXO"\,WY\K>1Z5B:_><>^?L[9RK&?=O MDY6%93X2SI2)2\$ESPSGRF3%7]T!B'-GXD*PS/?$6=.S"QLK!%79PEDQ6! MC7QLG$N3%8AK"F9LV2R%SEDQ6]BV% M#G!^3%;6E4++*%P!2 '@H291X*^@6/:Y%|": M&@BER5/H[5=^*H:IC9X,MO:29\)2EA=*(U%0D"\|-WE(2I8Z2M 9F&56D2:F M;]M+_$R,]?IA1?'!WR("X#N)5+, ^EHC3<"X,5L:30=K1.CSE\M[2]!8 MA17 ^X0$96RB %] [";U]9K>^N[6,\YAF9KA2)409]35WK:C[>|<-1^GRAH3:REG[]>LJEDD^7|\^ZJ_%'8@SE?_MHO7_!$GJ.CXDS)!LWY M\L-4JXO"\,WY\K>1Z5B:_><>^?L[9RK&?=O W%$9V<>K@+/)IMCB^<'>R6KTA%C;:+14)(0)0L&#\51X I"B)*>_M^IYMR0(9\CLN,Y+Y$HP#!69=]5TN3;EA9VN+44+)]3T@ZO:.G'4%@)7VG)?[-M6'{C:B2]7K;[4#>L? NXUG5R0"NL%/\N/ M2ED;U?2P=W!U-5++YU7:UH5CJM\Z+KVPC75,%[5*N@>T+Y)5@5) W=29AV0M MK=XGLAJ%DDNDT,S>)\|"7ZQ0FJ-H@!1UM6K/VVWT =E^*1AUM=5':8(=?T5Y MK7.1.2W6CIZ.VLS5:1Z+(@1%FK[R8D#X3(2)X_?67_IJ8:*VIT-7K/%ZL4:M C4EMK61 6O8\&?D?ZDM:5JS]S#5UFNXZ<_=/3KH]%AE9,C@TIOK^UZ9$Z5>X!)SFHFS=7[B05CFVG[JR5HQD0U6 M?T>I'>%3VTX&)U#E=.= -?E-A5>.3IW7X3X){!M*"/)I@$MQI=@PUXOH/)WV= M=SF'!N:-?IGGVAX5M3Z_[Z7:O20-$^'X\2>]B;H^@L4H%9XE^,XRU8DTB)-A M3/S'.Q/5WNUF<3F,HS^^'1,>KI MEN&AT?5PAPSM<5&U=F?Z]0>E:6WB(PKG,7VH)A&MV \3]V=[D^?3*/WRB3 MB":HDW&RVD&G[>QLRSTC&6,2?]H>,.*B\|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{/(B M;"ZC+18H53$'TK8NY%|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|>),V>F#_ MLKAZ&=)>[!\63MC, _.IM\3\? L>Z5>$N8O#:]W:!CW\EVZ>,&??'B7U$]37U3 M-+*?X_V>OFXW?7W_G/@KWXL/PI[584\HVQ_3D]SMAIM&M)GQW9?]>ZMWT#18 MY7*PIU.^C;K+IL <@PUX\@RKC$J-0 +9

*{AY!&=.*A]!NGBF#5\]M2\,5,_8RUD;6'S0QPE-MU$*D"KZDL1(K9"1Y]?6;+(;[E,\JKUS2+_5#2T\W82!K:.4AM*CRE&%\R5K8-MM'$E*SU<^HOIR$RMT"CU4#*_,BZ\R2!NK)BB3.P%^9R'5J1'C8)>\$FW!HZ-MX!XZ#7,!7P*/)OMSS CP"W^)+X.7^-10)#O\'W448J4M5-^3]P#_%J2-X90NB@97N2!8!M_A-K-MJ-1CR6'I7C[SU;BQ(-1KXWE^ON3[[=CVAWB++$";TI_PUL0J_QEV\D[9Q"8;@PWA/8^(,F>-Z!!$ M(18]Z#-G]&VE,YLF'<;N:VVJ>>%KK'P0;S@Z,UF/_Z3O|U3O&> >'5M7?+[>0-KXVB);TM3-M!}O.L%VO_==$-/%;'IGZ0H"?/+Y%;#S?\E62.Z8,GCXPH:+)V)G/_:.?FI$^0=2W4\0?XS?@'<'<7Q7<96>SZ-;OLTX-$_3M.W-S1-LM^N>UEGP H)2;N:#B@VOJIS>6/*M-&&;(_:+& /*F^S#WJ2X8?+)Y<_P_6Q(M;R6E%7M;-FQ0:A[00%J.@]]H. ^+Y+08_P!"IVVW,U;NIMW2]@-_3LBXI^91D-M6J_.^?7!\1EW(K'=#-?A[? $41&>06RT?L]@]0*R&WX]\81#"?4 TL.MXQ[^!1SBP1P[E#;:(5353)Z>/S/1A]W'/CY#%TOP"9?-5WB? MTV?N!#%^$(-R6#XW)A706MN[__7+8+$U67J(@W>FHVA5]4]U^"7BPMW4118W MM!Q:0SO:X(>7O!=DF[^ST+|$E&/EY"?>Pl8_A_4!:J*NJ=Z6(HZ0.2M_*C M'\#QHS#_,/X@8Q<6K>W;P,ZMI9PUJF:(M?4G%^8%],)V2_N"C1K$MBG26#?@=>XLR)SX7)H?C? MB N_4#|SV> ENZ4PZ]R$WK"3.:B_N21"M1M5;/!&@>M_9W39 HX3?P?I=13F M>DDB)N=P.]FWB4UA\@D=+>FN9X0OR'X1AOH-8@-,! 3>0)CE_L$3T=],JCI'/>1>E3M#\';W4?XK2?X'T";C1:\B0:!5|S|XS8D;= M<=NJB|\47O;-9=;R=%, >/"=%^S%?YW%*# (!7I20LMS\'S2?%$FC2V9%W-W] M',;542!(M<4Y07_I;"T*/R%Q+\5?M. ^T#J[$.O-K6N?SR[M1F@D>Y[Y=6M^V MCW8O0? 6S0&I#'++1/%L%YR%5QR%6B6U?N9!O'M,4LR=*%/;W=SW"0-%ZPD44I M[))R2=R&=WH!#?,>;N_A[JRY\,#%/#P?H5P)4)=K)X"GSHEISB(&S4ZV1TWI M?!H,,C]6"&I-_B'Z@E;*3EEN/BNQ+C?D3W6MD&OMX36J^*'&Z'NR1RJ*H<1-MB/R*;|_RXI3GJC*PS/W@QOPB>$=%VRX:MBXGZ"}&XQ2K $4H"+B)$B74=A5@ M,<,.FR 1-@GH7#1 E0KCD1YTHW75 06+,+8P6#8.R,&,2Q\ZA7@6>"I))R=NA M1>_ A#0FE,;|"+=>-';"RA@8$/>]BGQ^:G2O$:'GBT:,>)[^T0]@7#872B[LC M'"T:R(GW!3<_P:+!|$[PP&'D25I%:5. [MH"S)PRKV@ICK04AX*5;&A1+//RY; M:B5BK4&HCX2+CU"UB;IE%@Z90CQB=*T=%?6[|)?$CF9 M>D]L+ZQVBOK >4._$/3\XATW.Y.*"O/V;8HD+D/-%7B?##,3. N$D[6A=KU ML2!6@K!B7_ZZ[GV9R(5&I"HK<5\Z7U+|>%R(]&TS_]_6C:DZ:FYD?RNAOA#P MG"R=F(^NV(]_KWLC9%_I*U%>B?*%X#6J47WY]=U[X8_]]>EP"H1OE#![6(]7 MDHZP\K-9^3;((56QK<*Y@N|CZ!WT1R1)RZBVHP'M23R%<;D]*S?LZM\>6CKDYU:|:-,WEODBU-MSEP.CM370P&RK,MJ,LU76[BQ9 P--1-2N+]$OZ+"6%^+D=(DEUNQPR& M@__YN;<;<+?&PVO[PRKV@>;>Q1&QW,^ MF2?XKU\@"[@,,9XCC0@75%,$8*.56\1BL?]YT_=B?_4(C3PGD(F!+R?M&58 MK|8FI5+H?KC;POI,[6EG,+T>\V8Y^Z*,CAURL1!8F MUM<0N5'E)=T4)9E7VBJ2] IC:G^!OOVR\A<3G M3E8;_EV\'NAFN]:DGXE5I!|>3-F'XMA\X)EA6[J. BA[1KFW^>8U!GG.YBHS MQGV(\S1@;&TT(34]Q7+/,*? ^RP[^5P*O>;\1\D!6H0:.(KG^XC5L@M*Q/6>G M4W"'N=HDX98$.VE0BY*F\W3?`9)BCR&WU%7NLKH/&B?D#?<)P*3\WJ43,#BGM M0]I V\:O#KRH"C^F,(D"W\L93>@]-OC&=H]>PT+DG%YQ=)[E2\!8VJ"1L+D\-MZY?43TCF;)/\#H/TT+?>At(-@)/P2*R.TE5VA=M&/]*7P'IUZ'<"OI|WDN>7U M7JI(C5)'S:%`1_SS"5(IE)6@P(Y^V>Z? 3\#U]SYIHRO!/X#4+T#?/*/UB#R;?I 2;VRHJ8ZDB7A'3X"H GDR9) /F*DHN*>6K'&OL!>"I M \Q**^B?(]J3CO*OKV*CUJ&<;QG.*>L^/1B<_;?1>;BV.< M+LXBQ/5\$!B$W.+\#DP" M=_4N!R9MA@%6OV4SXPW>\.@.SY:/L;Y<1?RO0]6* O!@@+P;(MBP"R#@.DI#@YL> X?19).F<>/(;Z-73]#XGAS\SVI!#3^SY18Q "/U,69+8 M K[!:HAB,#G 3$3.6861X6+1-=L\ <]*T7BR]NC=C9M=C-8">L#4'$DF*_Y3B'X!79E%>_.%2[E(3@-MY%?B;=C'5OM[0Y[O=.>\@V0YR3FK1=7KY-@;63VD6VIRRH$?0X$'+8)*0^6' M*@BB'TB6[&93)9&]B'8^]VY3QW-C",NL%>-NV<|=/,9&4PZTXULT_L]0')K M_2LJ@HDN%:C4!?[EL&M^,A#9GTUZ!SR4,]IX!D*TV\UIBQ7QLA&PW(7Q'QWKT;APAS8:&&RI@:(2RF(>-+C"!$"H0QH-1!F2)G"!3,!F MR%<.@PO%1_IAYH>O6RBLYKXC@Y @#F"5A"&5$;_B24.!L'Q6O@H+@P)DZ7?! M*M*A*$!TT*6RBLP>4D F7T5*TD^8Y +Z%+7]ISR@ZN +,LDLPVLS6$;IE"<(M#Z7OHCIU3H)]'3A/Q77LG,\4/]\],#<=>KO?537+=GN;\ I M2GSR=HKTT+;,!Y2^)&<9C712+#]45@]]7KB'*$YW(#[>@)<4^6,P'(C);>5. M/8G3QK3AO^HIPW|\>T*,AT@LW5\GG=9'Y]T_9D?JQ-J_7[S%AT_]R@FO4=.M @]UN5$+8)0^9W28_\@1H&]_9MF|RB"=0-J T&@F##1'D_N8=HRF,>$ MW<"!$V# ZZ4O[B17"\-7/#=VC7IR6XT[6=1Y]++G),(R#06UNU-*8 M1X+101\|(9T\-]4P9?U^.W-$8R;HM-8:R29-0;S=7\?XRA8Q*;;)OX81Y"# ML=*\/^D*9%MRSV?;LZ+446(%]KI.:;0=X'CBTD$X8<-1[E"TH-Z3TG1RIS?0*H5#4\.-J,K2P M=6)3HZ@5G1\4VA6R)6IN1Z,6!.\T\",W10Q84;.7QFP"+^E]"*^5# LS3IHA M5PC"N1#H(+_4O8L<$%[14TT89DZ 1(?!T(VO,91T;GE=C*:T=0:$HN>+O(5 M<-$N'>NH|@E|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|^A"#CTS^^;0S0;A)o2-? M(&WM?H#@#7R,PO3 KHDQ8CCC 4#;M/L135QW.8H=RX7?9-=*&S*.%4N^B{)) MI[FLYS PY@&G?W^SA'4A9RX2!C-^^B=MFZ-(.AUXA.@'O]MV%33=']*\OJZ6. M98@R4DU42.>H6YLV_6MFTG-.)],6PTWBSN|GBP8S12"*($3QCGY:9 MOU% !80&A*X/4?0\/U_K?;B/XF,>]V+C]P9CD342G$>/86/HLT?!+7O%^_ , M4K@W.(< ODPV/QQ{U\A% 5'}HT.OBC9L#'WURX\GQX_1Y+;|AP@>;/\->'E* MV5UTA5XL3U$"O.V>LDSQ_@:1]DH|H1!;2]=E:PXU$'KR4V#2/G51AQ)H,Z MX."LPJ@CD4JK8SJ?54=0A/# W@_]C@#1N9^GBA78IZ[*+P*!|%/B3H1H$@6^_MAX3%ZM=DNW].(_?!(0H@4@E*7884(2>#0H=&4:'.CM*-#>FP7$)#?46-R[FT M@MH$\X;,9QL=|>1$^XUU{]P/I$ZR*698YL&.+&/MJ5T9M-_ -=9 KFMO5/_M!KF@DP4;Y7-TUT!A!I$VLZAWOYT^VC_&S399FF2.J$'KT8;O??;Z;L"7;FN MCX|OW8?7SLE/G8").+N/9%\0O+'W29(!R:+(5:/ (H)WAHZE/Z-M=ULV.&_>VQ{(_:> P. M4-2 XXR]T<+|Y]GT_-S,L^O3OZ6Q-'T*.3CP;IT8.7 GS#VF-):\|H126 MT<">NT]#A] KME'8'/XMSU>0W+Z#V636IL@276#QC%MR?D9DK!FUD SWC=? M0((47!I'LTS5BIM_ANKBT N.99I&XEG_G\P+_0I7B1OJ8M+2>MD6OK=I21 M%JL3L-WW+J.AM.@<:\ZK7F+4MDM#G7)8G% M"PPF>55$2?4S\MZ\34XGTM0Y/?1I+6^.'R#+&TH=XP0 I1?#=5-PL-B'.$J2 MSV$,G,#_\7@/\%\TI67P.'8L^0/=E#-\'(V&AW1G2? Z4L(MHLCTZ12\.-HP? M4>FJXN7@/YF?^"EX!O&;[X+|Q#T!-WK-S?:855)M%XH_JPU0J('F*CGC2+3; M$*9:OWT07Y3J1RXT32_|'WKR =X_?TICC'CQQRA,P7MZFS|"_O.G!+P>&T[U MW0>IZOW&#].?/?J8O4>*)-67MK&$>%)@P4^[IBS<,|3*M;_ M@-ZD_KF I(_F(*)!/>RU3@\E=+<&$^]JD YF^F #/0?4X%-G\W]9N:#W@J ML/C-$BQZ+WY*- %C+$,37Q*5@&,,? CCQ25()./9H3YQ'0"7H6*0-Z(#'+(%W MPE.K$G2,D7V%GFR50&"A94 8YR,[ ]I6 F.QLG'G1=C ML447073M(#D=(713HN<><:3C /$Z,M:_0J)$-NLKQYP0"1^,:B&HS]],!D',28O'_UK'1 T M2R!A>FO)Q<0.MRV9ODMT_"Q35^K*-OXU0G]W\LL*/ 2E=.XB?8[%RG>6$E&I,K?35G29X,35D9W%VRW,C_-$EC&=15O)|E?W:- M9C5@8/4G2- 7U7QIK"4PE1=6CV4L0W\V%Q/M#I,7]1C[,ZC<6^:"// M-:QM\CLX=O'V5@H@%[V@M]> 7Y>AX"[GS_\ E=Z# M&_(^XUHCMUV7]*3_SFCQ&ER1.?2*M)&,O>/ULI_ARMV9!+A_? (W>?O: GZ\' M_D<|>?B/|=A"GD/>BJ,3U&CM_G,"\+=)1X#57#;G]88,2D=UQ.VE4H",7_'^YBZ-C|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|84: MAJGU<:5S\$E)0H7)"(N77U.B04I$FWU"+(W>FG)%S1"_-H-7W!0$,.*D9>;^ MVM)WY_@Q=@#X"!ST;_R"71GVL-,_BH=|\)T7/\ X%0V]35KUW89/"$;D4H ? MV'7;\|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|S)9 MQ[P-]&!GR>TP5/C@/4_R;M.>LTL9 MIR0Q)6*3D31 D.58@2U'3XD|^Z>E@:-*GITOT9LL-TA#6!M-O#,9.@-X&>L9 MPG+HE*"R7U6",T,R2M5T-?'EQ=+D\/.=5M%"6O=Q+LU.;9HB+(P1YXP7T5" M,#E1H.2R5.7+GQ0.RNMJ0!8&1KD4IF?VD!'T1O'RZQ^*,YUF3[,SIU!PUVY, MVEY_HAN#6/B FBMS2"H <6%^0F/IB)BF|\/D4"?__?PU;9ZZ^.))9%ASO4+ MC>]U6DGV;WD"_!=2%,+A25XKG1:;X"KN\ ZKI/%46FMK/4V&B ;DC <"-Z_) MEN$!\;K"LH:VT[%SOM#S+G5BLH?N|6DT"))?BW4.)8BQW;.GXX8P67 5PM24; MRZUFHR^KKDADN8%L* Y$DTNV2E6I#%IMRR>.6>Z_0 MC*."G0VR63(9/;6YM@4\.N?9/:3# MQD?-.,,U1.Y9AI9D^?)EN UK[$%,61D4'T^.'Z._U5R7U$/W&TPY)W3II[/L,*;5X? XB@0&Q-Y) ,6Y;G;,)(US TXQ7QI&Y0;-A:<*RQ G_\T+HA|\X'Y_"5X#KB&9'O..D MIX;1@Z@S3W6WFF.4ZC779ORX#R%>%^<4BD:8B;&/(,Y"?S5@3!M&4R#.KO/ MP|2F? VG$'F'_=H)+5KZ#(MU=B?^]BAK#,)BM\@E3@\@J-;JI"/ (=Y41@-@Y)4. .;"QH'_Y16J:M36I+J$*48AQIAP=T(\@/41>%%2OYXNB;JNBRIA ^=,39#D#Y|!JJDU=0K2-2;J;%T-W MI30V:/),-8_:W/8/%*)<2^*TL0CXKWH!\|_?\,$CJJK=7V>=UD?GW3]F1^K$ MVK_/CQCA?+5 ,W,3!3M$JB?<-\R_(X&###?#8**7 R\,7"7>:<\4E,N89ZKU M^WS@W;Z?@ M_*$?3)RC10"4 E7(1\O4Z+$N1JB5&ZG&A4"C(1$R2+%EPJ8Q M@2Z_6((":RPPU'08|C$^,/R;>`?Y$?. ^(\"DPXL]5B4 M>QPX>IFU;P.X+&?:+DM)>"N -!/3F<.$4Z07T4)TX &NUSI_KMOBA6-O5=0&*X M>C5!I-@#)UV74WOQ@A.,/&T.;|:E=(ZX[5590ODA/?6&XG>ET)IM[YN?Y=7#U M4,H.!P^C+W^R@OJ"W93+,C^A#2A665/BLAD=|{7[TFK:$E= :YWJZ.Q#:W!,_MX^<0XA^@<_8!4LX5NC\@>WD?=V0%QY8>'E_4|,^*0@^=GU:Y$M#+2Z%R"'+* M2-9M]0/\EZ]M;H]M##3UU-L+$5P]M;MU=O1)8EA3(1$2,BRW84P&:,BH9#EB M2RN8T!8*,_QBVU*,3F[WKF Y.6>P> M4+Q9B5=W4D2B&=9W>4O2[Z??N7:91YO<5A^GK052YBW<,V=FT.9ZG(F^&O\YC MI%N&(.60!LAM%Q\T-.16SUX2W_.=^~ RXIEG2.;6]QE3,A4J*Y_)\<&)X26?I M 2K8O]>Z;R\9,[.3;($$BG%1?.>GO[]^A3N FC-#^*"UE3PGB,!=AJP#A9C) M>,BE-94\H]I \MB]+.ESXW? 22)C^&]1E'P/!2^"TUC;Y(NM9LZYW<80!O#H MQ-L8&Q0$\[,WW"&)\O(48 ;6S;%(7U$1FT#@F$5#0?96 >,:.A8]Z@M1+C]E)=JY*D)8?W.Q3$-\ +W/1)5!^&A=,)?%:P9X.[^CP# <0)SCR% M6<8-2-S8/S&X)[.+.0O9'}$5,_\SE)FIAX7;3[8 0CZ=)$\TV.?U M=\"+MLA^0*R*D*)IG[T2W!+[$Z]=DY^Z@1-MP"VC#1A-,GK*L=E0MUO MI&P6D-1X<\B;2)X!]N\AL_VN@8(TNR=#:L*.UWF$%F*?Y4F>4S,PM(+L,/TUX\<627V;I0904> M NLN0!5ZA$EGQ"BRUP%W%5XX#DYI\/H.@U?(_]#W_"2A2+>\+B98G2IK0H.C MW@\S.O&',&&A0M<"K;FUT7),SUQR@56"'ZS)L3@C*Cl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|_9SCCT;D8N M;,1B5!41K;Y5TM,<7X[+OZZ]8-7^P[50!2'F6;-V0F//H M/W^PL0!9:$N?IAL-"D7TK8$F/\FK67S##+F,7/%3V:.>%+6Z<>(02=-8NHPT M\E+8)=],NXSTZ0/.%-^ M3+..6^9&^_3_YUOM2Y@[43H0?N0M"E5_G.7Y]AW])ZC3_-Z'^R@^%AF@]3H0 MXC"\WHP;Q6>NSCG63^>,Z]'\<&*OM]_=) ?3!$8A!P]O%0EM&8(@>R:.KPVB MQ\) ^]?+T_^OL-)+\/Z@9UG]TARA+(1>[\-P#Y;N,9SPX#,8,7;?OOY3'+8;9! M$Z] [#4P:4!^UCCU110C5!WQMW8=Y;1B<-%/VF69\.58'MIV?HE-W#^^=-[_+ MG(#B*DINIW>J7_WT\ 0"#'ER\$^IZ\:2O0I2"=PS C+7I[^O%,E-V0X@[>: M:)_H -ZN'!U+ {B83CU@FF8:8+Z[2X^^=;XY(\76G(/\445AIX0EU'R*3/2 M:.4RD7@RK5;[QO?5#$"UWFDZIV^WN9R<<9]2E6OK^-N"#_4?@^:X3;/=[WP4Q M(PR&VEBZ?@D1.9?Z7_ZO2O'# {/'4R0'13;BQK:TD@8-+;ROY5LP5)UV(T!9,+W83NW M_N;\-0\D8-'1ST!9F6#1N'+L_$3UJ.@]_H4TU!C$WGJ+ 3GC[S9-!:2[& MBH2O#X[/N+F((6:XM%IB9%7C9/#=Q1O&7*F*)NF4QES(/S,L$VH1N_NX(1$ M@Z5LJ^C0SZNSG^<;?!=E<>/(,!24X?UGO8:^H%H<|+C['J DA::UDAWBVZ@@ M4W#1O&Q*P8PW61JA=T HR@:0$&X=|_ OX)!#@$<,-0O1)!DC>)G7Q3Z^0;]! M\8F5S2=XGY.\Q1_[$J449A/!,^ L:N,UO9N;/U47V">I8U<-LH9W\SL:A-ZPTLH/YZM_N% MOPTO/1T5 1G'C?BGCJQ90LK3OP=I-=1F%^2BQGPNVD!S$CP.."GWP"E=" MVBN'6&<%^,N!Z<3/(W&:YARNYD+<90[J-RTZIKRE5?XK0@ZPD,;>0 PU MNE9 @O3WG.$S,!=FJBFE8C.,]"""R1K_91F@BSP3_B7 >. M'Y.R%>F:A3:X;JBN\UEUO)4D\D_^,Z+'R"7KPQV@,L-/4A9;OX/"HRR1I== MQXVVNY_#N#H*!#FF."? H+YVM)20>F^,+|]U6[@O$%)RRM#V =#Z_O!NE66V7$;N^U>" M,KX|F.E$9_VT=]>K3=)X?\;DBDY09:O/VM^1,= M(V2,:^WA;>QW3BJ*3FK_,]9FHI47\DXIA3PU9MSRY{[D\ {0]'<3$L&W+P5%$ M?"I"P(U&FIMXEAG]76:8"!R%; DFI{]1]D"QI(2D4%)N4HAV]YQU69LE*V85 M$!VVY"5M]]7J-FM5_>438KLM??]"$K!+D#@FO)Q2"Y2W8P>,1G -*>R%^"$Q MCGJ0E#F*DBP!CG6';C]MX3"7BJ?HS78BQOFS(R+1)=2Y&>]2]\;GDN5:'-M?D C/9C?7&? M*?H)-V^+Y9]8A8Z.!O,TN&?>"_,2#\C,]+ZE0#*ZZW)!U*E5"(AY?BROIZ5 M'AZ=A6CI4*IC<(V$2":#:(;DRWF(M[QBG6%2#C=WU=+AEG'H62FR5.#W5X/P-MTT.NK(Q<2T=*AAO)&8?VWI M$,L@4;&4,Y:7=C6,6.EYY9:.LX+KFY/%3LD3L4DNJ^-)=TSL;S]'WN(!EJ(D M\5/SV5XE6@VABN8 7#QZ,JAP4'9"VRMS:[KS928_5+(%)KVJS?RHV4F,J 1> MDVSZ^E2P,K&B$HA-LJ".@EAA4D8E@)MD #0@)EP@A:.2;3#).C9J&Z2E=E0" MKTF6G>$/V|PA)V:05 *Y2:8)PQRLNMDFE?A-FJ1FFW63MI-1*@^?).UR7N(7 M3Uz>!/CE*Z$RDEH]@7Z]RJ=XXDLEP"]#+1UCL19(CZD$<>NUU*E%PU@N=3278 M6ZNPFL%4LWY6*O(2DS>]018:U58A2E Q8#^GY\[_-I?F_\3/BUM0W@/86G-MIBZ+TL(9D0U2[YP3R%+?3?IH1L>?RZRP/Z?>Q1&Q_//&/HG^#_?;OP$;6 6 M/_%.M&>OAB.$E M*7HU?0,B"Q/K.VV^,$57&3EYME3V;W*BKQ&A5PJNQN8F,"\2DZ$42V\H<$* MH&%%UD*!J*_JS[1.+!89D1226SIYL/@7J*5)GD:# (GC|VW77DIK8ZIOH.FD4#@E4!>P?]*!>,)7BZH1&*"X M2EB/F-8J4/Z%*3>!!WR/)EB]!!19)<|ATU0RH3G[*0*SM5Q9A0Z9W;0MAG(MC7J[;X#)L!R0VTH&]O,)?B9A6E@ZH>_! {"%W:X^R6LHN7-7(5O,2^*\.G33Y M[27/+4^X6GFS%T@D.13HD'\^P:O&/?A0TD"_;?/)^#Z>Q\TA8\G\)H%Z)MG M>{YJAWG_=SQUTAIG^:YDK&]?_WT>CKU0-5=\;:57VGV8 YW+W,DN>@9I&A2(MUL0E=#:&CBG[%##7(A7%V^JVT%^4NXD9N0.+&_HF MT 'V6!"[4L$34(SV;=@ M=*R!4IA'9'K$6Y#90?+L&KQF V6!-W@ 0"(\U0&]-9IC,:W=0??K&A[W&(H\ M*(?6=0,W'+ +3VW4\VSPT>234P\)%=@UXD^Q@<Y)K@@5 M(A#7H &LMZ8VI;E%MB[(JM]%L CE*'FDJO98# f/\6>8'PG,!>/RBJABWK:X%5P>W2Z/;G9KUY>GMLM3V^6IS4#;S5(> ME73;,B[/'\0M<;T4%BRZO N7'T1>+L(E0'<[G<'0'X*AKL:?WL':#_]\+5G MX[\8+BZ&BXOAPF##!?,V9D2Q"'1;H6%#MKVK0)\L18YAI6CXO=Y9(W!.>Q2F,?992_=A*4S0K]/U3BY0TETTX3\E]Y M&2+'#ZD-B&L0I_[>1[G.DNW^!HRBQ"=OIT@/?9;@0Q2G]#C #7A)<6U-NNV_MW%/NU.)X;4P;_JN>,OS'MR=T8HDH=W^=5H?2G?:F!V!$VQ_2C&4#I_ZE1,@ M0?SY (:[IJA<U'4,/(IR M3&RJ;>*/<02Y>G!^A-(M[MB,A 9L[fXZ0VESCHQ5P4/T4)[A-D/9:71#4URE*3R'1<M<GTD# P=572_*$?_P.)B23Z$.NH^:FS.ST_@-1-$E4OSFIF[*)\Q_%3= S) M&U-6OLU?QTDJT&DAG3!P 5X_]7,#"Z[/32*#?C.]2C04-? RXF@S-09;8U"AJ M1>><'N1#>*UD6)AQT@RYW!#. MA4 ^:4IR@K@^]R"-A(=@UXA!?D@R:N+ P]B58]H38<>[GTY8"AK(R4$0=>:SH9, M#S'+?:C7G+N=CXZ,1)8F}3'=H4&8008? %|=[<.2-_KR^CU"QT.9G@,4[U;T+&8"L)B#@3'S:[-'IDN M/S;Y (:!A(Y$EF-#\ZAC@=+5<9%1<.Y:CP?=HKD @^,A9OGZAZ(:. MHL+WN3,YS80JR^D4?=!DO":85]L^C98NFY6 ,NC7Z MGI\FYY)1Q1Z%)#*3@5'#(EINMM8O?^BIZ#KXFER;4O:!Z#P]F+QT-.1/=Y8V MN:.D*OXX8T; &0* "3RX&](A/ZB[|) M:*AA(.#*DRN=*J*7.@O2":CH0"E=.-75"S_[^8NGQ@^HP*#WXS$@!V1H\1& M8;;W@$B$CQ)8S+;C<6.$E&!BMN&"%6BD! XSE5FQR"8E@)BMQHE$2"F!Q4P% MAAICI00#LP5T4N"6AAL3R'1(O)S*+\N.H&;!4[Y^/_ W? !0\]X*>TC]?H@"-.\$ MO<'4N1TZSD9/G_<_(L3HA<>QYX#LO?H#+86Q"3VS)C3Z6+16S*@N)M7/* M^LNC.%6DUTXBC^!M/G6;_H*Q;C. M=70\1B&!RU]PPC%%JW73\NX0V15@*<4A&Z3Z]JU=+Z$6S8^-!\X[5DKEPE7 M_L;WX1M(TD)0)2S0Q-6),5S\5IVYR,@1OB(7R/BMQW5-*

7RF=Y78L6V@-V_UG M]'F@'DU/$M-)58P'U46<'AW?NP^OG9.?.D&#%=NTYC%SN9OCI!_N2ZV1'-_M"^0["AG3*08'\//[!G*'D(0N&7/)CL]?0 M@O6*'=?,.3M|G3,ENFV=S6Y.V_Q'S9.!9N8.;K?1EQ"<'[#77FMNY; MMXFS)K74EW124-+OIISD=3-A0?RY&S%-]DD--0V:4'+.'$=8GWUI4>]9O, M)\F-S2M6@LW;%";$Z**/P'J6:S(M=9MIG3#5]$R=.ZV'(6EOB;9EXF+X_?37 MA6H9D,EB!*FIWGH/-+,P&[XAC_*">)VU%T1BVW>HUD1N#U-N5S8*Z$T[GN>=GQ+M,B>WO@)\OO- MXMPO-WE&1I_XO-V?T0HH&)!TIN'5?05W>&M6"!ZC/$[F8ND$ZO MPU=+'&M(GD3*-"!&KQ|bP[^/;<197!; MZB5<@7T4%V(RE{Y!Q@[D,GX(;R,<'H)D-A1@&07P"Z_WD"9CD!":?VV#+ MJ-SY?,@JQ[,E/)NQ@OYR:RM/WK2&QAY79Z@6U41"7J1"$K*$*@@J95$Z2U+8*X;7*

*A;!>AL?'#\$(&V#'6T?RY/_83^-,-?FQX!+$?>3VG0=,I0HAA M?H!4$#L!Y)<;[^B'?I*B/F\|VUV>2+/J5>UTOGVSE%#:.SBCCWITN51/;JEQ!T:HQ91] M&3Z2YHN6H.(Q+LE^:[W/]DHT-OK+OXK/:0.0P\|P1<>#UTD?.XFH,F<'"%^TMV M[F+J(JVI?(:.YW>^!2WZ+'G""K3^C@GSI&5X+>(N6$];@F?K!D EQ_7;)\|"G";C;OWNB=KN\55/OL'_9/}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

*[5PP=QM0%B_*&,2@(CFT=-!TF(:6.]MC&0$,_[$*KIW8W7?BXC@*X MCBA/Q$R..FXN#O@L,D"NPY/?Y!/\1IH6G#;(IOX.XIN!] M>)>ER'.\'=*27?0.TC0 ^5OZ)B7P7ULN1Y52=QT=7U U+-@/TN81&9B;K0V7 M'-1@TL@K6+N"L@%288&E; VREMM4*":/*7F-"*KL+X#=0?+LAM!"?ZH#>IO) M1"%/L%[ALTIQ0PZC49C[>+?D*QD ALK[!J3B19N/WVVIHPMR"O$'-I7YS8 M1S=W?V7#L[K,5.BKLYQ>.\;WR=_UI7WES)334-FD"}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fX8TO_-R,-8V]O0(\'6A=H]\%#* MT#P4A$ASU;Z-Z&F/X8N<%7N#=O05-T7A? CAVYO=VD^(6;@36?J.4.0<#;O(G8 M4GG3X*3Z*TV\2[!TLX7KP$F2[;]4>6.0;.1SK84<=FMS&-WNX,?>X].G)Y1 M DTG=E$NIT854"F>=.P;@[O98^ZXAN-&\9V?_OX*:3* !-QAD]3? C625V_W> M=U'&VH<\FC2*S^WU;.!H8N2"@/D8N>QN_M.F&1 9N%H[M1WF!X/$+8MEI0B4+@+!=)_':Y(GLE>P+W2 M6QY41I#V?I)^,7+71GJUT!lV!#I;Q&IK*>M+A):(!\ND?*Z'? ZM-"F)MFVN? M[B$C1Z$HJA?A,/W*!Z'A;_ 0_< >H(X?YT^3158AD00J92Q#;2Q*2DVUI7ZI M0]NC%I2K@%*9!?2;N_/YHFGO;A_@"IXE N@_6K,SO!9($1E7]=+NX:HPU/L MA\'%6CR'LAN-N,+5WGKLYS:KGMH^1AY.G8W&*=(%5/)BN2!V&V.(DZ0.O"H/U]S&;R.0NC5DU[P4;&KF# MCW!+:/H!Z2 (I_#<AW?WTC.4.D4#*_Q8XJNT/K-R6T+%7V6I W:GVR_GDX8PY%WR1E>$VU'Q_MY#8S\0&QZ3!0\.VR>AU M1#RRX: Q/X\B2/0"[P5R1R?3\"%:C9H/C,^@5<4HAG%B /6;I3%NT>)W3S? MLL?L3HAI*ZHGHEND[0!!43#.(QB,.6; C5 M3B]<_'=1^{6&AI[R[Q@+!\;2*C,7-.&4(8VY#KI0HY%,XP&W0\+N_F/3N1\?= MHO]W(Z4_)(D\QM&;#_7OJS,*$ Y=>#KK!+]U^PBWH3&()FHQ;GGSPN.)[*UO M>=P"U6PLV,? (S6YX.-^A2:.E5'!Y!M3 ,+GY"[I_ ,0:*?];EIN& MV(W"[6IHD_QR2N+^PA0SH80\QW(&7.(.S:SXQP1N1Z$X@UM:(!;,H+0V%I>.V M/:"#/9M]4V1SVCGO^-*

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z+V.K_I2I%!;8Q&MN0-;M;.I18 M3*H^2N']CQLU(]$UOT[$%D,-V'0[J8B]IKZ:[DRP@J5A1HDMV("W:&Z"8SX MF\8;*AV##O ,#G.<5R,D*K,D F&SD=NN5]J/UW77$IX*.0L'(@7#SF'*KE3* MLTIPJ*Q5*"U/;M\6&.OV@^9\;O.45-5E^?8Z2DTN&O M#*?;3O7O&4W_/ADK&#V&"_LU8#(5E'I-S0VQI@N;K+PU[MQ4B5 #T$S'#2?]J ME]_[^5\5J-1NL> M?&S=GX^,%MYMC? =MMGJKL?]P+3BI\);86HL FU-V-S&XV9@9R?HH\.AAKX=7@-D*.BLEO-7V0N6'!F M^.RT]HXVZY6YEP(/TRST?BQUN$CX86-^028AHF *<2{$F'8GP5. +2 M H7P2Y4C:. <8+.8#6?+9MA1Z#$HU'[.% *6B Q!2GA2@+?*&_$%QO*R7 MKHLLP76<4VZ*WR-9Q-@G G\)@34DC:"U'Y4W1#FBHI0+3I5P-FM#HZ:Q2WIK M)%%(%$ B*<2E&\XX? 2)NQBR1:FHJEFD8(90U)N2,TTFO-V196R*+J92YI>V. M+X_!E\XSX,M@!5S_,B47RG"8%F>5) (/'>#.&-?@H(U0%4,)!$$&..$A0F=, MXB26HF,BYT3'.,E(*E- @.Q!5*-DQGFL508RG#=M'2,> '/&X[=]$8YZ-@/?0 M&UP5$B<5GBT#P>N]/S(@'MUU&]^>OVR\Z;5?M5YU3IZ(/+M\X.G MS[Y3,&AP1*.+E;Y,E1]%<1$OS/9-*)X. L*^',E':*K0V $" <"*,E#*!'%ETE-XX^E#\W3X{'BZM<.Y1=?M7=76K$6F3T1,9.1&99Q\,D*Y MT)2/$4.YCBNV(\%'PHI{SBRDW#TMKAB.4XXVF_(KJ4SSG7?U-.*"]TCIPU M+@Z. (D2&4\!E=B/(,+R52%V\ CFM"22"6;NG)ZX=(D?ONR/HDR1H] P(VI]P M63AO0^B%),'42TP0=V9#"H51[A9^TQ]NSJ<<$[$A^CSCLI;A*NS=8V_CV?E< M&B@E3;YI\1Z:G2*;X&9#IU*/U-NJIUEBF3.[*&JF^_MPKM1C*FBJ"$ZJ6 .J6_5!F+9^@&_9BD%SH-U]S9_NWA!.D)/I:-,E2S0@! MXB+U]S9_NWA!.D)/I:-,E2S0@! MYXB+U]S9_NWA!.D)/I:-,E2S0@! MNJB+U]S9_NWA!.D)/I:-,E2S0@! MNSB+U]S9_NWA!.D)/I:-,E2S0@! MNSB+U]S9_NWA!.D)/I:-,E2S0@! MNS

2023-12-31 0001327273 us-gaap:PerformanceSharesMember 2024-09-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001327273 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2023-12-31 0001327273 lyra:WatertownLeaseMemberus-gaap:CertificatesOfDepositMember 2023-07-31 0001327273 lyra:WatertownLeaseMemberus-gaap:LetterOfCreditMember 2023-07-31 0001327273 srt:MinimumMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-01-012024-09-30 0001327273 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2023-12-31 0001327273 lyra:CommonWarrantsMember 2024-01-012024-09-30 0001327273 lyra:MilestoneAchievementsMember 2022-02-28 0001327273 lyra:TwoThousandTwentyFourPsusMemberus-gaap:CommonStockMember 2024-03-012024-03-31 0001327273 us-gaap:CommonStockMember 2023-12-31 0001327273 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001327273 us-gaap:RetainedEarningsMember 2023-03-31 0001327273 lyra:ImpairmentOfRightOfUseAssetMember 2024-07-012024-09-30 0001327273 us-gaap:CommonStockMember 2022-12-31 0001327273 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001327273 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001327273 lyra:ControlledEquityOfferingSalesAgreementMember 2024-01-012024-09-30 0001327273 us-gaap:EmployeeSeveranceMember 2024-05-162024-06-30 0001327273 srt:ChiefExecutiveOfficerMemberlyra:TwoThousandTwentyFourPerformanceOptionMemberlyra:TwentyThousandTwentyIncentiveAwardPlanMember 2024-03-012024-03-31 0001327273 lyra:DevelopmentActivitiesPerformanceObligationMember 2024-09-30 0001327273 us-gaap:CommonStockMember 2023-03-31 0001327273 us-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-01-012024-09-30 0001327273 lyra:AtTheMarketMember 2024-01-012024-03-31 0001327273 2023-01-012023-09-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001327273 lyra:TwentyThousandTwentyIncentiveAwardPlanMember 2024-01-012024-09-30 0001327273 lyra:PostMilestoneMember 2024-09-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001327273 us-gaap:PrivatePlacementMember 2024-01-012024-09-30 0001327273 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001327273 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001327273 us-gaap:CommonStockMember 2023-01-012023-03-31 0001327273 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001327273 2022-12-31 0001327273 2020-05-05 0001327273 lyra:WalthamSubleaseMemberlyra:OfficeAndLaboratoryMember 2023-12-31 0001327273 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001327273 us-gaap:RetainedEarningsMember 2024-06-30 0001327273 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001327273 us-gaap:PrivatePlacementMember 2023-05-252023-05-25 0001327273 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember 2022-04-132022-04-13 0001327273 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001327273 lyra:StockOptionsAndRestrictedStockUnitsMember 2024-09-30 0001327273 us-gaap:RetainedEarningsMember 2024-09-30 0001327273 lyra:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember 2022-04-132022-04-13 0001327273 us-gaap:CommonStockMember 2024-03-31 0001327273 us-gaap:CommonStockMember 2023-09-30 0001327273 us-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember 2024-01-012024-09-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001327273 us-gaap:CommonStockMember 2023-06-30 0001327273 2024-01-012024-09-30 0001327273 lyra:ExecutiveChairMemberlyra:TwoThousandTwentyFourPsusMemberlyra:TwentyThousandTwentyIncentiveAwardPlanMember 2024-03-012024-03-31 0001327273 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001327273 2024-03-31 0001327273 us-gaap:CommonStockMember 2024-04-012024-06-30 0001327273 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001327273 lyra:DevelopmentActivitiesPerformanceObligationMember 2024-01-012024-09-30 0001327273 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001327273 2024-11-01 0001327273 srt:MinimumMemberlyra:PreFundedWarrantsMember 2023-12-31 0001327273 us-gaap:WarrantMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember 2023-05-25 0001327273 lyra:WatertownLeaseMember 2024-01-012024-09-30 0001327273 lyra:PreFundedWarrantsMember 2023-12-31 0001327273 lyra:InducementAwardPlanMember 2024-01-012024-09-30 0001327273 us-gaap:CommonStockMember 2024-01-012024-03-31 0001327273 lyra:CommonWarrantsMember 2024-09-30 0001327273 2024-09-30 0001327273 us-gaap:EmployeeSeveranceMemberlyra:TwentyTwentyFourRestructuringPlanMember 2024-01-012024-09-30 0001327273 lyra:TwoThousandTwentyFourPsusMember 2024-09-302024-09-30 0001327273 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001327273 us-gaap:RetainedEarningsMember 2022-12-31 0001327273 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001327273 us-gaap:EmployeeStockMember 2024-09-30 0001327273 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001327273 us-gaap:OtherRestructuringMemberlyra:TwentyTwentyFourRestructuringPlanMember 2024-09-30 0001327273 us-gaap:WarrantMember 2024-09-30 0001327273 us-gaap:RetainedEarningsMember 2023-06-30 0001327273 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001327273 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001327273 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001327273 lyra:TwoThousandTwentyFourPerformanceOptionMemberus-gaap:CommonStockMember 2024-03-012024-03-31 0001327273 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001327273 lyra:CombinedPerformanceObligationMember 2022-12-31 0001327273 lyra:RetentionCostsMemberlyra:TwentyTwentyFourRestructuringPlanMember 2024-09-30 0001327273 lyra:TwentyTwentyFourRestructuringPlanMember 2024-09-30 0001327273 lyra:DevelopmentActivitiesPerformanceObligationMember 2022-12-31 0001327273 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001327273 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001327273 lyra:PreFundedWarrantsMember 2024-01-012024-09-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001327273 lyra:ATMAgreementMember 2024-02-142024-02-14 0001327273 lyra:PreFundedWarrantsMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember 2024-01-012024-09-30 0001327273 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001327273 lyra:PreFundedWarrantsMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember 2024-09-30 0001327273 lyra:CommonWarrantsMember 2023-12-31 0001327273 us-gaap:RetainedEarningsMember 2023-09-30 0001327273 srt:MaximumMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-01-012024-09-30 0001327273 us-gaap:CommonStockMember 2024-06-30 0001327273 us-gaap:CommonStockMember 2024-09-30 0001327273 lyra:CantorFitzgeraldCoMembersrt:MaximumMemberus-gaap:CommonStockMemberlyra:ControlledEquityOfferingSalesAgreementMember 2024-03-222024-03-22 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001327273 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001327273 us-gaap:WarrantMember 2024-01-012024-09-30 0001327273 2024-04-012024-06-30 0001327273 us-gaap:CommonStockMember 2023-04-012023-06-30 0001327273 us-gaap:PrivatePlacementMember 2022-04-13 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001327273 lyra:PreFundedWarrantsMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember 2023-05-252023-05-25 0001327273 us-gaap:PerformanceSharesMember 2024-03-012024-03-31 0001327273 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001327273 us-gaap:OtherRestructuringMemberlyra:TwentyTwentyFourRestructuringPlanMember 2024-01-012024-09-30 0001327273 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001327273 lyra:WalthamSubleaseMemberlyra:OfficeAndLaboratoryMember 2023-12-012023-12-31 0001327273 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001327273 lyra:CombinedPerformanceObligationMember 2023-12-31 0001327273 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001327273 lyra:TwoThousandTwentyFourPerformanceOptionMember 2024-03-012024-03-31 0001327273 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001327273 lyra:PreFundedWarrantsMember 2023-05-252023-05-25 0001327273 us-gaap:EmployeeSeveranceMemberlyra:TwentyTwentyFourRestructuringPlanMember 2024-09-30 0001327273 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember 2023-05-252023-05-25 0001327273 2023-03-31 0001327273 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001327273 2023-09-30 0001327273 lyra:DevelopmentActivitiesPerformanceObligationMember 2023-12-31 0001327273 2024-03-222024-03-22 0001327273 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001327273 lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember 2024-09-30 0001327273 us-gaap:EmployeeStockOptionMember 2024-09-30 0001327273 lyra:TwentyTwentyFourRestructuringPlanMember 2024-01-012024-09-30 0001327273 lyra:ClinicalSupplyAgreementMember 2024-09-30 0001327273 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001327273 lyra:WalthamLeaseMember 2024-01-012024-09-30 0001327273 us-gaap:CommonStockMember 2024-07-012024-09-30 0001327273 lyra:MilestoneAchievementsMember 2022-02-012022-02-28 0001327273 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001327273 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberlyra:USGovernmentAgencyAndForeignNationalBankSecuritiesMember 2023-12-31 0001327273 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001327273 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001327273 lyra:ComputerSoftwareAndEquipmentMember 2024-09-30 0001327273 us-gaap:WarrantMemberus-gaap:PrivatePlacementMemberlyra:SecuritiesPurchaseAgreementMember 2024-01-012024-09-30 0001327273 2023-01-012023-03-31 0001327273 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001327273 lyra:CantorFitzgeraldCoMembersrt:MaximumMemberus-gaap:CommonStockMemberlyra:ControlledEquityOfferingSalesAgreementMember 2023-09-012023-09-01 0001327273 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001327273 lyra:MilestoneAchievementsMember 2024-09-30 0001327273 us-gaap:EquipmentMember 2024-09-30 0001327273 lyra:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember 2022-04-13 0001327273 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 pure iso4217:USD shares utr:sqft shares lyra:Lease lyra:Employee iso4217:USD lyra:Vote0001327273--12-31Q3false 2027-04-302028-05-3110-Qtrue2024-09-302024falseP1Y39273Lyra Therapeutics, Inc.DE84-1700838480 Arsenal WayWatertownMA02472617393-4600Common Stock, $0.001 par value per shareLYRANASDAQYesYesNon-accelerated Filertruetruefalsefalse6545764823800000223530002782600080400000281800020680005444400010482100016130002043000207070003323300019920001392000111000078393811000-311355000206190008942000078756000142600000195000544000132500014120005902000123680003740400035763000393100050030001488800014700000188300015920001244200016827000-84940000-506430005760001192000251700031610005760001192000251700031610001186600015635000-82423000-474820007000160003300042000-11873000-15651000-82456000-475240004720000200000-13000-17000-11849000-15631000-82469000-47541000-0.18-0.18-0.27-0.27-1.27-1.27-1.04-1.04654567356545673556953685569536856498121964981219459846434589464331827659320003293870001000024867500080754000211540004000704122000220001610000161000016255000-16255000318368153200033100100012000-26493000066091000333200017652962180000466500004666800055262970009700015000150001354000135400015468000-15618000495450395000037910200027000-28054800098577000-150000-150000520000200020000200001441000144100015651000-15651000495455595000038039500070002961990000842390005721455057000400685000330003111355000894200009183000300015000010416661000484900048500001255500100010002000142427220003806000380800027869800080000188100018810002245220006096477561000411225000250003338070007750400044908764000400080084290002900016250001625000-48131000-48131000654557356500041285400040003819380003097700010002400024000149100014910001187300065456735650004143450002000039381100020619000-8245600047524000477700044050003200001930001883000159200014000022836000200900024080007500005650005700001080000-1111000324000077400039850005400000625000485500024370008570001325000-1412000-58659000-442460002396000260000479490007276500010251900062800000521740001022500008819000500000002900003332000300010300085320004677100020470007700000237450003394200025792000262420008000493100015000027400001366700016100 1. Organization, Restructuring, Going Concern and Basis of Presentation Lyra Therapeutics, Inc. (the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. The Company’s proprietary technology is designed to consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company’s product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS. The Company was incorporated as a Delaware corporation on November 21, 2005 and is located in Watertown, Massachusetts. On July 16, 2018, the Company formerly changed its name from 480

Biomedical, Inc. to Lyra Therapeutics, Inc. The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates. Restructuring On May 16, 2024, the Company reported that topline results from the Company's Phase 3 ENLIGHTEN 1 trial evaluating LYR-210, a bioabsorbable sinonasal implant (7500µg mometasone furoate), as a six-month treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at 24 weeks. ENLIGHTEN 1 is one of two Phase 3 clinical trials evaluating LYR-210. The 52-week safety extension phase of the ENLIGHTEN 1 trial recently completed and data is expected in Q4 2024. ENLIGHTEN 2, the second pivotal Phase 3 trial of LYR-210 in CRS, is ongoing, and enrollment completed in October 2024. Topline results are expected in the second quarter of 2025. In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors of the Company (the "Board of Directors") approved a reduction in the Company's workforce impacting 87 employees, which occurred during May and June 2024. In connection with the reduction in force, the Company stopped manufacturing and commercialization efforts for LYR-210, as well as development efforts for LYR-220 in an effort to reduce operating expenses. Furthermore, the Company is currently in the process of marketing all three of its leased properties for sub-leasing arrangements. The Company has recorded a restructuring charge in the amount of $9.3 million for the nine months ended September 30, 2024, primarily related to severance and retention costs as further discussed in Note 4. The Company has also recorded an impairment charge for the write-down of property and equipment of $1.9 million and right-of-use assets in the amount of $22.8 million as further discussed in Notes 5 and 6. Going Concern The failure of the Company's Phase 3 ENLIGHTEN 1 trial to meet its primary endpoint, which resulted in the Company's restructuring during the second quarter of 2024, provides significant uncertainty regarding the Company's ability to meet its business plans and conduct its future operations. The Company has incurred recurring net operating losses every year since inception and has an accumulated deficit of approximately $393.8 million at September 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future. At September 30, 2024, the Company had approximately $23.8 million of cash and cash equivalents and $27.8 million of short-term investments. These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued. From inception through September 30, 2024, the Company has raised an aggregate of $424.8 million to fund its operations, of which $162.1 million were gross proceeds from sales of redeemable convertible preferred stock, $96.3 million were net proceeds from the April 2022 financing, $46.5 million were net proceeds from the May 2023 Financing (as defined below), $57.3 million were net proceeds from the Company's initial public offering, $23.9 million were net proceeds related to the Company's Controlled Equity Offering Agreement (the "Original Sales Agreement") dated September 1, 2023, $16.8 million were gross proceeds from government contracts, $17.0 million were gross proceeds from the LianBio License Agreement, and $3.8 million were gross proceeds from the exercise of common stock warrants. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") assuming the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is currently considering various operational and strategic options in light of the failure of the ENLIGHTEN 1 trial to meet its primary endpoint, including additional clinical trials, the sale of assets, or a strategic business combination. The Board of Directors has not decided on a specific plan other than to reduce operating expenses in order to manage its cash position. The Company is attempting to sublease all of its leased locations, and, may also seek to negotiate an early termination of its leases with its landlords. The Company may be unable to sublease its locations on favorable terms or at all. In addition, the Company may not be able to obtain an early termination of its leases with its landlords on favorable terms or at all. The Company will continue to evaluate its headcount of employees and may further reduce its workforce, which will result in additional severance and retention costs, which may impact the Company's ability to meet objectives. If the Company decides to pursue any form of growth strategy in the future, it will need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, it plans to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to obtain funding as and when needed would have a negative impact on the Company's financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company will need to generate significant revenue to achieve profitability, and it may never do so. Basis of Presentation The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company's audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on March 22, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB"). In management's opinion, these unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company's condensed consolidated financial statements for the periods presented. 2005-11-21873930000019000002280000-39380000023800000278000004248000001621000009630000046500000573000002390000016800000170000003800000 Basis of Presentation <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-

width:fit-content;">The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company's audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on March 22, 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB"). In management's opinion, these unaudited condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company's condensed consolidated financial statements for the periods presented. 2. Summary of Significant Accounting Policies The Company's significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2023, included in the Company's Annual Report on Form 10-K filed with the SEC on March 22, 2024. Since the date of those financial statements, there have been no changes to its significant accounting policies except as noted below. Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. For the three and nine months ended September 30, 2024, other comprehensive loss consisted of unrealized losses, net of taxes from its short-term investments. Restricted Cash The Company had restricted cash of approximately $2.0 million as of September 30, 2024 and approximately $1.4 million as of December 31, 2023. These balances were held as of September 30, 2024 at one of the Company's financial institutions to secure the Company's letters of credit for its facility leases. </p></div><div><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's statements of cash flows include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on such statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,800 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,353</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,992</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,392</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 25,792 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23,745 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;font-

family:'Calibri',sans-serif;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> </table> Net Loss per Share The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has included pre-funded warrants in its computation of basic net loss per share based on the nominal exercise price. The Company applies the two-class method to calculate its basic and diluted net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company's participating securities contractually entitle the holders of such shares to participate in dividends, but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) for the three and nine months ended September 30, 2024 and 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,387,089 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,838,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,606,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,030,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 867,472 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 243,703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,860,864 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,112,955 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's consolidated financial position, results of operations or cash flows. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, designed to improve reportable segment disclosures. The guidance expands the disclosures required

for reportable segments in our annual and interim condensed consolidated financial statements, primarily through enhanced disclosures about significant segment expenses. The standard will be effective for us beginning with our annual reporting for fiscal year 2024 and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact of this standard on our segment disclosures. This standard requires disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker, "CODM", and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The Company will include the required disclosure information in the notes to the financial statements for the year ending December 31, 2024 included in its 2024 Annual Report on Form 10-K and is required to apply ASU No. 2023-07 on a retrospective basis. The adoption of ASU No. 2023-07 will include expanded disclosure for its 2024 financial statements, but the Company does not expect that there will be a material impact to the financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes. Effective January 1, 2023, the Company adopted Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The adoption of ASU 2016-13 did not have a material impact on its consolidated financial statements. Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. For the three and nine months ended September 30, 2024, other comprehensive loss consisted of unrealized losses, net of taxes from its short-term investments. Restricted Cash The Company had restricted cash of approximately $2.0 million as of September 30, 2024 and approximately $1.4 million as of December 31, 2023. These balances were held as of September 30, 2024 at one of the Company's financial institutions to secure the Company's letters of credit for its facility leases. </p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's statements of cash flows include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on such statements. A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:67.313%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.843%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.5%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.843%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,800 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,353</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,992</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,392</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 25,792 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,745</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div>20000001400000A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,800 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,353</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,992</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,392</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 25,792 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,745 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> </table>2380000022353000199200013920002579200023745000 Net Loss per Share The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has included pre-funded warrants in its computation of basic net loss per share based on the nominal exercise price. The Company applies the two-class method to calculate its basic and diluted net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company's participating securities contractually entitle the holders of such shares to participate in dividends, but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not

allocated to such participating securities. Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) for the three and nine months ended September 30, 2024 and 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,387,089 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,838,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,606,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,030,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 867,472 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 243,703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,860,864 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,112,955 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) for the three and nine months ended September 30, 2024 and 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,387,089 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,838,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,606,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,030,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 867,472 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 243,703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,860,864 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,112,955 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>6387089583867786063031003057586747224370315860086416112955 Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's consolidated financial position, results of operations or cash flows. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, designed to improve reportable segment disclosures. The guidance expands the disclosures required for reportable segments in our annual and interim condensed consolidated financial statements, primarily through enhanced disclosures about significant segment expenses. The standard will be effective for us beginning with our annual reporting for fiscal year 2024 and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact of this standard on our segment disclosures. This standard requires disclosure of significant segment expenses that are regularly provided to the Chief Operating Decision Maker, "CODM", and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The Company will include the required disclosure information in the notes to the financial statements for the year ending December 31, 2024 included in its 2024 Annual Report on Form 10-K and is required to apply ASU No. 2023-07 on a retrospective basis. The adoption of ASU No. 2023-07 will include expanded disclosure for its 2024 financial statements, but the Company does not expect that there will be a material impact to the financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. In particular, the standard will require more detailed information in the income tax rate reconciliation, as well as the disclosure of income taxes paid disaggregated by jurisdiction, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the standard on the presentation of its consolidated financial statements and footnotes. Effective January1, 2023, the Company adopted Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 requires that credit losses be reported as an allowance using an expected losses model, representing the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The adoption of ASU 2016-13 did not have a material impact on its consolidated financial statements. 3. Fair Value Measurements The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.3%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at Reporting Date Using </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;">

</td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center

wrap;min-width:fit-content;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term investments:</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> U.S. treasury bills</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,826 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total Short-term investments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 27,826 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:51.3%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.68%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.26%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at Reporting Date Using </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,147</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,167 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,980</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Short-term investments: </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. treasury bills </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,918</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. Government Agency and foreign national bank securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,482 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,482 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total Short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-

bottom:2.25pt double #0000000;text-align:center;"> 80,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 80,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> As of September 30, 2024, the Company’s cash equivalents were invested in money market funds, which were valued based on Level 1 inputs. As of September 30, 2024, the Company’s short-term investments consisted of U.S. treasury bills which were valued based on Level 2 inputs. As of December 31, 2023, the Company’s cash equivalents were invested in money market funds and U.S. treasury bills, which were valued based on Level 1 and Level 2 inputs, respectively. As of December 31, 2023, the Company’s short-term investments consisted of U.S. treasury bills which were valued based on Level 2 inputs and U.S. Government Agency Securities and foreign national bank securities, which were valued based on Level 2 inputs. In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data for Level 2 investments. All available-for-sale securities have contractual maturities of less than one year. The Company did not have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level 3 inputs. The carrying values of the Company’s accounts payable, accrued expenses and deferred revenue approximate their fair values due to the short-term nature of these liabilities and as such these are considered Level 1 in the fair value hierarchy. The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:51.3%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.68%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.26%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at Reporting Date Using </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Assets: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td

style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;">

#ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,826</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total Short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,826</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,826</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">   </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.3%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at Reporting Date Using </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Quoted Prices in Active Markets for Identical Assets
(Level 1) </td> <td style="vertical-align:bottom;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Other Observable Inputs
(Level 2) </td> <td style="vertical-align:bottom;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant Unobservable Inputs
(Level 3) </td> <td style="vertical-align:bottom;text-align:left;">   </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">   </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;text-align:left;">   </td> <td style="vertical-align:bottom;text-align:left;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td style="vertical-

align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td>
</tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,167</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> U.S. treasury bills</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,980</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,167</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,980 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:top;"> Short-term investments: </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. treasury bills </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,918</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,918</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. Government Agency and foreign national bank securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,482 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,482 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total Short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">80,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">80,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1697600016976000169760001697600027826000278260002782600027826000111670001116700089800008980000201470001116700089800007691800076918000348206 4. Restructuring and Other Related Charges In connection with the ENLIGHTEN 1 trial failing to meet its primary endpoint, on May 16, 2024, the Board of Directors approved a reduction in the Company's workforce, impacting 87 employees, which occurred during May and June 2024. The Company incurred costs related to employee termination benefits and other costs associated with the restructuring mainly during the second quarter of 2024, with the remainder of the costs to be incurred through May 1, 2025. These amounts are recorded as restructuring and other related charges within our condensed consolidated statements of operations and comprehensive loss as they are incurred. For the three months ended September 30, 2024, restructuring and other related charges were $2.8 million, which consisted of $0.9 million of severance costs, $1.8 million of retention costs, and $0.1 million of other costs.

For the nine months ended September 30, 2024, restructuring and other related charges were $9.3 million, which consisted of $5.7 million of severance costs, $2.6 million of retention costs, and $1.0 million of other costs.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restructuring liability activities during the nine months ended September 30, 2024 (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:27.826%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.383000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.383000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.383000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">January 1,</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Accruals</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Cash Payments</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 Restructuring Plan</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,651 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3,435</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,216 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Retention Costs </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,608 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(74</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,534 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other Costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 995 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (890 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">105</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,254</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (4,399 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,855 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 0728000009000001800000100000930000057000002600000101000000 Restructuring liability activities during the nine months ended September 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.826%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.383000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.383000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.383000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> January 1, </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> September 30, </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> 2024 </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Accruals </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Cash Payments </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;">

  </td> <td colspan="2" style="vertical-align:bottom;"> 2024 </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> 2024 Restructuring Plan </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Severance Costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,651 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3,435</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,216 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Retention Costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,608</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (74 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,534</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other Costs</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">995</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(890</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 105 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-

wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,399</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,855 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>565100034350002216000260800074000253400099500089000010500092540004399000048550000 5. Property and Equipment and Related Impairment Property and equipment consist of the following (in thousands) as of September 30, 2024 and December 31, 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> September 30, </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> December 31, </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> 2024 </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> 2023 </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Property and equipment: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Laboratory equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,158</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,736 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Computer software and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 160 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Office furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 934 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 485 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 461 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,737</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,964 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: Accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> (2,241 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,921 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: Impairment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,883 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,613</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,043 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> During the second quarter of 2024 and as a result of the Company's Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, the Company performed a recoverability test for its property and equipment. The Company concluded that the undiscounted cash flows associated with its property and equipment was less than the carrying value of the property and equipment. The Company compared the fair value of the property and equipment to the carrying value and recorded an impairment charge in the amount of $1.9 million which is included as an impairment of property and equipment in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024. The Company determined fair market value of the equipment based on a third-party appraisal of the equipment through use of publicly available used equipment quotes. The equipment was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of September 30, 2024, and determined no additional impairment indicators existed. Property and equipment consist of the following (in thousands) as of September 30, 2024 and December 31, 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> September 30, </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> December 31, </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> 2024 </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> 2023 </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Property and equipment: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Laboratory equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,158</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,736 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Computer software and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 160 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Office furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 934 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 485 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 461 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,737</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,964 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: Accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,241 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,921 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: Impairment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,883 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,613</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">2,043 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>41580002736000160000105000934000662000485000461000573700039640002241000192100018830000161300020430001900000019000000 6. Impairment of Right-of-Use Assets In connection with the Company's Phase 3 ENLIGHTEN 1 trial failing to meet its primary endpoint, in May 2024, the Company engaged a commercial real estate broker to market the Company's three leased properties for sublease arrangements. As of September 30, 2024, the Company has not sublet any of its leased properties. Based upon these impairment indicators, the Company has performed a recoverability test over its right-of-use asset and concluded the right-of-use assets are impaired. As a result, the Company has recorded an impairment charge in the amount of $22.8 million, which is included as an impairment of right-of-use asset in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024. The right-of-use asset was valued as of May 15, 2024. The Company reassessed the need for any further impairment as of September 30, 2024, and determined no additional impairment indicators existed. The Company engaged a valuation specialist to perform a fair value determination of the right-of-use assets using a discounted cash flow methodology, which included the following range of assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.222%;box-sizing:content-box;"></td> <td style="width:2.222%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:33.555%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Discount Rate </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 9.5-10.5% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Term (years) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.96-9.13 </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected Sublease Rent Increases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> 32280000022800000 The Company engaged a valuation specialist to perform a fair value determination of the right-of-use assets using a discounted cash flow methodology, which included the following range of assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.222%;box-sizing:content-box;"></td> <td style="width:2.222%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:33.555%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Discount Rate </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 9.5-10.5% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Term (years) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 2.96-9.13 </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected Sublease Rent Increases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table>0.0950.105P2Y11M15DP9Y1M17D0.03 7. Preferred and Common Stock The Company has 10,000,000 shares of undesignated preferred stock, par value $0.001 per share. There were no shares issued or outstanding as of September 30, 2024 or September 30, 2023. The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. The Company currently has an effective shelf registration statement on Form S-3 (No. 333-278163) filed with the SEC on March 22, 2024 ("Form S-3"), under which it may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, warrants and units of up to $300.0 million in the aggregate. September 2023 Financing On September 1, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Original Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $50.0 million. The offering and sale of up to $50.0 million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-256020) (the "Registration Statement"), which was originally filed with the SEC on May 11, 2021, and declared effective by the SEC on May 20, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on September 1, 2023. Pursuant to the Original Sales Agreement, Cantor may sell the shares in sales deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company has no obligation to sell

any of the shares under the Original Sales Agreement and may at any time suspend or terminate the offering of the shares pursuant to the Original Sales Agreement upon notice to Cantor and subject to other conditions. Cantor will act as sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the shares requested to be sold by the Company, on mutually agreed terms between Cantor and the Company. The Original Sales Agreement contains customary representations, warranties and agreements by the Company, and indemnification obligations of the Company and Cantor and other obligations of the parties. Under the terms of the Original Sales Agreement, the Company has agreed to pay Cantor a commission equal to 3.0% of the aggregate gross proceeds from any shares sold through it pursuant to the Original Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by Cantor in connection with the Original Sales Agreement. On February 14, 2024, the Company issued 1,041,666 shares under the Company's ATM agreement with net proceeds of $4.8 million. On March 22, 2024, the Company amended and restated the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. ("Cantor") pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company's common stock for aggregate gross proceeds of up to $75.0 million. The offering and sale of up to $75.0 million of the common shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-278163) (the "Registration Statement"), which was originally filed with the Securities and Exchange Commission on March 22, 2024, the base prospectus contained within the Registration Statement, and a prospectus supplement relating to the shares that was filed with the SEC on March 22, 2024 (the "Prospectus Supplement"). May 2023 Financing On May 25, 2023, the Company entered into the Purchase Agreement, with the purchasers, pursuant to which the Company agreed to sell securities to the Investors in a private placement (the "Private Placement"). The Purchase Agreement provided for the sale and issuance by the Company of: 17,652,962 shares of the Company's common stock and accompanying warrants to purchase up to 8,826,481 shares of the Company's common stock (Purchase Warrants), with an exercise price of $2.67 per share, for aggregate gross proceeds of $44.0 million. Each Purchase Warrant became exercisable on November 30, 2023, and expires on November 30, 2028. Additionally, the Company issued Pre-Funded Warrants to purchase 2,408,188 shares of the Company's common stock (Pre-Funded Warrants), with an exercise price of $0.001 per share, and accompanying purchase warrants to purchase up to 1,204,094 shares of the Company's common stock (Purchase Warrants), with an exercise price of $2.673 per share, for aggregate gross proceeds of $6.0 million. In total 10,030,575 Purchase Warrants were issued and 2,408,188 Pre-Funded Warrants were issued. The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028. The closing of the Private Placement occurred on May 31, 2023. The Company received an aggregate of $50.0 million in gross proceeds, or $46.5 million after deducting issuance costs. The Company has allocated the net proceeds among the common stock, the Purchase Warrants and the Pre-Funded Warrants using the relative fair value method for each of the above transactions. The Company has allocated $30.5 million to the shares of common stock, $4.2 million to the Pre-Funded Warrants and $12.0 million to the Purchase Warrants. The Company's outstanding warrants are freestanding instruments and are classified within stockholders' equity since the warrants are indexed to the Company's common stock and meet the equity classification criteria. A total of 1,424,272 Purchase Warrants were exercised related to the May 2023 financing as of September 30, 2024 at a purchase price of $2.673 per share. April 2022 Financing On April 13, 2022, the Company announced the closing of its private placement of common stock (or, in lieu thereof, Pre-Funded Warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million (the "April 2022 Financing"). The Company received approximately $96.3 million in net proceeds after deducting estimated offering costs of $4.2 million. Pursuant to the securities purchase agreement, (i) certain investors purchased an aggregate of 18,815,159 shares of common stock at $4.22 per share for gross proceeds to the Company of $79.4 million and (ii) certain investors purchased Pre-Funded Warrants to purchase an aggregate of 5,000,000 shares of common stock, with the exercise price of $0.001 per share for gross proceeds of $21.1 million to the Company. The warrants are exercisable on or after April 13, 2022 and expire on April 12, 2027. The <span style="color:#000000;white-space:pre-

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-Funded Warrants were classified as a component of stockholders' equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company's common stock and meet the equity classification criteria. In addition, such Pre-Funded Warrants do not provide any guarantee of value or return. The Company valued the Pre-Funded Warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Pre-Funded Warrants, of which $19.7 million was allocated to the Pre-Funded Warrants and recorded as a component of additional paid-in capital. All Pre-Funded Warrants issued in the April 2022 Financing were exercised as of June 30, 2024. The Company has reserved for future issuances the following shares of common stock as of September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.04%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,606,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options and restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,075,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 723,906 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 19,405,374 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 100000000.0010000The holders of common stock are entitled to one vote for each share held.1300000000500000005000000000.031041666480000075000000750000001765296288264812.6744000000Each Purchase Warrant became exercisable on November 30, 2023, and expires on November 30, 2028.24081880.00112040942.67360000001003057524081881The Pre-Funded Warrants are immediately exercisable and expire on May 31, 2028.5000000046500000305000004200000120000001424272 2.67310050000096300000420000018815159 4.22794000005000000 0.00121100000197000 00 The Company has reserved for future issuances the following shares of common stock as of September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.04%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,606,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options and restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,075,165 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 723,906 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 19,405,374 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>8606303100751657239061940537 4 8. Common Stock Warrants <p style="text-indent:9.067%;font-

size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The following table represents a summary of the warrants outstanding and exercisable as of September 30, 2024, all of which are equity-classified. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:15.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:6.28%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:3.6%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:6.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:5.82%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.76%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:6.48%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:4.34%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:6.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:4.779999999999999%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.6%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Common Warrants </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Average Exercise Price </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Remaining Contractual Term (Years) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Expiration Date </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Pre-funded Warrants </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Exercise Price </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Remaining Contractual Term (Years) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Expiration Date </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at December 31, 2023 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,030,575 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.673</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.90</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25,700 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> November 30, 2028 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,756,349 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.001</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.92</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,200 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> April 2027-May 2028 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Exercised </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,424,272 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:nowrap;vertical-

align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.673</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,052 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,756,349 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.001</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,606,303 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.673</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> November 30, 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The following table represents a summary of the warrants outstanding and exercisable as of September 30, 2024, all of which are equity-classified: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:15.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:3.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:4.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:4.779999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Common Warrants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Average Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Remaining Contractual Term (Years) </td> <td

style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Expiration Date </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Pre-funded Warrants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Remaining Contractual Term (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Expiration Date </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,030,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.673</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.90</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25,700 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> November 30, 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,756,349 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.001</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.92</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> April 2027-May 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,424,272 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.673</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,052 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,756,349 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.001 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37,770</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,606,303</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.673 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> November 30, 2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>100305752.673P4Y10M24D257000002028-11-3057563490.001P3Y11M1D3020000014242722.673505200057563490.001377700086063032.673P4Y1M24D2028-11-30 9. Stock-Based Compensation Expense The Company currently grants equity-based awards under its 2020 Incentive Award Plan (“2020 Plan”) and its 2022 Employment Inducement Award Plan (“Inducement Award Plan”). The Company previously granted equity-based awards under its 2005 Equity Incentive Plan (“2005 Plan”) and 2016 Equity Incentive Plan (“2016 Plan” and together with the 2020 Plan, the Inducement Award Plan and the 2005 Plan, the “Plans”). The Company also maintains the 2020 Employee Stock Purchase Plan (the “ESPP”). A summary of the restricted stock unit activity under the Plans for the nine months ended September 30, 2024 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Grant Date Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105,048 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">984,929</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.49 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> (</td> <td style="white-space:nowrap;vertical-align:bottom;"> 27,869 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.29</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(194,636</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units outstanding as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 867,472 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.56</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">A summary of the stock option activity under the Plans for the nine months ended September 30, 2024 was as follows: </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.664%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.844000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.664%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Shares</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted-
Average
Exercise
Price</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted-
Average
Remaining
Contractual
Life
(in years)</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate
Intrinsic
Value
(in thousands)</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,709,980</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.68 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,605,002 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">4.89 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,002 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.96 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top;"> Cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,926,891 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.83 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,387,089 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.61</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.9</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of certain options granted to executive officers, with the following weighted-average assumptions for the three and nine months ended September 30, 2024 and 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.291%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.122%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.122%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.122%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:center;">2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> The weighted-average fair value of options granted to employees, directors and non-employees during the three months ended September 30, 2023 was $2.57. There were no options granted to employees, directors or non-employees during the three months ended September 30, 2024. The weighted-average fair value of options granted to employees, directors and non-employees during the nine months ended September 30, 2024 and 2023 was $2.80 and $2.08, respectively.</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock-based compensation expense included in the Company's consolidated statements of operations and comprehensive loss was as follows (in thousands): </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.951%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.262%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.362%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.262%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.362%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended
September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 214 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">294</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 627 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 865 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,277 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,150 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

3,540 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,491</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,441 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,777</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,405 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> For the period ended September 30, 2024, approximately $15,000 of the stock-based compensation expense was recorded as a liability. For the period ended September 30, 2023, the Company did not record any stock-based compensation expense as a liability. Unrecognized share-based compensation related to stock-based options amounted to $6.6 million at September 30, 2024 and is expected to be recognized over a weighted average period of approximately 2.86 years. Unrecognized share-based compensation related to restricted stock units amounted to $2.0 million at September 30, 2024 and is expected to be recognized over a weighted average period of approximately 2.4 years. In March 2024, the Company granted options to purchase 550,000 shares of common stock at an exercise price of $6.07 per share to its Chief Executive Officer (“2024 Performance Option”) and granted 385,000 RSUs to its Executive Chair (“2024 PSUs”), each with performance-based vesting conditions under the 2020 Plan. Vesting of the 2024 Performance Option and the 2024 PSUs are based on the achievement of various clinical and regulatory milestones during the specified periods. For the performance-based stock awards, the Company measures stock compensation expense based on the fair value of the award on the grant date and then once the Company determines the performance criteria is probable of achievement, recognizes such amount over the vesting term of the award, which is approximately 3.8 years. The Company determined the fair value of the 2024 Performance Option using the Black-Scholes option-pricing model using the following inputs: risk-free interest rate of 4.26%, volatility of 76.82%, expected dividend yield 0%, and expected term of 6.0 years. The Company measured the 2024 PSUs based on the fair value of the Company’s stock on the date of grant. As of March 31, 2024, the Company has determined that 183,333 shares of common stock subject to the 2024 Performance Option and 128,333 shares of common stock underlying the 2024 PSUs are probable to vest and as of September 30, 2024 has recognized approximately $214,000 of expense, which is included in stock-based compensation expense. As of September 30, 2024, there is $1.3 million of unrecognized stock compensation expense to be recognized in connection with all of the performance-based awards that are deemed to be probable as of September 30, 2024. As of September 30, 2024, there were 1,957,604 shares available for grant under the 2020 Plan and 863,000 shares available for grant under the Inducement Award Plan. During the nine month ended September 30, 2024, the Company issued 1,000 shares under the 2020 ESPP. As of September 40, 2024, there are a total of 723,906 shares available for issuance under the 2020 ESPP. A summary of the restricted stock unit activity under the Plans for the nine months ended September 30, 2024 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.313%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.323%;box-sizing:content-box;"></td> <td

style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Grant Date Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105,048 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">984,929</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.49 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (27,869 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.29</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(194,636</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units outstanding as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 867,472 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.56 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 1050483.29849295.49278693.291946364.288674725.56 A summary of the stock option activity under the Plans for the nine months ended September 30, 2024 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.664%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.844000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.664%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Exercise
Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Remaining
Contractual
Life
(in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic
Value
(in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,709,980 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.68</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.0</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,605,002 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.89 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,002 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.96 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,926,891 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.83 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,387,089 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.61 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>57099805.68P8Y633400026050024.8910023.96192689 14.8363870895.61P7Y10M24D The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, or a Monte Carlo simulation in the case of certain options granted to executive officers, with the following weighted-average assumptions for the three and nine months ended September 30, 2024 and 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.291%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.122%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.122%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.122%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.342%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table>00.0430.0420.037P6Y1M6DP6YP6Y00.800.8050.8292.5702.82.08 Stock-based compensation expense included in the Company's consolidated statements of operations and comprehensive loss was as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.951%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.262%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.362%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.262%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.362%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">214</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 294 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 627 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">865</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,277</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,147</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,150</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,540</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,491 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,441</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,777 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,405 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>2140002940006270008650001277000114700041500003540000149100014410004777000440500015000006600000P2Y10M9D2000000P2Y4M24D5500006.07385000P3
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">10. Collaboration Agreement Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of September 30, 2024, as all milestone amounts were fully constrained based on the probability of achievement.
The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2023. There was a side letter executed on December 27, 2022 which extended the negotiations of a supply agreement. The amendment did not result in any change in the Company's determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations. LianBio announced that in October 2023 its Board of Directors commenced a comprehensive strategic review of its business. The LianBio Board ultimately concluded that selling off assets and winding down operations was the best way to realize maximum shareholder value. LianBio reported that a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. LianBio announced in February 2024 that it was further reducing the size of its workforce to approximately 50 employees with plans to reduce that number further over the course of 2024. LianBio stated it will maintain a core group of employees necessary to implement an orderly wind down and support its efforts to maximize the value of its remaining business and assets including the collaboration with the Company. Due to these developments, the future of the Company's collaboration with LianBio is uncertain as LianBio continues its wind down, while seeking a third party to acquire LianBio's rights under the LianBio License Agreement. The Company will recognize the revenue associated with the Combined Performance Obligation as the clinical supply of LYR-210 is delivered. The Company recognizes revenue associated with the Development Activities Performance Obligation as the development activities are performed using an input method, according to the costs incurred as to the development activities related to the global Phase 3 clinical trial and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management's judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability on the Company's consolidated balance sheet and will be recognized as the clinical supply of LYR-210 is delivered and over the remaining time it takes to conduct the global Phase 3 clinical trial, respectively. There were no changes in the transaction price from December 31, 2023 to September 30, 2024. The

following table reflects the transaction price (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:68.234%;box-sizing:content-box;"></td><td style="width:1.46%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:28.305999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> As of September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Post-Milestone </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Combined Performance Obligation </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,862</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Development Activities Performance Obligation</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,138</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 17,000 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:58.517%;box-sizing:content-box;"></td><td style="width:1.259%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.975%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.299%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.737%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.299%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.916%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> As of September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Combined Performance Obligation </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Development Activities Performance Obligation </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Deferred revenue at December 31, 2022 </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,748</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,604 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,352 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Revenue recognized </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,558 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-

bottom:0.5pt solid #000000;text-align:center;"> (1,558 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred revenue at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,748 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,794 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Revenue recognized </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,325 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,325 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ccecff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Deferred revenue at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,748</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 721 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,469 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. Note that the allocated deferred revenue associated with the clinical supply agreement has been recorded as long term deferred revenue given the potential uncertainty of delivery within the next twelve months. As of September 30, 2024, the parties still have not completed their negotiations of the clinical supply agreement. At this point, it is uncertain whether such an agreement will be completed. In view of the uncertainty around the completion of the clinical supply agreement, the Company may decide to recognize such payments as revenue on an accelerated schedule. Entities affiliated with Perceptive Advisors, LLC are shareholders of both the Company and LianBio. Additionally, two of the Company's directors are Managing Directors at Perceptive Advisors, LLC and one of these directors is also the Executive Chairman of LianBio's board of directors. Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of September 30, 2024, as all milestone amounts were fully constrained based on the probability of achievement. 120000000840000036000005000000500000035000001500000The following table reflects the transaction price (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:68.234%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:28.305999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Post-Milestone</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Combined Performance Obligation</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,862 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Development Activities Performance Obligation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,138 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table>11862000513800017000000<p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The following table reflects the revenue recognized related to each of the performance obligations and the remaining deferred revenue (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.517%;box-sizing:content-box;"></td> <td style="width:1.259%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.975%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.737%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.916%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Combined Performance Obligation</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Development Activities Performance Obligation</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Deferred revenue at December 31, 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,748 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,604</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,352 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Revenue recognized </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,558 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,558 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Deferred revenue at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,748 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,794 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Revenue recognized </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,325 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,325 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ccecff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Deferred revenue at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,748</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 721 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,469 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1174800036040001535200015580001558000117480002046000137940001325000132500011748000721000124690000 11. Income Taxes The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. Given the Company's uncertainty regarding future taxable income, the Company maintains a full valuation allowance on its deferred tax assets. The Company recorded an income tax expense of $7,000 for the three months ended September 30, 2024 and $16,000 for the three months ended September 30, 2023 and $33,000 for the nine months ended September 30, 2024 and $42,000 for the nine months ended September 30, 2023, respectively. 70001600033000420000 12. Leases Watertown Lease In August 2007, the Company entered into an operating lease, as amended, for office and laboratory space in Watertown, Massachusetts. The lease includes certain rent escalations. In July 2023, the Company amended the lease to extend the expiration of the lease term from April 2024 to April 2027. Under the terms of the amended lease, the Company no longer has the right to terminate the lease after January 1, 2024. The Company maintains a letter of credit of approximately $0.3 million securing its obligations under the operating lease which is secured by approximately $0.3 million, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy. The Company also has two leases for two separate spaces in the same building at 880 Winter Street in Waltham, Massachusetts. The Company refers to the first lease as the "Waltham Lease" and the second lease arrangement as the "Waltham Sublease" as the Company, as a tenant, is subleasing space from under an existing lease arrangement whereby the lessee to the headlease has agreed to sublease the space to the Company under a sublease agreement. Waltham Lease In May 2022, the Company executed a lease agreement located at 880 Winter Street in Waltham, Massachusetts. The leased premises comprises approximately 29,000 square feet of office and lab space, and the lease initially provides for base rent of $2.2 million per year, which will increase 3% per year over the noncancellable term ending on June 30, 2033. The Company has the option to extend the lease for one additional five-year term and is responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company did not include the option to extend the lease for the additional five-year term in its measurement of the right-of-use asset and lease liability. In connection with the lease, a security deposit was delivered to the landlord in the form of an irrevocable standby letter of credit collateralized by $1.1 million of deposits with the financial institution which is recorded as restricted cash. Waltham Sublease In December 2023, the Company executed a sublease agreement for additional lab and office space located at 880 Winter Street in Waltham, Massachusetts. The subleased premises comprise approximately 24,000 square feet, and the sublease provides for base rent of $1.8 million per year, which will increase 3% per year over the noncancellable term ending on

November 30, 2032. The Company is also responsible for its share of real estate taxes, maintenance, and other operating expenses applicable to the subleased premises. Upon sublease commencement on January 3, 2024, the Company recorded the sublease as a component of its operating lease right-of-use asset and operating lease liabilities. In connection with the sublease, a security deposit was delivered to the sublandlord in the form of an irrevocable standby letter of credit collateralized by $0.6 million of deposits with the financial institution which is recorded as restricted cash.</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The components of lease cost recorded in the Company's condensed consolidated financial statements were as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:55.511%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.882%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.882%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.24%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.882%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended
September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Lease Cost:</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,346 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">483</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,082 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,371 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 608 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 399 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-

align:center;"> 1,866 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 893 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,954</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 882 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,948</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,264 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Variable lease payments include the Company's allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The weighted-average remaining lease term and discount rate related to the Company's operating leases were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:72.374%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:24.225%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 7.7 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> Maturity of the Company's operating lease liabilities in accordance with ASC 842 as of September 30, 2024 were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:71.5%;box-sizing:content-box;"></td> <td style="width:1.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:24.639999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Period ended December 31, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> From October 1, 2024 to December 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,546 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,121 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,131 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,507 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 20,652 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total maturities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44,451</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,127</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of operating lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,324 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion of operating lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total operating lease liability, net of current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,321 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company evaluated the above leases for impairment indicators and determined that the right-of-use assets were impaired. Additional details are included within Note 6 above. true2027-0430000030000022900022000000.03one additional five-year term1100000240001800000.03600000 The components of lease cost recorded in the Company's condensed consolidated financial statements were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.511%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.882%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.882%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.882%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.882%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Lease Cost: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,346</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 483 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">5,082</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,371 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 608 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 399 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,866 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 893 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,954</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 882 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,948</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,264 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1346000483000508200013710006080003990001866000893000195400088200069480000226400 The weighted-average remaining lease term and discount rate related to the Company's operating leases were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:72.374%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:24.225%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">7.7 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table>P7Y8M12D0.062 Maturity of the Company's operating lease liabilities in accordance with ASC 842 as of September 30, 2024 were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:71.5%;box-sizing:content-box;"></td> <td style="width:1.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:24.639999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Period ended December 31, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> From October 1, 2024 to December 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,546</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,121</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,494</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,507</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,652</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total maturities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,451 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (9,127 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Present value of operating lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,324</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: current portion of operating lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,003</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease liability, net of current portion</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,321 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
1546000612100064940005131000450700020652000444510009127000353240004003000313210000<p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">13. Commitments and Contingencies On May 10, 2023, the Company filed a complaint in the Superior Court of the State of Delaware against a former contract manufacturer alleging breach of contract. The Company alleged in its complaint that the former contract manufacturer breached the Master Clinical Supply Agreement ("MCSA"). The Company's complaint sought monetary damages and the return of equipment and materials that the Company owned. On July 20, 2023, the same contract manufacturer filed an answer and amended counterclaims to the Company's May 10, 2023 complaint (the "Litigation"). Due to the legal proceeding and termination of agreement with this manufacturer, the Company recognized $1.6 million loss on impairment of long-lived assets during the year-ended December 31, 2023. On November 2, 2023, the Company entered into a settlement and release agreement, related to the Litigation, pursuant to which each of the Company and the contract manufacturer provided broad mutual releases of all claims relating to or arising out of the MCSA, including without limitation, all claims brought in the Litigation or that could have been brought in the Litigation. The Company and the former contract manufacturer agreed to jointly file a Stipulation of Dismissal with prejudice relating to the Litigation. The Company has a remaining liability of $0.4 million to be paid to the contract manufacturer during 2024 included within accrued liabilities and other current liabilities. 1600000400000falsefalsefalsefalse

"